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Abstract 
Background: Specific nutrients such as glutamine have an important role in the management 
of critically ill patients, modulating the host response to stress, improving outcome. The 
mechanisms of action of glutamine are thought to be through the release of heat shock 
protein 70 (HSP70), which helps orchestrate an appropriate inflammatory response to 
critical illness. HSP70 release stimulates immune activation, maintenance of cell 
homeostasis, cellular protection, preventing apoptotic cell death and is associated with 
increased survival following severe trauma. However, much of the work considering the use 
of glutamine and HSP70 in critical illness has been completed in adults. The focus of the 
current research was therefore to investigate HSP70 release and its relationship to 
glutamine and inflammatory markers in healthy adults and paediatric volunteers using a 
whole blood endotoxin model. In addition to this, describing relationships between 
glutamine, HSP70 and inflammatory mediators, in a cohort of critically ill children. 
 
Methodology: An in vitro whole blood endotoxin stimulation model using lipopolysaccharide 
(LPS) was adapted for use in healthy adult (n=18) and paediatric volunteers (n=25) to 
investigate the effect of glutamine supplementation on the release of HSP70 and 
inflammatory mediators (IL-6, IL-8, IL-1β, IL-10, TNF-α). Plasma from children with acute 
meningococcal disease (MD) (n=143) and during convalescence (n=78) was analysed for 
levels of HSP70, inflammatory cytokines (IL-6, IL-8, IL-10, TNF-α) and glutamine.  Following a 
clinical folder review, transcriptomic analysis of differential gene expression between acute 
disease and convalescence was carried out in a subset of children. 
 
Results: A whole blood stimulation model was effective in measuring the inflammatory 
response to endotoxin in vitro over an incubation period of 4 to 24 hours. Glutamine 
supplementation significantly increased HSP70 expression over time in healthy adult and 
paediatric volunteers compared to unsupplemented controls (p<0.05). HSP70 levels in vitro 
rose over time and was correlated with inflammatory mediators (IL-1β, TNF-α, IL-8) in adults, 
and IL-6, TNF-α in paediatric samples at 4 hours, following glutamine supplementation. 
There was no relationship between HSP70 and IL-10 in either adults or children. Glutamine 
supplementation significantly attenuated the release of IL-8 at 24 hours (p<0.05) and in the 
paediatric in vitro endotoxin model significantly increased TNF-α release at 4 hours 
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(p<0.005). Although there were no other significant differences in the release of 
inflammatory mediators (IL 6, TNF-α, IL10) between conditions, glutamine supplementation 
appeared to attenuate the release of inflammatory mediators in adults in contrast to 
promoting the release of inflammatory mediators in children.  
  
In patients with MD, HSP70 was significantly increased (p=<0.0001) in the acute phase 
[26.7ng/ml; SD± 79.95 (median 5.7ng/ml; range 0.09 – 600.5ng/ml)] vs. convalescence 
[mean 3.16ng/ml ±SD; 5.67 (median 1.045ng/ml range 0.001 – 37.31ng/ml)]. Mean 
glutamine levels during the acute phase were 0.31mmol/l; ±SD 0.13 (median 0.31mmol/l; 
range 0.50 – 0.64) and for convalescence 0.40mmol/l; ±SD 0.14 (median 0.40mmol/l; range 
0.72 – 0.64). During the acute phase of illness, glutamine levels were 52% below the normal 
range, (using 0.6mmol/l as the lower reference range). In convalescent samples, taken on 
average 55 days later (35 – 135 days), glutamine levels were found to be 26% below normal 
range.  Results from the transcriptomic analysis show that genes associated with HSP70 and 
inflammatory signalling pathways, glycolysis and gluconeogenesis are significantly 
upregulated and those relating to adaptive immunity are downregulated during the acute 
phase of meningococcal disease compared to convalescence. There were numerous 
correlations between plasma glutamine and HSP70 with genes associated with p38MAPK 
signalling pathway during the acute phase of meningococcal disease, suggesting that 
glutamine and HSP70 could mediate the inflammatory response to infection.  
 
Conclusion: Glutamine supplementation increased the release of HSP70 in an in vitro 
endotoxin model in children and adults. Children with MD during the acute phase of their 
illness have significant glutamine depletion, occurring early during the course of the disease, 
with a concomitant increase in plasma levels of HSP70 and inflammatory mediators. A 
transcriptomic analysis of differential gene expression showed that genes associated with 
HSP70 (HSPA1A and HSPA1B) were differentially upregulated during the acute phase of 
illness. HSP70 genes and plasma levels of HSP70 were correlated, which was suggestive of a 
role in meningococcal disease.  Relationships were found with plasma levels of HSP70 and 
glutamine and genes associated with p38MAPK signalling pathway during the acute phase of 
meningococcal disease, suggesting that glutamine and HSP70 could mediate the 
inflammatory response to infection. Future work would aim to understand the effect of 
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glutamine supplementation on gene expression during critical illness, especially relative to 
the differential expression of genes associated with HSP70, inflammatory signalling 
pathways and those relating to the antigen presentation pathway. 
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IL Interleukin 
IL-1RA Interleukin 1 receptor antagonist 
IRAK Interleukin-1 receptor associated kinase 
IKK I Kappa B Kinase 
IV Intravenous 
IKKγ IκB kinase-gamma 
LPS Lipopolysaccharide 
LBP Lipopolysaccharide binding protein 
LPA Lipoteichoic acid 
MD Meningococcal disease 
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MIF Macrophage inhibitory factor 
MIP-1 Macrophage inhibitory factor-1 
MHC Major histocompatibility complex 
mRNA Messenger ribonucleic acid 
MAPK Mitogen activated protein kinase 
MCP-1 Monocyte chemotactic protein-1 
MYD88 Myeloid differentiation primary response protein 88  
NEMO NF-κB essential modulator 
NF-ΚB Nuclear factor kappa B 
NOD-LRR Nucleotide oligomerisation domain leucine rich repeat proteins 
O-GlcNAcase O-N-acetylglucosaminidase 
PICU Paediatric intensive care unit 
PAMPs Pathogen associated molecular patterns 
PRR Pattern recognition receptors 
PBMC Peripheral blood mononuclear cells 
PAF Platelet activating factor 
OGT Polypeptide O-β-acetylglucosamineamyltransferase 
PEPCK Phosphoenolpyruvate carboxykinase  
PKA Protein kinase A 
PKC Protein kinase C 
PP Protein phosphatase 
ROS Reactive oxygen species 
RIG-1 Retinoic acid inducing gene 1 
RLH's Retinoic acid inducing like helicase 
Rt-PCR Real time polymerase chain reaction 
SCCM Society of Critical Care Medicine 
sTNFR Soluble tumour necrosis factor receptor 
SD Standard deviation 
SDE Significantly differentially expressed 
SE Standard error 
SEM Standard error mean 
SIRS Systemic inflammatory response syndrome 
SVR Systemic vascular resistance 
TIR Toll interleukin-1 receptor 
TLR Toll like receptors 
TGF-β Transforming growth factor beta 
TNF Tumour necrosis factor 
TNF – α Tumour necrosis factor alpha 
TRAF-6 Tumour necrosis factor receptor associated factor 6 
VWF Von Willebrand factor 
UK United Kingdom 
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Chapter 1: Introduction 
1.1 Epidemiology and health economic burden of sepsis 
Globally, sepsis and septic shock remain a leading cause of mortality in adults and children 
(1, 2). Mortality from severe sepsis in children is reported to be between 10.3 – 14% (3-5), 
which is lower than the mortality rates reported in adults of between 27 - 54% (6). 
 
Prevalence studies estimate that paediatric sepsis occurs on average in 0.6 cases per 1000 
population (4) with severe sepsis being more common in neonates (5.2 cases per 1000 
population) (3) compared to children 5  – 14 years of age, where the incidence is 0.2 cases 
per 1000 population (3).  Recently published data shows that amongst children admitted to a 
paediatric intensive care unit (PICU) 82% had evidence of systemic inflammatory response 
syndrome (SIRS), with 23% of these meeting the criteria for sepsis, of which 4% had severe 
sepsis and 2% had septic shock (7).  An investigation into readmission rates and late 
mortality after severe sepsis in children (1 month to 18 years of age) revealed that 6.4% of 
children died either during their PICU stay or within 28 days of discharge. A further 6.5% died 
within 2 years of the initial admission and discharge from PICU, although the majority of 
these children had underlying disease pathology (8).  
 
Patients with severe sepsis often spend prolonged periods of time in an Intensive Care Unit 
(ICU) and are significantly more expensive to treat than those without sepsis (1, 9). The 
median length of stay for adults admitted to ICU’s in the United Kingdom (UK) with sepsis 
was 9.6 days compared to 2 days for those without sepsis (9). Owing to the severity of 
disease, the total costs of patient care in children with meningococcal disease is significantly 
greater, estimated at $US 49, 626 per patient, compared to $US 5, 041 for non septic 
critically ill children (10). In the US, paediatric sepsis costs nearly $2billion per annum and in 
the UK the estimated total cost of adult care was between £7000 and £28,000 per patient 
per admission (9, 11). The cost of healthcare during acute disease does not account for 
hidden costs relating to post discharge rehabilitation following severe sepsis, especially in 
children and the long term impact on cognitive abilities, executive functioning and psycho/ 
social difficulties experienced into adulthood (12-15).  
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1.2 Definition of SIRS, sepsis and septic shock 
Consensus criteria have been developed to define SIRS, sepsis, severe sepsis and septic 
shock for adults, which have been modified for the use in critically ill children. Severe sepsis 
and septic shock in children are defined as ‘sepsis plus evidence of organ dysfunction 
defined around paediatric parameters’ (Table 1.1) (16).  
 
Table 1.1: Definitions of paediatric SIRS, infection, sepsis and septic shock (16)    
Definition Criteria 
SIRS 
 
 
The presence of at least two of the following four criteria, one of which must 
be abnormal temperature or leukocyte count: 
Temperature 
 Core temperature > 38.5°C or <36°C  
Tachycardia  
 Mean heart rate >2 standard deviations (SD) for age (excluding pain, 
fever, or as a result of drug therapy)  
 Or protracted increase in heart rate over a ½ – 4 hour time period  
Bradycardia 
 Infant < 1 year of age - mean heart rate < 10th percentile for age 
(excluding side effects of drug therapy or where there is congenital heart 
disease)  
 Or protracted decrease in heart rate over a ½ hour time period 
Respiratory rate 
 Mean respiratory rate >2 SD above usual for age or mechanical 
ventilation (excluding those with underlying predisposition e.g. 
neuromuscular disease or following general anaesthesia) 
Immune response 
 Leukocyte count increased or decreased for age (excluding those with 
chemotherapy-induced leukopenia) 
 Or >10% immature neutrophils associated with a high probability of 
infection (e.g. evidence of white blood cells in a normally sterile body 
fluid, chest radiograph consistent with pneumonia, petechial or purpuric 
rash) 
Sepsis  SIRS with evidence of an infection as defined below 
Severe 
sepsis 
 
 Sepsis with concomitant cardiovascular dysfunction or acute respiratory 
distress syndrome (ARDS) 
 Or two or more other organ dysfunctions  
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Septic shock  Sepsis and cardiovascular organ dysfunction 
Infection 
 
 A suspected or proven (e.g. positive culture, tissue stain, polymerase 
chain reaction, infection caused by any pathogen  
 Or a clinical syndrome associated with a high probability of infection 
(evidence of infection includes positive findings on clinical examination, 
imaging, or laboratory tests (e.g. white blood cells in a normally sterile 
body fluid, perforated viscous, chest radiograph results consistent with 
pneumonia, petechial or purpuric rash, or purpura fulminans) 
Adapted, with permission (16) 
 
1.3 Causative pathogens 
Escherichia coli, Staphylococcus aureus and Neisseria meningitidis are the most common 
pathogens implicated in paediatric sepsis as outlined in Table 1.2 (5, 17-19). Severe sepsis is 
associated with multi-organ dysfunction syndrome (MODS) and the degree to which this 
occurs is dependent on factors such as age (3), gender (20, 21), ethnicity (22), immune-
competence (3), genetic predisposition (23, 24) in addition to any existent co-morbidities (3, 
25) as well as the specific pathogen involved (2, 26).  
 
N. meningitidis is a gram negative pathogen which causes meningococcal disease via 
bloodstream invasion. There are numerous groups, of which Group B and Group C are the 
most common in the UK. N. meningitidis usually presents in previously healthy children as 
meningococcal meningitis or bacteraemia which has a low mortality rate (<5%) (27). 
However, in some children it presents as overwhelming meningococcal septic shock and an 
associated risk of high morbidity and mortality (27, 28), which ranges from 9 – 35% in those 
admitted to a PICU, with significant neurological sequelae in up to 29% of patients (27). 
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Table 1.2: Principle pathogens in paediatric sepsis (5, 17-19) 
 Estimated prevalence  
Gram negative bacteria 23 – 47% 
E. coli 
Pseudomonas aeuroginosa 
N. meningitidis 
Klebsiella pneumoniae 
Other Enterobacter spp 
Acinetobacter spp 
Salmonella spp 
4.5 - 13.0% 
2 - 3.2% 
3 - 6% 
2 - 5.8% 
3 - 5.0% 
1 – 2% 
1 – 3% 
Gram positive bacteria 27 - 39% 
Coagulase – negative staphylococcus  
Staphylococcus aureus 
Staphylococcus pneumoniae 
Streptococcus spp 
Enterococcus spp 
Mirococcus spp 
Other gram positive bacteria 
27 -30% 
8 – 12% 
9 – 12% 
1 - 4% 
4 – 13% 
1 – 3% 
1 – 5% 
Fungus  
Candida albicans 9.3% 
Parasites 1 – 3% 
Viruses 
Others 
 
10 - 13% 
 
1.4 Pathophysiology of sepsis 
The pathogenesis of sepsis in adults differs from that in children in a number of ways. Adults 
usually present with vasodilatation (warm shock), low systemic vascular resistance (SVR), 
hypotension, average or elevated cardiac output, tachycardia and increased oxygen 
consumption (29). Neonates and children often present with fluid refractory shock (from 
decreased circulating intravascular volume, secondary to losses from diarrhoea, vomiting or 
capillary leak) also known as “cold shock” requiring vasodilators and aggressive fluid 
resuscitation (2, 29). Common to both adults and children is myocardial depression, 
depressed ejection fraction and ventricular dilation. Both adults and children usually require 
inotropes to act as either vasoconstrictors (in adults) and vasodilators (in children) (29), 
improving cardiac output and/or blood pressure maintenance (30).   
 
31 
 
In order to understand the physiological consequence of sepsis and septic shock, it is 
necessary to consider the interaction between colonisation and translocation of microbial 
organisms and the subsequent host response (31).  
 
1.5 Infectious process 
Young infants and those with underlying medical conditions (e.g. neurodevelopmental delay, 
chronic lung disease and primary immunodeficiency) are at particular risk of bacterial blood 
stream infections due to immature mucosal barriers and immune system (including 
macrophages, neutrophils, immunoglobulin (Ig) and complement) (18).  
 
Many blood stream infections in children are caused by colonising, pathogenic bacteria, 
which are present on the skin or mucosal surfaces such as the nasopharynx. Blood stream 
infections can arise when there is disruption to the mucosal-epithelia barrier allowing 
bacterial adherence to occur.  Colonisation is a highly complex and competitive process 
involving numerous bacterial ligands. Commensal organisms such as N. meningitidis also 
need to compete with endogenous flora and associated lymphoid tissue within the mucosal 
immune system in order to successfully persist.  N. meningitidis manages to do this by 
producing IgA proteases capable of breaking down IgA within the lymphoid tissue. N. 
meningitidis have evolved mechanisms to evade detection by complement mediated killing 
or opsonophagocytosis (18).  
 
The nasopharynx and gastrointestinal tracts are common sites of bacterial carriage into the 
blood stream and once the mucosal barrier is breached, bacterial translocation can occur 
(18). As such there are a number of primary defence mechanisms, which aim to prevent 
bacterial colonisation and subsequent translocation including structural barriers e.g. 
epithelial tight junctions and mucociliary ladders, within the respiratory epithelium, which 
move unwanted particles away from usually sterile surroundings of the lower respiratory 
tract. In addition compounds including surfactants and anti-bacterial peptides (cathelicidins 
and defensins) are capable of neutralizing both gram positive and gram negative bacteria 
through pore formation (32).   
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The endothelial mucosal layer acts as an early detection system for pathogen invasion, 
stimulating host defense mechanisms by recruiting leukocytes to the blood stream entry site 
(18). From blood stream infection to the development of sepsis there is an interplay 
between the invading organism and the host response; the systemic inflammatory response 
is the body’s organised response to infection promoting the activation of the complement 
system and innate immune response (33). These mechanism are initiated through the 
recognition of pathogen associated molecular patterns (PAMPs) by receptors sites on the 
cell surface such as toll like receptors (TLR) known as pattern recognition receptors (PRRs) 
(34). PRRs (such as TLR’s) form the first line of cellular defence, recognising and transducing 
signals via ligand receptors, on the host cell surface, when they come into contact with 
PAMPs (17, 32, 35). There are three main PRR families which comprise (1) TLR’s, (2) 
nucleotide-oligomerisation domain leucine rich repeat proteins (NOD-LRR) and (3) 
cytoplasmic caspase activation and recruiting domain helicases including retinoic acid 
inducible gene 1 (RIG-1) – like helicases (RLH’s) (35).  
 
Pathogens and the subsequent host response results in tissue and cell damage, stimulating 
the release of intracellular proteins, such as heat shock protein 70 (HSP70), known as 
alarmins, which aim to protect tissue or cells from further damage. As alarmins and PAMPs 
elicit similar innate and adaptive immune responses they are broadly known as damage-
associated molecular patterns (DAMPs) acting to promote an inflammatory response to 
infection (34).  
 
1.6 Innate immune response during sepsis 
Inflammation, as co-ordinated by the innate immune system, is a necessary response to 
infection promoting increased blood flow to the injured site (36). In the absence of an 
inflammatory response the host would succumb to overwhelming infection, however, an 
exaggerated host response results in septic shock and increased risk of mortality (32).   
 
During homeostasis, macrophages remove cell debris originating from normal tissue 
function. The function of PRRs and alarmins is to promote a burst of inflammatory mediators 
facilitating leucocyte penetration from within the blood vessels to the site of infection.  
Following infection or injury, macrophages are rapidly activated by a variety of alarmins 
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which signal via PRRs upregulating inflammatory signalling pathways and the secretion of 
cytokines and chemokines (37). The production of pro-inflammatory cytokines serves to 
stimulate the recruitment of macrophages/monocytes and neutrophils to the site of 
inflammation (38). The function of these cells is to phagocytose pathogens, repair tissue 
damage, mediate an adaptive immune response and restore homeostasis (38, 39). 
 
Endotoxin such as lipopolysaccharide (LPS) on the bacterial outer membrane of gram 
negative bacteria (such as N. meningitidis) is recognized by the host’s LPS-binding protein, 
which on monocytes forms a complex with CD14 signalling via TLR2/4 (40) and on 
neutrophils via β2-integrins and ligand receptors CD11b and CD18 (41). In contrast, 
lipoteichoic acid (LPA) from gram positive bacteria is recognized by lectin pathway of 
complement (42).  This process of PAMP-PRR recognition via TLR2/4, initiates a signalling 
cascade via adaptor protein MD-2, down through the intracellular Toll/IL-1 receptor (TIR) 
domains, recruiting myeloid differentiation primary response protein 88 (MyD88), which in 
turn activates IL-1 receptor associated kinase (IRAK). IRAK phosphorylation causes a 
disassociation from MyD88-TLR complex and subsequent binding to tumour necrosis 
associated factor 6 activating members of the kinase family including mitogen activated 
protein kinase family (MAPK) and the nuclear factor kappa beta (NF-κB) signalling pathway 
promoting the release of inflammatory mediators (43).  
 
NF-κB family has five related transcription factors capable of regulating genes associated 
with the inflammatory response (44-46) immunity and apoptosis (47). During homeostasis 
NF-κB is found in an inert state within the cytoplasm, bound to inhibitory κB (IKKs) proteins 
IKKα and IKKβ (33, 48). In response to stress IKKs are rapidly phosphorylated and degraded, 
leading to the disassociation of NF-κB from NEMO (IKKγ) complex leading to the release of 
NF-κB protein subunits, p65 and p50. These protein subunits translocate into the nucleus 
activating NF-κB transcription factors and subsequent downstream inflammatory signalling 
pathways promoting the release of inflammatory mediators such as TNF-α (49).  
 
During the early phase of sepsis, DAMPs are released in large amounts, both from the 
invading organism and the host’s damaged tissue promoting the release of inflammatory 
cytokines (TNF-α, IL-1, IL-6, IL-12, IL-8) in addition to free radicals and enzymes in large 
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amounts. HSP70 acts as a DAMPs and signal through CD14-TLR4 complex (50-52), eliciting 
rapid signal transduction via MYD88 –IKK/NF-κB pathway activating NF-κB and MAPK 
pathways (33, 53, 54) promoting the release pro-inflammatory mediators (TNF-a, IL-1β and 
1L-6)  (55-59).  
 
1.7 Cytokine release 
Cytokines are small peptides, which have a pivotal role in orchestrating the inflammatory 
response to infection. There are more than 200 cytokines including interleukins, interferons, 
colony stimulating factors and chemokines. Cytokine receptors are ubiquitous and are found 
on leucocytes, organs, vascular and epithelial cells. The response elicited is dependent on 
the type of cytokine that binds to cell surface receptors, the location of the cytokine and the 
timing of release. Cytokine production and release is tightly regulated, with members of the 
interleukin family and TNF-α being some of the most well studied (60).  
 
There are more than 27 interleukin cytokines with their principle role to promote cell 
signalling between various leucocytes promoting leucocyte proliferation and infiltration, in 
addition to facilitating systemic responses such as fever, malaise and anorexia. Members of 
the interleukin family have traditionally been considered to be either anti- or pro-
inflammatory although it is increasingly recognised that individual cytokines such as IL-6 can 
have dual functions (60). 
 
There is a characteristic pattern of cytokine release, following the activation MAPKs and NF-
κβ signalling pathways (45, 46). In a human endotoxaemia model using healthy volunteers, 
cytokines in plasma are detected early post endotoxin inoculation. TNF-α was detected in 
the plasma first, 45 – 60 minutes post inoculation, which was quickly followed by 
inflammatory cytokines including IL-6, IL-8 and IL-10. Plasma levels declined at 3 hours as the 
inflammatory response resolved (Figure 1.1) (26).  
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Figure 1.1: A graph showing cytokine release into the circulation over time, following 
endotoxin inoculation in a human endotoxin model (26). 
 
In critical illness the appearance of cytokines in the plasma follows a similar pattern although 
the time course is usually over several days (61, 62), rather than hours, with 50% of patients 
continuing to have elevated IL-6 levels at day 7 despite a resolution in clinical signs of SIRS 
(63).  
 
Early sepsis results in a “cytokine storm” with increased plasma protein levels. Cytokines 
promote the release of endothelial leucocyte adhesion molecule (ICAM-1) and vascular cell 
adhesion molecule (VCAM) encouraging T cell and monocyte adhesion. In response, 
neutrophils release reactive oxygen species (ROS) and a second wave of inflammatory 
mediators such as leukotrienes, prostaglandins, proteases and other cytokines leading to 
endothelial barrier dysfunction increasing the permeability and facilitating further bacterial 
translocation (64). 
 
1.7.1 IL - 6 
IL-6 is a pleiotropic cytokine exerting a multitude of effects. IL-6 has a longer half life than 
TNF-α and IL-1β and as such has been used as a predictor of outcome in a variety of disease 
states such as septic shock (65), trauma (65, 66), severe acute pancreatitis (67) and 
cardiogenic shock (68).  
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During the initial stages of inflammation IL-6 exerts a pro-inflammatory response 
upregulating the production and maturation of neutrophils, natural killer cells, B cells, acute 
phase protein production in addition to stimulating the release of IL-1 and TNF-α. Over time, 
IL-6 also has anti-inflammatory properties attenuating the production of TNF-α and IL -1 
through the upregulation of other anti-inflammatory mediators such as IL-1RA (interleukin-1 
receptor antagonist) and soluble tumour necrosis factor receptor (sTNFR) (60, 69). 
 
1.7.2 TNF-α 
TNF-α is seen early in the course of infection stimulating endothelial adhesion of leucocytes 
and neutrophil production. It also promotes hepatic production of acute phase proteins and 
the upregulation of other pro-inflammatory cytokines e.g. IL-6 and chemokines (60). Skeletal 
muscle mass is also affected by TNF-α with proteolysis and myopathy (69) and over 
production of TNF-α is associated with poor prognosis and diminished survival in septic 
patients (70). TNF-α promotes further cytokine release by signalling through TNFR I and II 
stimulating NF-κB to transcribe additional pro-inflammatory cytokine genes, which down 
regulate the usual pro-apoptotic mechanisms of TNFR and TNF-α  (32).  
 
1.7.3 IL-8 
IL-8 is a member of the CXC chemokine family and is the primary activator of neutrophil 
chemotaxis and has been used as a outcome biomarker for sepsis as it is seen early on in the 
disease process and low levels in children are negatively correlated with 28 day survival (71).
  
1.7.4 IL-10 
IL-10 is an anti-inflammatory and immunosuppressive cytokine produced by macrophages. 
Its principle function is to inhibit pro-inflammatory cytokine production by leucocytes. It 
forms a negative feedback mechanism helping to prevent excessive over production of pro-
inflammatory mediators, influencing in particular TNF surface receptors (60).  
 
The resolution of inflammation is as important as the ability to mount an appropriate stress 
response (72, 73). In order to counter the exaggerated pro-inflammatory response, the 
immune system simultaneously produces a compensatory anti-inflammatory response 
mediated by IL-10, IL-1RA, transforming growth factor β (TFGβ) and cytokine receptors 
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including soluble tumour necrosis factor receptor sTNFR (74). An equally excessive release of 
these anti-inflammatory mediators, especially IL-10 is also associated with poor outcome in 
sepsis, as they counter-regulate leucocyte functions (75).  
 
1.7.5 Cytokine release in N. meningitidis 
High levels of endotoxin released by meningococci are associated with shock, renal failure 
and respiratory distress and a potent inflammatory response (76). TNF-α is one of the first 
cytokines released in meningococcal disease stimulating the release of other cytokines, such 
as IL-1, IL-6 and IL-10 (77, 78). High concentrations of IL-6 described in meningococcal 
disease are associated with disease severity (79, 80) and myocardial dysfunction (81).  IL-6 
levels remain elevated during the acute phase of the disease declining during recovery (82). 
IL-10 is also shown to be released in high amounts, serving to inhibit further production of 
TNF-α and IL-1 (79). However, high levels of IL-10 in this population group are associated 
with increased risk of mortality (83). A pro-inflammatory response at the outset of 
meningococcal disease is replaced by an anti-inflammatory response later in the course of 
the disease (84), with an associated increased risk of immune paresis and risk of secondary 
infectious insult (85), tissue damage, organ dysfunction and death (86).  
 
Non-survivors of septic shock have a different time course of cytokine expression. There is 
the usual pattern of early release and initial resolution, but with a subsequent late (day 6) 
dynamic increase of both IL-6 and IL-10 (61). This pattern is confirmed in other studies, 
showing an association between significantly higher levels of IL-6 and IL-10 both of which 
lead to immune paresis and risk of early mortality (87-89). An increase in 1L-6:1L-10 ratio is 
also associated with a poor outcome and is thought to be related to an uncontrolled 
inflammatory response (90). 
 
There is a significant body of work, which has helped to progress our understanding relative 
to the dynamics of the inflammatory response (61, 88, 89). The effective modulation and 
management of the inflammatory response to infection however, remains elusive, as 
complete abrogation of inflammation and or over stimulation result in death (91).  
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Although cytokines are classically categorised into being either pro or anti-inflammatory it is 
increasingly recognised this definition may be too simplistic. It appears the promotion of an 
ongoing appropriate inflammatory response by a mix of pro- and anti-inflammatory 
mediators is the ideal, rather than previous models of an initial pro-inflammatory response 
which is then countered by an anti-inflammatory response days later (92). HSP70 influences 
the cytokine response and resolution to inflammation and as such may be able to influence 
the type of cytokine released during times of stress (93). 
 
1.7.6 Cytokine pathogenesis 
The release of cytokines has significant metabolic consequences causing anorexia, fever and 
abrogation of growth in children and weight loss in adults. Interrupted growth in children is 
as a result of the loss of metabolically active tissue such as muscle, fat reserves and growth 
factors (micronutrients). There is a complex interaction between cytokines (IL-1 and TNF-α), 
the hypothalamus and autonomic nervous system with increased production of 
glucocorticoids, catecholamines and corticotrophin releasing factor. The release of IL-1, TNF-
α and IL-6 cause a net efflux of glutamine (amongst other amino acids) from skeletal 
muscles, increasing glutamine synthesis and protein catabolism used for immune cells, acute 
phase protein mediators and glucose production (94). Through their release, cytokines 
promote the release of substrate for use by the innate and adaptive immune system, 
particularly amino acids from skeletal muscle breakdown (95). 
 
1.8 HSP70 and the relationship to the immune and inflammatory response  
The heat shock response was discovered in 1962 following the inadvertent overnight heating 
of Drosophila melanogaster (96), which resulted in the formation of a previously 
undescribed “puffing pattern” of the salivary chromosome (96-98). Through this discovery a 
new set of genes were described, which became upregulated with heat shock, 
environmental or cellular stress (96, 97). HSP’s are highly conserved proteins functioning in 
the unstressed state, as intracellular molecular chaperones, maintaining homeostatic 
function, including protein refolding, movement of proteins across membranes and gene 
regulation (99). As a result of cells being exposed to stress (acute and chronic), mechanisms 
have developed to allow for the detection and response to a range of stressors. Stress 
affects protein homeostasis resulting in misfolding and clumping of proteins (both self and 
39 
 
non-self). The HSP response has evolved with the principle task of restoring protein 
homeostasis; repairing damage to proteins and re-establishing normal growth conditions 
(33, 100). HSP’s are involved in numerous biological processes including the cell cycle, cell 
proliferation, differentiation and apoptosis (101, 102).  
 
Numerous HSP’s have been described and subsequently have been classified into 6 main 
families; HSP27, HSP40, HSP60, HSP70, HSP90 and HSP110. The HSP70 family, (one of the 
most well studied), ranges from 66-78 kilodalton (kDa) (101-103). Research into HSP70 has 
evolved into two main pathways: firstly to determine the molecular mechanism for HSP 
response and secondly to characterize the structure and function of HSP70 and how this may 
be of benefit in various disease conditions (104).  
 
HSP70 is constitutively expressed and required at all times for cells to function normally. 
HSP70 is present in various cells including; embryo cells, glial cells, dendritic cells (DC), 
endothelial cells, monocytes, granulocytes, macrophages, B and T lymphocytes, peripheral 
blood mononuclear cells (PMBC) and vascular smooth muscle cells (105). Within the cell, 
HSP70 comprises 1 -5 % of the cell protein content and is found in the cytoplasm, nucleus, 
mitochondria and endoplasmic reticulum (33).  
 
HSP70 also occurs in an inducible form (106). The heat shock response is rapid, occurring 
within minutes of stress recognition (33), resulting in the ubiquitous release of HSP70 (107). 
HSP70 is released in response to environmental stress (e.g. heat shock, heavy metals, 
oxidative stress) and pathological stress (e.g. ischaemic and reperfusion injury and 
inflammatory response) (100). Cytoplasmic HSP70 accumulation is relative to the degree of 
cellular stress (33), conferring cytoprotection, in addition to acting as an extracellular 
chemokine to neighbouring cells. Under these circumstances inducible HSP70 can comprise 
up to 20% of cell protein content (108). HSP70 also acts to increase phagocytosis and uptake 
of foreign antigens and upregulation of co-stimulatory molecules (109).  
 
Table 1.3 lists genes, which encode for human HSP70 protein, and inducible HSP70 
expression is under the control of HSPA1A and HSPA1B, (located in the MHC class III region 
on chromosome 6) (107). The heat shock response is mediated by cis-acting sequences 
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known as heat shock promoter elements (HSE) (33, 110, 111). HSE are positioned in multiple 
copies at various sites upstream of the HSP gene (98, 100).  
 
Table 1.3:  Members of the HSP70 family (112) 
Name Gene Alternative name Entrez 
Gene ID 
heat shock 70kDa 
protein 1A 
HSPA1A HSP70-1, HSP72, HSPA1 3303 
heat shock 70kDa 
protein 1B 
HSPA1B HSP70-2 3304 
heat shock 70kDa 
protein 1-like 
HSPAIL Hum70t 3305 
heat shock 70kDa 
protein 2 
HSPA2 HSP2 70 KD 3306 
heat shock 70kDa 
protein 5 (glucose-
regulated protein, 
78kDa) 
HSPA5 BIP, GRP78, MIF2 3309 
heat shock 70kDa 
protein 6 (HSP70B) 
HSPA6 HSP6 70 KD (HSP70B’) 3310 
heat shock 70kDa 
protein 7 (HSP70B) 
HSPA7*  3311 
heat shock 70kDa 
protein 8 
HSPA8 HSC70, HSC71, HSP71, 
HSP73 
3312 
heat shock 70kDa 
protein 9 (mortalin) 
HSPA9 GRP75, HSPA9B, MOT, 
MOT2, PBP74,  mot-2 
3313 
heat shock 70kDa 
protein 12A 
HSPA12A FLJI3874, KIAA0417 259217 
heat shock protein 
70kDa family, 
member 13 
HSPA13 Stch 6782 
heat shock 70kDa 
protein 14 
HSPA14 HSP70-4, HSP70L1, 
MGC131990 
51182 
*possibly a pseudogene 
 
Although HSE’s are essential for HSP70 transcription, heat shock transcription factors (HSF’s) 
regulate transcriptional activation of gene expression.  HSF’s bind to HSE’s inducing HSP 
gene expression and protein accumulation within the cell (113). Under normal conditions 
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HSP70 protein content of the cell is tightly controlled via a negative feedback mechanism 
involving HSF-1 and HSF-2 (114). Cellular stress results in the ubiquitous release of HSF-1 
(100), whereas HSF-2 is more selectively released (111). During times of stress, HSF-1 and 
HSF-2 can form heterodimers increasing the effectiveness of HSP70 gene transcription 
promoting an accumulation of HSP70 within the cell, promoting homeostasis (113). 
 
Elevated levels of HSP70 remain within the cell for several hours conferring protection from 
subsequent insults (115). However, ongoing HSP70 expression in an unstressed state has 
been found to be detrimental to cells and as a result mechanisms have evolved to ensure 
the timely resolution of the heat shock response (116, 117). These mechanisms include a 
negative regulatory feedback of heat shock factor binding protein 1 (HSBP1) at a 
transcriptional level (33). Once HSP70 levels within the cell exceed that of non-self proteins, 
a negative regulatory feedback mechanism, down regulates HSF-1 phosphorylation inhibiting 
the translocation of unphosphorylated HSF-1 from the cytosol into the nucleus. This action 
prevents HSF-1 binding with HSE in the nucleus, decreasing gene transcription of HSP70 
attenuating the production of HSP70 within the cytosol (118).  HSF trimers dissociate and are 
refolded back into their monomeric inert state (33, 98, 114).  
 
Other self limiting mechanisms include the production of HSP70 messenger ribonucleic acid 
(mRNA), which has a short half life of 1 hour in cells post insult (119, 120), and is decreased 
further in cells where there are high levels of HSP70 (121). This is only observed in cells 
hours after the initial stress, following restoration of homeostasis (121). A mechanism to 
limit the post-transcriptional production of HSP70 is necessary in order to regulate the 
production of protein within the cell from already synthesized HSP70 mRNA. HSP70 protein-
HSP70 mRNA interaction limits HSP70 gene expression as the HSP70 mRNA stability is 
reduced (allowing for selective degradation of the mRNA) and so limiting HSP70 production 
(115). It appears that HSP70 mRNA is only isolated for degradation when HSP70 protein 
levels exceed refolded proteins. HSP70 then acts on itself by either attenuating any further 
transcription or by increasing the degradation process relative to its own mRNA (115).   
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1.8.1 Clinical consequences of upregulated HSP70 release 
The biological significance of HSP70 release into the extracellular circulation is as part of a 
network of molecules arising from stressed or damaged cells which stimulate immune 
activation (122-125), maintenance of cell homeostasis, cellular protection (112), preventing 
apoptosis and death (119, 126-129). HSP70 expression has been shown to occur not only in 
critical illness but also in a wide variety of conditions (Table 1.4). 
 
Table 1.4: Heat shock protein 70 expression in health and acute, chronic and autoimmune 
disease 
 Physiological condition 
Health  exercise (130)  
 healthy adults (131) 
 aging process (132, 133) 
Acute disease  ischaemic reperfusion injury (134, 135)  
 burns (136, 137)  
 trauma (138)  
 lung injury (139)  
 infection (140)  
 septic shock (141, 142)  
 critical illness (143)  
 head injury (144)  
 fever (145-147) 
Chronic disease  cardiac disease (109, 148-150)  
 renal disease (151, 152)  
 atherosclerosis/ inflammation (153, 154) 
 vascular disease (155) 
 hypertension (156) 
 sickle cell disease (157) 
Auto immune disease  Crohn’s disease (106, 158)  
 rheumatoid arthritis (59, 159, 160)  
 multiple sclerosis (161)  
 
Experimental burn model in rats and severe burns in adults have shown that upregulation of 
HSP70 expression (136, 137) protects against organ damage, leading to increased survival 
(127, 162). In humans, HSP70 expression occurs within minutes of the stress/insult with 
detectable levels in the plasma within the first few hours post insult (138, 141, 142, 163), 
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with peaks between day 2 - 6 (164, 165) (although elevated levels are still detected at day 
28) (136, 137). In adults HSP70 levels ≥15 ng/ml is associated with increased survival 
following severe trauma (138).  
 
Conversely, high levels of HSP70 is associated with an increased risk of mortality in traumatic 
brain injury in adults (144), severe sepsis in both adults (166)  and children (141).  However, 
these high levels may be more reflective of overwhelming sepsis and pervasive HSP70 
release from dying or necrotic cells rather than a cytotoxic effect of HSP70 (141, 166), 
especially since overall enhanced expression of HSP70 in adults (143, 167) and in 
experimental animal models of sepsis appear to have a protective effect (41, 162, 168). 
Further work is required to determine the specific nature of HSP70 release and the clinical 
relevance, especially in critically ill children. There is paucity of data regarding HSP70 levels 
in critically ill children. Wheeler et al describe high levels of HSP70 on admission in children 
with septic shock (141), however, in this cohort convalescent or controls samples were not 
assessed over time.  
 
1.8.2 Upregulation and release of HSP70 into extracellular milieu 
Dendritic cells that are virally infected, (stressed or necrotic) produce danger signals, 
however healthy or apoptotic cells do not act in the same way (169, 170). During apoptosis, 
the cell contents are encapsulated into pro-apoptotic bodies, which are then scavenged by 
phagocytes. As a result, the cellular content is not released into the external milieu. 
Conversely, the intracellular contents of necrotic cells are expelled into the extracellular 
milieu, significantly increasing circulating levels of proteins such as HSP70 (171, 172). This 
release of HSP70 contributes to the circulating HSP70 levels during critical illness (141), 
trauma (138) and following coronary artery bypass graft (173-175), where it can 
subsequently activate the immune system (55, 176).  
 
It was thought that HSP70 release only occurred via this passive mechanism from necrotic 
cells (108, 170) especially as HSP70 does not have a consensual secretory signal allowing it to 
reach the extracellular environment (125). However, more recent work has shown that 
HSP70 is present in plasma of normal healthy individuals (177), psychologically stressed 
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animals (178) as well as in the absence of cell death (125) suggesting there is an active 
mechanism for release.  
 
Subsequent work showed that inducible HSP70 is secreted from the cytosol of intact cells via 
exosomes or by an endo-lysosomal-dependent pathway (179). Glial cells (180), B cells (181), 
natural killer cells (182) and peripheral blood mononuclear cells (PBMC’s) (105) all have 
these exosomes (179, 182) or an endo-lysosomal-dependent pathway (183). HSP70 is 
inserted into the plasma membrane before being released into the extracellular milieu via 
membrane associated structures from intact stressed cells either by inverse evagination, 
exocytosis or membrane shedding (125). As prolonged intracellular exposure to HSP70 is 
cytotoxic, some of the mechanisms relating to extracellular release may be a protective 
mechanism to limit internal exposure (117, 184).  HSP70 can become cell membrane bound 
during active release and in this form HSP70 is capable of activating macrophages through 
antigen presenting cells (APC), acting as both a chaperone and a DAMP (185-187).  
 
1.8.3 The effect of HSP70 on the inflammatory and immune response  
The inflammatory response has been described as “a process that begins following a 
sublethal injury and ends with complete healing” (188) and is involved in both defence and 
maintenance (189). HSP70 performs a range of immunoregulatory and inflammatory 
functions and is capable of promoting either a pro- or anti-inflammatory response 
dependent on its location (within and external to the cell)the receptor sites it binds to e.g. 
TLR 2/4 (185) and the type of T cells stimulated, which ultimately influences the mix of 
cytokines released (108).  
 
Under normal circumstances HSP70 is detectable in plasma of healthy individuals (who have 
no evidence of inflammation), suggesting that during times of homeostasis HSP70 does not 
promote an inflammatory response and its immunoregulatory/inflammatory functions are 
tightly controlled (108). During times of stress HSP70 is able to interact with APC’s 
performing two distinct functions, the first of which is to present HSP:protein complexes, 
which are taken up by APC for processing via MHC Class II receptors activating adaptive 
immunity. The second function relates to HSP70 being able to stimulate the innate immune 
response and the secretion of cytokines and chemokines from APC cells, such as TNF-α, IL-
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10, IL-6, IL-1β (amongst others) by macrophages and dendritic cells (189, 190) (Figure 1.2). 
As the stress response resolves, HSP70 acts to dampen down the inflammatory and 
immunoregulatory response, restoring homeostasis (190, 191). 
 
Endotoxin has been used extensively to understand the pathophysiological response to 
sepsis/stress (192). To understand the effect of HSP70 on cytokine release, endotoxin has 
been used as a stimulant in both in vivo and in vitro models (41, 193-197) and is known to be 
able to activate and deactivate NF-κB (48, 194) and MAPK signalling pathways (198, 199), 
mediating a pro- or anti-inflammatory response to stress (108).  
 
When healthy adult volunteers are administered a dose of endotoxin intravenously, HSP70 is 
released along with pro-inflammatory cytokines TNF-α and IL-6 (197). However, other work 
in vitro (using cDNA transfected HSP70 macrophages) has shown that overexpression of 
HSP70 can inhibit the release of inflammatory mediators (IL-10, IL-1β, TNF-α, IL-12) following 
endotoxin stimulation. It is hypothesised that HSP70 may play an important role in 
mediating the release of pro-inflammatory cytokine following exposure to endotoxin (93) 
and perhaps plays a crucial role in directly and indirectly preventing an over exuberant 
inflammatory response (93, 189).  
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Figure 1.2: Effect of HSP70 on inflammatory and immune response.  HSP70 signals via 
ligands such as TLR 2 and 4, which upregulates NF-κB signalling pathway via MYD88 and 
stimulates IKK disassociation. This leads to the release of inflammatory cytokines, 
chemokines, nitric oxide production, which concomitantly upregulates the expression of 
major histocompatibility complexes (MHC) receptor and other co-stimulatory molecules. 
With respect to the adaptive immune response HSP70 chaperoned peptide complexes are 
presented and processed via MHC class II via endocytosis. TNF-α, tumour necrosis factor 
alpha; IL, interleukin; NF-κB, nuclear factor kappa B (190). (Reproduced with permission) 
 
HSP70 therefore appears to play an important role in the modulation of both immune and 
inflammatory response in sepsis. However, laboratory mechanisms for stimulating HSP70 
release such as heat shock (96), sodium arsenite (200) and adenoviral transfection (201, 202) 
are not appropriate for use within a clinical setting, due to the negative consequences these 
agents have on the host. Glutamine, however, can be used as a vehicle to increase the 
expression of HSP70 (203-205). In adults, glutamine administration significantly increased 
HSP70 levels, which was associated with a decreased length of ICU stay and fewer ventilator 
days (143). As glutamine is safe, non-toxic and easy to administer, it could represent a 
potentially attractive modulator of the heat shock response (206-210). 
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1.9 Glutamine and the upregulation of heat shock response in sepsis 
Nutrition support, especially in children who have limited metabolic reserves, has 
traditionally been seen as a means to prevent malnutrition by providing substrate e.g. 
protein, fat and carbohydrate (211-213). Recent advances in the field of nutrition research 
have resulted in the realisation that specific nutrients such as glutamine, may be of benefit 
to critically ill patients (214) with immune modulating effects, altering the host response to 
stress (215). However, much of the work considering the use of glutamine in critical illness 
has been completed in adults (206-210), with little data available from paediatric critical 
illness (214).  
 
Glutamine is the most abundant extracellular amino acid in the plasma with a concentration 
of between 0.6 - 0.7mmol/l (216, 217). Conversely, glutamate is usually the most abundant 
intracellular amino acid with a concentration of 2 – 20mmol/l depending on the cell type 
(218). Glutamate facilitates de novo amino acid transamination, donating an amino group or 
ammonia. In some organs e.g. liver and cells e.g. astrocytes glutamate and ammonia are 
combined by glutamine synthetase to form glutamine, which is then exported from the cell.  
Organs and skeletal muscle are the main source of endogenous glutamine with high 
intracellular concentrations of 20 – 25mmol/L glutamine (216, 219, 220). Blood glutamine 
levels reflect the balance between synthesis, release and consumption by all types of cells 
(217).  Glutamine serves as a metabolic intermediate and precursor, providing carbon and 
nitrogen for the de novo synthesis of other amino acids, nucleic acids, fatty acids, 
nucleotides and proteins (221).  During times of stress, skeletal muscle is an active net 
exporter of free glutamine (222). Glutamine’s functions within the cell can be broadly 
categorized into four main categories:  1) nitrogen transport, 2) maintenance of the cellular 
redox state through glutathione, 3) a metabolic intermediate, 4) a source of energy (221). 
Figure 1.3 provides an overview of the metabolism of intracellular glutamine. 
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Figure 1.3: An overview of the intracellular metabolism of glutamine. Glutamine is a 
precursor for a number of molecules within the cell. Glutamine is deaminated by 
glutaminase to form glutamate, which can then be converted into γ-amino butyric acid 
(GABA), ornithine, 2-oxoglutarate, glucose or glutathione. The organ specific metabolism of 
glutamate and by-products are also indicated (218).  (Reproduced with permission) 
 
Glutamine exerts an effect on immune cells and has been shown to stimulate lymphocyte 
proliferation and optimises macrophage and lymphocyte production of cytokines in animal 
models (223) and lymphocyte numbers in acute pancreatitis in adults (224). In vitro, 
glutamine has also been shown to upregulate the bactericidal killing activity of neutrophils 
from post operative and thermally injured patients (225). 
 
Glutamine homeostasis is tightly controlled. Synthesis occurs in the cytosol and is controlled 
by glutamine synthetase (GS) and is metabolised by mitochondrial glutaminase (GA) (226, 
227). GS transcription is upregulated by glucocorticoid release (228) and in response to 
plasma glutamine levels (229). Glutamine functions as an inter-organ nitrogen transporter, 
taking excess nitrogen from peripheral tissues and the brain, to the liver and kidney for 
assimilation into ammonia. The residual carbohydrate backbone is then used in 
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gluconeogenesis. As such glutamine is a readily available source of fuel, which is utilized by 
the intestine and immune cells (in particular macrophages) (230, 231).  
 
Glutamine has an important role in ammoniagenesis and gluconeogenesis in the kidney. 
Glutamine is used as a nitrogen transporter from organs such as the brain and plays a vital 
role in ammonia detoxification in the kidney (218). Glutamine is deaminated in the kidney by 
glutaminase to glutamate, which then undergoes oxidative deamination (232, 233). 
Gluconeogenesis in the liver only becomes established in infants at around 6 months of age 
and before then is mainly restricted to renal gluconeogenesis. In infants, skeletal muscle 
represents 60 – 80% of the total body protein synthesis and in order to achieve protein 
deposition in light of ongoing protein degradation and turnover, amino acid and nitrogen 
losses need to be conserved. This is achieved through decreased nitrogen excretion and 
increased re-use of amino acids derived from ammonia than compared to adults (234). 
 
Within the gluconeogenic pathway, glutamine exerts some control on the expression and 
activity of phosphoenolpyruvate carboxykinase (PEPCK) a key regulatory enzyme in the 
gluconeogenic pathway, PEPCK is also influenced by hormone levels in addition to other 
dietary factors (235). In vitro work with hepatocytes has shown that glutamine (5mM) 
facilitates cell swelling, which decreases PEPCK mRNA accumulation thereby downregulating 
gluconeogenesis. Cell shrinkage favours gluconeogenesis and proteolysis and is associated 
with increased activity of PEPCK mRNA and glucose-6-phosphate promoting the production 
of glucose from glutamine (236). Glucose production from the gluconeogenic pathway 
provides up to 25% of circulating plasma glucose (218). 
 
Glutamine is used as a fuel source, by rapidly dividing cells, and involves the conversion to 
glutamate, which is then hydrolysed by glutaminase to form 2-oxoglutarate and glutamate 
dehydrogenase. These products enter the citric acid cycle where 2-oxoglutarate is converted 
to malate via succinate and fumarate. An NADP+ dependent malic enzyme creates pyruvate 
and, following an amination process involving alanine-aminotransferase, produces L-alanine. 
Pyruvate is converted to lactate via lactate dehydrogenase, which is either released in the 
circulation or taken into the citric acid cycle via pyruvate dehydrogenase so completing the 
oxidation of glutamine carbon (235).  
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The fuel derived from glutamine arises from the reduced forms of nicotinamide adenine 
dinucleotide (NADH) and flavin adenine dinucleotide (FADH2) produced, which are 
subsequently used in the electron transport chain, in the mitochondria, donating electrons 
for adenosine tri-phosphate (ATP) synthesis (235). Following its production, L-alanine is 
exported from the epithelial cell via the portal vein to the liver (218). 
  
In a healthy state, there is a large circulating pool of free glutamine, mainly arising from 
skeletal muscle (226) and under these conditions it is considered to be a non-essential amino 
acid (237). However, glutamine is released into the system to provide fuel for the 
accelerated metabolic functions such as RNA synthesis and perhaps as a cell primer against 
further injury, making it a conditionally essential amino acid during periods of severe stress 
(237-239).   
 
Muscle glutamine depletion occurs within hours of severe illness by up to 72% (240). 
Griffiths et al have shown that in adults there is a precipitous drop in plasma glutamine 
levels by up to 58% with the onset of catabolism, which can last for up to 21 days, increasing 
mortality (209). Up to 14g of free glutamine is reported as being depleted from skeletal 
muscle, in uncomplicated critically ill adults (241). Furthermore, during the first few days of 
acute illness, nutrition support is often sub-optimal and up to 40% of children are 
malnourished on admission to PICU (242). Plasma glutamine levels of ≤ 0.43mmol are 
associated with increased mortality (243) and non-surviving adult septic patients lost up to 
90% of their skeletal muscle glutamine mass (244). The extent of glutamine depletion has 
been correlated with mortality (241), although this is not widely accepted (245). Glutamine 
homeostasis has been shown to not return to normal for up to 30 days post injury (209). 
Intravenous glutamine supplementation has been shown to restore plasma glutamine levels. 
Cells throughout the body utilize exogenous glutamine, although glutamine supplementation 
is not able to replete skeletal muscle stores due to an unfavourable concentration gradient 
preventing uptake (246) e.g. muscle cell glutamine content is up 25mmol/l, which is 
considerably higher than the 0.7mmol/l of plasma (219, 220). 
 
During times of stress there is a net export of glutamine from muscle stores, which become 
rapidly depleted (234).  Protein flux and turnover in rapidly growing children is considerably 
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higher than in adults and as such the need for amino acids such as glutamine is considerably 
more, suggesting a preferential use by rapidly dividing cells such as enterocytes and immune 
cells (247). Protein kinetic studies using leucine isotopes have shown glutamine 
supplementation attenuates protein breakdown. However, glutamine supplementation is 
not able to increase the rate of protein synthesis, but does exert a protein sparing effect, in 
very low birth weight infants (248) and in surgical neonates (249). Increased amino acid 
delivery in stressed, very-low-birth-weight infants, resulted in an increase in de novo 
glutamine synthesis (250-252).  
 
1.9.1 Glutamine requirements in infancy 
Glutamic acid and taurine are the most abundant amino acids in breast milk. Glutamine 
increases 20 fold as lactation becomes established and in an infant, at 3 months of age 
represents more than 50% of the free amino acids in breast milk providing protection to the 
gut mucosa and precursors for neurotransmitters. The abundance of glutamine and glutamic 
acid provide a protein sparing effect for essential amino acids and promote net protein 
synthesis (253). Infant formulas contain very little glutamine compared to breast milk (254), 
which is likely to become significant during critical illness with volume restriction and 
decreased enteral intake. Neonatal animal models show glutamine deficiency is linked to 
intestinal atrophy (255, 256), decrease electrolyte absorption (257) and immune function 
(258).  
 
1.9.2 Glutamine and anabolism 
Glutamine is associated with anabolism with some research suggesting that glutamine 
supplementation partially attenuates muscle loss and promotes muscle synthesis in steroid 
induced muscle wasting (259). These findings have not been replicated in critically ill adults 
given enteral glutamine although the dose of glutamine may have been suboptimal at 
~0.3g/kg (260). 
A link exists between cell volume, glutamine levels and protein metabolism. Glutamine 
promotes anabolism via a sodium/potassium transport mechanism promoting an 
intra/extracellular glutamine concentration gradient generating a sodium flux, drawing 
water into the cell stimulating the production of DNA/RNA and proteins within the cell. At a 
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concentration of 0.7 – 2mmo/l, glutamine optimises the cell’s hydration status (261). The 
hydration status of the cell can undergo rapid change mediating effects on hormones, cell 
metabolism and gene expression. Cell shrinking appears to be associated with upregulation 
of p38MAPK and extracellular signal regulated kinase (ERK) signalling pathways whereas cell 
swelling has the opposite anabolic effect promoting catabolism and apoptosis (262, 263). 
Hydration status of the cell can be affected by HSP70 in addition to glutamine, which has 
been shown to have a protective effect against hypertonic challenges in vitro. The effect of 
glutamine and HSP70 appear to be through their influence on Na+/K+ flux across the cell 
membrane by maintaining intracellular ions (264) and preventing cell signalling triggering 
net protein breakdown (265-267), supporting protein synthesis (268, 269). Liver and muscle 
cells have been shown to swell by 10 – 12% within 2 minutes in the presence of glutamine 
and this increase in cell hydration status is maintained as long as the amino acid is present 
(266). It has been postulated that changes to cellular hydration through intracellular 
glutamine depletion is a primary mediator of muscle protein catabolism in critical illness 
(270) and perhaps the augmentation of this through exogenous supplementation could 
attenuate some of the losses seen. 
Although glutamine is shown to be involved in many cellular and metabolic process, it should 
be noted that many of the in vitro cell line work attributing the beneficial effects have been 
completed using supraphysiological doses of glutamine varying between 2 and 10mM, which 
is in excess of plasma concentrations (0.7mmol/l), as such some of the results should be 
interpreted with caution (235).  
 
1.9.3 Enteral vs. parenteral administration of glutamine 
The American Society of Parenteral and Enteral Nutrition (ESPEN)/ European Society of 
Enteral and Parenteral Nutrition (ASPEN)/ Society of Critical Care Medicine (SCCM) 
recommend that 0.3 – 0.5g/kg of glutamine is added to parenteral nutrition for critically ill 
adults, which is based on a number of meta-analysis showing benefit at this level (271-273). 
This dose has been shown to restore glutamine levels in critical illness (274, 275).  
 
Healthy adults usually produce 50 – 80g per day (276) and during critical illness 20 – 30g of 
exogenous glutamine is required to maintain plasma levels (274, 275). Glutamine synthesis 
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primarily occurs within the skeletal muscle. It is a primary fuel for gut enterocytes and 
immune cells and is exported from the muscle for use within the splanchnic circulation. 
During critical illness, de novo glutamine synthesis is not altered but skeletal muscle is 
quickly depleted (especially in children), diminishing supply resulting in hypoglutaminaemia 
(277, 278). The benefit of intravenous compared to enteral administration is that glutamine 
is available for systemic circulation benefitting immune cells in addition to those within the 
gut. Glutamine given intravenously (IV) mimics endogenously produced glutamine as shown 
by its even uptake across the splanchnic area (274). On the other hand, enteral glutamine is 
rapidly metabolised within the upper part of the small bowel (jejunum) leaving little 
available for the remainder of the bowel (276, 279). Portal circulation studies also show that 
little glutamine makes it across the “first pass elimination” to the liver and for subsequent 
systemic circulation (280). Enteral administration of glutamine is not as effective at restoring 
plasma glutamine levels to within normal range when compared to parenteral glutamine 
(281, 282).  
 
In adults, IV glutamine given as ≥ 0.3g/kg (283, 284) as part of parenteral nutrition (PN) 
following surgery is associated with decreased infectious morbidity (206, 283, 284), mortality 
(209, 285, 286), improved organ function and decreased length of hospital stay (238, 287, 
288). The potential mechanisms for glutamine during critical illness include; tissue 
protection, immune / inflammatory modulation, maintenance of glutathione levels and 
metabolic functions as outlined in Table 1.5 (238, 287).  
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Table 1.5: Organ specific function of glutamine therapy in critical illness (238, 287)  
Lung  Major source of energy for endothelial cell 
 May protect epithelial cells against endotoxin/ oxidant 
related injury 
 Enhanced HSP expression post stress 
 Preserves cell metabolism (ATP) following endotoxin injury 
 Reduces lactate and glucose accumulation in the lung 
Heart  Major source of energy via conversion to glutamate for 
cardiomyocytes 
 Protects cardiomyocyte against ischemia related injury 
 Enhances HSP expression post stress 
Liver  Supports hepatocyte glutathione biosynthesis 
 Regulator of ammonia metabolism 
Gastrointestinal 
tract 
 Major source of energy for enterocytes 
 Support nucleotide biosynthesis 
 May protect epithelial cells against endotoxin/ oxidant 
related injury 
 Enhanced heat shock protein expression post stress 
Immune cell 
function 
 Major source of energy for proliferating cells 
 Supports neutrophil killing and macrophage function 
 Enhances HSP expression post stress 
 Vital for appropriate cytokine secretion 
 Attenuates pathological pro inflammatory cytokine release 
following endotoxaemia 
Kidney  Acid base regulation 
 Ammonia metabolism 
  
1.9.4 Use of glutamine in children 
In children, the use of glutamine remains largely undefined with paucity of data regarding 
the benefits of glutamine as a pharmacological agent in paediatric critical illness (214). 
Conflicting results with respect to the benefits of glutamine supplementation was found in 
pre-term infants (289-294), infants with gastrointestinal disease and surgery (295, 296), 
burns (206, 277) and malnutrition (297-299). Reasons for the lack of consistent results, 
following glutamine supplementation in children may be as a result of the different 
individual study designs, heterogeneity of the populations studied, route of enteral 
administration chosen e.g. enteral or IV, dosage g/kg given and duration of glutamine 
supplementation (300, 301). 
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However, beneficial effects of glutamine have been reported in children which include, 
decreased duration of acute diarrhoea (302), reduced severity of mucositis post bone 
marrow transplant (241), decreased muscle catabolism in Duchene muscular dystrophy (303) 
and improved growth in sickle cell anaemia (304).   
 
The use of glutamine in pre-term infants has received considerable attention, with some 
results showing benefit with respect to infectious complications and time to full enteral 
feeds (291, 305), with other studies showing no difference (294, 306). However there are 
inherent difficulties with trying to interpret the data from these studies as outlined below. 
 Heterogeneous groups e.g. sick versus relatively well versus surgical neonates (300, 
301) 
 L-glutamine – most of the studies used L-glutamine, which rapidly degrades to the 
unusable pyroglutamate (301). Adult studies have used the stable alanyl-dipeptide of 
glutamine with much better effects relative to morbidity and mortality at 6 months 
(307).  
 Isonitrogenous – many of the pre-term studies compared the use of total parental 
nutrition enriched with glutamine to isonitrogenous control, the issue with this is 
that it potentially leads to suboptimal delivery of other essential amino acids, 
especially tyrosine and phenyl alanine (301, 308). 
 Time taken to get to goal rate – due to the delivery method some of the studies took 
up to ten days to reach the goal rate of delivery e.g. 0.3g/kg (301). 
 
A Cochrane review concluded that glutamine supplementation confers no benefits to pre-
term infants and as such glutamine should not be an active research stream (289). However, 
other groups argue the mode, timing, duration and type of analogue used in the randomised 
controlled trials included in the Cochrane review influenced the outcome measures. 
Furthermore, the beneficial effects of glutamine supplementation especially in pre-term 
population may only be seen beyond the neonatal period (300), as is evident from studies at 
1 year and 6 years of age respectively that showed lower incidence of atopic dermatitis and 
gastrointestinal infections post neonatal supplementation of glutamine (305, 309). 
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1.9.5 Mechanisms for glutamine supplementation on HSP expression   
The beneficial effects of glutamine in critical illness are postulated to be due to increased 
production of HSP70. In vitro glutamine supplementation upregulates HSP70 release in lung 
macrophages and epithelial cells (310) protecting against sepsis related injury (310, 311). 
The beneficial effect of glutamine appears to be HSP70 dependent, since when a knockout 
septic mouse model was used HSP70 (-/-) no benefit  was derived from glutamine 
supplementation (215). In experimentally induced ARDS, glutamine supplementation 
improved ATP levels reversing lactate accumulation, by restoring HSP70 levels (143, 239, 
312). HSP70 deficiency led to a decline in lung tissue metabolism, lung injury and organ 
failure in a rat model of sepsis (215).  
 
Eliasen et al. has shown that glutamine depletion affects HSP70 production downstream of 
transcriptional and translational sites, affecting mRNA HSP70 stability, which in glutamine 
depleted cells had a significantly reduced half life, resulting in decreased HSP70 expression 
(313).  
 
Glutamine has also been shown to exert an effect on HSP70 production relative to the 
upstream influence of glutamine on HSF-1 and HSE (314). Hamiel et al (315) hypothesise that 
glutamine effects on HSP70 upregulation is dependent on the hexosamine biosynthetic 
molecular pathway (HBP) (Figure 1.4). Glutamine is metabolised via the HBP, which appears 
to be part of an early cellular protective response to stress and is a key substrate required 
for optimal activity of the HBP. It appears that glutamine enhances HBP activity leading to  
O-linked glycosolation, nuclear transcription and transcriptional activation of HSF-1 and SP1 
in the nucleus. HSF-1 and SP1 induces gene promoter activity leading to an increase of 
HSP70 protein levels within the cell. It is thought that glutamine deficiency leads to a loss of 
HBP activity and HBP mediated HSP expression (315, 316).  
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Figure 1.4: Proposed mechanism by Hamiel et al. (315) for glutamine mediated 
upregulation of heat shock protein 70 (HSP70). Glutamine (GLN) has been shown to be 
metabolised via the hexosamine biosynthetic pathway (HBP) to UDP-N-acetylglucosamine 
(GlcNac). This pathway appears to be part of an early cellular protective response to stress. 
Principle enzymes within the HBP are; glutamine, fructose-6-amidotransferase (GFAT), 
polypeptide-O-β-acetylglucosamineamyltransferase (OGT) and O-N-acetylglucosaminidase 
(O-GlcNAcase). It is thought that glutamine deficiency could lead to a loss of HBP activity and 
HBP mediated HSP expression (Reproduced with permission). 
 
1.10 Novel therapeutic strategies in sepsis 
Septic patients in the ICU are resource demanding, requiring intensive multi-organ system 
support (32). Artificial nutrition, especially in children, is required to provide sufficient 
substrate with the aim of preventing endogenous catabolism of protein and preventing 
malnutrition (214) . Following discharge from the ICU survivors of sepsis often require long-
term follow-up and rehabilitation (317). 
 
The medical management of sepsis and septic shock uses targeted anti-microbials (318), 
prevention of enteric bacterial translocation and secondary bacterial infections (319). Other 
therapies such as the use of monoclonal antibodies (320), activated protein C (321), anti-
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TNF-α therapies (322), arginine (323, 324) have all had limited, or sometimes harmful effects 
(32) (Table 1.6). 
 
Table 1.6: Clinical trials of therapeutic agents used to mediate sepsis (325) 
Harm 
 Soluble tumour necrosis factor (TNF) receptor p75  
 Inhibition of nitric oxide with L-N-monomethyl arginine (L-NMMA) 
Benefit 
 Neutralisation of endotoxin with polyvalent anti-plasma or monoclonal antibody HA-
1A 
 Neutralisation of endotoxin with recombinant bactericidal permeability increasing 
           protein (reduced morbidity) 
 Neutralisation of TNF by monoclonal antibody 
 Acceleration of removal of platelet-activating factor (PAF) with recombinant PAF 
acetylhydrolase 
 Administration of recombinant human activated protein C4 (clinical use) 
 Administration of pharmacological doses of corticosteroids (clinical use) 
Indeterminate or no effect – due to heterogeneity or underpowered study design 
 Neutralisation of endotoxin by monoclonal antibody, antibody to enterobacterial 
common antigen, or polymyxin B 
 Inhibition of TNF by monoclonal antibody or soluble receptor p55 
 Inhibition of interleukin-1 (IL-1) with recombinant IL-1 receptor antagonist 
 Inhibition of PAF with a receptor antagonist 
 Inhibition of nitric oxide with L-NMMA or methylene blue 
 Inhibition of bradykinin 
 Inhibition of prostaglandins with ibuprofen 
 Nonspecific suppression of inflammation with high dose corticosteroids or 
pentoxifylline 
 Administration of granulocyte colony-stimulating factor (G-CSF) or interferon-γ 
 Inhibition of coagulation with anti-thrombin III or tissue factor pathway inhibitor 
 
The focus of recent research has been to understand the relationship between pro- and anti- 
inflammatory mediators (326) and whether multi-organ failure and mortality is as a result of 
a dysregulation between this balance (327). It has been postulated that mortality arising 
from sepsis is secondary to a prolonged immunosuppressive state (29, 40, 328) which is 
more common in children than adults (329) and may be as a result of reduced bacterial 
clearance and hypo-responsive immune system (330). However, trials using therapeutics 
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such as non steroidal anti-inflammatory agents and corticosteroids (331-333) aimed at 
controlling the systemic inflammatory response have not yielded promising results thus far 
(40, 334, 335). 
 
Part of the issue with therapeutic and nutrition trials in sepsis, is the “one size fits all” 
approach. Critically ill children represent a heterogeneous cohort, however many of the 
medical and nutrition management strategies are homogenous. As a result many 
interventional studies have failed to deliver significant positive outcomes despite exciting 
pre-clinical findings as seen with the anti-TNF-α and activated protein C (drotrecogin) and 
CRISIS trials (glutamine, zinc, whey protein, metoclopramide, selenium) (325, 336).  As a 
result, many groups are endeavouring to develop clinically relevant biomarkers to stratify 
treatment (337). The mediation of the heat shock response may fit into this stratification 
plan given recent advances in the understanding of biological mechanisms and influences of 
alarmins within the inflammatory, coagulation, immune and neuroendocrine response to 
sepsis. New management strategies are being developed with the aim of upregulating 
alarmins, such as HSP70, in the hope that benefit to the host will be conferred (32, 239) and 
with increasing understanding being derived from transcriptomic analysis, a more targeted 
approach to treatment may be able to be developed (338, 339).  
 
During the last 50 years there has been a significant body of research into the role of heat 
shock response and its role in mediating a response to danger. The heat shock response (by 
heat shock proteins), confers cytoprotection by refolding damaged proteins, upregulating 
cellular defence mechanisms (119, 127, 340) in addition to alerting surrounding cells to 
danger through extracellular signalling (341). HSP have also been shown to reduce gut 
endothelial permeability and prevent post infectious metabolic dysfunction (342) and it is 
thought that through the mediation of this response using nutraceuticals such as glutamine 
better long term outcomes will be achieved. 
 
1.11 Conclusion   
HSP70 is part of a family of highly conserved proteins that are involved in the most 
fundamental aspects of cellular protection and homeostasis (239). The heat shock response 
has been shown to be beneficial following various types of injury such as ischaemia and 
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reperfusion injury (343), acute lung injury (344) and septic shock/ sepsis (128). The release of 
HSP70 has also been shown to activate and attenuate the inflammatory response, which has 
been associated with survival post sepsis (126).  In addition to this, elevated levels of HSP70 
post trauma are associated within improved outcome (138). Previously there had been no 
practical way of upregulating the expression of HSP70 as methods used in vitro and in animal 
models were of detriment to humans e.g. sodium arsenite, glutamate, heat shock etc (239). 
 
Glutamine has been used in critically adults to upregulate HSP70 release with some evidence 
to suggest survival benefits (143). Glutamine depletion is associated with increased cellular 
stress (313), programmed cell death (apoptosis) (345), pro-inflammatory response (86) and 
immune paresis (346, 347) and some of these effects are thought to be mediated by 
downregulated HSP70 production (314, 348). 
 
Although the development of stratified treatment plans requires investment 
(methodological, validation and application processes) (337), it is possible in the future that 
treatment modalities may include the targeting of endogenous danger signals such as heat 
shock proteins with therapeutic agents such as glutamine to improve outcomes within 
clearly defined groups of patients (1, 207).  
 
Whilst elevated HSP70 levels have been described in critically ill children (141), to our 
knowledge, the effect of glutamine on HSP70 release and the influence on the inflammatory 
response has not been described. Understanding the effects of glutamine supplementation 
on HSP70 release will enable the development of a greater understanding as to whether or 
not severely ill children could benefit from glutamine supplementation early in the course of 
their disease, through regulation of the immune and inflammatory response, and so 
improving outcome. 
 
The focus of the current research was therefore to investigate HSP70 release and its 
relationship to glutamine and inflammatory markers in healthy adults and paediatric 
volunteers using a whole blood endotoxin model. In addition, this study also aimed to 
describe relationships between glutamine, HSP70 and inflammatory mediators, in a cohort 
of critically ill children. 
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1.12 Hypothesis 
During times of stress, glutamine promotes the release of HSP70. 
 
1.13 Research Aims  
1. To set up an in vitro model of sepsis examining the effect of glutamine on the release 
of HSP70 and inflammatory mediators 
 
 To investigate the effect of glutamine on HSP70 release using a whole blood in vitro 
endotoxin stimulation model in healthy adult volunteers, and its association with 
markers of an inflammatory response. 
 
 To investigate the effect of KNK437 (HSP70 inhibitor), on the release of HSP70 and 
inflammatory mediators in response to endotoxin stimulation of whole blood, from 
healthy adult volunteers. 
 
 To investigate the effects of endotoxin and glutamine on HSP70 in healthy children 
using whole blood, and its associations with markers of the inflammatory response. 
 
2. To measure levels of HSP70, glutamine and markers of inflammation in critically ill 
children with acute meningococcal disease compared to convalescence. 
 
 To investigate relationships between HSP70, glutamine and inflammation in critically 
ill children with acute meningococcal disease compared to convalescence. 
 
 To investigate relationships between clinical variables, HSP70, markers of 
inflammation and glutamine in critically ill children with acute meningococcal disease 
compared to convalescence. 
 
3. Use of gene expression analysis of whole blood to examine relationships between 
genes associated with HSP70 and inflammatory signalling in children with 
meningococcal disease 
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 Investigating relationships between HSP70, glutamine and inflammatory mediators 
and significantly differentially expressed gene transcripts in critically ill children with 
acute meningococcal disease compared to convalescence. 
63 
 
 
Chapter 2:  
Materials and Methods 
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Chapter 2: Materials and Methods 
2.1 Ethical consideration 
2.1.1 In vitro experiments 
In vitro aspects of this study, including all methods were approved by the Local Research 
Ethics Committee (reference number 09/H0712/98). Inclusions and exclusion criteria for 
healthy adult and paediatric volunteers were based on signed informed consent. Participants 
were free to withdraw their consent at any point without any prejudice. 
 
2.1.2 Children with meningococcal disease 
Following informed parental consent, and with approval of the Local Research Ethics 
Committee, (reference number EC3263), venous blood was collected from children admitted 
to St. Mary’s Imperial College NHS Trust, PICU with suspected meningococcal disease at the 
time of admission to the intensive care. The diagnosis was confirmed by isolation of the 
organism from blood, CSF, or by PCR amplification of meningococcal DNA from peripheral 
blood (349).  
2.2 In vitro experiments  
Experiments 1 - 3 were designed to consider the effect of endotoxin stimulation on the 
release of HSP70 and inflammatory markers using a whole blood model as outlined in Figure 
2.1a.   
 
Experiment 1 was designed to optimise the use of a whole blood in vitro model examining 
the effects of endotoxin and glutamine on the release of HSP70 and markers of 
inflammation in healthy adult volunteers, using a variety of doses of endotoxin and 
glutamine.  
 
Experiment 2 was designed to investigate the in vitro effects of KNK437, endotoxin and 
glutamine on HSP70 release and markers of inflammatory response, using a whole blood 
model, in healthy adult volunteers.  
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Experiment 3 was designed to investigate the in vitro effects of endotoxin and glutamine on 
HSP70 release, using a whole blood model, in healthy paediatric volunteers and its 
association with markers of inflammatory response. 
 
 
Figure 2.1a: A schematic outline of the experimental plan for whole blood stimulation 
assays using endotoxin from healthy adult and paediatric volunteers 
 
2.2.1 Optimisation phase 
A whole blood in vitro endotoxin model was used to replicate conditions of sepsis seen in 
vivo. The Department of Paediatrics at Imperial College London has previously demonstrated 
that this is a valid model to study the process of inflammation in sepsis (350). HSP70 is 
ubiquitously present and produced by a large variety of cells and as such an in vitro whole 
blood endotoxin model was used to replicate the septic in vivo cell mix. Endotoxin derived 
from E.coli (0111:B4) was chosen as a well established stimulant in previous models 
investigating the release of HSP70 in vitro (193, 194, 351, 352). Glutamine free culture 
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medium (RPMI -1640) was used throughout the experimental phase, enabling the effect of 
subsequent glutamine supplementation on HSP70 release following endotoxin stimulation to 
be examined.  
 
Optimisation of the whole blood endotoxin stimulation assay in adults, where blood volume 
was less limited, evaluated a range of doses of endotoxin (0.01μg/ml - 1μg/ml), glutamine 
(2mM – 3.4mM – 6.8mM), KNK437 (50 -200μM) and different time points (0, 1, 2, 4, 6 and 
24 hours). Following this, a more limited model was developed for use in blood samples 
obtained from children where blood volume was more restricted. 
 
Optimisation of sample dilutions were completed using Meso Scale Discovery (MSD) 4-plex II 
ultra sensitive plate (1:10 dilution) and HSP70 ELISA plates (1:2 dilution). To control for 
variance between ELISA plates (HSP70 and inflammatory mediators) a positive plasma 
control from endotoxin stimulated blood (1µg/ml endotoxin at 24 hour timepoint) from one 
volunteer was used in duplicate on all of the ELISA plates. The results derived from the 
positive control on all ELISA plates were evaluated. An acceptable coefficient of variance 
from the mean was 20% either side of the positive control mean value. Samples on plates 
where the positive control was outside this range were adjusted.  
 
2.2.2 Experiment 1: To examine the in vitro effects of endotoxin and glutamine using a 
whole blood model on HSP70 expression in healthy adult volunteers and its association 
with markers of inflammatory response 
The experimental design analysed the effect of time, glutamine and endotoxin dose on the 
release of HSP70 in vitro. 
 
Whole blood (8ml) with 60 USP Units of Sodium Heparin was diluted 1:1 with an equal 
volume of warmed RPMI 1640 without glutamine (SIGMA Aldrich). A time zero aliquot of 
whole blood (500µl) was centrifuged for 10 minutes at 1200g. The supernatant was 
aliquoted and immediately stored at -80OC.  
 
Whole blood (180µl) and 20µl endotoxin (0µg/ml, 0.01µg/ml, 0.1µg/ml or 1µg/ml) was 
aliquoted in duplicate into a 96 well plate, representing four conditions. The plate was 
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incubated at 37oC, 5% CO2 for 2 hours. After 2 hours 2mM of glutamine was added to half 
the conditions and incubated up to 4 and 24 hours. At each time point glutamine/-glutamine 
blood was aspirated and centrifuged for 10 minutes at 1200g.  
 
Plasma (60µl) from each condition was aliquoted in duplicate into a 96 well plate and mixed 
equal measure (60µl) with HSP70 Assay Buffer (Catalogue No. 80-1599) in preparation for 
completing a high sensitivity HSP70 ELISA plate (Enzo Life Sciences Catalogue No. EKS-715 
CA; USA). 
 
Plasma (25μl) was aliquoted in duplicate into a 96 well plate and mixed with 225μl of 10% 
phosphate buffer solution and 0.05% Tween 20 (PBS-T) in preparation for completing MSD 
Human pro-inflammatory – 4 and 3 II ultra sensitive kit, measuring inflammatory mediators 
(IL-6, IL-8, IL-1β, TNF-α,) and (IL-6, TNF-α, IL-10) respectively. Following processing, all 
samples were immediately stored at -80oC until the ELISA kits were processed and analysed. 
 
2.2.3 Experiment 2: To examine the in vitro effects of endotoxin, glutamine and a HSP70 
inhibitor KNK437, on HSP70 expression, using a whole blood model, in healthy adult 
volunteers and its association with markers of inflammatory response 
Experiment 2 was based on methods in experiment 1 using one dose of endotoxin (1μg/ml) 
in addition to KNK437.  Cells were lysed to investigate differences between intracellular and 
extracellular release of HSP70 and inflammatory mediators following the addition of 
KNK437. 
 
A range of KNK437 doses were evaluated (50μM – 200μM), with a dose of 200μM KNK437 
being used in the inhibition model. To diluted whole blood aliquots of 180µl, 20μl of 200μM 
of KNK437 was added to half of the conditions and incubated at 37⁰C, 5% CO2 for an hour, 
after which to half of the conditions, 1µg/ml of endotoxin was added, followed by 2mM of 
glutamine 2 hours thereafter. Samples were incubated at 37⁰C, 5% CO2 for up to 4 and 24 
hours. Samples were centrifuged for 10 minutes at 1200g. Plasma was harvested, diluted 
and stored as outlined in experiment 1. 
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Any remaining supernatant was discarded and the cell pellet was resuspended and washed 
with Dulbecco’s Phosphate Buffered Saline (DPBS) and centrifuged for 5 minutes at 450g and 
repeated twice.  
 
Cells were lysed according to the manufacturer’s instruction using CellLytic M (Catalogue 
number C2978; Sigma Aldrich) and a protease inhibitor cocktail (Catalogue number P8340; 
Sigma Aldrich). To lyse 400μl of cells, 50μl of CellLytic M and 40μl of the protease inhibitor 
cocktail were used.  The cell pellet was resuspended in CellLytic M reagent and protease 
inhibitor cocktail, and incubated at room temperature for 15 minutes on a shaker at a 
vigorous speed of 250g. Cells were subsequently centrifuged for 15 minutes at 3,000g 
pelleting cell debris.  The protein containing lysate was harvested, diluted and stored as 
outlined in experiment 1. 
 
2.2.4 Experiment 3: To examine the in vitro effects of endotoxin and glutamine on HSP70 
expression, in whole blood obtained from healthy paediatric volunteers and its association 
with markers of inflammatory response. 
 After obtaining informed parental consent, 25 healthy children were prospectively enrolled 
from a general paediatric outpatient clinic. As the available blood sample volume was 
considerably smaller compared to amounts available from adults, the experimental 
conditions were rationalised to those with the most significant effect. As such there were 
two conditions, (a) 0µg/ml LPS, with and without glutamine and (b) 1μg/ml LPS, with and 
without glutamine cultured for 4 and 24 hours. All of the volunteers were well on the day of 
phlebotomy and a total of 3ml of blood was collected from each volunteer via venipuncture 
into lithium heparin tubes. Plasma was harvested, diluted and stored as outlined in 
experiment 1. 
 
2.2.5 Experiment 4: To examine the in vivo relationship between clinical variables, plasma 
HSP70, glutamine and inflammatory mediators and genome-wide transcriptional profiles 
in children with acute meningococcal disease compared to convalescence. 
To examine the in vivo relationships between clinical variables, plasma HSP70, glutamine, 
inflammatory mediators and genome-wide transcriptional profiles in children with acute 
meningococcal disease (n=143) compared to convalescence (n=78), a variety of techniques 
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were used to analyse the samples. These included a) inflammatory mediators using MSD, 4-
plex kit on a smaller cohort (acute n=34, convalescence n=8) and 3-plex (acute n=109, 
convalescence n=70)  b) HSP70 using ELISA kit (Enzo Life Sciences), c) glutamine analysis 
using AminoTac 500, in addition to d) a transcriptomic analysis of differentially expressed 
genes considering relationships between HSP70, glutamine inflammatory mediators and e) 
analysis of clinical variables from a clinical notes folder review as outlined in Figure 2.1b.  
 
2.2.5.1 Study population  
Venous blood was collected from paediatric Caucasian patients admitted to PICU at St 
Mary’s Hospital with suspected meningococcal sepsis, meningococcal meningitis or both. 
Samples were collected in EDTA tubes and processed. Whole blood was centrifuged for 10 
minutes at 1200g, plasma was harvested and aliquoted (400µl) and stored at -800C freezers 
in anonymised Ependorf tubes, (Department of Paediatric, Imperial College, St. Mary’s 
Campus). The remaining cell pellet was similarly stored for later use in real time polymerase 
chain reaction (rt-PCR) microarray analysis. Convalescent samples were collected in children 
during outpatient follow-up on average 55 days [range 35 – 153] post discharge from the 
PICU and processed as above.  Samples included in the analysis were selected using the 
following inclusion criteria: 
 
Inclusion criteria: 
 length of PICU stay for ≥ 3 days,  
 mechanical ventilation  
 PRISM score (353) of ≥ 10 
 Caucasian  
Exclusion criteria: 
 length of PICU stay for ≤ 3 days,  
 breathing in room air 
 PRISM score (353) of ≤ 10 
 Non-Caucasian  
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Samples were identified using inclusion criteria and in batches of forty were brought to room 
temperature. During processing, samples were kept on ice. Aliquots for ELISA’s were diluted 
as outlined in experiment 1 and re-frozen within 30 minutes of being processed. 
 
Figure 2.1b: A schematic outline of the experimental plan for sample analysis of plasma 
obtained from blood samples of children with meningococcal disease during acute illness 
and in convalescence.  
 
2.3 Techniques for protein measurement, clinical variable and transcriptomic analysis 
 
2.3.1 Method a: Analysis of levels of inflammatory mediators by multiplex ELISA (Meso 
Scale Discovery) multiplex assay kit  
Pro- and anti-inflammatory mediators selected were based on previous work in 
meningococcal disease (77, 78) and available validated multiplex plates from Meso Scale 
Discovery (MSD). MSD Human inflammatory 4-plex II ultra sensitive kits were used to 
measure a range of inflammatory mediators (IL-1β, IL-6, IL-8, TNF-α) in samples, from 
Experiments 1 and 4. MSD Human inflammatory - 3 plex II ultra sensitive kits were used to 
measure a range of inflammatory mediators (IL-6, IL-10, TNF-α) in samples, from 
Experiments 2 - 4. MSD platform uses electrochemiluminescence technology which emits 
light following electrochemical stimulation of the electrode surfaces in the multi-spot plates 
and is a well described technique for measuring inflammatory mediators (354-356). Due to 
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the limited plasma volumes available from paediatric patients there was insufficient samples 
to run independent plates for all of the cytokines. 
 
Standards, samples and diluents (No.2, No.3) were thawed to room temperature. Diluents, 
antibodies, read buffer and plate analysis were completed as per the manufacturer’s 
instructions. Twenty five µl of diluent 2 was pipetted onto the 96 well MSD plate, ensuring 
equal coverage. The plate was shaken vigorously (700rpm) for 30 minutes, after which 25µl 
of reference kit standards, samples, positive control and blank were aliquoted in duplicate. 
The sealed plate was shaken vigorously for 2 hours followed by PBS-Tween (PBS-T) wash x 3. 
A detection antibody (25µl) was added to each well, followed by vigorous shaking for a 
further 2 hours and subsequent PBS-T wash x 3. One hundred and fifty microlitres of “read 
buffer” was added in duplicate allowing the plate to be analysed using the MSD Multiplex 
platform Sector Image 4000. The mean value was used for all duplicates if the coefficient of 
variance < 20%.  
 
2.3.2 Method b: Measurement of HSP70 Stressgen EKS-715 High Sensitivity ELISA Kit  
HSP70 high sensitivity EKS-715 kit, measuring inducible HSP70 release in plasma samples is 
described by others (141, 143, 151, 152) and was used in all experiments as per the 
manufacturer’s instructions. 
 
Samples and reagents were thawed to room temperature. One hundred microlitres of 
reference kit standards, samples, positive control and blank were aliquoted in duplicate onto 
the HSP70 ELISA plate, which was sealed and shaken at 50g for 2 hours, followed by a 3 x 
plate wash using HSP70 wash buffer. Following that the addition of 100µl high sensitivity 
polyclonal antibody was aliquoted into each well (except for the blank). The plate was 
shaken for 1 hour and washed x 3. A further 1 hour incubation with 100µl IgG followed and 
washed x 3. One hundred microlitres of substrate solution was added for 30 minutes 
followed by 100µl of a stop solution. The optical density for each duplicate sample was 
measured at 450nm using a spectrophotometer, calibrating against the substrate blank. The 
mean value was used for all duplicates if the coefficient of variance < 20%.  
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2.3.3 Method c: Analysis of plasma glutamine  
Plasma glutamine levels were measured using ninhydrin cation exchange chromatography, 
in collaboration with Dr Margaret Hancock, Department of Chemical Pathology, Charing 
Cross Hospital.  
 
Samples were thawed to room temperature, 160µl of sample were aliquoted and then re-
frozen to -80oC. Glutamine was measured in supernatant using AminoTac JLC500/V (Amino 
Acid Analyser). AminoTac JLC500/V uses a cation exchange chromatography system, using a 
post column sorting with ninhydrin (2,2-Dihydroxyindane-1,3-dione). Ninhydrin is used to 
detect primary and secondary amines in addition to ammonia. Ninhydrin reacts with these 
free amines to form a deep blue or purple colour which is known as Ruhemann’s purple 
leading to the identification of indivdual aimo acids.Amino acids are separated according to 
their net charge determined by the pKa of their ionised groups. The mobile phase 
incorporates 5 lithium citrate buffers used in an incremental process of increasing pH and 
molarity maximised through the use of a temperature gradient, involving five mechanistic 
steps (Table 2.1) (357). 
 
Table 2.1: Mechanistic steps for cation exchange chromatography system using ninhydrin 
Step 1 alpha-amino acid + ninhydrin ---> reduced ninhydrin + alpha-amino acid + 
water 
Step 2 alpha-amino acid + water ---> alpha-keto acid + ammonia 
Step 3 alpha-keto acid + ammonia ---> aldehyde + carbon dioxide 
Step 4 & 5 alpha-amino acid + 2 ninhydrin ---> carbon dioxide + aldehyde + final 
complex (blue) + water 
 
Analysed glutamine samples met quality assurance and control standards as defined by the 
European Network of Inherited Disorders of Metabolism plasma amino acid quantification. 
Glutamine results were expressed as the sum total of glutamine and glutamic acid, to 
account for the breakdown of glutamine to glutamic acid on storage (358).  
 
To investigate the effect of freeze-thaw cycles on glutamine levels in stored plasma samples 
from children with meningococcal disease, a series of freeze-thaw cycles on whole blood 
samples from adults were completed. Following venipuncture 8ml of blood from adult 
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volunteers (n=3), was aliquoted into equal 1ml samples with time zero sample stored at -
80oC. The remaining samples were spiked with 2mM of glutamine and underwent the 
following experimental conditions: a) baseline sample with 2mM glutamine added b) stored 
at room temperature for 1 hour, c) frozen at -80oC, then brought to room temperature and 
refrozen at -80oC (a freeze thaw cycle), d) 2 freeze thaw cycles e) 3 freeze thaw cycles, f) 4 
freeze thaw cycles g) 5 freeze thaw cycles h) 6 freeze thaw cycles. 
 
2.3.4 Methods d: Transcriptomic analysis 
2.3.4.1 Study population  
Venous blood was collected from paediatric Caucasian patients admitted to PICU at St 
Mary’s Imperial NHS Trust Hospital between December 2002 and May 2005 with suspected 
meningococcal sepsis, meningococcal meningitis or both. All patients had a clinical diagnosis 
of meningococcal disease, with a confirmed Group B positive sample (blood, CSF or bacterial 
DNA PCR amplification) identified in 33 out of 39 patients. Six of thirty nine cases had 
unconfirmed meningococcal disease (4 were ‘negative’ and 2 were ‘not known’).  
 
Thirty-nine patients were successfully arrayed. Twenty eight patients had meningococcal 
sepsis (MS), 3 with meningococcal meningitis (MM) and 8 with both. The 28 sepsis only and 
the 8 meningococcal meningitis and sepsis patients were combined to form a ‘sepsis’ cohort 
(n=36), of which there were 32 acute samples (15 acute only), 21 convalescent (4 
convalescent only) and 17 paired acute and convalescent samples.  
 
2.3.4.2 RNA extraction, amplification and labelling 
Total ribonucleic acid (RNA) extraction, amplification, hybridisation and microarray data 
analyses were previously completed by Dr Victoria Wright, Department of Paediatrics, 
Imperial College London and the data arising from the analyses was used to complete the 
transcriptomic analysis. Human RNA was extracted from whole blood collected into PAXgene 
tubes according to manufacturer’s instructions (PreAnalytix/Qiagen), reverse transcribed to 
cDNA and biotinylated amplified cRNA generated by in vitro transcription using Illumina 
TotalPrep RNA Amplification kit (Ambion) according to the manufacturer’s instructions. After 
purification, 500ng of cRNA was hybridised to an Illumina Human Ref 8 V3 Beadchip 
(containing probes to 24,526 RefSeq (Build 36.2, Release 22) gene sequences) at 55°C for 18 
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1/2 hours, washed, blocked and stained with streptavidin-Cy3 according to the 
manufacturer’s instructions. The arrays were scanned with an Illumina Bead Array reader 
confocal scanner. 
 
2.3.4.3 Data analysis 
Standard normalisation procedures for 1-colour array data were used with GeneSpring GX 
software (version 11.02, Agilent). Fold induction values were normalised by log 
transformation and differences in gene expression in the patients compared to 
convalescence determined using unpaired Mann-Whitney and corrected for multiple testing 
using Bonferroni Family Wise Error Rate. 
 
2.3.4.4 GeneSpring – normalisation and filtering 
Data was normalised by a shift to the 75th percentile, baseline transformed to the median of 
all samples, and flags that were “present” used (defined with the lower cut off for a 
“present” flag of 0.9899, and the default upper cut off for an absent flag of 0.6). The probe 
must be flagged as ‘present’ in 90% of the samples in any 1 out of 2 conditions (i.e. acute vs. 
convalescence). All filtering was unsupervised and the Mann Whitney unpaired tests was 
used for significance testing with the most stringent multiple comparison test, Bonferroni 
Family Wise Error Rate (BFWER), as well as the least stringent, Benjamini Hochberg (BH). A 
fold change of ≥2 were the cut-offs. 
 
2.3.4.5 Ingenuity Pathway Analysis 
Ingenuity Pathway Analysis application ((IPA), Ingenuity Systems, Redwood City, CA, USA) is 
a tool enabling the discovery of signalling pathways and gene networks within an uploaded 
gene list (359, 360).  
 
IPA generates gene networks by mapping each gene identifier to its corresponding gene 
object within the IPA Knowledge base. Focus genes are then overlayed into a global 
molecular network that is generated from information within the Knowledge Base. The focus 
genes are then assigned into networks using algorithms based on their connectivity. Each 
IPA network can be set to have a maximum of 35 focus genes, to which a significance score 
is assigned (based on a P value). This is representative of the likelihood that the focus gene 
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within the network is there by random chance. A high number of focus genes within a 
dataset results in a higher network score, which is equal to the negative exponent of the P 
value e.g. score of 47 is equal to 10E-47 (359, 360). 
 
2.3.4.6 Independent cohort validation of transcriptomic analysis 
Since Illumina array render highly reproducible results, rt-PCR was not completed in this 
cohort. Validation of the significantly differentially expressed (SDE) transcripts within the 
dataset was completed functionally using plasma protein levels of glutamine, HSP70 and 
inflammatory mediators (IL-1β, TNF-α, IL-6 and IL-8). An independent gene ontology 
database (ToppGene) (361), was used to determine the most significant functional signaling 
pathways from the dataset and to corroborate pathway findings identified by IPA e.g. 
antigen presentation, adaptive immunity and inflammatory signaling pathways.  
 
An independent cohort of children with meningococcal septicaemia (n=6) compared to age 
matched controls from Gene Expression Omnibus (362) was used as a validation cohort. A 
log2 fold change of ≥2 was used as the cut off with P values adjusted using Benjamini- 
Hochberg multiple comparison testing. The top 250 SDE gene probes (from analysis using 
IPA) were used for validation of the biological functions and signaling pathways in the 1,780 
SDE transcripts from the acute meningococcal cohort. 
 
2.3.5 Methods e: Analysis of clinical variables from clinical notes folder review  
For those children with identified plasma samples, clinical and nutrition variables were 
collected using a password encrypted anonymised data-base. Paediatric specific criteria was 
used to determine organ failure, severity of injury score and mortality was followed for 28 
days after enrolment (16). Although this study was not powered to examine the significance 
of clinical associations between the changes in biomarkers, genome-wide expression 
patterns and disease severity, relationships were investigated for associations between 
transcriptomic data, clinical biomarkers and nutrition indices. The following clinical and 
nutritional data was collected for all patients: 
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Clinical Data  
 Demographic data: age, gender 
 Diagnosis: Clinical and microbiological diagnosis obtained from blood culture, 
serology, latex agglutination or PCR 
 Inflammation: SIRS criteria (363), CRP and white cell count 
 PRISM and PIM2 score on admission as a predictor of mortality (364, 365) 
 Worst daily lactate and glucose (366, 367) 
 Duration of mechanical ventilation and PICU stay 
 
Nutritional data:  
 Anthropometry: Weight 
 Route of feeding e.g. nasogastric, nasojejunal, total parenteral nutrition 
 Type and volume of feed e.g. name 
 Days to goal rate of feeds 
 Glutamine g/kg at goal rate of feeds 
 Gastric aspirates e.g. ml/kg 
 Complications e.g. abdominal distension, constipation, vomiting, diarrhoea 
 
2.4 Data analysis 
The Imperial College Statistical Advisory Service was engaged for this study. Statistical 
analysis of clinical variables, HSP70, glutamine and cytokine data was completed using 
statistical analysis package Graphpad Prism 4.0 for Windows (Graphpad Software, San Diego, 
CA) and Statistical Package for Social Sciences 19.0 (SPSS: An IBM Company, Chicago, IL). 
Anthropometric data was analysed using Epi InfoTM Version 3.5.3 (CDC, USA). 
 
2.4.1 Statistical analysis plan for the in vitro model of sepsis examining the effect of 
glutamine on the release of HSP70 and inflammatory mediators 
Continuous variables (HSP70 and cytokines) were tested for normality and linearity and were 
found to be significantly skewed with a non-Gaussian distribution as a result the variables 
were analysed using non-parametric tests.   
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To determine statistical significance with respect to the release of HSP70 and inflammatory 
mediators at comparative time points, (e.g. varying doses of endotoxin, KNK437, with and 
without glutamine), Mann-Whitney t-test (non-parametric) were used (368).  
 
One way ANOVA’s were used to compare HSP70 and inflammatory mediators between 
groups e.g. adults and paediatric using Krauskal-Wallis test (non-parametric) to test for 
significant with a post hoc analysis of Dunn’s to compare all groups for significant differences 
(368).  
 
Results are presented in this study as means and standard deviations (± SD) and median with 
range. Statistical significance was achieved with a p-value < 0.05.  
 
2.4.2 Statistical analysis plan to examine relationships between HSP70, glutamine and 
inflammation in children with acute meningococcal disease compared to convalescence 
Applying statistical methods described in similar work (369), a range of statistical methods 
were used as follows:  
 
Continuous variables (HSP70, glutamine and inflammatory mediators) were tested for 
normality and linearity. Variables were significantly skewed with a non-Gaussian distribution 
and as such were analysed using non-parametric tests. Difference between acute and 
convalescent samples were analysed using Mann-Whitney t-test (non-parametric) to 
determine statistical significance.  
 
Spearman rank order correlation (non-parametric correlation) coefficient (r) was used to 
determine the correlation between plasma protein measurements of HSP70, glutamine and 
inflammatory mediators. Pearson correlation coefficient (parametric) was used to analyse 
normalised log10 transformed variables of HSP70, glutamine and inflammatory mediators. 
Correlation was deemed to be low when r = +/- 0.10-0.29, medium +/- 0.30-0.49 and high +/- 
0.50 – 1.0 (368). 
 
To explore further the relationships between clinical variables of interest and glutamine, 
HSP70 or cytokines, logistic regression was used, allowing multiple comparisons between 
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variables. Within the clinical database, categorical dependent variables e.g. steroid (yes/no) 
were used to predict the likelihood of a relationship between continuous clinical variables 
such as glutamine, HSP70 and cytokines. Using this technique does not imply causality but it 
does inference about the possibility of certain relationships (368).  
 
Results in this study, are presented as means and standard deviations (±SD), median with 
the range, correlation coefficients (r) and R2 and adjusted R2 values for regression models. 
Statistical significant was achieved with a  p-value < 0.05 (368). 
 
2.4.3 Statistical plan for analysis of gene expression of HSP70, glutamine and pathways 
associated with inflammation during acute and convalescence in children with 
meningococcal disease. 
Pearson correlation coefficient was used to analyse transcriptomic data and plasma levels of 
HSP70, glutamine and inflammatory mediators. Correlation was deemed to be low when r = 
+/- 0.10-0.29, medium +/- 0.30-0.49 and high +/- 0.50 – 1.0 (368). 
 
Results of this study are presented as means and standard deviations (±SD), median with the 
range, correlation coefficients (r). Statistical significant was achieved with p-value < 0.05 
(368). 
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In vitro models to consider the effect of glutamine supplementation 
on endotoxin stimulated release of HSP70 and inflammatory 
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80 
 
Chapter 3:  In vitro models to consider the effect of glutamine supplementation on 
endotoxin stimulated release of HSP70 and inflammatory mediators  
 
3.1 Introduction 
In vitro whole blood endotoxin stimulation models mimic the effect of sepsis, allowing for 
the study of cellular responses to infection, providing insight into the host response (26, 193, 
370). Endotoxin stimulation models have been used for the study of cytokine (371, 372) and 
HSP70 release (197) in addition to increasing the understanding of the overlap between pro- 
and anti-inflammatory mediator release following immune activation (26). The use of 
endotoxin stimulation models have also provided the opportunity to study any potentially 
unwarranted side effects of a potential therapeutic strategy (26). However, there are 
limitations to the use of such models in that they cannot completely replicate the individual 
response to infections as confounding factors also influence individual disease pathogenesis 
and the specific pathogen involved, as discussed in Chapter 1 (2, 26).  
 
3.2 HSP70 activation of inflammatory signalling pathways 
As discussed in Chapter 1, HSP70 release primes immune cells to a potential attack from 
pathogenic organisms promoting the rapid release of bactericides such as nitric oxide and 
inflammatory mediators. If no attack ensues, the cell can quickly “stand down” with the 
rapid decline in extracellular HSP70 levels (373). In vitro work by Campisi et al. has shown 
that when HSP70 forms a complex with endotoxin, there is a greater immunostimulatory 
effect on pro-inflammatory cytokine release than with either HSP70 or endotoxin alone 
(176). It has been suggested that the priming of a cell may determine the type of immune 
response elicited following stress (176). It has been questioned which occurs first i.e. the 
release of pro-inflammatory cytokines stimulating the release of HSP70 or the converse 
where the release of HSP70 promotes signalling via TLR2/4 – CD14 and activation of 
inflammatory pathways such as NF-κB (93, 108, 352). 
 
3.3 Inhibition of heat shock protein 70 and the effect of inflammatory mediators 
In order to understand the effect of HSP70 on endotoxin release of inflammatory mediators, 
a range of HSP70 inhibitors have been used (93, 374-376), such as KNK437 (N-formyl-3,4-
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methylenedioxy-benzylidene-γ-butyrolactam), a benzylidene lactam (198, 375, 377), 
quercitin (376, 378) and HSP70 anti-sense oligomers (93). 
 
Quercitin is part of the flavanoid family. Flavanoids are phenolic compounds found in some 
plants which have a wide number of biological actions including antioxidant, antimicrobial, 
anti-inflammatory and anti-allergenic effects (379). In vitro work using cell lines has shown 
that quercitin is an effective HSP70 inhibitor (380, 381) although the mechanisms of action 
are not understood. However, it is known that quercitin also inhibits several kinases 
including CK2 and MAPK2/ERK (376). As the kinase family are known to be inflammatory 
mediators (382), effective blocking of their action has an indirect effect on HSP70. CK2 has 
been shown to upregulate HSP70 production through HSF-1 phosphorylation, therefore by 
blocking CK2, quercitin inhibits HSP70 production (383). As such the use of quercitin within a 
whole blood model may not effectively elucidate the effect HSP70 may have on the 
upregulation of inflammatory mediators.   
 
Unlike quercitin, KNK437 does not have any effect on the kinase family. It inhibits HSP70 
production (374, 384-386) by blocking HSF-1 phosphorylation (198) and transcription (387) 
and is more effective than quercitin (385). The use of KNK437 in an in vitro endotoxin 
stimulation model, using monocytes, inhibited the release of HSP70 attenuating the release 
of TNF-α, suggesting that HSP70 facilitates the upregulation of TNF-α via the NK-κB signalling 
pathway (377). 
 
Anti-sense oligomers have been successfully used in cell line work but not in whole blood. 
Transfection work shows that endotoxin induced HSP70 mediates inflammatory cytokine 
release. Conversely when HSP70 production is inhibited, mRNA expression of TNF-α, IL-10, 
IL-1β and IL-12 is diminished (93). Inhibition of HSP70 only partially prevented cytokine 
release as the accumulation of TNF-α, IL-10, IL-1β, IL-6 and IL-12 was not completely 
abrogated in the presence of endotoxin stimulation, suggesting that there are other factors 
that mediate the release of inflammatory cytokines (93). These results suggest that HSP70 
influences the cytokine milieu released mediating an optimal inflammatory response on 
dependent on the level of stress (93), an effect supported by others (191, 388).  
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3.4 The effect of glutamine on inflammatory mediators via HSP70 release 
Glutamine has been shown to attenuate the release of pro-inflammatory cytokines in animal 
models of sepsis through the inhibition of IKK (IκKα) and the subsequent downregulatory 
effect on the NF- κB pathway and MAPK pathways (86). In an endotoxin stimulation model 
TNF-α upregulation is suppressed by glutamine supplementation (2 – 10mM) (389, 390) and 
in rats pre-treatment with glutamine (through increased HSP70 release) resulted in 
decreased expression of IL-6 and TNF-α following endotoxin stimulation compared to 
untreated controls (391). Other endotoxin and injury animal models show similar results, 
with glutamine attenuating the release of IL-6, TNF-α (86, 390, 392-394), IL -8 (395), IL 1β 
(393) and IL-10 (392), all of which are potentially mediated by upregulated HSP70 production 
and provide examples of the dampening effect that HSP70 upregulation can have on the 
inflammatory response (390). The beneficial effect of glutamine supplementation is lost in 
the absence of HSP70 gene upregulation in HSP70.1/3 knock-out mice with a subsequent 
uncontrolled release of TNF-α and IL-6, increasing the rate of mortality compared to normal 
wild type mice (396).  Glutamine depletion in lymphocytes is associated with impaired 
expression of HSP70 (397) . However, in many of the in vitro sepsis models supra-
physiological doses of glutamine e.g. up to 10mM were administered (390, 398, 399) and in 
other studies where doses of glutamine administered to septic rat models ranged from 
0.5g/kg - 0.75g/kg the effect on inflammatory mediators were less pronounced (86, 392, 
394, 395, 400). 
 
Thus HSP70 is able to act as a DAMP, upregulating the inflammatory response (401, 402) in 
addition to acting as a “DAMPERs”  resolving inflammation (191, 401, 403), and restoring cell 
homeostasis (191). As such, the maintenance of an appropriate HSP70 response may 
diminish the risk of immune paralysis and overwhelming inflammation seen in the severely 
ill child. Effective therapeutic strategies that harness endogenous defence mechanisms, 
reducing sepsis and septic shock morbidity are still to be elucidated. However, the use of 
glutamine to stimulate HSP70 release is an attractive proposition (207, 237).  
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3.5 Aims  
In order to understand the effect of glutamine supplementation on HSP70 release and the 
association with inflammatory markers, we sought to mimic the effects of sepsis through the 
use of an in vitro endotoxin whole blood model.  
 
3.6 Results 
A series of experiments were completed to optimise a whole blood endotoxin stimulation 
model. With respect to glutamine, there were no significant differences in endotoxin 
(10µg/m) induced HSP70 release between glutamine doses of 2mM, 3.4mM and 6.8mM. 
However, there was a trend towards significance (p=0.063) in HSP70 release with glutamine 
supplementation of 2mM at 4 hours (mean 0.51ng/ml, ±SD 0.36) compared to 24 hours 
(mean 0.78ng/ml, ±SD 0.39), suggesting this dose of glutamine effectively promoted HSP70 
release in response to endotoxin stimulation of whole blood in vitro. Therefore, a dose of 
2mM of glutamine supplementation was chosen for the remaining whole blood endotoxin 
stimulation assays (Figure 3.1).  
 
3.6 Optimisation of in vitro HSP70 release with glutamine supplementation in endotoxin 
stimulated whole blood  
No LPS 2mM 2mM 2mM 3.4mM 3.4mM 3.4mM 6.8mM 6.8mM 6.8mM
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Figure 3.1: The effect of various doses of glutamine supplementation on HSP70 release 
using 10µg/ml of endotoxin in whole blood from healthy adult volunteers (n=5). Results 
are expressed as mean; ± standard error of mean (SEM). Gln = glutamine * NS p=0.063 
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3.7 An in vitro whole blood endotoxin stimulation assay to investigate the relationship 
between glutamine, HSP70 and inflammatory mediators 
 
3.7.1 Glutamine supplementation promotes HSP70 release in endotoxin stimulated whole 
blood from healthy adult volunteers at 4 hours and 24 hours 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: The effect of glutamine supplementation (2mM) on endotoxin stimulated 
HSP70 release in whole blood from healthy adult volunteers (n=16) Results are expressed 
as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, **p<0.005 
 
There was a significant difference in HSP70 release between groups (p<0.0001). HSP70 
release was significantly increased with glutamine supplementation (2mM) in endotoxin 
stimulated blood at 24 hours in all conditions compared to controls without glutamine, 
including those conditions with no endotoxin. In addition there was a significant difference 
in HSP70 release with glutamine supplementation at 4 hours with 1µg/ml endotoxin 
compared to control condition without glutamine. The release of HSP70 also significantly 
increased over time from 4 hours to 24 hours, including those conditions with no endotoxin. 
The relative similarity in HSP70 release between conditions are in contrast to those 
pertaining to the release of inflammatory mediators, indicating this phenomenon is not as a 
result of endotoxin contamination and is more likely to be reflective of a physiological 
response to the experimental conditions (Figure 3.2).  
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3.7.2 Glutamine supplementation in endotoxin stimulated whole blood appears to 
attenuate the release of inflammatory cytokines  
 
The effect of glutamine supplementation on endotoxin stimulated release of inflammatory 
cytokines (IL-6, IL-8, IL-1β and TNF-α) was investigated. 
 
3.7.3 Glutamine supplementation in endotoxin stimulated whole blood from healthy adult 
volunteers attenuates the release of IL-1β at 4 hours and 24 hours 
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Figure 3.3: The effect of glutamine supplementation on endotoxin stimulated release of IL-
1β at 4 hours and 24 hours in whole blood from healthy adult volunteers (n=12) Results 
are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, **p<0.005, *** 
p<0.0005  
 
There was a significant difference in IL-1β release between groups (p<0.0001). As expected 
endotoxin stimulation significantly increased IL-1β release over time with (p<0.005) and 
without (p<0.0005) glutamine supplementation at 24 hours with 1µg/ml endotoxin and at 
0.01µg/ml 24 hours with glutamine supplementation compared to 4 hours (p<0.05). 
Although there were no other significant differences glutamine supplementation (2mM) 
appears to attenuate 1L-1β release at 24 hours compared to those without glutamine 
supplementation, although this effect was not significant (Figure 3.3).  
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3.7.4 Glutamine supplementation in endotoxin stimulated whole blood from healthy adult 
volunteers attenuates the release of IL-8 at 4 hours and 24 hours 
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Figure 3.4: The effect of glutamine supplementation (2mM) on LPS stimulated release of 
IL-8 at 4 hours and 24 hours in whole blood from healthy adult volunteers (n=12). Results 
are expressed as mean; ± SEM. Gln = glutamine. LPS = endotoxin *p<0.05, **p<0.005 
 
There was a significant difference in IL-8 release between groups (p<0.0001). Glutamine 
supplementation (2mm) significantly attenuated the release of IL-8 at 24 hours 1µg/ml 
endotoxin compared to control conditions with no glutamine (p<0.05). Although there were 
no other significant differences in glutamine supplemented conditions at 24 hours with 0.01 
– 0.1 µg/ml endotoxin compared to control conditions, glutamine appeared to attenuate the 
release of IL-8. Over time, IL-8 release was significantly increased in 0.1µg/ml (p<0.05) and at 
1µg/ml endotoxin groups (p<0.005) at 24 hours compared to 4 hours without glutamine 
supplementation (Figure 3.4).  
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3.7.5 Glutamine supplementation in endotoxin stimulated whole blood from healthy adult 
volunteers attenuates the release of TNF-α at 4 hours and 24 hours 
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Figure 3.5: The effect of glutamine supplementation (2mM) on endotoxin stimulated 
release of TNF-α at 4 hours and 24 hours in whole blood from healthy adult volunteers 
(n=12). Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin. 
 
There was a significant difference in TNF-α release between groups (p<0.0001). Although, 
there was no significant effect on TNF-α release with glutamine supplementation (2mM), 
TNF-α release at 4 hours and 24 hours appeared to be attenuated in glutamine conditions 
compared to those without glutamine supplementation (Figure 3.5).  
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3.7.6 Glutamine supplementation in endotoxin stimulated whole blood from healthy adult 
volunteers attenuates the release of IL-6 at 4 hours and 24 hours 
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Figure 3.6: The effect of glutamine supplementation (2mM) on LPS stimulated release of 
IL-6 at 4 hours and 24 hours in whole blood from healthy adult volunteers (n=12). Results 
are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p=0.05 
 
There was a significant difference in IL-6 release between groups (p<0.0001). Endotoxin 
stimulation significantly increases IL-6 release at 24 hours compared to 4 hours with and 
without glutamine supplementation (p<0.05).  There were no significant differences 
between conditions with and without glutamine supplementation (2mM). Although not 
statistically significant, glutamine supplementation appears to attenuate 1L-6 release at 4 
hours and 24 hours compared to those without glutamine supplementation (Figure 3.6). 
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3.7.7 Glutamine supplementation in endotoxin stimulated whole blood from healthy adult 
volunteers attenuates the release of IL-10 at 4 hours and 24 hours 
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Figure 3.7: The effect of glutamine supplementation (2mM) on LPS stimulated release of 
IL-10 at 4 hours and 24 hours in whole blood from healthy adult volunteers (n=18). Results 
are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, **p<0.005 
 
There was a significant difference in IL-6 release between groups (p<0.0001). As expected, 
endotoxin stimulation significantly increases IL-10 release at 24 hours compared to 4 hours 
with and without glutamine supplementation (p<0.05).  There was a significant difference 
between IL-10 release at 4 hours with glutamine compared to control conditions (p<0.05). 
Although not significant at 24 hours glutamine supplementation appears to attenuate 1L-10 
release compared to control conditions (Figure 3.7). 
 
3.7.8 Relationships between HSP70 and inflammatory mediators in adult in vitro 
endotoxin stimulated whole blood following glutamine supplementation (2mM) 
Spearmen’s correlation was used to investigate whether there were relationship between 
HSP70 and inflammatory mediators (IL-1β, TNF-α, IL-6, IL-8, IL-10) in adult in vitro endotoxin 
stimulated whole blood following glutamine supplementation (2mM). Interestingly there 
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were no relationships between IL-6 or IL-10 or HSP70 release at any of the endotoxin doses 
or time points, following glutamine supplementation. Positive and inverse correlations were 
found at 4 hours for IL-1β, TNF-α, IL-8 and IL- (Table 3.1) but none at 24 hours. 
 
Table 3.1 Relationships between adult in vitro endotoxin stimulated HSP70 release and 
inflammatory mediators following glutamine supplementation (2mM) 
 IL-1β (pg/ml) 
0.01μg/ml LPS 
4 hours Gln 
 IL-1β (pg/ml) 
1μg/ml LPS  
4 hours Gln 
TNF-α (pg/ml) 
0.1μg/ml LPS  
4 hours Gln 
 IL-8 (pg/ml) 
0.1μg/ml LPS 
4 hours Gln 
HSP70  (ng/ml) 
4 hours Gln 
0.01μg/ml LPS 
r=0.51 
p=0.03 
n=16 
  
HSP70 (ng/ml) 
4 hours Gln 
0.1μg/ml LPS 
 r=-0.56 
p=0.02 
n=16 
r=-0.52 
p=0.03 
n=16 
HSP70 (ng/ml) 
4 hours Gln 
1μg/ml LPS 
r=0.47 
p=0.04 
n=16 
 
 
3.7.9 Summary of results for glutamine supplementation (2mM) in endotoxin stimulation 
model and the effect on the release of HSP70 and inflammatory mediators 
Glutamine supplementation (2mM) significantly upregulates HSP70 release in endotoxin 
stimulated whole blood at 24 hours compared to conditions without glutamine. There were 
some positive and inverse correlations between HSP70 release and inflammatory mediators 
at 4 hours (IL-1β, TNF-α, IL-8) although there were no correlations between HSP70 and IL6 or 
IL-10. Glutamine supplementation significantly attenuated the release of IL-10 at 4 hours 
and IL-8 at 24 hours compared to conditions without glutamine. In endotoxin stimulated 
blood there were no significant differences in the release of IL-6, TNF-α and IL-1β with 
glutamine supplementation at 4 and 24 hours. However, glutamine supplementation (2mM) 
appeared to attenuate the release of inflammatory mediators (IL-1β, IL-6, TNF-α), although 
this effect was not statistically significant.  
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3.8 Results of the in vitro model examining the inhibitory effects of KNK437 on HSP70 
release and markers of the inflammatory responses following endotoxin stimulation and 
glutamine supplementation (2mM) in healthy adult volunteers 
 
To investigate whether HSP70, in part, mediates the release of inflammatory markers, an 
experiment was designed using KNK437 with the aim of inhibiting HSP70 release.   
 
3.8.1 With the addition of KNK437 to endotoxin stimulated whole blood the effect of 
glutamine supplementation (2mM) on extracellular HSP70 release at 24 hours is abrogated 
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Figure 3.8: The effect of KNK437 on extracellular HSP70 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM)  
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin, *p<0.05, 
**p<0.005 
  
There was a significant difference in extracellular HSP70 release between groups (p<0.0001). 
The addition of KNK437 significantly inhibited extracellular HSP70 release in conditions at 24 
hours with glutamine supplementation (2mM) (p<0.05) and without glutamine (p<0.005), 
suggesting the beneficial effect of glutamine on HSP70 release is lost with the use of KNK437 
at 24 hours but not at 4 hours. In addition, in the endotoxin stimulated group with the 
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addition of KNK437 there were no significant differences between extracellular HSP70 
release in conditions with and without glutamine (p>0.05) (Figure 3.8). 
 
3.8.2 The effect on glutamine supplementation (2mM) on intracellular HSP70 release at 4 
hours and 24 hours in endotoxin stimulated whole blood is abrogated with the use of 
KNK437 
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Figure 3.9: The effect of KNK437 on intracellular HSP70 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM) 
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin. *p=<0.05, 
**p=<0.005 
 
There was a significant difference in intracellular HSP70 release between groups (p<0.0001). 
In the endotoxin stimulated group the addition of KNK437 significantly inhibited the 
intracellular HSP70 release at 4 hours and 24 hours with glutamine supplementation (2mM) 
(p<0.005). In addition there were significant differences between the intracellular release of 
HSP70 at 4 hours (p<0.005) and 24 hours (p<0.05) without glutamine supplementation. 
These results suggest the release of intracellular HSP70 in endotoxin stimulated whole blood 
is inhibited following the addition of KNK437, when compared to endotoxin stimulation 
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alone. In addition, in the endotoxin stimulated group with the addition of KNK437 there 
were no significant differences between intracellular HSP70 release in conditions with and 
without glutamine (p>0.05). The effect of glutamine on HSP70 release also appears to be lost 
following the addition of KNK437 (Figure 3.9).  
 
3.8.3 The addition of KNK437 diminishes the release of inflammatory mediator in 
endotoxin stimulated whole blood 
To consider the effect of HSP70 on in endotoxin stimulated whole blood following the 
addition of KNK437, the release of inflammatory markers were investigated. 
 
3.8.4 KNK437 attenuates the release of extracellular IL-6 in endotoxin stimulated whole 
blood  
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Figure 3.10: The effect of KNK437 on extracellular IL-6 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM) 
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine. *p<0.05, **p<0.005 
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There was a significant differences in extracellular IL-6 release between groups (p<0.0001). 
Following the addition of KNK437 in endotoxin stimulated whole blood, the release of IL-6 
was significantly attenuated compared to conditions without the addition of KNK437. 
Extracellular release of IL-6 was significantly inhibited with the addition of KNK437 at 4 hours 
with glutamine supplementation (2mM) (p<0.05) and without (p<0.005), in addition to 24 
hours with and without glutamine (p<0.05). In the endotoxin stimulated condition there was 
no significant difference between IL-6 release with glutamine supplementation (2mM) at 4 
or 24 hours compared to conditions without glutamine supplementation (Figure 3.10). 
 
3.8.5 KNK437 attenuates the release of intracellular IL-6 in endotoxin stimulated whole 
blood  
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Figure 3.11: The effect of KNK437 on intracellular IL-6 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM)  
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin. *p<0.05, 
**p<0.005  
 
There was a significant differences in intracellular IL-6 release between groups (p<0.0001). In 
the endotoxin stimulated group KNK437 had a significant inhibitory effect on intracellular IL-
6 release in conditions with and without glutamine at 4 hours (p<0.05) and 24 hours with 
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glutamine (p<0.05) and without glutamine (p<0.005), suggesting that HSP70 inhibition 
affects the intracellular release of IL-6. There was no significant difference between 
endotoxin stimulated groups with glutamine supplementation (2mM) compared to the 
control condition without glutamine at either time point (Figure 3.11). 
 
3.8.6 KNK437 attenuates the release of extracellular TNF-α in endotoxin stimulated whole 
blood  
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Figure 3.12: The effect of KNK437 on extracellular TNF-α release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM)  
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin * p<0.05  
 
There was a significant differences in extracellular TNF-α release between groups 
(p<0.0001). KNK437 had a significant inhibitory effect on extracellular TNF-α release with 
and without glutamine (p<0.05) at 4 hours and 24 hours, suggesting that HSP70 inhibition 
affects the release of TNF-α. In the endotoxin stimulated conditions with KNK437 there were 
no significant differences between conditions with and without glutamine at 4 and 24 hours 
(Figure 3.12). 
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3.8.7 KNK437 attenuates the release of intracellular TNF-α in endotoxin stimulated whole 
blood  
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Figure 3.13: The effect of KNK437 on intracellular TNF-α release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (2mM) 
(n=18). Results are expressed as mean; ± SEM. Gln = glutamine, LPS=endotoxin. **p<0.005, 
***p<0.0001  
 
There was a significant difference in intracellular TNF-α release between groups (p<0.0001). 
In the endotoxin stimulated group KNK437 had a significant inhibitory effect on intracellular 
TNF-α release with glutamine (2mM) (p<0.005) and without glutamine (p<0.0001) at both 4 
hours and 24 hours with and without glutamine (p<0.0001), suggesting that HSP70 inhibition 
affects the release of TNF-α. In the endotoxin stimulated conditions with KNK437 there was 
no significant difference between glutamine supplemented groups compared to control 
groups (Figure 3.13) 
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3.8.8 KNK437 attenuates the release of extracellular IL-10 in endotoxin stimulated whole 
blood  
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Figure 3.14: The effect of KNK437 on extracellular IL-10 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (n=18). 
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, 
**p<0.005 
 
There were significant differences in extracellular IL-10 release between groups (p<0.0001). 
In endotoxin stimulated conditions the addition of KNK437 had a significant inhibitory effect 
on extracellular IL-10 release at 4 hours without glutamine (p<0.05), in addition to 24 hours 
with (p<0.005) and without (p<0.05) glutamine, suggesting the inhibition of HSP70 with 
KNK437 affects the release of IL-10. There was no significant difference between glutamine 
supplementation conditions in endotoxin stimulated blood with the addition of KNK437 
(Figure 3.14). 
 
 
 
 
98 
 
3.8.9 KNK437 attenuates the release of intracellular IL-10 in endotoxin stimulated whole 
blood  
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Figure 3.15: The effect of KNK437 on intracellular IL-10 release at 4 hours and 24 hours in 
endotoxin stimulated whole blood with and without glutamine supplementation (n=18). 
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, 
**p<0.005 
  
There were significant differences in intracellular IL-10 release between groups (p<0.0001). 
In the endotoxin stimulated group KNK437 had a significant inhibitory effect on intracellular 
IL-10 release without glutamine at 4 hours (p<0.05) in addition to with and without 
glutamine at 24 hours (p<0.05), suggesting that with KNK437 the release of IL-10 is inhibited. 
In the endotoxin stimulated KNK437 group there were no significant differences between 
conditions with and without glutamine (Figure 3.15). 
 
3.8.10 Summary of KNK437 results from in vitro adult endotoxin stimulation model 
The addition of KNK437 to the endotoxin stimulation model appeared to significantly inhibit 
the intracellular and extracellular release of HSP70 and inflammatory mediators (IL-6, IL-10, 
TNF-α) abrogating the effect of glutamine supplementation.  
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3.9 An in vitro model examining the effects of endotoxin and glutamine on HSP70 release 
and markers of the inflammatory responses in healthy paediatric volunteers 
 
The effect of glutamine supplementation on HSP70 and inflammatory mediator release in 
endotoxin stimulated blood from children was investigated.  Samples were processed using 
methods described in Chapter 2. 
 
3.9.1 Glutamine supplementation upregulates HSP70 release in endotoxin stimulated 
whole blood from healthy paediatric volunteers 
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Figure 3.16: The effect of glutamine supplementation (2mM) on LPS stimulated HSP70 
release at 4 hours and 24 hours in whole blood from healthy paediatric volunteers (n=25). 
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin **p<0.005, 
***p<0.0005 
 
There were significant differences in HSP70 release between 4 hours and 24 hours 
(p<0.0001).  Glutamine supplementation significantly upregulates HSP70 release at 24 hours 
in 1μg/ml endotoxin stimulated whole blood (p<0.05) compared to conditions without 
glutamine supplementation. As expected the release of HSP70 significantly increased over 
100 
 
time at 4 hours and 24 hours in all conditions (p<0.0005) As with the adult endotoxin model 
the release of HSP70, similarly increased over time from 4 hours to 24 hours in conditions 
with no endotoxin. As the release of inflammatory mediators, within the paediatric model 
indicated low levels of release with no endotoxin it is likely the methods are robust and the 
release of HSP70 in unstimulated blood is in response to the experimental conditions (Figure 
3.16). 
 
3.9.2 The effect of glutamine supplementation on release of inflammatory cytokines using 
endotoxin stimulated whole blood from healthy paediatric volunteers  
 
The effect of glutamine supplementation on the release of inflammatory cytokines IL-6, TNF-
α and IL-10, in endotoxin stimulated whole blood using one dose of LPS, 1µg/ ml LPS without 
and without glutamine supplementation was investigated.  
 
3.9.3 The release of IL-10 in endotoxin stimulated whole blood from healthy paediatric 
volunteers was not influenced by glutamine supplementation (2mM) 
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Figure 3.17: The effect of glutamine supplementation on endotoxin stimulated release of 
IL-10 in whole blood from healthy paediatric volunteers at 4 hours and 24 hours (n=25).  
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin. *p=0.05, 
**p<0.005, ***p<0.0005 
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There were significant differences in IL-10 release between groups (p<0.0001). There was a 
significant difference between IL-10 release with glutamine supplementation (2mM) with no 
endotoxin at 24 hours (p<0.05) but not in the endotoxin stimulated conditions. As would be 
expected there were significant differences in the release of IL-10 in the endotoxin 
stimulation group at 4 hours and 24 hours with and without glutamine supplementation 
(p<0.0005). Glutamine supplementation had no significant effect on the release of IL-10 
(Figure 3.17).  
 
3.9.4 The release of IL-6 in endotoxin stimulated whole blood from healthy paediatric 
volunteers was not influenced by glutamine supplementation (2mM) 
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Figure 3.18: The effect of glutamine supplementation on endotoxin stimulated release of 
IL-6 in whole blood from healthy paediatric volunteers at 4 hours and 24 hours (n=25).  
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin ***p<0.0005 
 
There were significant differences between IL-6 groups (p<0.0001). As expected in endotoxin 
stimulated whole blood there was a significant increase in the release of IL-6 at 24 hours 
compared to 4 hours with and without glutamine supplementation (2mM) (p<0.0005). There 
was no significant difference in IL-6 release following glutamine supplementation in 
endotoxin stimulated whole blood, at 4 or 24 hours, though at the latter timepoint there 
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appeared to be a slightly higher level of measured IL-6 in glutamine supplemented wells 
compared to non-supplemented controls Figure 3.18). 
 
3.9.5 The release of TNF-α in endotoxin stimulated whole blood from healthy paediatric 
volunteers was augmented with glutamine supplementation (2mM) 
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 Figure 3.19: The effect of glutamine supplementation on endotoxin stimulated release of 
TNF-α in whole blood from healthy paediatric volunteers at 4 hours and 24 hours (n=25).  
Results are expressed as mean; ± SEM. Gln = glutamine, LPS = endotoxin *p<0.05, 
**p<0.005 
 
There were significant differences between TNF-α groups (p<0.0001). As to be expected 
there were statistically significant differences in TNF-α release in endotoxin stimulated blood 
at 4 hours and 24 hours with (p<0.005) and without glutamine (p<0.05). Glutamine 
supplementation in endotoxin stimulated conditions stimulated TNF-α release at 4 hours 
(p<0.05), suggesting under these conditions glutamine promoted a pro-inflammatory 
response (Figure 3.19). 
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3.9.6 Relationships between HSP70 and inflammatory mediators in paediatric in vitro 
endotoxin stimulated whole blood following glutamine supplementation (2mM) 
Spearmen’s correlation was used to investigate whether there was a relationship between 
HSP70 and inflammatory mediators in paediatric in vitro endotoxin stimulated whole blood 
following glutamine supplementation (2mM). There were relationships between HSP70 and 
IL-6, TNF-α at 4 hours following glutamine supplementation but no relationship between 
HSP70 and IL-10 (Table 3.2). 
 
Table 3.2 Relationships between paediatric in vitro endotoxin stimulated HSP70 release 
and inflammatory mediators following glutamine supplementation (2mM) 
 IL-6 (pg/ml) 
1μg/ml LPS 
4 hours Gln 
TNF-α (pg/ml) 
0.1μg/ml LPS  
4 hours Gln  
HSP70  (ng/ml) 
4 hours Gln 
1μg/ml LPS 
r=0.61 
p=0.004 
n=25 
r=0.60 
p=0.005 
n=25 
 
3.9.7 Summary of experimental results of in vitro paediatric endotoxin stimulation model 
Glutamine supplementation significantly increases HSP70 release in paediatric endotoxin 
stimulation model at 24 hours. The effect of glutamine supplementation on the release of 
inflammatory mediators was less clear. There were positive correlations with IL-6 and TNF-α 
in glutamine supplemented conditions at 4 hours, but no relationships between HSP70 and 
IL-10 following glutamine supplementation at either time point. In endotoxin stimulated 
whole blood there was a significant difference in the release of TNF-α at 4 hours with 
glutamine supplementation compared to conditions without glutamine. In these 
circumstances glutamine supplementation appeared to promote the release of TNF-α 
suggesting a pro-inflammatory effect. A similar effect was seen with IL-6, although this was 
not significant. Glutamine supplementation appeared to have no effect on the release of IL-
10. 
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3.10 Comparison between HSP70 in a whole blood endotoxin stimulation model with 
healthy paediatric volunteers and healthy adult volunteers  
There were significant differences in HSP70 release between healthy adult volunteers (n=18) 
and healthy paediatric volunteers (n=25) (p<0.0001). HSP70 release in paediatric samples 
was statistically significantly higher than in adults in all comparable conditions with and 
without glutamine supplementation (Table 3.3) 
 
Table 3.3: A comparison of HSP70 release in adult and paediatric samples 
Conditions HSP70 Adult ng/ml 
mean (±SD) 
HSP70 Paediatric 
ng/ml mean (±SD) 
Statistical 
Significance 
4 hours no LPS without 
glutamine 
0.53 (0.31) 4.50 (2.9) p<0.01 
4 hours no LPS with 
glutamine 
0.50 (0.47) 4.65 (2.5) p<0.01 
24 hours no LPS 
without glutamine 
1.05 (0.76) 10.20 (5.57) p<0.001 
24 hours no LPS with 
glutamine 
1.18 (0.65) 12.97 (6.92) p<0.001 
4 hours 1µg/ml LPS 
without glutamine 
0.45 (0.32) 3.79 ( 3.6) p<0.01 
4 hours 1µg/ml LPS 
with glutamine 
0.83 (0.69) 4.62 (2.3) p<0.01 
24 hours 1µg/ml LPS 
without glutamine 
1.26 (1.37) 13.1 (4.4) p<0.001 
24 hours 1µg/ml LPS 
with glutamine 
1.91 (1.41) 16.01 (6.7) p<0.001 
 
3.10.1 Comparison between inflammatory mediator (IL-6, IL-10 and TNF-α) release in a 
whole blood endotoxin stimulation model with healthy paediatric volunteers and healthy 
adult volunteers  
Using Kruskal-Wallis one way ANOVA of variance there was a significant difference in the 
release of inflammatory mediators (IL-6, IL-10, TNF-α) between comparable conditions in the 
healthy adult and paediatric groups (p<0.0001). However, a post-hoc test using Dunn’s 
multiple comparisons showed there were no significant differences between comparative 
adult and paediatric samples (p>0.05). In endotoxin stimulated blood, HSP70 release in 
children was significantly higher than in adults, although there was no significant difference 
in the release of inflammatory mediators. 
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3.11 Discussion 
The use of in vitro endotoxin stimulation models to study the effects of sepsis are well 
described (26, 193, 370), and have been used to investigate the release of HSP70 (93, 197) 
and inflammatory mediators (371, 372), furthering the understanding of the inflammatory 
response following immune activation (26). In experimental models of sepsis, HSP70 release 
has been shown to improve outcome (129), decreasing mortality (310), which is associated 
with diminished release of inflammatory mediators such as TNF-α (404). 
 
The use of endotoxin from E. coli 0111:B4 has been used in other in vitro models considering 
HSP70 release (41, 128, 193-196) and doses of 0.1μg – 10μg/ml have been shown to be 
effective to upregulate the release of HSP70 (93, 390, 405-407). The results from the in vitro 
stimulation model showed a range of endotoxin doses (0.1μg – 1μg/ml) were effective in 
promoting HSP70 release in both children and adults, although these levels of endotoxin are 
in excess of any described during critical illness (0.03 – 0.3μg/ml) (372, 408).  
 
Glutamine supplementation (2mM) in the adult and paediatric in vitro endotoxin stimulation 
model significantly increased HSP70 release at 24 hours, compared to conditions without 
glutamine, including those conditions with no endotoxin. There was a significant release of 
HSP70 in unstimulated whole blood control wells although, this was unlikely to be as a result 
of endotoxin contamination given that inflammatory mediator levels were low at each 
timepoint in control wells. Instead it is likely to be a physiological response to the 
experimental conditions, and has previously been described in vitro and in vivo studies (215, 
310, 311, 409). Glutamine has been shown to effectively promote HSP70 release in 
experimental sepsis (in vivo and in vitro) (310, 311, 345, 390) and during critical illness (143), 
as described in Chapter 1. The concomitant administration of endotoxin and glutamine 
(0.75g/kg) together in a septic rat model was shown to significantly increase the release of 
HSP70, improving ADP/ATP ratio reducing metabolic dysfunction (311). The dose of 
glutamine supplementation (2mM) used in this experimental model was modest compared 
to those reported  in other in vitro models, considering HSP70 release, where between 
0.5mM – 10mM glutamine have been used (203, 314, 390, 407). Doses of less than 2mM 
glutamine did not significantly increase HSP70 release (390). The endotoxin stimulated 
release of HSP70 was significantly higher with glutamine supplementation in children (mean 
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16.01ng/ml; ±SD 6.7) compared to adult (mean 1.91ng/ml; ±SD 1.41). This pattern of release 
has previously been described in critically ill adults (143) and children with septic shock 
(141). HSP70 transcription decreases with age and the release in adults and mature animal 
models is considerably less than observed in youth (135, 410) as confirmed by the results 
seen in the paediatric and adult in vitro endotoxin stimulation model.  
 
The clinical concern, relative to this phenomenon, would be the effect of significantly higher 
HSP70 levels on the inflammatory response and the potential to over stimulate the release 
of inflammatory mediators in response to sepsis (141), especially since an excessive release 
of inflammatory mediators is associated with increased risk mortality (63, 87-89). Even 
though, the in vitro release of HSP70 between adults and children was significantly different, 
this did not appear to result in a heightened release of inflammatory mediators in the 
paediatric model, and there were no significant differences relative to the release of TNF-α, 
IL-6 and IL-10 between the two comparable models.  As such, although HSP70 levels were 
considerably higher in endotoxin stimulated whole blood from healthy children this did not 
appear to result in a significantly elevated release of inflammatory mediators.  
 
Glutamine supplementation significantly attenuated the in vitro release of IL-10 at 4 hours 
and IL-8 at 24 hours in endotoxin stimulated adult whole blood, which has been described in 
experimental rat endotoxin models (392, 411) and from human duodenal biopsies (412). 
There was however, no significant difference in endotoxin stimulated release of IL-1β, IL-6 
and TNF-α following glutamine supplementation, although glutamine did appear to 
attenuate the release of inflammatory mediators. Results from other in vitro work has 
shown that glutamine supplementation in doses greater than 2mM significantly attenuates 
the release of TNF-α and IL-10 in human blood peripheral mononuclear cells (86) and in a rat 
model of sepsis (392), in addition to IL-6 and IL-8 in human intestinal epithelial and cell lines 
(203, 398, 412, 413). As a result it is likely that glutamine supplementation in excess of 2mm 
is required to significantly attenuate the release of inflammatory mediators. 
 
Glutamine supplementation in endotoxin stimulated blood from paediatric volunteers 
significantly increased the release of TNF-α at 4 hours. Although, at 24 hours the release of 
IL-6 and TNF-α in endotoxin stimulated blood was not significantly different, glutamine 
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supplementation appeared to promote the release of these inflammatory mediators. 
Glutamine supplementation significantly increased IL-10 release at 24 hours in endotoxin 
free conditions, but had no discernible effect on IL-10 at 4 or 24 hours following endotoxin 
stimulation. Glutamine supplementation has been reported to promote a pro-inflammatory 
response in other in vitro work using human macrophages (399, 407). As glutamine is rapidly 
consumed by immune cells, it could be argued that glutamine supplementation provided 
substrate for optimal HSP70 production supporting an appropriate inflammatory response 
(409), which in the paediatric model may be pro-inflammatory. It could also be that in the 
paediatric model where HSP70 release is significantly higher compared to adults, a larger 
dose of glutamine may be required to mediate a dampening or anti-inflammatory effect on 
the release of inflammatory mediators (203, 398, 412, 413). Further to this, doses of  
between 4 – 10mM of glutamine are required to attenuate TNF-α, IL-8 and IL-6 release 
following HSP70 upregulation (86, 314, 348) and although a dose of 2mM of glutamine was 
able to significantly upregulate the release of HSP70 it may not have been sufficient to 
attenuate the release of inflammatory mediators as described elsewhere (390).  
 
The amount of HSP70 released may influence the temporal mix of inflammatory mediators. 
However, the relationship relative to the amount of HSP70 protein released and subsequent 
inflammatory response is not well explored. There is some work from an in vitro (PBMC’s) 
model of sepsis showing over production of HSP70 limits the release of IL-1β, TNF-α, IL-10 
and IL-12, however, the relative amount of HSP70 released is not provided (93) and it may 
still be lower than recorded in the in vitro paediatric model. It could argued that in the adult 
model, glutamine supplementation attenuated the release of the inflammatory mediator 
relative to the low HSP70 release (1.91ng/ml; ±SD 1.41) when compared to HSP70 levels in 
children (16.01ng/ml; ±SD 6.7) and it may be that the difference in the patterns of HSP70 
release influence the mix of inflammatory mediators.  
 
In this work, HSP70 levels in vitro rose over time and were correlated with inflammatory 
mediators (IL-1β, TNF-α, IL-8) in adults, and IL-6, TNF-α in paediatric samples at 4 hours, 
following glutamine supplementation (2mM). The effects seen suggest the release of HSP70 
influences the inflammatory response, as described in other work (93), although further 
work would be required to investigate these relationships to establish causality. Interestingly 
108 
 
there were no relationships between HSP70 and IL-10 in either adults or children following 
glutamine supplementation, which may be relative to the small sample size. 
 
It has been hypothesised that, in the presence of an infection, glutamine is rapidly consumed 
reducing the amount available for stimulating HSP70 production and the subsequent 
influence on the inflammatory response (409). Glutamine (2mM) is the equivalent to 0.3g/kg 
glutamine, and it may be that a larger dose of 4mM glutamine is required (0.6g/kg) to 
significantly attenuate the release of inflammatory mediators (390), which is also reflected in 
the result from glutamine clinical trials in critically ill adults (237).  The dichotomy of these 
results, with respect to the release of inflammatory mediators are surprising, however 
results from other endotoxin in vitro work show the release of HSP70 can mediate both a 
pro- (399, 407) or anti-inflammatory (414-416) response. Furthermore, glutamine 
supplementation has been also been shown to stimulate a pro-inflammatory response in 
vitro (399) but in vivo is shown to attenuate pro-inflammatory cytokine release during sepsis 
(86, 399, 417, 418), which is likely to be as a result of increased HSP70 release (390).  
 
In order to understand the influence of HSP70 on the release of inflammatory mediators, a 
HSP70 inhibitor (KNK437) was used. KNK437 has been shown to be effective at preventing 
HSP70 release in vitro (387) and in vivo models (419) by inhibiting HSF-1 transcription (198) 
significantly reducing the amount of HSP70 release (385). Other work using quercitin as the 
HSP70 inhibitor, show the effects of glutamine on HSP70 release are almost completely 
inhibited (311). Results from the adult endotoxin stimulation model show KNK437 
significantly inhibited the extracellular release of HSP70 at 24 hours in conditions with and 
without glutamine supplementation (2mM). In addition, the intracellular release of HSP70 in 
endotoxin stimulated blood was significantly inhibited at 4 hours and 24 hours in conditions 
with and without glutamine supplementation compared to comparable endotoxin 
stimulated whole blood, a finding reported in other similar models (420, 421). The effect of 
glutamine supplementation, following the addition of KNK437, on HSP70 release in the adult 
endotoxin stimulation model was abrogated, similar to findings described by Singleton et al. 
(311).  
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In endotoxin stimulated blood KNK437 had a significant inhibitory effect on the intracellular 
and extracellular release of inflammatory mediators (IL-6, IL-10, TNF-α) at 4 hours and 24 
hours in conditions with and without glutamine compared to similar endotoxin stimulated 
blood. There was no significant difference in the release of inflammatory mediators between 
glutamine and unsupplemented conditions in endotoxin stimulated blood with KNK437.  Lee 
et al. showed the use of KNK437 in endotoxin pre-treated rat macrophages, inhibited the 
expression of HSP70, partially preventing the release of TNF-α (422). In a hyperthermic 
mouse model, the addition of KNK437 inhibited the release of HSP70 and IL-6 (423). The 
inhibitory effect of KNK437 on HSP70 release, suggests that in part, HSP70 orchestrates the 
release of inflammatory mediators in response to stress, which is reported in other models 
(93).  
 
Within the context of a whole systems perspective, it is hypothesised that during an 
infection HSP70 forms complexes with pathogens, promoting a pro-inflammatory response, 
activating innate immune cells, upregulating TLR signalling and inflammatory pathway 
signalling. As pathogenic organisms are eliminated and supra-physiological levels of alarmins 
are no longer required, HSP70 acts to downregulate the immune and inflammatory response 
promoting homeostasis (191).  Glutamine is likely to play an important role in the response 
to infection and has been shown to reduce the risk of sepsis in pre-term infants (424) and 
decrease the incidence of gram-negative bacteraemia in severely burned patient (206) and 
multiple trauma (281). By contrast, glutamine depletion in sepsis is associated with 
increased risk of mortality (243). It may be that providing glutamine supplementation 
potentiates an appropriate immune response to infection (409), which may differ in adults 
compared to children but involves a timely resolution to the inflammatory response within 
both age groups. 
 
There are a number of limitations to this work which include the investigation of only one 
dose of glutamine (2mM), which significantly upregulated HSP70 release in both adult and 
paediatric endotoxin stimulation models. The effect of glutamine supplementation on the 
release of inflammatory mediators is less clear. In adults, glutamine supplementation 
significantly attenuated the release of IL-8 but in children significantly promoted the release 
of TNF-α. It may be that a large dose of glutamine (≥2mM) is required in both adult and 
110 
 
paediatric models to significantly mediate the release of inflammatory mediators. Although 
a range of pro- and anti-inflammatory mediators were selected for study based on previous 
work in meningococcal disease, it was not possible to examine all those of interest (TNF-α, 
IL-8, IL-6, IL-10) within a single validated multiplex plate. Due to the limitation on blood 
volume available from paediatric samples there was insufficient to be able to run separate 
plates for all of the inflammatory mediators of interest. The inflammatory mediators (TNF-α, 
IL-6, IL-10) chosen for study in the paediatric in vitro stimulation model have been extremely 
well studied in meningococcal disease (77, 78) and were chosen for this reason. Further to 
this, the directional release of inflammatory mediators in the adult in vitro stimulation model 
is the converse to the paediatric model (e.g. in the adult model inflammatory mediator 
release including IL-8 appears to be attenuated following glutamine supplementation). It 
could therefore be postulated that IL-8 release in the paediatric model would increase 
following glutamine supplementation as seen with IL-10, TNF-α and IL-6. However, in order 
to confirm, this future assasys in children would be required to examine the relationship 
between HSP70 and IL-8 release following glutamine supplementation. Other limitations in 
the in vitro models of this study, was the lack of discrimination between live and dead cells, 
which may be a criticism with respect to the source of HSP70 release (e.g. passive release or 
as a result of necrosis).  
 
3.12 Conclusion 
These results would suggest that glutamine supplementation (2mM) promotes HSP70 
release in an in vitro endotoxin stimulation model in adults and children. When HSP70 
production was partially inhibited through the use of KNK437 the release of inflammatory 
mediators (IL-6, IL-10, TNF-α) was attenuated. This would suggest that glutamine given at 
therapeutic doses ≥0.3g/kg (≥2mM) could augment HSP70 production, although a large dose 
of 0.6g/kg (4mM) may be required to influence the mix of cytokines released. As glutamine 
depletion is common in sepsis (425), the mediation of HSP70 release during critical illness, 
may make it a useful therapeutic strategy. A randomised clinical trial administering 
glutamine, as a nutraceutical, in critically ill children would be required to test this 
hypothesis further.  
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The results from this work highlight the need to explore the relationships of glutamine, 
HSP70 and inflammatory mediators further. In order to achieve this stored plasma from a 
cohort of children with meningococcal disease during the acute phase of illness was 
analysed to investigate protein levels of HSP70, glutamine and inflammatory mediators. 
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Chapter 4: 
Heat shock protein 70, glutamine and inflammatory 
markers during the course of meningococcal disease 
and the relationship to clinical indices 
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Chapter 4: Heat shock protein 70, glutamine and inflammatory markers during the course 
of meningococcal disease and the relationship to clinical indices 
 
4.1 Introduction 
Following infection, signalling pathways associated with inflammation and immunity become 
upregulated, influencing cell to cell signalling and promoting a gene regulated response to 
stress (338, 426). Activation of these pathways stimulates the release of numerous 
chemokines, cytokines and other mediators including catabolic hormones (glucagon, growth 
hormone, cortisol), prostaglandins and catecholamines promoting catabolism (breakdown 
and release of substrate for energy).  
 
4.2 Glutamine and critical illness 
During critical illness glutamine synthesis is not diminished when compared to normal 
healthy volunteers, however as a result of the net efflux of glutamine from skeletal muscle, 
depletion occurs (427). Although plasma concentrations do not accurately reflect the 
intracellular glutamine concentration (428) which varies dependent on the type of cell (429, 
430), it is currently the best proxy for glutamine depletion (431). 
 
Glutamine deficiency in adult ICU patients is well documented and has been shown to be an 
independent risk factor for mortality (209, 240, 243, 432). Plasma glutamine levels of 0.3 – 
0.5mmol/l and of 15mmol/l of glutamine in muscle are known to occur post surgery, trauma 
and in sepsis (433), which are lower than in healthy individuals with a usual range of 0.6 – 
0.7mmol/l in plasma (216, 217) and 20 - 25mmol/l (216, 219, 220) in muscle.  
 
Administration of glutamine has been shown to be safe and is not associated with a rise of 
toxic ammonia or glutamate levels (206, 209, 424). Orally administered glutamine has less of 
an effect on plasma levels, as it is rapidly metabolised by enterocytes within the 
gastrointestinal tract (434) and as such during critical illness IV glutamine has greater efficacy 
(282, 435). Pharmacokinetic studies investigating clearance and tolerance of glutamine have 
indicated no adverse effects and plasma levels of ≥2mmol/l are well tolerated (274). 
Glutamine dipeptides are metabolised almost immediately into their individual amino acids 
e.g. L-glutamine and L-alanyl (436, 437). In order to increase plasma levels to 0.6mmol/l an 
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infusion of 40 – 60g/24 hours was required in adults. A dose of 0.57g/kg/24 hours resulted in 
a plateauing of plasma glutamine approximately 25% above controls, which did increase  
ammonia or glutamate levels (438). Intravenous glutamine given at a dose of ≥0.3g/kg has 
been shown to restore plasma glutamine levels in critically ill adults, but larger doses of up 
to 0.86g/kg of glutamine are also shown to be are well tolerated (275). In post operative 
adult patients, a daily IV dose of glutamine prevented further skeletal muscle loss (439, 440), 
although it is not clear whether supplementation influences endogenous skeletal losses 
during critical illness (275). In stable critically ill adults with MODS net glutamine loss from 
muscles continued for 2 weeks (441), suggesting that losses continue despite a resolution of 
the immediate response to infection. In addition, if glutamine supplementation is 
discontinued prematurely then glutamine levels fall again (209).  
 
Glutamine upregulates HSP70 release in vitro (203) and in vivo models of injury and adult 
trauma (204, 311, 442, 443), and has been correlated with decreased organ damage and 
mortality (310, 443), it could potentially be of benefit to critically ill children. 
 
As children with meningococcal disease are often severely ill, they are a good clinical model 
for studying the effect of critical illness on glutamine, HSP70 and inflammatory mediators 
and the relationship to clinical indices.  
 
4.3 Aims 
1. To examine levels of HSP70, glutamine and markers of inflammation in children with 
meningococcal disease during the acute phase of illness compared to convalescence. 
 
2. To examine relationships between clinical variables (including nutrition support), 
HSP70, markers of inflammation and glutamine in children with meningococcal 
disease during the acute phase of illness compared to convalescence. 
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4.4 Results 
4.4.1 Patient demographics and sample collection 
Acute plasma samples were obtained from 143 Caucasian children and 78 convalescent 
samples. Eighty-three (58%) were males and 60 (42%) were females. The median age of was 
2 years (min 0.02 months – maximum 17.2 years) and the mortality rate was 4.7% (n=7). 
Blood samples were also obtained from 35 healthy aged matched paediatric controls, of 
which 13 (27%) were female and 22 (63%) were males, median age 3.8 years (min 0.38 – 
max 16 years). Table 4.1 outlines the patient demographics. 
 
Samples were analysed for HSP70, inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TNF-α) in 
addition to glutamine using methods described in chapter 2. In addition to this a folder 
review was completed. Patients with acute meningococcal disease were severely ill and 
required multi-organ support, including ventilation and renal support. Patient demographics 
and  PICU support data is shown in Table 4.1, laboratory data in Table 4.2 and nutrition data 
in Table 4.3.  
 
Table 4.1: Patient demographics and PICU support of children with acute meningococcal 
disease 
 Number  
Percentage 
(%) 
Median Range 
(min – max) 
Mean 
(±SD) 
Decimal age (years)  2.0 0.02 -17.2 3.1 (±3.1) 
Weight (kg)   12  3 -  70 15.3 (±10.4) 
Weight for age Z 
scores * 
 0.1 -4.1 - 4.8 0.2 (±1.2) 
PRISM  26 10 - 89.8 31.9 (±20.3) 
PIM2  9.1 3.6 - 65.5 13.7 (±18.4) 
Days on PICU  7 3 – 63 8.8 (±7.6) 
ICU free days  21 0 – 25 18.7 (±6.7) 
Mechanic ventilation 143 (100%)    
Duration of 
ventilation 
 6 2 – 45 7.4 (±5.9) 
Deaths 7 (4.7%)      
Renal support 124 (81%)     
Urea (mmol/l)** 
 
 6.40 1 – 42.7 8.9 (±8.5) 
Creatinine (μmol/L)  60 24 – 535 88 (±92.5) 
Inotropes 123 (83%)     
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Steroids 108 (73%)     
Glucose (mmol/l)  8.8 3.8 – 29.5 10.4 (±5.7) 
Noradrenaline 
(mcg/kg/min) 
 0.25 0.4 – 2.4 0.5 (±0.7) 
Adrenaline 
(mcg/kg/min) 
 0.6 0.01 - 6.3 1.0 (±0.6) 
Dobutamine 
(mcg/kg/min) 
 10  5 – 40 12.6 (±7.7) 
Dopamine 
(mcg/kg/min) 
 10 2.5 – 28 12.2 (±6.9) 
*(normal range -1 to 1), **(normal range 2.5 – 7.8) 
 
Patients with acute meningococcal disease had deranged clinical parameters. Although 
median levels of clinical variables including white cell count (WCC), internationalized normal 
ratio (INR), potassium, sodium, calcium, phosphate and magnesium were all found to be 
within normal range, 81% of the cohort were receiving renal support for raised levels of 
renal function markers. Up to 83% of children required inotropic support, which were 
administered in high doses. The majority of patients received steroids 73% which may have 
contributed to the high glucose levels seen within the cohort of 10.4mmol/l; ±SD 5.68 (Table 
4.2). 
 
Table 4.2: Patient demographics and clinical values of children with acute meningococcal 
disease 
Laboratory Value Paediatric 
reference  
range  
Median Range 
(min-max) 
Mean  
(±SD) 
WCC (x 109/l) 4.0 - 11.0 5.7 1.1 – 46 8.4 (±9.1) 
Platelets (x 109/l) 150 – 400 162 15 – 513 180 (±88.1) 
INR 0.9-1.2 1.5 0.9 - 5.9 2.4 (±1.3) 
CRP (mg/l) < 10 78.5 4.5 – 483 93.7 (±82.4) 
Potassium (mmol/l) 3.5 – 5.0 3.55 2.2 – 6 3.6 (±0.7) 
Base Excess (mEq/L) −2 - +2  -8.8  -24.4 – 20 -9.5 (±6.0) 
Lactate (mmol/l) 0.6 – 2.5 3.8 0.5 - 18.5 3.3 (±3.9) 
Sodium (mmol/l) 133 – 146 140 127 – 164 138 (±5.7) 
Albumin (g/L) 35 – 50 36 23 – 46 34 (±7.2) 
Calcium corrected 
(mmol/l) 
2.2 – 2.6 2.2 0.9 - 3.1 2.1 (±0.4) 
Phosphate (mmol/l) 0.9 – 1.8 0.9 0.5 - 3.2 0.94 (±0.4) 
Magnesium (mmol/l) 0.7 – 1.0 0.7 0.4 - 1.5 0.8 (±0.1) 
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4.4.2 Nutrition Support 
Although enteral feeding was initiated early post admission, it took a number of days before 
the prescribed goal rate was achieved which was likely to be related to the high prevalence 
of gastrointestinal disturbances and inotropic support. Thirty nine percent of feeds were 
delivered via NGT, with the remainder receiving NJT feeds and combination enteral/ 
parenteral (Table 4.4). The glutamine content of all the standard feeds (except Nutrini 
Energy, Infatrini) contained less than 0.5g per 100ml of glutamine. Even at full feeds the 
amount of glutamine delivered enterally was suboptimal at 0.14g/kg day providing only 28% 
of the recommended intake based on 0.5g/kg/day (Table 4.3).  
 
Table 4.3: Feeding characteristics with glutamine intake and plasma levels 
 Reference 
range 
Median Range Mean (±SD) 
Hours nil per mouth  4.5 1 – 96 13.3 (±15.8) 
Days to goal rate  3 0.3 – 10 3.2 (±2.0) 
Goal (ml/hr)  40 5 – 86 39.4 (±14.1) 
Glutamine (g/kg) at 
goal rate of feed  
≥ 0.3 – 0.5 0.14 0 - 0.7 0.14 (±0.1) 
Glutamine (mmol/l)  0.6 – 0.7 0.29 0.05 – 0.6 0.3 (±0.1) 
HSP70 (ng/ml)  0.4 - 0.5 5.7 0.09 - 600.5 26.7 (±79.9) 
Gastric aspirates 
(ml/kg) 
<5 9.3 0.5 – 63 10.4  
(±10.8) 
 
Table 4.4: Nutrition Support, Route & Complications  
 Percentage % 
Age  
0 - 1 yr 15 
> 1 - 5 yrs 68 
> 5 yrs 16 
Feeding Complications  
NPM - too unstable 4 
Tolerated 24 
Gastrointestinal Disturbances* 72 
Gastric Aspirates 
0 - 5ml/kg 19.6 
> 5 - 10ml/kg 33.7 
>10ml/kg 46.7 
Route of Feeding 
NGT 39 
NJT 31.5 
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Enteral & PN 28.5 
PN 1 
Type of feed % (glutamine content per 100ml) 
EBM 2 
Infant formula   48.4 
Infatrini  (glutamine 0.542mg/l00ml) 1 
Pediasure  (glutamine 0.3mg/l00ml) 36.5 
Nutrini Energy  (glutamine 0.9 mg/100ml) 1 
Jevity  (glutamine 0.39mg/100ml 4.5 
PN & Enteral 5.6 
PN  (no glutamine) 1 
Glutamine g/kg at full feeds 
Glutamine g/kg 0.17 
*vomiting/ abdominal distention/ large gastric aspirate/ diarrhoea; **recommendations ≥0.3 – 0.5g/kg 
 
In summary these patient demographics reflect a cohort of severely ill children, requiring 
invasive monitoring and multi-organ system support to maintain haemodynamic stability, 
who received suboptimal amounts of glutamine. 
 
4.5 The effect of freeze thaw cycles on glutamine stability 
As the paediatric plasma samples had been stored for more than 5 years in the department 
freezer, it was necessary to evaluate if repeated freeze/thaw cycles would have an effect on 
glutamine levels in this samples. Therefore, a series of freeze thaw (FT) cycles (B – H) on 
whole blood from healthy adult volunteers were completed prior to measuring plasma 
glutamine levels in the paediatric samples (Figure 4.1).  
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Figure 4.1: Effect of freeze-thawing on glutamine plasma levels in healthy adult volunteers 
(n=3). Results are expressed as mean; ± SEM. FT = freeze-thaw 
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Using Kruskal-Wallis one way ANOVA of variance there were no significant difference in 
glutamine concentration between samples B - H (p>0.05), suggesting that the paediatric 
samples may not be significantly affected by the freeze-thaw cycle. Plasma glutamine levels 
in the healthy volunteers (A) were within normal range mean (±SD) 0.64 mmol/l ± 43.1.  
 
4.6.1 Plasma glutamine levels in children with acute meningococcal disease compared to 
convalescence 
Children with acute meningococcal disease were found to have significantly lower levels of 
glutamine 0.31mmol/l; ±SD 0.13 (median 0.31mmol/l; range 0.05 – 0.64) (p<0.001) 
compared to convalescence 0.40mmol/l; ±SD 0.14 (median 0.40mmol/l; range 0.07 – 0.64) 
(Figure 4.2). During the acute phase of illness, glutamine levels were 52% below the normal 
range (using 0.6mmol/l as the lower reference range) and levels in the convalescent 
samples, taken on average 55 days later (35 – 135 days) were also found to be 26% below 
normal range.  
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Figure 4.2: Glutamine levels in children with acute (n=132) meningococcal disease and 
during convalescence (n=65). Results are expressed as mean; ± SEM ***p<0.0001 
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4.6.2 HSP70 levels in critically ill children with meningococcal disease during the acute 
phase of their illness compared to convalescence 
Mean HSP70 level in children during the acute phase of illness was 26.7ng/ml; ±SD 79.95 
(median 5.7ng/ml; range 0.09 – 600.5ng/ml) which was significantly higher compared to the 
levels in healthy controls (mean 1.26ng/ml; ±SD 1.38 (median 0.703ng/ml range 0.001 – 
5.45ng/ml) (p<0.0001) and to convalescence mean levels, 3.16ng/ml; ±SD 5.67 (median 
1.045ng/ml range 0.001 – 37.31ng/ml) (p<0.0001). HSP70 levels were also significantly 
higher in convalescent samples compared to healthy controls (p<0.05) (Figure 4.3).  
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Figure 4.3: HSP70 levels on admission in children with acute meningococcal disease 
compared to convalescence and healthy paediatric controls. Controls n=35, acute samples 
n=143, convalescent samples n=78. Results are expressed as mean; ± SEM *p<0.05, 
***p<0.0001 
 
4.6.3 Inflammatory mediators in children with acute meningococcal disease compared to 
convalescence  
During the acute phase of illness patients with meningococcal disease had significantly 
higher levels of inflammatory mediators (IL-6, IL-10, TNF-α, IL-8, IL-1β) compared to 
convalescence and levels in healthy controls. There was a significantly higher IL-10: IL-6 ratio 
in children with acute meningococcal disease (mean 12.62pg/ml; ±SD 111.6) compared to 
convalescence (mean 1.47pg/ml; ±SD 3.61) (p= 0.0093) (Figure 4.4). 
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Figure 4.4: Log10 of inflammatory mediators (IL-6, TNF-α, IL-10, IL-8 and IL-1β) in children 
with acute meningococcal disease compared to convalescence. Acute n=132, convalescent 
n=78, controls = 35. Results are expressed as mean; ± SEM **p<0.005, ***p<0.0001 
 
4.6.4 Relationships between HSP70, glutamine and inflammatory mediators 
As the data was skewed with a non-Gaussian distribution it was normalised by a log10 
transformation and a Pearson’s correlation (parametric test) was used. HSP70 was positively 
correlated with IL-10 (n=88, r=0.425; p<0.0001), IL-6 (n=141, r=0.318; p<0.0001) and TNF-α 
(n=145, r=0.206; p=0.013). There were positive correlations of IL-6 with IL-10 (n=87, r=0.916; 
p<0.0001), TNF-α (n=88, r=0.911; p<0.0001) and for IL-8 with IL-1β (n=146, r=0.898; 
p<0.0001). However, glutamine levels did not correlate with levels of HSP70 or the 
inflammatory mediators. 
 
4.6.5 Relationships with HSP70 levels and clinical indices in meningococcal disease cases 
during the acute phase of illness 
There were significant positive correlations with HSP70 levels and i) length for PICU stay 
(n=99, r=0.30, p<0.001), ii) duration of mechanical ventilation (n=99, r =0.31, p<0.001), iii) 
PRISM score (n=99, r = 0.26, p=<0.01), iv) lactate (n=99, r =0.26, p<0.001) and v) CRP (n=99, r 
=0.29, p<0.001). However, there were no correlations with any feeding or nutrition support 
indices. 
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4.6.6 Relationships with glutamine and clinical measures in meningococcal disease cases 
during the acute phase of illness 
There were significant inverse correlations between the amount of glutamine (g/kg) 
administered at the goal rate of feeding and PRISM score (n=98, r= -0.27, p=0.007) and 
between glucose (mmol/l) (n=75, r= -0.26, p=0.015). The number of days to reach the goal 
rate of feeding was positively correlated with the amount of glutamine delivered (n=63, r= 
0.242 p=0.026). Interestingly, no significant correlation was found between glucose and 
plasma glutamine levels, although there was a trend towards a significant inverse correlation 
(n=75, r=-0.20, NS p=0.069). Plasma glutamine and lactate were also inversely correlated 
(n=98, r=-0.41, p<0.001) as was plasma glutamine and CRP (n=98, r=-0.51, p<0.001).  
 
There were other inverse correlations with plasma glutamine levels and i) number of days 
spent in PICU (n=98, r=-0.520, p<0.001) and ii) number of days spent on mechanical 
ventilation (n=98, r=-0.513, p<0.001). 
 
4.6.7 Relationships within clinical variables of children with acute meningococcal disease 
The administration of adrenaline was significantly positively correlated with the number of 
hours a child was nil by mouth (n=62, r=0.229, p=0.046). Positive correlations were also 
found between lactate and PRISM score (n=98, r = 0.451, p<0.001). 
 
In summary, HSP70 was positively correlated with cytokines IL-6, IL-10 and TNF-α, in addition 
to CRP, length of ICU stay and mechanical ventilation, suggesting that HSP70 is closely 
associated with the acute phase of critical illness. Glutamine levels and the amount of 
glutamine administered were inversely correlated with mechanical ventilation and the 
number of days spent in ICU, suggesting that low levels of glutamine are associated with an 
increase in morbidity. The amount of glutamine delivered at goal rate was also found to be 
positively correlated with the number of days to achieve goal rate of nutrition support. The 
amount of glutamine delivered via nutrition support was also associated with 
hyperglycaemia and PRISM score. However, there was a lack of association between 
glutamine and HSP70 levels and inflammatory mediators. 
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4.6.8 Relationships between categorical and clinical variables in children with acute 
meningococcal disease 
To explore the strength of relationships between clinical variables further, direct logistic 
regression was performed on a number of categorical and continuous variables. A number of 
different models were constructed considering, for example the effect of insulin 
administration on a range of variables including glucose, glutamine, IL-6, HSP70 and IL-10. 
No significant impact was found and therefore these models were not included. The only 
model showing significance was the likelihood of certain variables in predicting steroid 
administration during the acute phase of illness.  The model contained 7 independent 
variables (glutamine, HSP70, IL-10, IL-6, TNF-α, glucose, CRP). The model was able to predict 
which children received steroid or not in the acute phase with statistical precision of χ2 (7, 
n=49 = 17.1 p=0.014). The model as a whole explained between 30.2% (Cox and Snell R2) and 
46.1% (Naglekerke R2) of the variance in steroid administration, and correctly classified 
81.6% of cases. As shown in Table 4.5 four independent variables made a unique statistically 
significant contribution to the model (glutamine, IL-10, IL-6, TNF-α) although there was a 
trend towards significance with (glucose and CRP). The strongest predictor of steroid 
administration was IL-10, recording an odds ratio of 18.3. This indicated that children with 
acute meningococcal disease were 18.3 times more likely to require steroids if they had 
elevated IL-10 levels compared to those who did not. The odds ratio for glutamine was 1 
indicating a weak relationship with steroid administration and glutamine levels.  
 
Table 4.5: Factors predicting the use of steroid administration in children with acute 
meningococcal disease 
 
B 
values 
Standard 
error 
Wald 
Test 
p 
value 
Odds 
ratio 
95% Confidence interval 
for odds ratio 
 Upper Lower 
Glutamine (mmol/l) 0.009 0.004 4.12 0.04 1.00 1.000 1.0 
HSP70 (ng/ml) 0.95 0.62 2.34 0.12 2.59 0.76 8.78 
IL-10 (pg/ml) 2.90 1.51 3.69 0.05 18.32 0.94 355.79 
IL-6 (pg/ml) -0.51 0.72 0.50 0.47 0.60 0.14 2.45 
TNF-α (pg/ml) -3.35 1.37 6.01 0.01 0.03 0.002 0.51 
Glucose (mmol/l) 0.18 0.09 3.51 0.06 1.19 0.99 1.44 
CRP (mg/l) -0.04 0.02 3.23 0.07 0.96 0.92 1.00 
Constant -6.59 2.49 6.98 0.008 0.001   
 
 
124 
 
4.7 Discussion 
Children with severe infection and trauma admitted to a PICU usually require multi-organ 
support, including mechanical ventilation and multiple drugs to sedate, paralyse and support 
cardiac output. Nutrition support during the acute phase of illness remains challenging, as 
infants and young children have limited metabolic stores (444), increasing the risk of 
malnutrition (214). The negative effects of malnutrition are not restricted to the PICU stay 
and can last for up to 6 months post discharge, especially in those children with prolonged 
illness (445).   
 
Although early enteral nutrition support in PICU should be the norm, it is usually balanced 
against potential risk of feeding in clinically unstable patients (446). High severity of injury 
scores and cardiovascular support (inotropes) are associated with delayed commencement 
of enteral feeding (447, 448), and under these circumstance parenteral nutrition is often 
established in its place (426). However, the amino acid profile of parenteral and most enteral 
feeds lack sufficient amounts of some conditionally essential amino acids, thus increasing 
the risk of morbidity and mortality (206, 241). This is reflected in the above results, which 
show that a high PRISM score is correlated with lower glutamine levels and high IL-6 levels 
and lactate levels, reflective of the severity of inflammation, cellular dysfunction and 
possibly poor nutrition intake and or rapid use of endogenous glutamine stores. Inotrope 
administration, associated with delayed enteral feeding and feeding intolerance (448), was 
also predictive of low glutamine levels.  
 
There is increasing recognition that nutrients (nutraceuticals) given in pharmacological doses 
could have a positive impact on outcome in critical illness through the better regulation 
inflammatory and immune response (207), of which glutamine is probably one of the most 
well studied (237). In critical illness there is a precipitous drop in plasma glutamine levels 
with the onset of catabolism increasing the risk of mortality (206, 241). During the acute 
phase of meningococcal disease, glutamine levels  were found to be significantly lower 
(p<0.001) compared to convalescence and were 52% below the normal range. Convalescent 
samples taken on average 55 days later (35 – 135 days) were also found to be 26% below 
normal range. Griffiths et al showed that glutamine levels were depleted in critically ill adults 
by 58% up to 30 days post injury (209), which concurs with the findings in this cohort. 
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Glutamine depletion occurred early on during the course of meningococcal disease and 
appeared to be related to the severity of disease. In this cohort of meningococcal patients, it 
took > 4 days to achieve goal rates of feeding in 33%, and 72% of the patients had 
gastrointestinal disturbances, which is similar to findings in other studies (214, 449).  
 
In this cohort the total amount of glutamine delivered was only 0.14g/kg glutamine, which is 
insufficient to restore levels to within normal range. ASPEN/ ESPEN/ SCCM have given Level 
A recommendation for glutamine supplementation in doses of 0.3 – 0.5g/kg (271-273), 
which is been shown to replete plasma glutamine levels (274, 275) could be postulated to 
optimise HSP70 expression. These levels of supplementation are associated with decreased 
infectious morbidity (206, 283, 284), mortality (209, 285, 286), improved organ function and 
decreased length of hospital stay (238, 287, 288).  
 
Given the low levels of glutamine derived from enteral sources in this cohort of children, it is 
not surprising that plasma glutamine levels were significantly below that of the normal 
range. Whilst paediatric enteral feeds such as Pediasure and adult enteral feeds such as 
Jevity have added L-glutamine (0.3 – 0.39g/100ml) respectively, standard infant feeds 
contain very little glutamine and this is in the form of glutamic acid. However, as most of the 
research has suggested that oral glutamine is not an effective route to restore glutamine 
levels (282, 435), glutamine supplementation should be administered parenterally. It has 
been suggested in order to ameliorate the inflammatory response during severe infections, a 
higher dose of glutamine is required (281) and in the most severely ill children, glutamine 
supplementation should be administered intravenously aiming for 0.5g/kg day (207, 438), 
especially as standard PN solutions also do not have any L-glutamine or glutamine dipeptides 
added. 
 
The effects of glutamine are presumed to be through increased release of HSP70, which may 
help to first promote and then effectively attenuate, the inflammatory and immune 
response to critical illness (207, 239). In children with acute meningococcal disease, 
significantly higher levels of HSP70 were found during the acute phase of illness which 
declined during convalescence, in parallel with other inflammatory mediators. Acute HSP70 
levels (median 5.7ng/ml; range 0.09 – 600.5ng/ml), were higher than those described in 
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adult critical illness (n=15, median 1.75ng/ml; 0.71 – 4.32ng/ml) (143) but lower than those 
found in paediatric septic shock (n=94, median 51.6ng/ml (0.75–294.9ng/ml) (141). 
However, the mortality rate in the study by Wheeler et al (141) was 13.4% compared to 
4.7% in this cohort, and the septic shock children who died had significantly higher HSP70 
levels 78.1ng/ml (range 1.43–319.1 ng/ml) compared to survivors 51.6ng/mL (range 0.75–
294.9ng/ml), which the authors suggest could be related to necrotic release of HSP70 into 
the extracellular milieu (141), rather than any cytotoxic effects of HSP70. In this cohort, 
HSP70 levels were high during the acute phase of illness and declined during convalescence, 
in parallel with inflammatory mediators. 
 
There were significant differences between inflammatory mediators (1L-6, TNF-α, IL-10, IL-8 
and IL-1β) release in children with acute meningococcal disease compared to convalescent 
samples and those from healthy controls. Inflammatory cytokines were high on admission 
and declined in convalescence, showing a pattern as described in other critically ill cohorts 
(61, 62). In addition to this, inflammatory mediators (IL-6, IL-10 and TNF-α) were positively 
correlated with HSP70 levels, although there was no relationship with glutamine. Although 
levels of HSP70 (136, 137), inflammatory mediators (72, 90, 450) and glutamine (209, 240, 
243, 432) during critical illness have previously been described in adults, there are no reports 
of  relationships between HSP70, glutamine and inflammatory mediators in critically ill 
children. 
 
Inverse correlations were found between glutamine (g/kg) administered at the goal rate of 
feeding and the PRISM score and plasma glucose concentration, suggesting that low plasma 
glutamine levels were associated with disease severity and insulin resistance. Several 
investigators have found similar relationships between glutamine supplementation, glycemic 
control and outcome (284, 451, 452), although further work is required to understand the 
mechanisms. Although the correlation was not significant, there was a trend suggesting a 
relationship between glucose and plasma glutamine levels. It is also important to note that 
83% of this cohort received renal support in the form of continuous renal replacement 
therapy.  Amino acid losses in children receiving renal replacement therapy through the 
dialysate is documented as being 0.2g/kg per day with glutamine contributing 34.5µg/kg to 
those losses (453), further contributing to glutamine depletion.  
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Other inverse correlations with plasma glutamine levels were found, such as the number of 
days spent in PICU (n=98, r=-0.520, p<0.001), number of days spent on mechanical 
ventilation (n=98, r=-0.513, p<0.001), which have been well described elsewhere with 
respect to increased risk of morbidity and mortality (209). The number of days to reach the 
goal rate of feeding was also positively correlated with the amount of glutamine delivered 
(n=63, r= 0.242 p=0.026). 
 
Positive correlations between HSP70 levels were found with length of PICU stay, duration of 
mechanical ventilation, PRISM, lactate and CRP, suggesting that elevated levels of HSP70 
may be associated with disease severity, inflammation and cell dysfunction, which is seen in 
adults with chronic inflammatory disease (diabetes) who have higher levels of HSP70, CRP 
and other inflammatory markers compared to healthy controls (454). 
 
During critical illness CRP levels are used as a marker of inflammation (455, 456) and are 
associated with oxidative stress and increased production of reactive oxygen species (457) 
and levels decline as the inflammatory response resolves (456). Glutamine administration 
(0.5g/kg) is associated with significantly lower CRP levels post surgery in children (455) and 
in adults with acute pancreatitis (458), where it effectively mediates the inflammatory 
response (224). Children with acute meningococcal disease had elevated CRP and lactate 
levels, suggesting marked metabolic dysregulation. Plasma glutamine and CRP levels were 
inversely correlated.  
 
High lactate levels in critical illness are correlated with disease severity and are a marker of 
tissue hypoxia, mitochondrial dysfunction (459, 460) with derangements in levels of ATP/ 
ADP (461) and NAD+/ NADH(462). In this meningococcal disease cohort, lactate levels were 
elevated above the reference range at 3mmol/l; ±SD 4.08, indicating cellular dysfunction. In 
rat models of sepsis glutamine supplementation preserved ATP and NAD+ levels, mediated 
by an increase in HSP70 levels (310, 311). Inhibition with quercitin abrogated the beneficial 
effect of glutamine supplementation by preventing HSP70 release (311). Other work has 
shown that when glutamine levels are replete to within normal range cellular homeostasis is 
restored with a resolution of lactic acidosis (270).  
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Using regression analysis to predict factors involved in shocked children requiring steroids, 
the strongest predictor of steroid administration was the measured level of IL-10. The 
likelihood of steroid administration was also influenced by glutamine levels, albeit weakly. 
The majority of children received steroids (73%) which are known to exacerbate insulin 
resistance in critical illness (463), evident in this cohort with elevated plasma glucose levels 
(10.4mmol/l; ± SD 5.7). IL-6 has been shown to promote a net efflux of amino acids notably 
glutamine from muscles, attenuating protein synthesis in favour of protein breakdown with 
a net release of amino acids from skeletal muscle (94).  Experimental models of sepsis work 
show that the concomitant administration of steroids and cytokines (IL-6 and TNF-α) 
stimulated alanine and glutamine transport in human hepatocytes (464) and rats (465, 466), 
providing substrate for the gluconeogenic pathway. 
 
Glutamine can be used as a vehicle to increase the release of HSP70 (203-205). In adults 
glutamine administration significantly increased HSP70 levels, which was associated with a 
decreased length of ICU stay and fewer ventilator days (143). As glutamine is safe, non toxic 
and easy to administer it makes it an attractive modulator of the heat shock response (206-
210). In order for paediatric glutamine trials to be of success it is important to carefully 
select the patient population group as the lack of success in glutamine trials could be due to 
the heterogeneity of the study population, in addition to the use of supplementation in 
glutamine replete children. Routine measures of inflammation, such as CRP may be a useful 
proxy of low glutamine and high HSP70 levels, as CRP was positively correlated with HSP70 
and negatively correlated with glutamine levels, suggesting that in this cohort of critically ill 
children, they may be useful in predicting who would benefit from glutamine 
supplementation with the aim of mediating HSP70 release.  
 
There were several limitations of this work which included the use of stored plasma samples. 
There was also a lack of associated between glutamine and HSP70 levels which may be 
related to small sample size. Future work would aim to investigate the relationship between 
glutamine, HSP70 and inflammatory mediators in a larger samples size in addition to 
stratifying children into age based categories to investigate potential age related differences 
relative to HSP70 release. 
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4.8 Conclusions 
The results from this work show that during the acute phase of illness both HSP70 and 
inflammatory mediators are significantly increased and glutamine levels are depleted. 
Glutamine supplementation may decrease morbidity and mortality associated with 
sepsis/septic shock by maintaining an appropriate heat shock response mediating the 
immune and inflammatory response to critical illness.  
 
To explore the immunological/inflammatory benefit of glutamine, through HS70 release in 
critical illness further, the aim a future randomised controlled trial would be to supplement 
glutamine at a dose of 0.5g/kg in addition to enteral/PN support.  
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Chapter 5: Transcriptomic profiling during the acute phase of meningococcal disease and 
the associations with HSP70, glutamine and inflammatory mediators 
 
5.1 Introduction 
During sepsis innate and adaptive immune functions are dysregulated (467). However, due 
to the heterogeneity amongst critically ill individuals there have been conflicting results with 
respect to the pathophysiological process of critical illness, especially related to the immune 
and inflammatory response (468, 469) . 
 
Target based studies of genes and proteins have limitations arising from the timing of the 
measurement, the supervised nature of targets chosen and the challenges surrounding the 
interpretation of the host response based on the measurement of  plasma inflammatory 
mediators alone (467). The use of genome-wide transcriptomic analysis has provided a 
global insight into changes and inter-relationships of gene transcripts during sepsis and 
critical illness providing greater insight into the host response to infection (470, 471). 
Transcriptomic studies of experimental and clinical sepsis in paediatric and adult patients 
have revealed, activation of genes relating to inflammatory mediator, with the use of IL-8 as 
a stratification biomarker for septic shock (71).  Enrichment of pathways relating to signal 
transduction and inflammatory signalling pathways, such as TLR4, NF-κB, MAPK’s, janus 
kinase (JAK) and signal transducer and activator of transcription protein (STAT) is well 
described (467). In contrast there is significant downregulation of genes associated with 
immune function, notably the antigen presentation pathway (360, 472). The aim of this 
phase of the study was to examine how HSP70 gene expression is affected by meningococcal 
disease, and its association with inflammation and metabolism regulating genes and with 
clinical disease profile. 
 
5.2 Endotoxin induced activation of inflammatory signalling pathways 
In order to investigate the inflammatory effects of MD it is important to understand the 
intracellular mediators associated with downstream endotoxin signalling. As discussed in 
Chapter 1, endotoxin activates genes associated with the IKK/ NF-κB signalling pathway, 
essential for the transcription of immune and inflammatory response genes leading to the 
release of inflammatory mediators such as TNF-α (45, 46). Endotoxin also stimulates the 
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activation of various MAPK’s. The MAPK’s family comprises of ERK, p38 kinase and JNK’s. 
Following activation the MAPK’s mediate the cell response to stress via the phosphorlyation 
of transcriptional factors and initiation of other kinases (473) promoting the production of 
inflammatory mediators IL-1, IL-8 and TNF-α (49). 
 
Following the activation of inflammatory pathways such as CD14-MYD88-IKK/NF-κB and 
p38MAPK, genes associated with downstream inflammatory mediators become activated, 
particularly those associated with the p38MAPK pathway driving the release of inflammatory 
mediators and the pathogenesis of septic shock (360, 474). Inhibition of the p38MAPK 
pathway prevents septic lung damage in an endotoxin mouse model ameliorating the 
negative consequences of an over exuberant inflammatory response (475). In a genome-
wide transcriptome analysis of children with acute meningococcal disease, the p38MAPK 
pathway was shown to be a feature during IL-6 mediated myocardial dysfunction. The 
authors hypothesise, there may be a clinical benefit in modulating the activation of up- or 
downstream effector molecules, in the p38MAPK pathway, attenuating the release of 
deleterious amounts of inflammatory mediators such as IL-6 (476).  
  
5.3 HSP70 release and the regulation of MAPK and NF-κB signalling pathways 
The release of HSP70 in response to endotoxin has been shown to mediate the activation of 
genes associated with inflammatory mediators (IL-1, IL-10 and TNF-α) (352, 477), thus 
reducing mortality in experimental animal models of sepsis, endotoxaemia and adult 
respiratory distress syndrome (128). Following in vitro endotoxin stimulation of 
macrophages, HSP70 effectively mediates the inflammatory response via the inhibition of 
IKK and the NF-κB pathway (194). Other in vitro work using monocytes, has shown that 
preconditioning with heat shock (e.g. heating the cells up to 42oC) before endotoxin 
stimulation, is associated with the inhibition of mitogen activated protein kinase 
phosphatase-1 (MKP-1) phosphorylation and downstream activation of ERK, p38MAPK 
pathways inhibiting the release of TNF-α release (478).  
 
There is growing evidence to suggest that phosphatases have a central role in the 
modulation of inflammatory signal transduction during times of stress in which MPK-1 has a 
pivotal role (478, 479). The p38MAPK pathway serves to regulate mRNA stability of genes 
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associated with inflammation (480). MPK-1 has been shown to inactivate p38MAPK pathway 
via dephosphorylation, suggesting cross talk between MPK-1 and p38MAPK and a possible 
mechanism for control over the release of inflammatory mediators during times of stress 
(199). During times of stress, MKP-1 and HSP70 appear to have protein: protein cross talk 
and HSP70 release increases MKP-1 phosphorylation, modulating p38MAPK activity and 
kinase activation (481) mediating an inflammatory response (199). 
 
5.4 Glutamine supplementation and the regulation of MAPK and NF-κB signalling 
pathways 
Glutamine is known to regulate the expression of numerous genes associated with 
metabolism, signal transduction, cell defence and repair (235). Glutamine exerts a complex 
regulatory activity with respect to the activation of intracellular signalling pathways 
associated with inflammation including those related to MAPK (ERK and JNK’s) (482, 483). 
Glutamine has been shown to specifically stimulate MEK-1, an upstream kinase responsible 
for the activation of ERK-1 and ERK-2, which promotes the phosphorylation of ELK-1 involved 
in cellular differentiation. Glutamine also activates JNK signalling pathway switching on 
factor AP-1 involved in cellular proliferation (484).  
 
The cellular response to infection is a complex process co-ordinated by a wide range of intra- 
and extracellular mediators. Within this dynamic, glutamine and HSP70 influence, and are 
influenced by the mix of inflammatory mediators, activating protective cellular defence 
mechanisms one of which includes the increased production of glutathione stimulated by 
HSP70 release (485). Glutathione (GSH) serves as a regulator of the cellular redox potential 
determining the antioxidant capacity of the cell (486) and is also dependent (in part), on the 
availability of sufficient precursor glutamine (487).  During times of stress, glutamine and 
glutathione levels are correlated (488) and as glutamine levels are proportional to the 
severity of disease (243), glutathione levels become depleted (489). GSH exists in two forms, 
GSH (reduced) and GSSH (oxidised). Increased levels of GSSH alter the redox potential 
favouring oxidation with subsequent activation of inflammatory signalling pathways JNK, 
MAPK and NK-κB (486, 487). Glutamine supplementation has been shown to restore the 
GSH:GSSH redox balance by increasing glutathione levels, attenuating redox sensitive 
kinases (ERK 1-2, p38) inhibiting NF-KB activation and the inflammatory response (486). 
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5.5 Glutamine and HLA expression during critical illness 
Secondary infectious complications following severe illness are a considerable problem in 
critically ill patients, occurring as a result of immune paresis (490, 491), which is 
characterized by diminished expression of MHC Class II antigens on monocytes. MHC Class II 
antigens are essential to the induction of the adaptive immune response to foreign antigen 
(492), as T lymphocytes will only recognize bacterial antigen when HLA-DR molecules are 
expressed on monocytes and macrophages (493). The maintenance of antigen presentation 
by MHC Class II receptors is necessary for an appropriate response to infection and 
preventing infectious complications, as diminished antigen presentation response is 
correlated with poorer clinical outcome in trauma patients (490, 494) and critically ill 
children (495). Glutamine depletion has been associated with reduced HLA-DR expression 
and it may be that be maintaining glutamine levels during critical illness forms part of an 
effective strategy to maintaining immune competence (347). 
 
Genome-wide transcriptomic studies have been used successfully to profile inflammatory 
response pathways in sepsis that are significantly dysregulated , including innate immune 
responses and adaptive immunity (472, 496). Glutamine is known to influence the 
expression of numerous genes (235), however to date, there are no studies, considering the 
effect of glutamine supplementation on gene enrichment of HSP70, inflammatory signalling 
pathways and those of adaptive immune function during critical illness in children. This 
chapter will use gene expression profiling to investigate the network of relationships of 
genes related to HSP70 and the host response in children with meningococcal disease.  
 
5.6 Aims 
1. To examine the gene expression associated with HSP70 and inflammatory pathways 
in children with meningococcal disease compared to convalescence.  
 
2. To examine whether the differential gene expression had any biological relevance 
with respect to plasma protein levels of HSP70, inflammatory mediators and 
glutamine. 
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5.7 Results 
As discussed in Chapter 2, RNA extraction, amplification, hybridisation and microarray data 
analysis were previously completed by Dr Victoria Wright, Department of Paediatrics, 
Imperial College London. The data arising from these experiments were prospectively 
analysed using GeneSpring (Chapter 2.3.4.4) and Ingenuity Pathway analysis (IPA) (Chapter 
2.3.4.5). 
 
This group is a subset from the larger cohort (n=143) that was used to determine levels of 
HSP70, glutamine and inflammatory markers. The patient demographics include 23 males 
and 16 females, with a mean age 4.54 years; SD ± 4.53 (median 2.844 years; range 1.75 – 
4.78 years).  There was no significant difference p>0.05 between protein levels in this sub-
cohort of acute and convalescent HSP70, glutamine, IL-1β and IL-8 samples (Table 5.1) and 
the sub-cohort was therefore a representative sample.  Demographic, clinical and nutrition 
support data for the entire cohort have been summarized earlier in Chapter 4.4.1.  
 
Table 5.1 Protein levels of HSP70, glutamine and inflammatory mediators in a sub-cohort 
of children with acute meningococcal disease and during convalescence 
 Acute (mean; ±SD) Convalescence (mean; ±SD) 
HSP70 (ng/ml)  24.6; ±69.3 1.19; ± 4.961 
Glutamine (mmol/l)  299; ± 148.4 486.5; ± 158.5 
IL-1β (pg/ml) 291.6; ± 773.8 56.1; ± 14.18 
IL-8 (pg/ml) 1238; ± 2777 132.4; ± 278 
 
In order to understand whether there were any significantly differentially genes (SDE) genes 
in children with acute meningococcal disease compared to convalescence, a list of SDE genes 
was generated using GeneSpring, to examine HSP70 and its relationship to changes with the 
wider network of inflammation and metabolic pathways in meningococcal disease compared 
to convalescence. 
 
The complete dataset is detailed in Appendix 8.1. There were 1,780 SDE gene transcripts 
with 1,614 unique genes (p<0.05) with a log2 fold change ≥ 2 between the acute compared 
to convalescent samples. Median values were used for duplicate genes were used due to 
similarities in fold changes. The dataset was explored using IPA. The SDE genes during the 
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acute phase were represented in 3 main biological categories as defined by IPA; infectious 
disease (p=1.89E-33), respiratory disease (p=1.89E-33) and inflammatory response (p=3.27E-
31), as expected given that meningococcal disease is associated with the release of 
inflammatory mediators. 
 
5.8.1 Immune pathways were dysregulated during the acute phase of meningococcal 
disease adaptive compared to convalescence  
To understand how genes from within the dataset were related a pathway analysis was 
completed. Pathway analysis provides a two dimensional representation of the data by 
linking interconnected genes. Amongst genes most affected by meningococcal disease were 
those controlling T cell function and the adaptive immune response, and pathways 
controlling these functions were amongst the most dysregulated in acute disease compared 
to convalescence (Figure 5.1a and b). The notable exception for this was the 
glycolysis/gluconeogenic pathway (p=2.53E-06), which contained mainly upregulated genes, 
with up to 16% of the pathway represented by genes from the dataset. The most highly 
dysregulated pathway was “CD28 signalling in T helper cells” (p=3.83E-10), which was 
significantly downregulated with up to 25% of the pathway represented by genes from the 
dataset. Other signalling pathways to be affected  included “Calcium induced T lymphocyte 
apoptosis” (p=1.4E-07), which was significantly downregulated with up to 30% of the 
pathway represented by genes from the dataset, and “role of NFAT in regulation if the 
immune response” (p=7.62-10) with 17% of the pathway represented by genes from the 
dataset, representing pathways associated with adaptive immunity. 
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Figure 5.1 a and b: Top signalling pathways represented by the significantly differentially 
expressed genes between patients with meningococcal disease compared to 
convalescence (a) and a stacked representation of the same data in (b) indicating the 
proportion of genes upregulated (red) and downregulated (green). The y-axis is the –log of 
the Benjamini-Hochberg adjusted p-value, providing an indication of how likely a pathway is 
enriched in the dataset. The –log (p-value) of 1.3 as indicated by the horizontal line, 
represents a P value of 0.05.  
a 
b 
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5.8.2 Comparison of signalling pathways of SDE upregulated and downregulated genes 
To provide an overview of the signalling pathways within the dataset the 1,780 SDE gene 
transcripts was analysed using IPA, in an unsupervised manner. Following on from this to 
compare differences between significantly differentially expressed up- and downregulated 
genes within the dataset, separate datasets were created using IPA. The upregulated dataset 
contained 933 SDE gene transcripts compared to the downregulated dataset which 
contained 492 SDE gene transcripts, the nature of pathways within the separate datasets 
were examined. Appendices 2 show molecules within the signalling pathways for all, up- and 
downregulated datasets. 
 
5.8.3 Upregulated genes, during the acute phase of meningococcal disease, were 
associated with pathways associated with cell to cell signalling and activation of the 
inflammatory response  
Amongst the upregulated dataset, genes most affected by meningococcal disease were 
those controlling cell to cell signaling, signal transduction via the TLR pathway (p=2.57E-08) 
(Figure 5.4) and inflammatory signaling pathways of IL-6 (p=1.7E-05) and IL-10 (p=1.37E-05) 
amongst others. The glycolysis and gluconeogenesis signalling pathway was the most 
significantly enriched (p=1E-09), with up to 17% of the pathway represented by the genes 
from the dataset. The TLR pathway had 27% of the pathway and IL-6 and IL-10 had between 
12 – 18% of the pathways represented by the genes from the dataset.  
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Figure 5.2: Top signalling pathways represented by the 933 SDE upregulated genes 
between patients with meningococcal disease compared to convalescence.  The y-axis is 
the –log of the Benjamini-Hochberg adjusted p-value, providing an indication of how likely a 
pathway is enriched in the dataset. The –log (p-value) of 1.3 as indicated by the horizontal 
line, represents a P value of 0.05.  
 
5.8.4 Downregulated genes, during the acute phase of meningococcal disease, were 
associated with apoptosis  
In contrast in the downregulated dataset, genes most affected by meningococcal disease 
were those controlling associated with adaptive immune functions specifically T cell 
signaling, cell growth, proliferation, development and apoptosis (Figure 5.3). Other 
downregulated pathways included calcium-induced T lymphocyte apoptosis (p=4.98E-15) 
with 30% of the pathway represented within the dataset. Adaptive immune cell signalling 
such as CD28 signalling in T helper cells was also significant enriched (p=1.56E-12) with 17% 
of the pathway represented within the dataset.  
 
140 
 
 
Figure 5.3: Top signalling pathways represented by the 492 SDE differentially 
downregulated genes between patients with meningococcal disease compared to 
convalescence. The y-axis is the –log of the Benjamini-Hochberg adjusted p-value, providing 
an indication of how likely a pathway is enriched in the dataset. The –log (p-value) of 1.3 as 
indicated by the horizontal orange line, represents a P value of 0.05.  
 
5.8.5 Summary of the results from signalling pathway analysis 
During the acute phase of meningococcal disease signalling pathways representing T cell 
function and adaptive immune response, particularly antigen presentation pathways were 
significantly downregulated compared to convalescence. Significantly upregulated signalling 
pathways were associated with glycolysis and gluconeogenic pathway and cell to cell 
signalling.  
 
5.9.1 Gene network analysis of dataset with 1,780 SDE transcripts in acute meningococcal 
disease compared to convalescence and the role of HSP70 
Network analysis allows for the multi-dimensional representation of the dataset based on 
statistical probability, showing direct and indirect physical interactions. A network analysis 
creates a list of possible networks, ranked according to how many genes in the IPA 
knowledge base correspond to the genes in the dataset. Every gene interaction within the 
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network is supported by published information.  Network generation allows for the 
exploration of interconnections between genes, highlighting functional relationships. 
 
To gain further understanding of the biological meaning of the genes relating to HSP70 
expression within the dataset, a network analysis was focused on HSP70 related gene 
expression. The subsequent figures provide an overview of HSP70 gene interaction on a 
global level in addition to those within the up- and downregulated datasets. The dataset of 
1,780 SDE transcripts yielded a highly significant gene network associated with HSP70. The 
network contained 35 genes of which 25 were represented in the dataset, and had a P value 
of 1.0E-28 (Figure 5.4).  
  
The main functions represented by the network were protein folding, cell death and cell 
compromise.  Within this network HSP70 gene expression was significantly differentially 
upregulated and had a number of direct relationships with genes within the network, (solid 
light blue lines), suggesting that HSP70 has a role in the acute phase of meningococcal 
disease.  Several of the connected genes relate to apoptosis (APAF-1, PGLYRP1), a process 
which HSP70 is known to regulate.  Genes are represented as nodes and the biological 
relationship between 2 molecules is represented as a line. The intensity of the node colour 
indicates the degree of upregulation (red) or downregulation (green). Corrected p-value and 
relative differential fold change are represented below each molecule. All direct 
relationships (solid line) are supported by at least 1 reference from the literature, textbook 
or from signalling pathway analysis information generated by the Ingenuity Knowledge Base.   
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Figure 5.4: Representative gene network within the 1,780 SDE transcripts (upregulated and 
downregulated) in acute meningococcal disease compared to convalescence and the role 
of HSP70 
 
5.9.2 Gene network analysis focused on 933 upregulated SDE transcripts in acute 
meningococcal disease compared to convalescence and the role of HSP70 
The main functions represented by this network were cellular assembly and organisation, 
cellular function and maintenance and cell-cycle (Figure 5.5). This network has a score of 32 
is equivalent to a P value of 1.0E-32. It contains 28 focus molecules, of which genes 
associated with HSP70 (HSPA1A/HSPA1B) are one. Several of the connected genes within 
this network relate to inflammatory signalling pathways including an indirect relationship 
with MAKP14 a member of the p38MAPK signalling pathway, which required further 
investigation. Other relationships were with apoptotic genes for example CARD16 (caspase 
recruitment domain family, member 16). 
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Figure 5.5: Representative gene network within the 933 upregulated SDE transcripts in 
acute meningococcal disease compared to convalescence and the role of HSP70 
 
5.9.3 Gene network analysis focused on 492 downregulated SDE transcripts in acute 
meningococcal disease compared to convalescence and the role of HSP70  
The main functions represented by this network were DNA replication, recombination and 
repair, cell death and protein degradation (Figure 5.6). This network has a score of 23, which 
is equivalent to a P value of 1.0E-23. It contains 18 focus molecules, of which HSP70 is one. 
Considering the downregulated dataset only the network analysis revealed the genes 
associated with HSP70 is upregulated. Other connected genes within relate to other HSP 
families, which are downregulated, such as DNAJA3. HSP70 is known to have a link with ATR, 
which is protein kinase which promotes the assembly of DNA repair complexes at damaged 
sites with the chromosome. DNAJA3 is part of the HSP40 family and is an essential co-
chaperone with HSP70 to enhance ATPase and substrate release. 
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Figure 5.6: Representative gene network within the 492 downregulated SDE transcripts in 
acute meningococcal disease compared to convalescence and the role of HSP70 
 
5.9.4 Summary of network analysis considering the differential expression of HSP70 in 
acute meningococcal disease compared to convalescence 
To understand the biological relevance of HSP70 within the acute phase of meningococcal 
disease a network analysis was completed examining the entire dataset and then genes 
differentially up- or downregulated separately. Considering the network analysis from the 
1,780 SDE gene transcripts (up- and downregulated), where HSP70 is SDE, the main 
functions of the gene network were; protein folding, cell death and cell compromise. HSP70 
is known to regulate cell homeostasis, through protein folding of damaged self and non-self 
proteins.  
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With respect to the 933 upregulated SDE genes transcripts the main functions of the gene 
network were; cellular assembly and organisation, cellular function and m maintenance and 
cell-cycle.  Several of the connected genes within this network relate to inflammatory 
signalling pathways including an indirect relationship with MAKP14. HSP70 is known to 
mediate the inflammatory response to infection and is able to signal via the p38MAPK 
pathway.  
 
With respect to the 492 downregulated SDE genes transcripts the main functions of the gene 
network were DNA replication, recombination and repair, cell death and protein 
degradation. HSP70 is known to co-chaperone with other HSP’s increasing its affinity for cell 
repair and substrate release in an ATP dependent manner.  
 
5.10.1 Relationships between plasma protein levels of HSP70, glutamine, inflammatory 
mediators (IL-8, IL-6, IL-1β and TNF-α) and SDE transcripts associated with inflammatory 
and immune functions 
Pearson correlation was used to investigate whether there was a relationship between 
individual SDE genes of interest (> 2log2 fold change) and corresponding plasma protein 
levels of HSP70, glutamine, inflammatory mediators (IL-8, IL-6, IL-1β, TNF-α) during acute 
disease and in convalescence, as described by Sonna et al (497). Genes selected were those 
associated with HSP70, HLA, inflammatory mediators IL-1β, IL-8 and inflammatory signalling 
pathways p38MAPK. There are 164 genes within the p38MAPK signalling pathway (476) and 
25% (n=40) were SDE within the dataset (Table 5.2), which are ordered by fold change. SDE 
gene transcripts for HSP70 IL-1β and IL-8 were upergulated and those associated with HLA 
were downregulated.  
 
Genes associated with IL-6, TNF-α were not significantly differentially expressed (at a log2 FC 
≥ 2) in the acute phase of meningococcal disease when compared to convalescence and 
were therefore not included in the analysis. For each patient, protein levels were linked to 
the expression values for each gene of interest. Where there was more than 1 transcript for 
the gene the median P value was taken, as there were very little differences between values.  
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Table 5.2: SDE gene transcripts associated with p38MAPK signalling pathway in children 
with acute meningococcal disease compared to convalescence  
Symbol Entrez 
Gene 
ID 
Official full name Direction 
of 
regulation 
Corrected 
p-value 
Absolute 
Fold 
Change 
IL1R2 7850 interleukin 1 receptor, type II  5.13E-06 43 
GADD45A 1647 growth arrest and DNA-damage-inducible, alpha  5.27E-06 15.74 
IL1RAP 3556 interleukin 1 receptor accessory protein  5.35E-06 9.2 
MKNK1 8569 MAP kinase interacting serine/threonine kinase 1  5.13E-06 6.28 
ZAP70 7535 zeta-chain (TCR) associated protein kinase 70kDa  8.66E-06 4.57 
STK3 6788 serine/threonine kinase 3 (STE20 homolog, yeast)  1.09E-05 4.47 
DUSP1 1843 dual specificity phosphatase 1 (MPK-1)  5.35E-06 4.08 
CEBPB 1051 CCAAT/enhancer binding protein (C/EBP), beta  5.13E-06 3.89 
CDC25B 994 cell division cycle 25 homolog B (S. pombe)  5.47E-06 3.7 
MAPK14 1432 mitogen-activated protein kinase 14  3.55E-04 3.54 
CDC42 998 cell division cycle 42 (GTP binding protein, 25kDa)  3.09E-05 3.41 
RPS6KA5 9252 ribosomal protein S6 kinase, 90kDa, polypeptide 5  4.18E-05 3.29 
LCK 3932 lymphocyte-specific protein tyrosine kinase  2.18E-05 3.15 
STAT1 6772 signal transducer and activator of transcription 1, 
91kDa 
 9.15E-05 3.13 
MAP3K8 1326 mitogen-activated protein kinase kinase kinase 8  5.27E-06 2.97 
NCF2 4688 neutrophil cytosolic factor 1, (chronic 
granulomatous disease, autosomal 2) 
 9.15E-05 2.94 
CASP5 838 caspase 5, apoptosis-related cysteine peptidase  0.007 2.86 
CD14 929 CD14 molecule  7.68E-06 2.8 
JAK2 3717 Janus kinase 2 (a protein tyrosine kinase)  2.33E-05 2.77 
CREB5 9586 cAMP responsive element binding protein 5  0.002 2.7 
NCF4 4689 neutrophil cytosolic factor 1, (chronic 
granulomatous disease, autosomal 4) 
 5.17E-05 2.69 
FOSL2 2355 FOS-like antigen 1  0.015 2.66 
ATF6 22926 activating transcription factor 6  3.50E-05 2.56 
MYD88 4615 myeloid differentiation primary response gene (88)  5.27E-06 2.53 
STK39 27347 serine threonine kinase 39 (STE20/SPS1 homolog, 
yeast) 
 1.67E-05 2.5 
MEF2C 4208 myocyte enhancer factor 2C  4.26E-05 2.49 
PRKCD 5580 protein kinase C, delta  6.74E-06 2.49 
MAPK 
APK2 
9261 mitogen-activated protein kinase-activated protein 
kinase 2 
 7.25E-06 2.45 
SOCS2 8835 suppressor of cytokine signalling 2  5.70E-04 2.41 
IL1B 3553 interleukin 1, beta  1.34E-04 2.4 
JUNB 3726 jun B proto-oncogene  1.17E-05 2.4 
ZAK 51776 sterile alpha motif and leucine zipper containing 
kinase AZK 
 1.67E-04 2.36 
DDIT3 1649 DNA-damage-inducible transcript 3  8.28E-05 2.31 
TNFRSF1A 7132 tumour necrosis factor receptor superfamily, 
member 1A 
 6.88E-05 2.22 
TOLLIP 54472 toll interacting protein  5.13E-06 2.22 
MEF2A 4205 myocyte enhancer factor 2A  0.002 2.09 
PPM1B 5495 protein phosphatase 1B (formerly 2C), magnesium-
dependent, beta isoform 
 2.63E-05 2.08 
ZFP36 7538 zinc finger protein 36, C3H type, homolog (mouse)  1.28E-05 2.07 
MAPK 
APK3 
7867 mitogen-activated protein kinase-activated protein 
kinase 3 
 5.13E-06 2.05 
MAP2K1 5604 mitogen-activated protein kinase kinase 1  7.68E-06 2.02 
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5.10.2 Plasma protein levels of HSP70, glutamine are positively correlated with genes 
associated with HSP70, p38MAPK and HLA during meningococcal disease  
Plasma levels of HSP70 are positively correlated with genes (> 2log2 fold change)  during the 
acute phase of meningococcal disease and in convalescence implying that during infection 
there is significant upregulation of genes associated with HSP70 resulting in increased 
plasma levels HSP70 (Table 5.3).  
 
During the acute phase of meningococcal disease plasma levels of glutamine and HSP70 
were correlated with genes from the MAPK family suggesting a relationship between 
glutamine, HSP70 and genes associated with the inflammatory response. During 
convalescence there were a number of negative correlations with respect to plasma levels of 
glutamine and gene transcripts from the MAPK family, suggesting that glutamine levels may 
impact on the MAPK signalling pathway. Negative relationships were also seen relative to 
immune function with multiple gene transcripts associated with HLA antigen presentation 
being negatively correlated with convalescent glutamine levels, suggesting that plasma 
glutamine levels may be an important determinant for effective antigen presentation. 
 
Plasma protein levels of IL-1β were correlated with genes associated with IL-1β and IL-8. 
There was no relationship was found between glutamine and genes associated with HSP70 
or plasma levels of inflammatory mediators; IL-8, IL-6, IL-1β, TNF-α, suggesting in this cohort 
there is no relationship between glutamine and genes associated with HSP70 and 
inflammatory mediators. However, the sample size was small and this could have impacted 
on the likelihood of achieving significance. 
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Table 5.3: Correlations between protein levels and gene transcripts related to 
inflammation and immune function during the acute phase of meningococcal disease and 
convalescence 
Plasma 
protein 
(number) 
Gene 
association 
Enterez 
Gene 
symbol 
Direction 
of 
regulation 
Absolute 
Fold 
Change 
Correlation 
(r)/significance (p) 
Acute 
HSP70 
(n=27) 
HSP70  HSPA1A 
HSPA1B 
 2.45 
2.89 
r= 0.53; p=0.004  
r= 0.72; p=<0.0001 
p38MAPK  JUNB  2.40 r= 0.44; p=0.01 
Glutamine 
(n=25) 
p38MAPK  IL1RAP  
MAP3K8 
CREB5 
 JUNB 
MAP2K1 
TOLLIP 
CD14 
JAK2  
ZAP70 
 9.20 
2.97 
2.70 
2.40 
2.02 
2.22 
2.80 
2.77 
4.57 
r= 0.41; p=0.041  
r= 0.41; p=0.04 
r= 0.51; p=0.009 
r= 0.4; p=0.04 
r= 0.4; p=0.04  
r= -0.47; p=0.01  
r= -0.47; p=0.01  
r= -0.54; p=0.005  
r= -0.47; p=0.01 
 
IL-1β 
(n=27) 
Inflammatory 
response 
IL-1β  
IL-8 
 2.40 
5.65 
r= 0.38; p=0.048 
r= 0.38; p=0.048 
Convalescence 
HSP70 
(n=15) 
HSP70  HSPA1A 
HSPA1B 
 2.45 
2.89 
r= -0.54; p=0.04 
r= -0.45; p=0.09 
p38MAPK  CD14  
GADD45A  
SOCS2 
CASP5  
MEF2C 
RPS6KA5 
STAT1 
 2.80 
15.74 
2.41 
2.80 
2.49 
3.29 
3.13 
r= -0.58; p=0.02 
r= -0.54; p=0.03  
r= -0.53; p=0.03  
r= 0.52; p=0.04  
r= -0.53; p=0.03  
r= -0.52; p=0.04  
r= -0.56; p=0.02 
 
 
 
Glutamine 
(n=12) 
p38MAPK 
 
LCK  
MAP2K1 
CDC258 
CREB5 
DUSP-1  
JUNB 
JAK2 
MAPK14 
MAPKAPK3 
 3.15 
2.45 
3.70 
2.70 
4.08 
2.40 
2.77 
3.54 
2.05 
r= 0.58; r=0.04  
r= -0.40; p=0.04 
r= -0.65; p=0.02 
r= 0.67; p=0.01 
r= 0.62; p=0.03 
r= 0.64; p=0.02  
r= -0.65; p=0.02 
r= -0.74; p=0.005 
r= -0.66; p=0.018 
 
HLA – 
antigen 
presentation 
HLA-DMA 
HLA-DPA1 
HLA-DQA1 
HLA-DRB3 
HLA-DRB6 
 3.18 
3.92 
3.73 
3.68 
3.09 
r=- 0.69; p=0.01 
r= -0.84; p=0.001 
r= -0.65; p=0.02 
r= -0.58; p=0.05 
r= -0.76; p=0.004 
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5.11.1 Validation of SDE gene transcripts using ToppGene confirms dysregulated adaptive 
immune function and inflammatory signalling pathways in meningococcal disease  
Validation of 1,780 SDE gene transcripts, using gene ontology from ToppGene, confirms in 
acute meningococcal disease compared to convalescence, there was significant enrichment 
of signalling pathways representing adaptive immune function, the antigen presentation 
pathway and inflammatory signalling pathways as seen using IPA (Figure 5.7). 
 
Figure 5.7: Validation of SDE gene transcripts using ToppGene molecular functions. 
Signalling pathways represent adaptive and innate immunity and the antigen presentation 
pathway in acute meningococcal disease compared to convalescence 
 
5.11.2 Validation of SDE genes using an independent cohort of children with acute 
meningococcal disease compared to controls 
The SDE genes (log2 fold change ≥ 2) in a comparable dataset of children with meningococcal 
sepsis were compared with the 1,780 SDE dataset using IPA (Figure 5.8). Signalling pathways 
in the independent cohort of children with acute meningococcal disease compared to 
controls were similarly enriched, representing adaptive immunity, inflammatory signalling 
pathways, the antigen presentation pathway and apoptotic pathways. These findings 
confirm the validity of the results generated from the transcriptomic analysis of children 
with acute meningococcal disease compared to convalescence. 
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Figure 5.8: Significant terms for signalling pathways comparing an independent validation 
dataset with SDE gene transcripts for acute meningococcal disease. Dark blue bars (acute 
meningococcal disease); light blue bars (validation dataset) 
 
5.12 Discussion 
Monocyte and macrophage stimulation by endotoxin leads to the upregulation of genes and 
transcription factors that promote the expression and release of inflammatory mediators, 
including cytokines (49).The pathophysiology of severe meningococcal disease is associated 
with high levels of endotoxaemia leading to a significant release of these inflammatory 
mediators provoking shock and multi-organ failure (498). Within the dataset, children with 
acute meningococcal disease had 1,780 SDE gene transcripts with 1614 unique genes (≥ 2 
log2 fold change) compared to convalescence. The data was validated using protein levels 
from the cases during the acute and convalescent disease stages as well as assessing 
biological functions and pathways represented in the dataset by using a second 
meningococcal disease dataset and a different biological database. As expected the 
biological processes that the genes represented in the dataset fell into three main 
categories: respiratory disease, infectious disease and inflammatory response, of which the 
latter two are associated with the pathophysiology of meningococcal disease (498). 
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The glycolysis and gluconeogenesis signalling pathway was the most significantly enriched, 
with up to 25% of the pathway in the dataset. Increased gluconeogenic and glycolytic 
pathways are hallmarks of critical illness and are associated with protein efflux from muscle 
delivering glutamine and alanine for participation in the citrate cycle for de novo glucose 
synthesis (499). Most of the genes were significantly upregulated in the gluconeogenic 
pathway in our children with meningococcal disease which may have contributed to the 
significantly decreased levels of plasma glutamine seen in this cohort. 
 
Severe infection is associated with increased expression of PRR such as TLRs (500). In this 
database signal transduction pathways associated with TLR (p=2.63E-03) and NF-κB (p=5.74-
03) were significantly enriched with 12% and 20% of the pathways respectively represented 
within the dataset. The TLR pathway was significant in children with acute meningococcal 
disease highlighting the role of signal transduction via TLR2/4-CD14-MD2 activating the 
inflammatory pathways of NK-κB and p38MAPK, as has been described in other cohorts of 
septic patients (467) and in children with acute meningococcal disease (476).   
 
Acute plasma glutamine was positively correlated with TLR 2 expression (n=25, r=0.45, 
p=0.02) and TLR4 expression (n=25, r=0.59; p=0.002). Interestingly, in a septic rat model, 
enteral glutamine administration attenuated TLR4, MYD88 and TRAF mRNA accumulation in 
the intestinal mucosa, downregulating the release of TNF-α, IL-6 and IL-1 (501), although in 
critically ill adults glutamine supplementation had no effect on TLR4 expression (502). In the 
context of this cohort it is known that malnutrition affects bacterial defence mechanism, 
including the release of DAMPs in response to PAMP’s and activation of PRRs. Therefore, 
glutamine depletion could affect bacterial recognition and phagocytosis resulting in the 
accumulation of bacterial wall fragments, which may intensifying the inflammatory response 
and release of inflammatory mediators (503), which is supported by data from the current 
research. 
 
The network analysis of the SDE (up- and downregulated) transcripts revealed that genes 
associated with HSP70 are differentially upregulated during the acute phase of illness 
suggesting they have a role in meningococcal disease. Although not previously described in 
meningococcal disease, genes associated with HSP70 family have been shown to be 
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upregulated in adult patients, both with sepsis and non-infectious SIRS (497). In this cohort, 
plasma levels of HSP70 were positively correlated with HSPA1A and HSPA1B during the acute 
phase of illness, suggesting that upregulation of genes associated with HSP70 may be linked 
to the accumulation of HSP70 within the plasma. Although it would seem likely that an 
increase in HSPA1A and HSPA1B gene expression would result in changes to plasma levels of 
the protein, is that it is not possible to establish causality based on correlation alone (497).  
 
The gene network associated with HSP70, included annotations for cell death, protein 
degradation and cell compromise. Several of the connected genes relate to apoptosis; 
apoptotic peptidase activating factor 1 (APAF-1) is involved in apoptosis, binding to 
cytochrome C, activating caspase-3 and caspase-7. HSP70 is known to mediate apoptosis by 
regulating APAF-1/ cytochrome C aggregation (504). Within the cohort, signalling pathways 
associated with apoptosis were significantly downregulated during acute phase of 
meningococcal disease, suggesting the influence of HSP70 on inhibiting apoptosis is 
dysregulated.  
 
Another apoptotic protein, which is directly linked in this network, was peptidoglycan 
recognition protein 1 (PGLYRP-1), which functions as an innate immune regulator during 
times of stress forming a cytotoxic complex and provoking apoptotic cell death (505). 
CARD16 was also highly expressed within the network of only upregulated genes and directly 
connected to HSPA1A and HSPA1B (506). CARD16 is a member of the caspase family 
representing apoptotic genes, this in combination with upregulation of APAF-1 is often 
suggestive of an immunosuppressive effect mediated by meningococcal disease (507). 
HSP70 have been shown to prevent mitochondrial-mediated apoptosis by inhibiting APAF-1 
and apoptosis inducing factor (AIF), leading to the suppression of caspase-dependent and 
independent apoptosis (508, 509). Thus in this cohort, where APAF-1 is upregulated, the 
anti-apoptotic effect of HSP70 may be reduced, increasing the risk of cell death, consistent 
with results of HSP70 inhibition studies. 
 
Amongst genes that were represented in meningococcal disease the representative 
downregulated gene network associated with HSP70 included annotations for DNA 
replication, recombination and repair, cell death and protein degradation. Genes associated 
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with HSP70 were upregulated within the dataset, however, several of the connected genes 
within the network related to other HSP families such as DNAJA3, were differentially 
downregulated. HSP70 is known to have a link with ATR, a protein kinase, which promotes 
cell repair through the assembly of DNA repair complexes at damaged sites within the 
chromosome. Depletion of HSP70 is associated with impaired phosphorylation of ATR, 
increasing the cell related damage (510). DNAJA3 is part of the HSP40 or DnaJ family of 
chaperones DNAJA3 is part of the HSP40 family and is an essential co-chaperone with HSP70 
to enhance ATPase and substrate release (33), by transiently binding to ATP promoting 
HSP70 function (511) and facilitating the folding of newly synthesized proteins in an ATP 
dependent manner (512). HSP70 is vital to the maintenance of protein folding and protein-
protein interactions within the cell, preventing protein aggregation (512), however depletion 
of HSP70 can lead to cell death (513). Where there is mitochondrial dysfunction with 
reduced ability to produce ATP, necrotic cell death ensues (514). Within this network, 
housekeeping gene transcripts associated with HSP70 were downregulated (DNAJA3), which 
has been described in transcriptomic analysis of septic adults (497) and there may therefore 
by an increased risk of necrotic cell death in this cohort of children.  
 
Within the dataset of upregulated genes only, signalling pathways for IL-6 (p=5.64E-04), IL-
10 (p=6.03E-04) were enriched, with 17% of the pathway represented within the dataset for 
both, during the acute phase of meningococcal disease.  The upregulation of genes 
associated with signalling pathways for IL-8, IL-6 and IL-10 has been described in children 
with septic shock and meningococcal disease (338, 476). Genes associated with IL-1β and IL-
8, in children during the acute phase of their illness, was strongly correlated with plasma 
levels of inflammatory mediators (TNF-α, IL-1β, IL-8 and IL-6) during the acute and 
convalescent stages of the disease, although there were no correlations with either HSP70 or 
glutamine. As seen in Chapter 4, during the acute phase of meningococcal disease levels of 
inflammatory mediators were significantly higher when compared to convalescence. Other 
genome-wide trascriptomic studies of sepsis, including children, describe significant gene 
enrichment of signal transduction and inflammatory pathways early in the course of sepsis 
(467). It is increasingly recognised that the classic pattern of early an pro-inflammatory 
response with the upregulation of genes associated with TNF-α, IL-1β followed by a second 
phase of anti-inflammatory mediators (IL-10) may be too simplistic and that within a clinical 
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setting this classic response to infection is rarely seen (515). This is reflected in 
transcriptomic studies as there appears to be no consistent progression from an early pro-
inflammatory state to a subsequent anti-inflammatory phase (467). HSP70 plays a central 
role in mediating the inflammatory response to stress, activating the NF-κB pathway (108), 
and then countering the inflammatory response by inhibiting the transcription of IL-1β (414) 
and TNF-α (516) preventing the further release of IL-8 and IL-6 (415), but this was not seen in 
this dataset as HSPA1A and HSPA1B were not correlated to cytokine levels or expression 
levels.  
 
During the acute phase of meningococcal disease glutamine was positively correlated with 
JAK2 (n=27, r=0.41; p=0.04) and during convalescence HSP70 was negatively correlated with 
STAT (n=27, r-=0.56; p=0.02) and SOCS2 (n=27, r=-0.56; p=0.02). JAK2 is part of the JAK-STAT 
cascade, which is reported as being upregulated during sepsis. JAK-STAT inflammatory 
cascade has anti-inflammatory properties, which include negative feedback mechanisms 
involving suppressor of cytokine signalling (SOCS) induction, involved in the early inhibition 
of TLRs and inflammatory mediator signalling. Sepsis is associated with dysregulation of this 
pathway as a result of significant downregulation of genes associated with mitochondrial 
activity, decreasing cell metabolism including protein synthesis machinery (517). Glutamine 
has been shown to mediate anti-inflammatory effects through STAT pathways (483), it could 
be that glutamine depletion diminishes the efficacy of JAK2 expression during acute 
meningococcal disease compared to convalescence.  
 
Genome-wide transcriptional studies of children with septic shock reveal that a large 
number of genes are differentially downregulated particularly those associated with 
adaptive immunity, such as those linked to a T-cell mediated immune response (518). The 
top signalling pathways, within the dataset of studied children with meningococcal disease 
were mainly associated with downregulated activity of genes associated with adaptive 
immunity. The antigen presentation pathway was also found to be affected since most of 
the genes in these pathways were significantly downregulated in the acute phase of the 
disease compared to convalescence.  
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Genes associated with antigen presentation (particularly those related to MHC Class II) have 
also been found to be as being downregulated during adult trauma (496) and paediatric 
septic shock (360, 472). During critical illness there is depressed macrophage and monocytic 
expression of MHC class II particularly HLA-DR (519) and HLA-DQ (520). Ex vivo studies show 
monocytes from these patients have a decreased ability to mount an appropriate 
inflammatory response when stimulated with LPS (347). Reduced expression of HLA-DR is 
seen as a marker of the degree and duration of immune paralysis (521, 522) and within a 
clinical context is a good predictor of septic complications (490, 523) and mortality (347, 
524, 525).  
 
Maintenance of HLA-DR expression may be an important strategy to prevent infectious 
complications (347). It may be that maintenance of effective HLA-DR expression is 
dependent on glutamine availability (526) as there is evidence to suggest that APC cells 
including macrophages and monocytes are dependent on glutamine for optimal function 
(527).  In vitro work has shown a 40% reduction in HLA-DR expression over the course of a 
week as glutamine levels declined (526) and that levels of < 0.4 mMol/L were associated 
with a 30% reduction in HLA-DR expression (346, 526). However, glutamine supplementation 
is not able to completely restore HDL-DR functionality (347). It could be that maintenance of 
plasma glutamine levels during critical illness could in some way promote an effective 
immune and inflammatory response to infection, through maintenance of MHC Class II 
expression on APC cells allowing optimal HSP70:antigen presentation. Further work would 
be required to corroborate such a hypothesis.  
 
There were significant inverse correlations with plasma glutamine levels and SDE genes 
associated with MHC Class II during convalescence. In this subset of children, glutamine 
levels during convalescence were found to be 58% below the normal range. No correlation 
could be found with of HLA gene expression and low glutamine during the acute phase of 
the disease, suggesting that glutamine levels may contribute to an increased secondary 
infection risk during convalescence. The pattern of differentially downregulated genes 
associated with MHC Class II (HLA-DMA, HLA-DPA1, HLA-DQA1, HLA-DRB3 and HLA-DRB6) 
has been described in genome-wide analysis of trauma patients and was strongly correlate 
with multi-organ failure and 28 day mortality (496). Depressed MHC Class II expression on 
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monocytes/ macrophages is associated with increased risk of late infectious complications in 
septic adults (490)  and critically ill children (495). Both parenteral and enterally 
administered glutamine in critically ill adults has been shown to be effective in promoting 
increased HLA-DR expression, in part due to the maintenance of normal plasma glutamine 
levels (346, 347). 
 
HSP70 forms complexes with pathogenic bacteria (and endogenous proteins), which are 
capable of activating CD4+ (528, 529) and CD8+ complexes on T cells (530) facilitating MHC 
class I and II peptide assembly in addition to receptor-facilitated endocytosis (528). In 
experimental in vitro and in vivo models MHC Class II activation following HSP70 interaction 
facilitates the induction of innate immunity including the LPS-CD14+ signal transduction of 
NF-κB pathway leading to the release of inflammatory mediators (531). Although HSP70 
antigenic protein presentation has not been described in paediatric critical illness, it could be 
hypothesised that if antigen presentation is downregulated, HSP70 processing of pathogenic 
proteins (including endotoxin), via MHC Class II receptors, may be impaired. However, there 
was no correlation between HLA and HSP70 protein levels. 
 
Genes associated with p38MAPK and JNK play a pivotal role in the transcriptional and post-
transcriptional regulation of inflammatory mediators (532). Within this cohort, there were 
multiple positive and negative correlations with plasma levels of glutamine, HSP70 and 
genes associated with the p38MAPK signalling pathway during the acute phase of illness and 
convalescence. This suggests that these proteins could influence the inflammatory response 
to meningococcal disease. In vitro mouse models of sepsis have shown that glutamine 
supplementation inhibits the activation of p38MAPK and JNK through de-phosphorylation of 
MAPK’s. This is affected by the activation of MKP-1 (also known as DUSP-1), an important 
regulator of the MAP kinases. The activation of MKP-1 following glutamine supplementation 
is rapid and protects against shock and mortality in animal models of sepsis (533). An in vivo 
model involving septic rats has shown that glutamine supplementation attenuates the 
activation of p38MAPK and ERK, through HSP70 upreguation, downregulating the release of 
TNF-α, IL-6 and IL-8 (534).  In this study cohort MKP-1 was only correlated to plasma 
glutamine levels during the convalescent phase. HSP70 has also been shown to 
phosphorylate MKP-1 preventing the activation of p38MAPK (199, 535).  
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In the context of this study cohort, glutamine levels were depleted for up to 55 days post 
admission of meningococcal disease. This could have a negative impact of the host’s ability 
to attenuate the inflammatory response, especially as there were numerous positive and 
negative correlations with both HSP70 and glutamine and p38MAPK signalling pathway. 
Further work will be required to understand the impact of glutamine supplementation on 
the transcriptional control of p38MAPK and the role of glutamine on HSP70 upregulation 
may play.  
 
There are a number of limitations to this work. Due to the small sample size transcriptomic 
analysis based on age related stratification was not possible. Of note, other transcriptomic 
analysis of paediatric sepsis have shown that neonates with septic shock have more 
significantly downregulated expression of genes associated with innate and adaptive 
immunity compared to school aged  children (338). Future work would aim to collect blood 
samples for proteomic and gene analysis at standardized time points throughout the study, 
in addition to stratifying patients into relevant age based categories matched to appropriate 
age matched controls. Although the transcriptomic findings reported in this cohort are well 
described in other related studies (360, 472, 536), further work is required to validate the 
functional importance of the transcriptomic results using functional assays (such as 
phytohemagglutinin (PHA) stimulation of whole blood) and flow cytometry, to describe cell 
surface expression of markers associated with T lymphocyte function e.g. CD11b and 
adaptive immunity e.g. HLA,  as described in other critically ill cohorts (495, 537-540). 
 
5.13 Conclusion 
The results from this transcriptomic analysis showed inflammatory signalling pathways were 
significantly upregulated whereas those relating to adaptive immunity and antigen 
presentation were downregulated. Genes associated with HSP70 were correlated with 
plasma levels of HSP70 suggesting that HSP70 does play a role in the pathophysiology of 
meningococcal disease. During the acute phase of the disease, plasma levels of glutamine 
and HSP70 were correlated with numerous genes associated with p38MAPK signalling 
pathways. In addition, convalescent plasma glutamine levels were correlated with genes 
associated with HLA suggesting a role for glutamine in antigen presentation. As glutamine 
levels were significantly depleted in the acute and convalescent phase it could be that the 
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positive results of glutamine supplementation is mediated by an appropriate resolution of 
inflammation in addition to promoting adaptive immunity. Future work would aim to 
understand the effect of glutamine supplementation on gene expression during critical 
illness, especially relative to genes associated with HSP70, inflammatory signalling pathways 
and those relating to HLA. 
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Chapter 6: 
General Discussion and Conclusion 
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Chapter 6: General Discussion and Conclusion  
6.1 General Discussion 
Paediatric sepsis affects a significant proportion of children annually with a mortality rate of 
10% (3-5). The inflammatory response to infection forms part of the host response to sepsis 
and is vital to survival. However, the dysregulated release of inflammatory mediators can 
result in organ damage increasing the risk of early and late mortality (17). There is renewed 
interest in the concept that nutraceuticals, such as glutamine may present as therapeutic 
strategies, particularly in promoting HSP70 release, thus mediating the immune and 
inflammatory response thereby improving outcome (207).  
 
Glutamine supplementation in critically ill adults is associated with decreased morbidity and 
mortality (271-273), although the same benefits with respect to glutamine supplementation 
have not been reported in critically ill children (541). The beneficial effects of glutamine 
supplementation during critical illness may relate to the upregulation of HSP70 release. 
During times of stress HSP70 release is associated with improved outcome in experimental 
models of sepsis (310, 311, 345) and in critically ill adults (143).   
 
The aim of this study was to investigate the effects of sepsis on the release of HSP70 and the 
relationship with glutamine and inflammatory mediators. The study was conducted in two 
parts, firstly using whole blood in an experimental in vitro endotoxin stimulation model and 
secondly in vivo analysis of HSP70 release and the relationship to glutamine and 
inflammatory mediators in children with acute meningococcal disease. 
 
The aim of the in vitro study was to investigate the effect of glutamine supplementation on 
HSP70 release, using an in vitro endotoxin model. The results showed that 2mM glutamine in 
endotoxin stimulated blood significantly increased HSP70 release in whole blood from adults 
and children, in agreement with previous studies (93, 203, 407). HSP70 release was 
significantly higher in children when compared to adults with a similar pattern of release as 
described in critically ill adults (143) and children with septic shock (141).  
 
The different effects of glutamine supplementation on the release of inflammatory 
mediators, in adults compared to children were surprising. In adults, glutamine 
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supplementation appeared to attenuate the release of inflammatory mediators, whereas in 
children glutamine supplementation was associated with pro-inflammatory response.  In 
vitro work by others has shown that HSP70 can mediate both a pro- (399, 407) and anti-
inflammatory (414-416) response. Glutamine supplementation has also been shown to be 
associated with a pro-inflammatory response in vitro (399) with the converse effect in vivo 
during sepsis (86, 399, 417, 418). Since in vitro studies cannot completely replicate 
conditions within a host, future work should focus on the relationship between glutamine 
and HSP70 release over time in critically ill children, investigating the role that HSP70 plays in 
the formation of complexes with pathogens and the subsequent immune and inflammatory 
responses with respect to gene transcription and protein levels within the cells/ tissue. 
Recent theories have focused on the concept that HSP70 acts as a DAMP in the presence of 
large amounts of pathogens; as infection resolves HSP70 helps to restore homeostasis by 
acting as a “DAMPER” downregulating the immune and inflammatory response (191).   
 
The use of a HSP70 inhibitor KNK437 significantly decreased the intracellular and 
extracellular release of HSP70 and inflammatory mediators (IL-6, IL-10, TNF-α). These results 
suggest that HSP70, in part, mediates the endotoxin stimulated release of inflammatory 
mediators (IL-6, IL-10, TNF-α), as the addition of KNK437, diminishes HSP70 release with a 
concomitant downregulated release of IL-6, IL-10 and TNF-α release as described by other 
groups (385, 420, 421).  
 
Results from the in vivo aspect of the study revealed HSP70 levels were significantly higher in 
children with meningococcal disease during the acute phase of illness, which has been 
reported in children with septic shock (141). Glutamine depletion was apparent early on 
during the disease, and in convalescent samples, taken up to 2 months later, an effect also 
reported in critically ill adults (209). Although feeding was initiated early, it took up to 4 days 
before goal rate was achieved. Even at goal rate the level of glutamine delivered was only 
0.14g/kg glutamine, which is likely to be insufficient to restore levels to within normal range. 
A dose of 0.3 – 0.5g/kg has been shown to restore plasma glutamine levels to within normal 
range (274, 275) and benefits are possibly associated with increased HSP70 release during 
critical illness (207, 239).  
162 
 
Inflammatory mediators were positively correlated with HSP70 levels, but not with 
glutamine. Positive correlations between HSP70 levels were found with length of PICU stay, 
duration of mechanical ventilation, severity of illness score PRISM, lactate and CRP. These 
relationships suggest that elevated levels of HSP70 may be associated with disease severity, 
inflammation and cell dysfunction, which is seen in adults with chronic inflammatory disease 
who have been found to have higher levels of HSP70, CRP and other inflammatory markers 
compared to healthy controls (454). In this cohort, plasma glutamine and CRP were inversely 
correlated consistent with the findings by others that administration of glutamine was 
associated with significantly lower CRP levels post surgery in children (455) and adults (458). 
 
In adult patients, glutamine supplementation of PN significantly increased HSP70 levels 
which was associated with a decreased length of ICU stay and fewer ventilator days (143). As 
glutamine is safe, non toxic and easy to administer it is a potentially attractive modulator of 
the heat shock response (206-210). Glutamine administration is recommended by numerous 
nutrition associations including ESPEN as being of benefit (273). However, the results in 
children have been less convincing, the studies fraught with problems relating to design, 
dose of glutamine and heterogeneity of the study population (541).  It has been suggested 
that plasma glutamine levels should be routinely measured, aiming to target treatment for 
maximal efficacy (246). However, as amino acids are not routinely measured in critically ill 
children other proxy measures could be used. C-reactive protein may be a more useful proxy 
of low glutamine and high HSP70 levels as it was positively correlated with HSP70 and 
negatively correlated with glutamine levels, suggesting that in this cohort of critically ill 
children, it may well be useful in predicting who would benefit from glutamine 
supplementation. Steroid administration was also predictive of low glutamine levels and 
could potentially also serve as a indicator for when glutamine supplementation should be 
used. 
 
As glutamine levels remained low into convalescence, future work should consider the 
efficacy of post discharge glutamine supplementation and the impact this may have on 
rehabilitation and long term outcome. Follow up studies of survivors of N. meningitidis 
report that 5 – 20% of patients continue to have problems with intellectual functioning and 
illness related physical or social consequences (12). Since glutamine depletion has an impact 
163 
 
on 6 month mortality (209) it could be that glutamine supplementation is required in some 
children post ICU discharge.  
 
Transcriptomic analysis of differentially regulated genes in children with meningococcal 
disease during the acute phase compared to convalescence was undertaken. Genes 
associated with HSP70 (HSPA1A and HSPA1B) were differentially upregulated during the 
acute phase of illness, suggesting that HSP70 plays a role in meningococcal disease. Although 
not previously described in meningococcal disease, genes associated with HSP70 family have 
been shown to be upregulated in adult patients, both with sepsis and non-infectious SIRS 
(497). 
 
The top signalling pathways within the entire dataset of children with meningococcal disease 
during the acute phase of illness were mainly associated with downregulated activity of 
genes associated with adaptive immunity such as CD28 signalling in T helper cells, NUR77 
signalling in T lymphocytes, which represented between 24 - 27% of genes within the entire 
dataset. The antigen presentation pathway was found to be significantly differentially 
downregulated in the entire dataset of children with meningococcal disease with up to 20% 
of genes from the entire dataset represented in the pathway, a finding described in other 
genomic work considering paediatric septic shock (360, 472).  
 
When comparing plasma glutamine levels with differentially expressed genes associated 
with MHC Class II, there were significantly inverse correlations with glutamine levels 
(mmol/l) during convalescence. No correlation was found with acute measures of HLA gene 
expression and glutamine, suggesting that glutamine levels may contribute to an increased 
secondary infection risk during convalescence. The pattern of differentially downregulated 
genes associated with MHC Class II presentations has been described in genome-wide 
analysis of trauma patients and was found to strongly correlate with multi-organ failure and 
28 day mortality (496). Depressed MHC Class II expression on monocytes/macrophages is 
associated with increased risk of late infectious complications in septic adults (490) and 
critically ill children (495). Both parenteral and enterally administered glutamine in critically 
ill adults has been shown to be effective in promoting increased HLA-DR expression, in part 
due to the maintenance of normal plasma glutamine levels (346, 347). 
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The glycolysis and gluconoegenesis signalling pathway was the most significantly enriched 
and differentially upregulated signalling pathway, with up to 25% of the entire gene set 
represented in this pathway. Increased gluconeogenic and glycolytic pathways are hallmarks 
of critical illness and are associated with protein efflux from muscle delivering glutamine and 
alanine for participation in the citrate cycle for de novo glucose synthesis (499). It could be 
hypothesised that glutamine levels are depleted as a result of the upregulation of the 
gluconeogenic pathway in children with meningococcal disease. 
 
During the acute phase of meningococcal disease plasma levels of HSP70 and glutamine 
were positively and negatively correlated with the expression of several up- and 
downstream kinases within the p38MAPK pathway including JAK2, STAT-1 and DUSP-1 (MKP-
1). p38 and JNK plays a pivotal role in the transcriptional and post-transcriptional regulation 
of inflammatory mediators (532). Other in vivo septic rat models have shown glutamine 
supplementation inactivates p38MAKP and ERK activation through HSP70 release, 
attenuating the release of TNF-α, IL-6 and IL-8 (534).   
 
As glutamine is able to inactivate p38 and JNK through phosphorylation of MKP-1 (533) the 
administration of glutamine during critical illness may be a useful therapeutic adjunct. The 
beneficial effect of glutamine relative to the transcriptional activation of p38MAPK and JNK 
may be lost when glutamine levels are depleted, which has been described for up to 30 days 
post ICU admission (209). In the context of this meningococcal disease cohort glutamine 
levels were depleted for up to 55 days post admission which may have a negative impact 
over the host’s ability to limit the intensity of the inflammatory response, especially as there 
were numerous positive and negative correlations with both HSP70 and glutamine and 
p38MAPK. Further work will be required in the future to understand the impact of glutamine 
supplementation on transcriptional control of p38MAPK and the role HSP70 upregulation by 
glutamine may play.  
 
As glutamine depletion is common in critical illness (307), this could lead to an insufficient 
ongoing HSP70 response in severe sepsis, which may contribute to cell injury, organ damage 
(388) and increased risk of secondary infections (189). Perhaps the role of glutamine 
supplementation, in severe sepsis is to facilitate an appropriate HSP70 response reducing 
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organ damage and enhancing survival (128, 143, 196). By promoting glutamine homeostasis, 
cells which rapidly consume glutamine (macrophages, lymphocytes, neutrophils and 
monocytes) (399) are able to continue producing appropriate amounts of HSP70 in addition 
to inflammatory mediators, in response to stress. As stress resolves, HSP70 is then able in 
inhibit the transcription of inflammatory mediators (414, 516).  
 
The results from this transcriptomic analysis show that genes associated with HSP70 and 
inflammatory signalling pathways within the dataset are differentially upregulated and those 
relating to adaptive immunity are downregulated. In a glutamine deficient state, optimal 
upregulation of genes (237) and post transcriptional inactivation of genes associated with 
the inflammatory response does not occur (533). The transcriptomic findings reported in this 
cohort are well described in other related studies (360, 472, 536). However, it will also  be 
important to validate the functional importance of these results data using multiplex assays 
and flow cytometry to measure T lymphocyte function, PRR function and adaptive immunity 
such as MHC II expression, as described in other critically ill cohorts (2, 495, 537-539, 542). 
 
6.2 Conclusion  
This study showed in an experimental model of sepsis, that glutamine supplementation 
significantly increased HSP70 release. Children with meningococcal disease were glutamine 
depleted early in the course of the disease and well into convalescence. SDE gene transcripts 
associated with inflammatory signalling pathways and adaptive immunity were correlated 
with protein levels of HSP70 and glutamine, suggesting temporal relationships between 
plasma protein levels and gene expression. Future work should aim to understand the effect 
of glutamine supplementation on gene expression during critical illness, especially relative to 
genes associated with HSP70, inflammatory signalling pathways and those relating to HLA. 
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Appendix 8.1: Differential fold changes of gene transcripts in children with acute 
meningococcal disease compared to convalescence 
Entrez 
Gene ID 
Symbol Official Name Corrected p-
value 
Fold 
Change 
Absolute 
Up or 
down 
regulation 
51257 March-2 Homo sapiens membrane-associated ring finger 
(C3HC4) 2 (MARCH2), mRNA. 
7.32E-04 2.1228623 up 
23157  SEPT6-1 Homo sapiens septin 6 (SEPT6), transcript variant I, 
mRNA. 
1.14E-05 2.9239087 down 
23157  SEPT6-111 Homo sapiens septin 6 (SEPT6), transcript variant 
III, mRNA. 
1.96E-04 2.3934422 down 
23157  SEPT6-V Homo sapiens septin 6 (SEPT6), transcript variant 
V, mRNA. 
5.78E-05 2.2580981 down 
10801  SEPT9 Homo sapiens septin 9 (SEPT9), mRNA. 5.13E-06 2.1564415 down 
55752  SEPT11 Homo sapiens septin 11 (SEPT11), mRNA. 6.49E-05 2.0454085 down 
9403  SEPT15 Homo sapiens 15 kDa selenoprotein (SEP15), 
transcript variant 1, mRNA. 
6.31E-06 2.0176182 up 
19 ABCA1 Homo sapiens ATP-binding cassette, sub-family A 
(ABC1), member 1 (ABCA1), mRNA. 
2.63E-05 2.9242759 up 
25864 ABHD14A Homo sapiens abhydrolase domain containing 14A 
(ABHD14A), mRNA. 
1.34E-04 2.427685 down 
84836 ABHD14B Homo sapiens abhydrolase domain containing 14B 
(ABHD14B), mRNA. 
0.0025 2.05323 down 
11057 ABHD2 Homo sapiens abhydrolase domain containing 2 
(ABHD2), transcript variant 2, mRNA. 
6.99E-04 2.9495397 up 
51099 ABHD5 Homo sapiens abhydrolase domain containing 5 
(ABHD5), mRNA. 
7.68E-06 3.468925 up 
3983 ABLIM1 Homo sapiens actin binding LIM protein 1 
(ABLIM1), transcript variant 4, mRNA. 
6.31E-06 4.8815417 down 
30 ACAA1 Homo sapiens acetyl-Coenzyme A acyltransferase 1 
(peroxisomal 3-oxoacyl-Coenzyme A thiolase) 
(ACAA1), nuclear gene encoding mitochondrial 
protein, mRNA. 
5.47E-06 2.552882 up 
84129 ACAD11 Homo sapiens acyl-Coenzyme A dehydrogenase 
family, member 11 (ACAD11), mRNA. 
4.78E-05 2.0209713 down 
57001 ACN9 Homo sapiens ACN9 homolog (S. cerevisiae) 
(ACN9), mRNA. 
1.82E-05 2.6151311 up 
23597 ACOT9 Homo sapiens acyl-CoA thioesterase 9 (ACOT9), 
mRNA. 
4.53E-05 2.3838916 up 
51 ACOX1 Homo sapiens acyl-Coenzyme A oxidase 1, 
palmitoyl (ACOX1), transcript variant 1, mRNA. 
3.18E-05 2.8341515 up 
55 ACPP Homo sapiens acid phosphatase, prostate (ACPP), 
mRNA. 
5.22E-04 3.3458211 up 
2180 ACSL1 Homo sapiens acyl-CoA synthetase long-chain 
family member 1 (ACSL1), mRNA. 
5.13E-06 4.1557355 up 
2181 ACSL3 Homo sapiens acyl-CoA synthetase long-chain 
family member 3 (ACSL3), transcript variant 1, 
mRNA. 
4.6E-03 2.2107027 up 
2181 ACSL3 Homo sapiens acyl-CoA synthetase long-chain 
family member 3 (ACSL3), transcript variant 2, 
mRNA. 
1.00E-05 2.1797078 up 
2182 ACSL4 Homo sapiens acyl-CoA synthetase long-chain 
family member 4 (ACSL4), transcript variant 1, 
mRNA. 
5.35E-06 4.180476 up 
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84532 ACSS1 Homo sapiens acyl-CoA synthetase short-chain 
family member 1 (ACSS1), nuclear gene encoding 
mitochondrial protein, mRNA. 
9.48E-06 2.3971343 down 
55902 ACSS2 Homo sapiens acyl-CoA synthetase short-chain 
family member 2 (ACSS2), transcript variant 2, 
mRNA. 
5.27E-06 2.471739 up 
55902 ACSS2 Homo sapiens acyl-CoA synthetase short-chain 
family member 2 (ACSS2), transcript variant 2, 
mRNA. 
5.13E-06 2.4205906 up 
55860 ACTR10 Homo sapiens actin-related protein 10 homolog (S. 
cerevisiae) (ACTR10), mRNA. 
1.52E-05 2.4555352 up 
10097 ACTR2 Homo sapiens ARP2 actin-related protein 2 
homolog (yeast) (ACTR2), transcript variant 1, 
mRNA. 
1.39E-05 2.0837154 up 
10096 ACTR3 Homo sapiens ARP3 actin-related protein 3 
homolog (yeast) (ACTR3), mRNA. 
5.13E-06 2.145069 up 
91 ACVR1B Homo sapiens activin A receptor, type IB (ACVR1B), 
transcript variant 1, mRNA. 
5.13E-06 4.154476 up 
100 ADA Homo sapiens adenosine deaminase (ADA), mRNA. 2.42E-05 2.4412327 down 
8751 ADAM15 Homo sapiens ADAM metallopeptidase domain 15 
(ADAM15), transcript variant 2, mRNA. 
2.1E-03 2.0619636 up 
104 ADARB1 Homo sapiens adenosine deaminase, RNA-specific, 
B1 (RED1 homolog rat) (ADARB1), transcript 
variant 4, mRNA. 
5.13E-06 3.298978 down 
90956 ADCK2 Homo sapiens aarF domain containing kinase 2 
(ADCK2), mRNA. 
5.27E-06 2.2083964 down 
79934 ADCK4 Homo sapiens aarF domain containing kinase 4 
(ADCK4), mRNA. 
6.22E-03 2.2813466 up 
109 ADCY3 Homo sapiens adenylate cyclase 3 (ADCY3), mRNA. 6.53E-04 3.1877859 up 
123 ADFP Homo sapiens adipose differentiation-related 
protein (ADFP), mRNA. 
5.13E-06 2.709949 up 
133 ADM Homo sapiens adrenomedullin (ADM), mRNA. 5.13E-06 4.2016716 up 
135 ADORA2A Homo sapiens adenosine A2a receptor (ADORA2A), 
mRNA. 
4.15E-04 2.085995 up 
166 AES Homo sapiens amino-terminal enhancer of split 
(AES), transcript variant 1, mRNA. 
5.27E-06 2.3638194 down 
166 AES Homo sapiens amino-terminal enhancer of split 
(AES), transcript variant 3, mRNA. 
5.13E-06 3.0469098 down 
10555 AGPAT2 Homo sapiens 1-acylglycerol-3-phosphate O-
acyltransferase 2 (lysophosphatidic acid 
acyltransferase, beta) (AGPAT2), transcript variant 
2, mRNA. 
5.27E-06 2.6327765 up 
10555 AGPAT2 Homo sapiens 1-acylglycerol-3-phosphate O-
acyltransferase 2 (lysophosphatidic acid 
acyltransferase, beta) (AGPAT2), transcript variant 
1, mRNA. 
7.25E-06 3.3010685 up 
10555 AGPAT2 Homo sapiens 1-acylglycerol-3-phosphate O-
acyltransferase 2 (lysophosphatidic acid 
acyltransferase, beta) (AGPAT2), transcript variant 
1, mRNA. 
4.0E-03 3.4558003 up 
23287 AGTPBP1 Homo sapiens ATP/GTP binding protein 1 
(AGTPBP1), mRNA. 
3.27E-05 3.9650426 up 
57085 AGTRAP Homo sapiens angiotensin II receptor-associated 
protein (AGTRAP), mRNA. 
5.13E-06 3.645217 up 
57085 AGTRAP Homo sapiens angiotensin II receptor-associated 
protein (AGTRAP), transcript variant 2, mRNA. 
5.13E-06 3.9348745 up 
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79026 AHNAK Homo sapiens AHNAK nucleoprotein (AHNAK), 
transcript variant 1, mRNA. 
3.50E-05 2.3069205 down 
199 AIF1 Homo sapiens allograft inflammatory factor 1 
(AIF1), transcript variant 3, mRNA. 
1.66E-05 2.925644 up 
199 AIF1 Homo sapiens allograft inflammatory factor 1 
(AIF1), transcript variant 3, mRNA. 
2.42E-05 2.4036589 up 
51390 AIG1 Homo sapiens androgen-induced 1 (AIG1), mRNA. 6.13E-05 2.7312293 up 
231 AKR1B1 Homo sapiens aldo-keto reductase family 1, 
member B1 (aldose reductase) (AKR1B1), mRNA. 
5.27E-06 2.5981205 down 
214 ALCAM Homo sapiens activated leukocyte cell adhesion 
molecule (ALCAM), mRNA. 
1.33E-05 4.5643463 up 
216 ALDH1A1 Homo sapiens aldehyde dehydrogenase 1 family, 
member A1 (ALDH1A1), mRNA. 
1.22E-04 3.0390568 down 
221 ALDH3B1 Homo sapiens aldehyde dehydrogenase 3 family, 
member B1 (ALDH3B1), transcript variant 2, mRNA. 
5.91E-06 3.0088317 up 
8659 ALDH4A1 Homo sapiens aldehyde dehydrogenase 4 family, 
member A1 (ALDH4A1), nuclear gene encoding 
mitochondrial protein, transcript variant P5CDhS, 
mRNA. 
6.53E-04 2.427308 up 
226 ALDOA Homo sapiens aldolase A, fructose-bisphosphate 
(ALDOA), transcript variant 2, mRNA. 
3.50E-05 2.1466763 up 
226 ALDOA Homo sapiens aldolase A, fructose-bisphosphate 
(ALDOA), transcript variant 2, mRNA. 
5.13E-06 2.3350735 up 
91801 ALKBH8 Homo sapiens alkB, alkylation repair homolog 8 (E. 
coli) (ALKBH8), mRNA. 
5.11E-04 2.0812833 down 
240 ALOX5 Homo sapiens arachidonate 5-lipoxygenase 
(ALOX5), mRNA. 
1.08E-05 2.9613776 up 
241 ALOX5AP Homo sapiens arachidonate 5-lipoxygenase-
activating protein (ALOX5AP), mRNA. 
5.13E-06 3.6183558 up 
80216 ALPK1 Homo sapiens alpha-kinase 1 (ALPK1), mRNA. 1.66E-05 3.0632231 up 
249 ALPL Homo sapiens alkaline phosphatase, 
liver/bone/kidney (ALPL), mRNA. 
3.18E-05 4.5773597 up 
251 ALPPL2 Homo sapiens alkaline phosphatase, placental-like 
2 (ALPPL2), mRNA. 
7.68E-06 3.0623443 up 
150864 ALS2CR13 Homo sapiens amyotrophic lateral sclerosis 2 
(juvenile) chromosome region, candidate 13 
(ALS2CR13), mRNA. 
1.52E-05 2.2309058 down 
272 AMPD3 Homo sapiens adenosine monophosphate 
deaminase (isoform E) (AMPD3), transcript variant 
2, mRNA. 
4.67E-04 2.5294275 up 
64682 ANAPC1 Homo sapiens anaphase promoting complex 
subunit 1 (ANAPC1), mRNA. 
8.34E-06 2.602417 down 
118932 ANKRD22 Homo sapiens ankyrin repeat domain 22 
(ANKRD22), mRNA. 
4.70E-04 10.628527 up 
341405 ANKRD33 Homo sapiens ankyrin repeat domain 33 
(ANKRD33), mRNA. 
6.31E-06 3.2745109 up 
57182 ANKRD50 Homo sapiens ankyrin repeat domain 50 
(ANKRD50), mRNA. 
2.51E-04 2.6015894 up 
79722 ANKRD55 Homo sapiens ankyrin repeat domain 55 
(ANKRD55), transcript variant 2, mRNA. 
4.18E-04 2.0538769 up 
23294 ANKS1A Homo sapiens ankyrin repeat and sterile alpha 
motif domain containing 1A (ANKS1A), mRNA. 
5.13E-06 3.2355926 up 
118429 ANTXR2 Homo sapiens anthrax toxin receptor 2 (ANTXR2), 
mRNA. 
2.86E-04 2.0358493 up 
301 ANXA1 Homo sapiens annexin A1 (ANXA1), mRNA. 5.13E-06 4.4185266 up 
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302 ANXA2 Homo sapiens annexin A2 (ANXA2), transcript 
variant 2, mRNA. 
6.10E-05 2.2237422 up 
306 ANXA3 Homo sapiens annexin A3 (ANXA3), mRNA. 6.38E-05 13.930081 up 
308 ANXA5 Homo sapiens annexin A5 (ANXA5), mRNA. 5.27E-06 2.6713386 up 
1176 AP3S1 Homo sapiens adaptor-related protein complex 3, 
sigma 1 subunit (AP3S1), transcript variant 2, 
mRNA. 
2.28E-05 2.7825558 up 
10239 AP3S2 Homo sapiens adaptor-related protein complex 3, 
sigma 2 subunit (AP3S2), mRNA. 
1.22E-04 2.235738 up 
317 APAF1 Homo sapiens apoptotic peptidase activating 
factor 1 (APAF1), transcript variant 5, mRNA. 
5.47E-06 2.7191226 up 
83464 APH1B Homo sapiens anterior pharynx defective 1 
homolog B (C. elegans) (APH1B), mRNA. 
5.13E-06 5.455491 up 
55911 APOB48R Homo sapiens apolipoprotein B48 receptor 
(APOB48R), mRNA. 
8.78E-04 2.0926363 up 
80833 APOL3 Homo sapiens apolipoprotein L, 3 (APOL3), 
transcript variant alpha/b, mRNA. 
5.50E-05 3.018701 down 
353 APRT Homo sapiens adenine phosphoribosyltransferase 
(APRT), transcript variant 1, mRNA. 
2.20E-05 2.3390777 down 
353 APRT Homo sapiens adenine phosphoribosyltransferase 
(APRT), transcript variant 2, mRNA. 
2.24E-05 2.281276 down 
375318 AQP12A Homo sapiens aquaporin 12A (AQP12A), mRNA. 1.96E-04 2.1761649 up 
366 AQP9 Homo sapiens aquaporin 9 (AQP9), mRNA. 5.13E-06 3.3863466 up 
375 ARF1 Homo sapiens ADP-ribosylation factor 1 (ARF1), 
transcript variant 2, mRNA. 
9.68E-04 2.0372055 up 
378 ARF4 Homo sapiens ADP-ribosylation factor 4 (ARF4), 
mRNA. 
4.16E-05 2.125652 up 
383 ARG1 Homo sapiens arginase, liver (ARG1), mRNA. 1.3E-02 39.776466 up 
9824 ARHGAP11A Homo sapiens Rho GTPase activating protein 11A 
(ARHGAP11A), transcript variant 2, mRNA. 
9.97E-06 2.6994462 up 
93663 ARHGAP18 Homo sapiens Rho GTPase activating protein 18 
(ARHGAP18), mRNA. 
4.90E-05 2.4310317 up 
83478 ARHGAP24 Homo sapiens Rho GTPase activating protein 24 
(ARHGAP24), transcript variant 1, mRNA. 
2.0E-03 2.272303 up 
1820 ARID3A Homo sapiens AT rich interactive domain 3A 
(BRIGHT- like) (ARID3A), mRNA. 
6.31E-06 2.3753872 up 
10124 ARL4 Homo sapiens ADP-ribosylation factor-like 4 
(ARL4), transcript variant 1, mRNA. 
5.24E-04 3.6588619 up 
10124 ARL4 Homo sapiens ADP-ribosylation factor-like 4 
(ARL4), transcript variant 1, mRNA. 
5.41E-04 2.6687455 up 
10550 ARL6IP5 Homo sapiens ADP-ribosylation-like factor 6 
interacting protein 5 (ARL6IP5), mRNA. 
5.27E-06 2.025481 up 
10552 ARPC1A Homo sapiens actin related protein 2/3 complex, 
subunit 1A, 41kDa (ARPC1A), mRNA. 
5.35E-06 2.07487 up 
10094 ARPC3 Homo sapiens actin related protein 2/3 complex, 
subunit 3, 21kDa (ARPC3), mRNA. 
9.10E-06 2.4239552 up 
10092 ARPC5 Homo sapiens actin related protein 2/3 complex, 
subunit 5, 16kDa (ARPC5), mRNA. 
5.91E-06 2.273194 up 
409 ARRB2 Homo sapiens arrestin, beta 2 (ARRB2), transcript 
variant 2, mRNA. 
1.17E-05 2.8576148 up 
91947 ARRDC4 Homo sapiens arrestin domain containing 4 
(ARRDC4), mRNA. 
5.33E-05 4.0111256 up 
414 ARSD Homo sapiens arylsulfatase D (ARSD), transcript 
variant 1, mRNA. 
3.59E-04 2.5105703 up 
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427 ASAH1 Homo sapiens N-acylsphingosine amidohydrolase 
(acid ceramidase) 1 (ASAH1), transcript variant 1, 
mRNA. 
9.08E-05 2.5698562 up 
430 ASCL2 Homo sapiens achaete-scute complex-like 2 
(Drosophila) (ASCL2), mRNA. 
6.31E-06 2.4324753 down 
444 ASPH Homo sapiens aspartate beta-hydroxylase (ASPH), 
transcript variant 2, mRNA. 
1.2E-02 2.8206544 up 
79058 ASPSCR1 Homo sapiens alveolar soft part sarcoma 
chromosome region, candidate 1 (ASPSCR1), 
mRNA. 
7.25E-06 2.2351763 down 
22926 ATF6 Homo sapiens activating transcription factor 6 
(ATF6), mRNA. 
3.50E-05 2.5570004 up 
10533 ATG7 Homo sapiens ATG7 autophagy related 7 homolog 
(S. cerevisiae) (ATG7), mRNA. 
2.42E-05 2.0359898 up 
471 ATIC Homo sapiens 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP 
cyclohydrolase (ATIC), mRNA. 
7.68E-06 2.3492987 down 
472 ATM Homo sapiens ataxia telangiectasia mutated 
(ATM), transcript variant 1, mRNA. 
2.20E-05 2.2496457 down 
475 ATOX1 Homo sapiens ATX1 antioxidant protein 1 homolog 
(yeast) (ATOX1), mRNA. 
5.47E-06 2.3077657 up 
23200 ATP11B Homo sapiens ATPase, Class VI, type 11B (ATP11B), 
mRNA. 
5.27E-06 3.285318 up 
493 ATP2B4 Homo sapiens ATPase, Ca++ transporting, plasma 
membrane 4 (ATP2B4), transcript variant 1, mRNA. 
1.1E-03 2.1196537 up 
509 ATP5C1 Homo sapiens ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma polypeptide 1 
(ATP5C1), nuclear gene encoding mitochondrial 
protein, transcript variant 2, mRNA. 
2.86E-04 2.117162 up 
537 ATP6AP1 Homo sapiens ATPase, H+ transporting, lysosomal 
accessory protein 1 (ATP6AP1), mRNA. 
5.27E-06 2.3823411 up 
533 ATP6V0B Homo sapiens ATPase, H+ transporting, lysosomal 
21kDa, V0 subunit b (ATP6V0B), transcript variant 
2, mRNA. 
6.31E-06 2.6505432 up 
533 ATP6V0B Homo sapiens ATPase, H+ transporting, lysosomal 
21kDa, V0 subunit c'' (ATP6V0B), mRNA. 
5.27E-06 2.245184 up 
9114 ATP6V0D1 Homo sapiens ATPase, H+ transporting, lysosomal 
38kDa, V0 subunit d isoform 1 (ATP6V0D1), mRNA. 
6.31E-06 2.246149 up 
8992 ATP6V0E1 Homo sapiens ATPase, H+ transporting, lysosomal 
9kDa, V0 subunit e1 (ATP6V0E1), mRNA. 
5.13E-06 2.2897472 up 
155066 ATP6V0E2L Homo sapiens ATPase, H+ transporting V0 subunit 
E2-like (rat) (ATP6V0E2L), mRNA. 
5.13E-06 3.9404657 down 
523 ATP6V1A Homo sapiens ATPase, H+ transporting, lysosomal 
70kDa, V1 subunit A (ATP6V1A), mRNA. 
1.39E-05 2.476419 up 
526 ATP6V1B2 Homo sapiens ATPase, H+ transporting, lysosomal 
56/58kDa, V1 subunit B, isoform 2 (ATP6V1B2), 
mRNA. 
8.44E-06 2.096081 up 
528 ATP6V1C1 Homo sapiens ATPase, H+ transporting, lysosomal 
42kDa, V1 subunit C1 (ATP6V1C1), transcript 
variant 1, mRNA. 
5.13E-06 4.5077534 up 
51382 ATP6V1D Homo sapiens ATPase, H+ transporting, lysosomal 
34kDa, V1 subunit D (ATP6V1D), mRNA. 
5.13E-06 2.702841 up 
529 ATP6V1E1 Homo sapiens ATPase, H+ transporting, lysosomal 
31kDa, V1 subunit E1 (ATP6V1E1), transcript 
variant 3, mRNA. 
5.13E-06 2.2574718 up 
529 ATP6V1E1 Homo sapiens ATPase, H+ transporting, lysosomal 
31kDa, V1 subunit E isoform 1 (ATP6V1E1), mRNA. 
5.13E-06 2.375929 up 
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79895 ATP8B4 Homo sapiens ATPase, Class I, type 8B, member 4 
(ATP8B4), mRNA. 
5.13E-06 3.5032446 up 
10079 ATP9A Homo sapiens ATPase, Class II, type 9A (ATP9A), 
mRNA. 
5.27E-06 7.854341 up 
545 ATR Homo sapiens ataxia telangiectasia and Rad3 
related (ATR), mRNA. 
5.9E-03 2.2117977 down 
6310 ATXN1 Homo sapiens ataxin 1 (ATXN1), mRNA. 6.31E-06 3.1478345 up 
389289 AXIIR Homo sapiens chromosome 5 open reading frame 
39 (C5orf39), mRNA. 
5.13E-06 2.8115764 down 
8313 AXIN2 Homo sapiens axin 2 (conductin, axil) (AXIN2), 
mRNA. 
3.3E-03 2.4288762 down 
64651 AXUD1 Homo sapiens AXIN1 upregulated 1 (AXUD1), 
mRNA. 
1.22E-04 2.1785872 up 
54947 AYTL1 Homo sapiens acyltransferase like 1 (AYTL1), 
mRNA. 
3.14E-04 2.5456052 up 
64343 AZI2 Homo sapiens 5-azacytidine induced 2 (AZI2), 
mRNA. 
3.10E-05 2.7625904 up 
51582 AZIN1 Homo sapiens antizyme inhibitor 1 (AZIN1), 
transcript variant 2, mRNA. 
2.35E-03 2.0683444 up 
51582 AZIN1 Homo sapiens antizyme inhibitor 1 (AZIN1), 
transcript variant 1, mRNA. 
3.18E-05 2.1084754 up 
374907 B3GALT7 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 8 (B3GNT8), mRNA. 
5.32E-04 3.2319646 up 
84002 B3GNT5 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 5 (B3GNT5), mRNA. 
3.6E-03 6.9917035 up 
146712 B3GNTL1 Homo sapiens UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase-like 1 (B3GNTL1), 
mRNA. 
1.74E-03 2.7826777 up 
8702 B4GALT4 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 4 (B4GALT4), 
transcript variant 2, mRNA. 
1.81E-04 2.159077 up 
9334 B4GALT5 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 (B4GALT5), 
mRNA. 
5.47E-06 4.0208426 up 
60468 BACH2 Homo sapiens BTB and CNC homology 1, basic 
leucine zipper transcription factor 2 (BACH2), 
mRNA. 
1.19E-04 2.4713762 down 
9530 BAG4 Homo sapiens BCL2-associated athanogene 4 
(BAG4), mRNA. 
1.1E-03 2.0753407 up 
10409 BASP1 Homo sapiens brain abundant, membrane 
attached signal protein 1 (BASP1), mRNA. 
2.42E-05 2.8821824 up 
7920 BAT5 Homo sapiens HLA-B associated transcript 5 
(BAT5), mRNA. 
5.35E-06 2.311769 up 
10538 BATF Homo sapiens basic leucine zipper transcription 
factor, ATF-like (BATF), mRNA. 
5.13E-06 4.0594397 up 
11177 BAZ1A Homo sapiens bromodomain adjacent to zinc 
finger domain, 1A (BAZ1A), transcript variant 2, 
mRNA. 
1.17E-05 3.4623272 up 
11177 BAZ1A Homo sapiens bromodomain adjacent to zinc 
finger domain, 1A (BAZ1A), transcript variant 1, 
mRNA. 
6.88E-05 2.54265 up 
10134 BCAP31 Homo sapiens B-cell receptor-associated protein 
31 (BCAP31), mRNA. 
5.47E-06 2.0151117 up 
55653 BCAS4 Homo sapiens breast carcinoma amplified 
sequence 4 (BCAS4), transcript variant 1, mRNA. 
5.47E-06 3.270653 down 
55653 BCAS4 Homo sapiens breast carcinoma amplified 
sequence 4 (BCAS4), transcript variant 1, mRNA. 
5.47E-06 2.6149397 down 
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10295 BCKDK Homo sapiens branched chain ketoacid 
dehydrogenase kinase (BCKDK), mRNA. 
1.28E-05 2.2914066 up 
53335 BCL11A Homo sapiens B-cell CLL/lymphoma 11A (zinc 
finger protein) (BCL11A), transcript variant 1, 
mRNA. 
1.39E-05 2.4021606 down 
64919 BCL11B Homo sapiens B-cell CLL/lymphoma 11B (zinc 
finger protein) (BCL11B), transcript variant 2, 
mRNA. 
6.34E-06 5.764843 down 
596 BCL2 Homo sapiens B-cell CLL/lymphoma 2 (BCL2), 
nuclear gene encoding mitochondrial protein, 
transcript variant alpha, mRNA. 
5.88E-06 3.32775 down 
597 BCL2A1 Homo sapiens BCL2-related protein A1 (BCL2A1), 
mRNA. 
6.38E-05 9.320875 up 
602 BCL3 Homo sapiens B-cell CLL/lymphoma 3 (BCL3), 
mRNA. 
7.25E-06 2.5529904 up 
604 BCL6 Homo sapiens B-cell CLL/lymphoma 6 (zinc finger 
protein 51) (BCL6), transcript variant 1, mRNA. 
1.39E-05 3.5367644 up 
604 BCL6 Homo sapiens B-cell CLL/lymphoma 6 (zinc finger 
protein 51) (BCL6), transcript variant 2, mRNA. 
2.28E-02 2.4570224 up 
199786 BCNP1 Homo sapiens family with sequence similarity 129, 
member C (FAM129C), mRNA. 
5.17E-05 2.9546525 down 
274 BIN1 Homo sapiens bridging integrator 1 (BIN1), 
transcript variant 1, mRNA. 
5.13E-06 3.4572208 down 
274 BIN1 Homo sapiens bridging integrator 1 (BIN1), 
transcript variant 6, mRNA. 
5.13E-06 3.3422344 down 
329 BIRC2 Homo sapiens baculoviral IAP repeat-containing 2 
(BIRC2), mRNA. 
1.39E-05 2.0821064 up 
330 BIRC3 Homo sapiens baculoviral IAP repeat-containing 3 
(BIRC3), transcript variant 1, mRNA. 
4.71E-04 2.2116282 down 
330 BIRC3 Homo sapiens baculoviral IAP repeat-containing 3 
(BIRC3), transcript variant 1, mRNA. 
3.48E-03 2.0205636 down 
641 BLM Homo sapiens Bloom syndrome (BLM), mRNA. 6.26E-03 2.4511328 up 
2647 BLOC1S1 Homo sapiens biogenesis of lysosome-related 
organelles complex-1, subunit 1 (BLOC1S1), mRNA. 
5.13E-06 4.292033 up 
643 BLR1 Homo sapiens Burkitt lymphoma receptor 1, GTP 
binding protein (chemokine (C-X-C motif) receptor 
5) (BLR1), transcript variant 2, mRNA. 
1.67E-05 2.5610785 down 
9790 BMS1L Homo sapiens BMS1 homolog, ribosome assembly 
protein (yeast) (BMS1), mRNA. 
5.27E-06 2.3050718 down 
663 BNIP2 Homo sapiens BCL2/adenovirus E1B 19kDa 
interacting protein 2 (BNIP2), mRNA. 
5.35E-06 3.4055154 up 
666 BOK Homo sapiens BCL2-related ovarian killer (BOK), 
mRNA. 
2.20E-05 2.4652698 up 
669 BPGM Homo sapiens 2,3-bisphosphoglycerate mutase 
(BPGM), transcript variant 1, mRNA. 
3.67E-03 2.4872093 up 
671 BPI Homo sapiens bactericidal/permeability-increasing 
protein (BPI), mRNA. 
3.18E-05 13.339196 up 
25798 BRI3 Homo sapiens brain protein I3 (BRI3), mRNA. 5.13E-06 2.886382 up 
25874 BRP44 Homo sapiens brain protein 44 (BRP44), mRNA. 5.13E-06 2.109027 up 
254065 BRWD3 Homo sapiens bromodomain and WD repeat 
domain containing 3 (BRWD3), mRNA. 
1.2E03 2.0850143 up 
683 BST1 Homo sapiens bone marrow stromal cell antigen 1 
(BST1), mRNA. 
5.13E-06 5.1550226 up 
84280 BTBD10 Homo sapiens BTB (POZ) domain containing 10 
(BTBD10), mRNA. 
5.13E-06 2.9469848 up 
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121551 BTBD11 Homo sapiens BTB (POZ) domain containing 11 
(BTBD11), transcript variant 1, mRNA. 
1.55E-03 2.2038865 down 
138151 BTBD14A Homo sapiens BTB (POZ) domain containing 14A 
(BTBD14A), mRNA. 
1.17E-05 2.4902163 up 
11119 BTN3A1 Homo sapiens butyrophilin, subfamily 3, member 
A1 (BTN3A1), transcript variant 1, mRNA. 
5.47E-06 4.2925014 down 
11118 BTN3A2 Homo sapiens butyrophilin, subfamily 3, member 
A2 (BTN3A2), mRNA. 
1.52E-05 3.2264793 down 
10384 BTN3A3 Homo sapiens butyrophilin, subfamily 3, member 
A3 (BTN3A3), transcript variant 2, mRNA. 
1.29E-05 3.0910273 down 
221061 C10orf38 Homo sapiens chromosome 10 open reading frame 
38 (C10orf38), mRNA. 
1.31E-03 2.558776 down 
64115 C10orf54 Homo sapiens chromosome 10 open reading frame 
54 (C10orf54), mRNA. 
5.27E-06 3.1372325 up 
8872 C10orf7 Homo sapiens cell division cycle 123 homolog (S. 
cerevisiae) (CDC123), mRNA. 
6.31E-06 2.5030859 up 
738 C11orf2 Homo sapiens chromosome 11 open reading 
frame2 (C11orf2), mRNA. 
6.31E-06 2.131858 down 
120534 C11orf46 Homo sapiens chromosome 11 open reading frame 
46 (C11orf46), mRNA. 
7.68E-06 2.2513816 down 
84067 C11orf56 Homo sapiens chromosome 11 open reading frame 
56 (C11orf56), mRNA. 
5.35E-06 2.6234212 up 
113246 C12orf57 Homo sapiens chromosome 12 open reading frame 
57 (C12orf57), mRNA. 
7.57E-05 2.6421273 down 
51528 C14orf100 Homo sapiens chromosome 14 open reading frame 
100 (C14orf100), mRNA. 
5.13E-06 2.8320215 up 
51527 C14orf129 Homo sapiens chromosome 14 open reading frame 
129 (C14orf129), mRNA. 
2.24E-05 2.334114 up 
80017 C14orf159 Homo sapiens chromosome 14 open reading frame 
159 (C14orf159), mRNA. 
1.82E-05 2.6340868 down 
64423 C14orf173 Homo sapiens chromosome 14 open reading frame 
173 (C14orf173), transcript variant 2, mRNA. 
1.28E-05 2.4499786 down 
9556 C14orf2 Homo sapiens chromosome 14 open reading frame 
2 (C14orf2), mRNA. 
5.17E-05 2.1398838 up 
55640 C14orf58 Homo sapiens feline leukemia virus subgroup C 
cellular receptor family, member 2 (FLVCR2), 
mRNA. 
5.27E-06 5.4932256 up 
54930 C14orf94 Homo sapiens chromosome 14 open reading frame 
94 (C14orf94), mRNA. 
2.24E-03 2.8377788 up 
51187 C15orf15 Homo sapiens chromosome 15 open reading frame 
15 (C15orf15), mRNA. 
1.65E-03 2.1335464 up 
79652 C16orf30 Homo sapiens chromosome 16 open reading frame 
30 (C16orf30), mRNA. 
1.12E-03 2.762675 down 
79650 C16orf57 Homo sapiens chromosome 16 open reading frame 
57 (C16orf57), mRNA. 
5.13E-06 3.4210134 up 
64755 C16orf58 Homo sapiens chromosome 16 open reading frame 
58 (C16orf58), mRNA. 
5.27E-06 2.233512 down 
255919 C16orf69 Homo sapiens chromosome 16 open reading frame 
69 (C16orf69), mRNA. 
1.19E-05 2.7329924 up 
9605 C16orf7 Homo sapiens chromosome 16 open reading frame 
7 (C16orf7), mRNA. 
1.82E-05 2.6783915 up 
80233 C17orf70 Homo sapiens chromosome 17 open reading frame 
70 (C17orf70), mRNA. 
1.82E-05 2.0779722 down 
125488 C18orf17 Homo sapiens chromosome 18 open reading frame 
17 (C18orf17), mRNA. 
7.97E-06 2.7321863 down 
83636 C19orf12 Homo sapiens chromosome 19 open reading frame 
12 (C19orf12), transcript variant 1, mRNA. 
5.28E-05 2.0819197 down 
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8725 C19orf2 Homo sapiens chromosome 19 open reading frame 
2 (C19orf2), transcript variant 2, mRNA. 
2.42E-05 2.0990937 down 
29071 C1GALT1C1 Homo sapiens C1GALT1-specific chaperone 1 
(C1GALT1C1), transcript variant 2, mRNA. 
9.97E-06 2.9396925 up 
128346 C1orf162 Homo sapiens chromosome 1 open reading frame 
162 (C1orf162), mRNA. 
5.13E-06 2.8794515 up 
54680 C1orf181 Homo sapiens chromosome 1 open reading frame 
181 (C1orf181), mRNA. 
5.35E-06 2.8106399 down 
116496 C1orf24 Homo sapiens chromosome 1 open reading frame 
24 (C1orf24), transcript variant 1, mRNA. 
3.46E-04 2.4415965 up 
713 C1QB Homo sapiens complement component 1, q 
subcomponent, beta polypeptide (C1QB), mRNA. 
7.57E-03 7.21154 up 
22918 C1QR1 Homo sapiens complement component 1, q 
subcomponent, receptor 1 (C1QR1), mRNA. 
1.39E-05 2.4950087 up 
51279 C1RL Homo sapiens complement component 1, r 
subcomponent-like (C1RL), mRNA. 
3.50E-05 2.6868606 up 
84969 C20orf100 Homo sapiens chromosome 20 open reading frame 
100 (C20orf100), mRNA. 
1.52E-05 2.8502917 down 
54675 C20orf155 Homo sapiens cardiolipin synthase 1 (CRLS1), 
mRNA. 
7.68E-06 2.053593 up 
128611 C20orf174 Homo sapiens chromosome 20 open reading frame 
174 (C20orf174), mRNA. 
1.84E-04 2.2091079 down 
55969 C20orf24 Homo sapiens chromosome 20 open reading frame 
24 (C20orf24), transcript variant 1, mRNA. 
5.13E-06 3.8125732 up 
55969 C20orf24 Homo sapiens chromosome 20 open reading frame 
24 (C20orf24), transcript variant 1, mRNA. 
5.13E-06 3.026176 up 
55969 C20orf24 Homo sapiens chromosome 20 open reading frame 
24 (C20orf24), transcript variant 4, mRNA. 
5.13E-06 3.0735211 up 
57136 C20orf3 Homo sapiens chromosome 20 open reading frame 
3 (C20orf3), mRNA. 
1.01E-04 2.7450454 up 
140823 C20orf52 Homo sapiens chromosome 20 open reading frame 
52 (C20orf52), mRNA. 
2.42E-05 2.0341792 up 
755 C21orf2 Homo sapiens chromosome 21 open reading frame 
2 (C21orf2), mRNA. 
2.20E-05 2.4869087 down 
54059 C21orf57 Homo sapiens chromosome 21 open reading frame 
57 (C21orf57), transcript variant 1, mRNA. 
5.13E-06 2.3074672 up 
192137 C2orf12 PREDICTED: Homo sapiens chromosome 2 open 
reading frame 12, transcript variant 2 (C2orf12), 
mRNA. 
9.97E-06 3.0588775 up 
27249 C2orf25 Homo sapiens chromosome 2 open reading frame 
25 (C2orf25), mRNA. 
5.13E-06 2.964137 up 
719 C3AR1 Homo sapiens complement component 3a 
receptor 1 (C3AR1), mRNA. 
1.42E-04 6.5555315 up 
25871 C3orf17 Homo sapiens chromosome 3 open reading frame 
17 (C3orf17), transcript variant 1, mRNA. 
5.13E-06 2.4203558 up 
84984 C3orf34 Homo sapiens chromosome 3 open reading frame 
34 (C3orf34), mRNA. 
2.86E-04 2.2390769 up 
56941 C3orf37 Homo sapiens chromosome 3 open reading frame 
37 (C3orf37), transcript variant 2, mRNA. 
5.91E-06 2.0405183 down 
131408 C3orf40 Homo sapiens family with sequence similarity 131, 
member A (FAM131A), mRNA. 
6.13E-05 2.0521533 up 
56983 C3orf9 Homo sapiens KTEL (Lys-Tyr-Glu-Leu) containing 1 
(KTELC1), mRNA. 
5.27E-06 2.0646598 down 
51313 C4orf18 Homo sapiens chromosome 4 open reading frame 
18 (C4orf18), transcript variant 2, mRNA. 
6.25E-05 2.647916 up 
728 C5AR1 Homo sapiens complement component 5a 
receptor 1 (C5AR1), mRNA. 
9.97E-06 3.1329455 up 
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10591 C6orf108 Homo sapiens chromosome 6 open reading frame 
108 (C6orf108), transcript variant 2, mRNA. 
4.90E-05 2.2198157 down 
55122 C6orf166 Homo sapiens chromosome 6 open reading frame 
166 (C6orf166), mRNA. 
5.13E-06 2.551163 up 
387357 C6orf190 Homo sapiens chromosome 6 open reading frame 
190 (C6orf190), mRNA. 
5.72E-04 2.4721549 down 
79624 C6orf211 Homo sapiens chromosome 6 open reading frame 
211 (C6orf211), mRNA. 
1.57E-05 2.9303398 up 
79020 C7orf25 Homo sapiens chromosome 7 open reading frame 
25 (C7orf25), mRNA. 
6.11E-05 2.7131867 up 
51337 C8orf55 Homo sapiens chromosome 8 open reading frame 
55 (C8orf55), mRNA. 
5.13E-06 2.7348912 down 
414328 C9orf103 Homo sapiens chromosome 9 open reading frame 
103 (C9orf103), mRNA. 
1.22E-04 2.7826786 up 
399665 C9orf132 Homo sapiens chromosome 9 open reading frame 
132 (C9orf132), mRNA. 
6.95E-03 2.0030742 down 
286257 C9orf142 Homo sapiens chromosome 9 open reading frame 
142 (C9orf142), mRNA. 
5.13E-06 2.042369 down 
81571 C9orf45 Homo sapiens chromosome 9 open reading frame 
45 (C9orf45), mRNA. 
9.97E-03 2.1675062 down 
157983 C9orf66 Homo sapiens chromosome 9 open reading frame 
66 (C9orf66), mRNA. 
1.98E-05 2.251992 up 
84270 C9orf89 Homo sapiens chromosome 9 open reading frame 
89 (C9orf89), mRNA. 
5.13E-06 2.610029 up 
203197 C9orf91 Homo sapiens chromosome 9 open reading frame 
91 (C9orf91), mRNA. 
2.20E-04 2.0844665 down 
759 CA1 Homo sapiens carbonic anhydrase I (CA1), mRNA. 2.16E-03 3.3545828 up 
762 CA4 Homo sapiens carbonic anhydrase IV (CA4), mRNA. 5.13E-06 14.921277 up 
11238 CA5B Homo sapiens carbonic anhydrase VB, 
mitochondrial (CA5B), nuclear gene encoding 
mitochondrial protein, mRNA. 
3.82E-05 2.37991 down 
51719 CAB39 Homo sapiens calcium binding protein 39 (CAB39), 
mRNA. 
5.13E-06 2.9890585 up 
774 CACNA1B Homo sapiens calcium channel, voltage-
dependent, L type, alpha 1B subunit (CACNA1B), 
mRNA. 
5.94E-05 2.4060564 up 
777 CACNA1E Homo sapiens calcium channel, voltage-
dependent, R type, alpha 1E subunit (CACNA1E), 
mRNA. 
2.7E-02 2.810861 up 
91860 CALML4 Homo sapiens calmodulin-like 4 (CALML4), 
transcript variant 1, mRNA. 
7.25E-06 2.3930612 up 
820 CAMP Homo sapiens cathelicidin antimicrobial peptide 
(CAMP), mRNA. 
4.15E-04 2.447115 up 
10487 CAP1 Homo sapiens CAP, adenylate cyclase-associated 
protein 1 (yeast) (CAP1), mRNA. 
5.13E-06 2.2343907 up 
822 CAPG Homo sapiens capping protein (actin filament), 
gelsolin-like (CAPG), mRNA. 
5.13E-06 3.7426062 up 
825 CAPN3 Homo sapiens calpain 3, (p94) (CAPN3), transcript 
variant 1, mRNA. 
1.46E-05 3.5455084 up 
825 CAPN3 Homo sapiens calpain 3, (p94) (CAPN3), transcript 
variant 3, mRNA. 
3.66E-02 3.1070983 up 
830 CAPZA2 Homo sapiens capping protein (actin filament) 
muscle Z-line, alpha 2 (CAPZA2), mRNA. 
5.13E-06 3.4337802 up 
84433 CARD11 Homo sapiens caspase recruitment domain family, 
member 11 (CARD11), mRNA. 
5.13E-06 3.557567 down 
58484 CARD12 Homo sapiens NLR family, CARD domain containing 
4 (NLRC4), mRNA. 
1.46E-05 9.0580435 up 
211 
 
113201 CASC4 Homo sapiens cancer susceptibility candidate 4 
(CASC4), transcript variant 2, mRNA. 
1.04E-04 2.004669 up 
838 CASP5 Homo sapiens caspase 5, apoptosis-related 
cysteine peptidase (CASP5), mRNA. 
7.33E-03 2.8615973 up 
831 CAST Homo sapiens calpastatin (CAST), transcript variant 
1, mRNA. 
9.97E-06 2.176052 up 
117144 CATSPER1 Homo sapiens cation channel, sperm associated 1 
(CATSPER1), mRNA. 
4.10E-03 2.1907773 up 
868 CBLB Homo sapiens Cas-Br-M (murine) ecotropic 
retroviral transforming sequence b (CBLB), mRNA. 
5.91E-06 2.4897604 down 
875 CBS Homo sapiens cystathionine-beta-synthase (CBS), 
mRNA. 
2.0E-02 2.0217743 up 
55246 CCDC25 Homo sapiens coiled-coil domain containing 25 
(CCDC25), transcript variant 2, mRNA. 
6.14E-06 2.082612 down 
6352 CCL5 Homo sapiens chemokine (C-C motif) ligand 5 
(CCL5), mRNA. 
5.13E-06 4.938709 down 
894 CCND2 Homo sapiens cyclin D2 (CCND2), mRNA. 1.08E-05 2.8811862 down 
896 CCND3 Homo sapiens cyclin D3 (CCND3), mRNA. 5.27E-06 2.41005 up 
23582 CCNDBP1 Homo sapiens cyclin D-type binding-protein 1 
(CCNDBP1), transcript variant 2, mRNA. 
5.13E-06 2.2842042 up 
23582 CCNDBP1 Homo sapiens cyclin D-type binding-protein 1 
(CCNDBP1), transcript variant 1, mRNA. 
2.49E-04 2.1258645 up 
9236 CCPG1 Homo sapiens cell cycle progression 1 (CCPG1), 
transcript variant 2, mRNA. 
1.22E-03 3.1285686 up 
9236 CCPG1 Homo sapiens cell cycle progression 1 (CCPG1), 
transcript variant 1, mRNA. 
5.13E-06 4.030477 up 
1230 CCR1 Homo sapiens chemokine (C-C motif) receptor 1 
(CCR1), mRNA. 
9.97E-06 3.8070688 up 
1232 CCR3 Homo sapiens chemokine (C-C motif) receptor 3 
(CCR3), transcript variant 2, mRNA. 
6.85E-04 4.8691397 down 
1236 CCR7 Homo sapiens chemokine (C-C motif) receptor 7 
(CCR7), mRNA. 
1.52E-05 3.168401 down 
929 CD14 Homo sapiens CD14 antigen (CD14), mRNA. 7.68E-06 2.7952507 up 
929 CD14 Homo sapiens CD14 molecule (CD14), transcript 
variant 2, mRNA. 
1.17E-05 2.1337862 up 
9332 CD163 Homo sapiens CD163 molecule (CD163), transcript 
variant 2, mRNA. 
5.13E-06 20.528105 up 
9332 CD163 Homo sapiens CD163 molecule (CD163), transcript 
variant 1, mRNA. 
2.20E-04 23.009604 up 
8763 CD164 Homo sapiens CD164 molecule, sialomucin 
(CD164), mRNA. 
4.26E-05 2.144466 up 
930 CD19 Homo sapiens CD19 antigen (CD19), mRNA. 4.18E-04 2.2766738 down 
914 CD2 Homo sapiens CD2 antigen (p50), sheep red blood 
cell receptor (CD2), mRNA. 
5.13E-06 4.5879564 down 
934 CD24 Homo sapiens CD24 molecule (CD24), mRNA. 5.17E-05 4.0911636 up 
919 CD247 Homo sapiens CD247 molecule (CD247), transcript 
variant 1, mRNA. 
5.13E-06 4.7183876 down 
919 CD247 Homo sapiens CD247 molecule (CD247), transcript 
variant 1, mRNA. 
5.13E-06 4.827429 down 
57124 CD248 Homo sapiens CD248 molecule, endosialin 
(CD248), mRNA. 
4.15E-04 2.6990235 down 
146722 CD300LF Homo sapiens CD300 molecule-like family member 
f (CD300LF), mRNA. 
5.13E-06 3.3200364 up 
948 CD36 Homo sapiens CD36 molecule (thrombospondin 
receptor) (CD36), transcript variant 1, mRNA. 
1.96E-04 2.13865 up 
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915 CD3D Homo sapiens CD3d molecule, delta (CD3-TCR 
complex) (CD3D), transcript variant 1, mRNA. 
1.52E-05 3.9694395 down 
915 CD3D Homo sapiens CD3d molecule, delta (CD3-TCR 
complex) (CD3D), transcript variant 2, mRNA. 
7.68E-06 4.237124 down 
916 CD3E Homo sapiens CD3e molecule, epsilon (CD3-TCR 
complex) (CD3E), mRNA. 
1.14E-05 4.158275 down 
917 CD3G Homo sapiens CD3g molecule, gamma (CD3-TCR 
complex) (CD3G), mRNA. 
3.00E-05 4.8877897 down 
920 CD4 Homo sapiens CD4 antigen (p55) (CD4), mRNA. 1.39E-05 2.7685466 down 
960 CD44 Homo sapiens CD44 molecule (Indian blood group) 
(CD44), transcript variant 3, mRNA. 
9.10E-06 2.3961015 up 
960 CD44 Homo sapiens CD44 molecule (Indian blood group) 
(CD44), transcript variant 5, mRNA. 
2.20E-05 2.699219 up 
921 CD5 Homo sapiens CD5 molecule (CD5), mRNA. 2.20E-05 4.3049035 down 
963 CD53 Homo sapiens CD53 antigen (CD53), mRNA. 5.13E-06 2.6352615 up 
963 CD53 Homo sapiens CD53 antigen (CD53), mRNA. 5.13E-06 2.6252496 up 
1604 CD55 Homo sapiens CD55 molecule, decay accelerating 
factor for complement (Cromer blood group) 
(CD55), mRNA. 
5.13E-06 4.717547 up 
965 CD58 Homo sapiens CD58 molecule (CD58), mRNA. 5.13E-06 6.3527145 up 
923 CD6 Homo sapiens CD6 molecule (CD6), mRNA. 5.13E-06 5.6552644 down 
967 CD63 Homo sapiens CD63 antigen (melanoma 1 antigen) 
(CD63), mRNA. 
5.27E-06 5.858538 up 
924 CD7 Homo sapiens CD7 molecule (CD7), mRNA. 5.13E-06 4.597035 down 
972 CD74 Homo sapiens CD74 molecule, major 
histocompatibility complex, class II invariant chain 
(CD74), transcript variant 2, mRNA. 
5.13E-06 3.0446384 down 
972 CD74 Homo sapiens CD74 molecule, major 
histocompatibility complex, class II invariant chain 
(CD74), transcript variant 3, mRNA. 
5.27E-06 2.9287467 down 
973 CD79A Homo sapiens CD79A antigen (immunoglobulin-
associated alpha) (CD79A), transcript variant 1, 
mRNA. 
4.69E-05 2.4491968 down 
973 CD79A Homo sapiens CD79A antigen (immunoglobulin-
associated alpha) (CD79A), transcript variant 1, 
mRNA. 
4.85E-04 2.1259444 down 
974 CD79B Homo sapiens CD79b molecule, immunoglobulin-
associated beta (CD79B), transcript variant 3, 
mRNA. 
7.57E-05 2.333049 down 
974 CD79B Homo sapiens CD79B antigen (immunoglobulin-
associated beta) (CD79B), transcript variant 1, 
mRNA. 
5.69E-05 2.680019 down 
974 CD79B Homo sapiens CD79B antigen (immunoglobulin-
associated beta) (CD79B), transcript variant 2, 
mRNA. 
3.50E-05 2.7322147 down 
3732 CD82 Homo sapiens CD82 antigen (CD82), transcript 
variant 1, mRNA. 
5.88E-06 2.9834602 up 
3732 CD82 Homo sapiens CD82 molecule (CD82), transcript 
variant 2, mRNA. 
5.13E-06 4.1557465 up 
942 CD86 Homo sapiens CD86 antigen (CD28 antigen ligand 
2, B7-2 antigen) (CD86), transcript variant 1, 
mRNA. 
6.74E-06 2.2853835 down 
925 CD8A Homo sapiens CD8a molecule (CD8A), transcript 
variant 2, mRNA. 
5.13E-06 4.806471 down 
925 CD8A Homo sapiens CD8 antigen, alpha polypeptide 
(p32) (CD8A), transcript variant 1, mRNA. 
5.13E-06 5.052119 down 
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10225 CD96 Homo sapiens CD96 molecule (CD96), transcript 
variant 2, mRNA. 
5.13E-06 4.9419694 down 
10225 CD96 Homo sapiens CD96 antigen (CD96), transcript 
variant 1, mRNA. 
8.68E-05 3.9020596 down 
978 CDA Homo sapiens cytidine deaminase (CDA), mRNA. 1.11E-04 2.7909765 up 
994 CDC25B Homo sapiens cell division cycle 25 homolog B (S. 
pombe) (CDC25B), transcript variant 2, mRNA. 
5.47E-06 3.699055 down 
998 CDC42 Homo sapiens cell division cycle 42 (GTP binding 
protein, 25kDa) (CDC42), transcript variant 1, 
mRNA. 
5.13E-06 2.2075868 up 
998 CDC42 Homo sapiens cell division cycle 42 (GTP binding 
protein, 25kDa) (CDC42), transcript variant 2, 
mRNA. 
3.09E-05 3.407237 up 
10435 CDC42EP2 Homo sapiens CDC42 effector protein (Rho GTPase 
binding) 2 (CDC42EP2), mRNA. 
9.15E-05 2.4797053 up 
10602 CDC42EP3 Homo sapiens CDC42 effector protein (Rho GTPase 
binding) 3 (CDC42EP3), mRNA. 
1.19E-02 2.862828 up 
1019 CDK4 Homo sapiens cyclin-dependent kinase 4 (CDK4), 
mRNA. 
2.63E-05 2.1375792 down 
1020 CDK5 Homo sapiens cyclin-dependent kinase 5 (CDK5), 
mRNA. 
3.14E-04 2.0153193 up 
55755 CDK5RAP2 Homo sapiens CDK5 regulatory subunit associated 
protein 2 (CDK5RAP2), transcript variant 2, mRNA. 
1.55E-03 2.992742 up 
55755 CDK5RAP2 Homo sapiens CDK5 regulatory subunit associated 
protein 2 (CDK5RAP2), transcript variant 2, mRNA. 
8.96E-04 7.327741 up 
1021 CDK6 Homo sapiens cyclin-dependent kinase 6 (CDK6), 
mRNA. 
3.14E-05 2.1420696 down 
1030 CDKN2B Homo sapiens cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) (CDKN2B), transcript variant 2, 
mRNA. 
4.44E-03 2.1050932 up 
1032 CDKN2D Homo sapiens cyclin-dependent kinase inhibitor 2D 
(p19, inhibits CDK4) (CDKN2D), transcript variant 1, 
mRNA. 
5.13E-06 3.649528 up 
1039 CDR2 Homo sapiens cerebellar degeneration-related 
protein 2, 62kDa (CDR2), mRNA. 
7.25E-06 2.7418623 down 
634 CEACAM1 Homo sapiens carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary glycoprotein) 
(CEACAM1), transcript variant 1, mRNA. 
8.44E-06 14.709088 up 
634 CEACAM1 Homo sapiens carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary glycoprotein) 
(CEACAM1), transcript variant 2, mRNA. 
5.27E-06 11.678248 up 
634 CEACAM1 Homo sapiens carcinoembryonic antigen-related 
cell adhesion molecule 1 (biliary glycoprotein) 
(CEACAM1), transcript variant 2, mRNA. 
5.27E-06 11.331404 up 
1089 CEACAM4 Homo sapiens carcinoembryonic antigen-related 
cell adhesion molecule 4 (CEACAM4), mRNA. 
7.88E-05 3.9512918 up 
1088 CEACAM8 Homo sapiens carcinoembryonic antigen-related 
cell adhesion molecule 8 (CEACAM8), mRNA. 
1.19E-04 9.751434 up 
1050 CEBPA Homo sapiens CCAAT/enhancer binding protein 
(C/EBP), alpha (CEBPA), mRNA. 
9.10E-06 3.0340652 up 
1051 CEBPB Homo sapiens CCAAT/enhancer binding protein 
(C/EBP), beta (CEBPB), mRNA. 
5.13E-06 3.8940663 up 
1052 CEBPD Homo sapiens CCAAT/enhancer binding protein 
(C/EBP), delta (CEBPD), mRNA. 
5.47E-06 3.6535134 up 
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51816 CECR1 Homo sapiens cat eye syndrome chromosome 
region, candidate 1 (CECR1), transcript variant 1, 
mRNA. 
1.52E-05 3.6679435 down 
1675 CFD Homo sapiens complement factor D (adipsin) 
(CFD), mRNA. 
5.61E-03 2.3166604 down 
118487 CHCHD1 Homo sapiens coiled-coil-helix-coiled-coil-helix 
domain containing 1 (CHCHD1), mRNA. 
6.17E-06 2.0627074 up 
55790 ChGn Homo sapiens chondroitin beta1,4 N-
acetylgalactosaminyltransferase (ChGn), mRNA. 
8.39E-05 3.3370051 up 
26511 CHIC2 Homo sapiens cysteine-rich hydrophobic domain 2 
(CHIC2), mRNA. 
6.74E-06 2.2700129 up 
1119 CHKA Homo sapiens choline kinase alpha (CHKA), 
transcript variant 1, mRNA. 
3.09E-05 2.2814727 up 
27243 CHMP2A Homo sapiens chromatin modifying protein 2A 
(CHMP2A), transcript variant 1, mRNA. 
1.03E-04 2.2441735 up 
27243 CHMP2A Homo sapiens chromatin modifying protein 2A 
(CHMP2A), transcript variant 1, mRNA. 
1.52E-05 2.016407 up 
11261 CHP Homo sapiens calcium binding protein P22 (CHP), 
mRNA. 
6.31E-06 2.4448466 up 
56994 CHPT1 Homo sapiens choline phosphotransferase 1 
(CHPT1), mRNA. 
1.28E-05 2.6655567 up 
166012 CHST13 Homo sapiens carbohydrate (chondroitin 4) 
sulfotransferase 13 (CHST13), mRNA. 
5.61E-03 2.0742118 up 
22856 CHSY1 Homo sapiens carbohydrate (chondroitin) synthase 
1 (CHSY1), mRNA. 
1.82E-05 2.6951137 up 
1147 CHUK Homo sapiens conserved helix-loop-helix 
ubiquitous kinase (CHUK), mRNA. 
5.27E-06 2.8588862 up 
27141 CIDEB Homo sapiens cell death-inducing DFFA-like 
effector b (CIDEB), mRNA. 
3.50E-05 2.126732 up 
10970 CKAP4 Homo sapiens cytoskeleton-associated protein 4 
(CKAP4), mRNA. 
5.13E-06 5.6540203 up 
51192 CKLF Homo sapiens chemokine-like factor (CKLF), 
transcript variant 6, mRNA. 
5.13E-06 4.214922 up 
51192 CKLF Homo sapiens chemokine-like factor (CKLF), 
transcript variant 3, mRNA. 
5.13E-06 4.150689 up 
1178 CLC Homo sapiens Charcot-Leyden crystal protein 
(CLC), mRNA. 
3.46E-04 3.859848 down 
51266 CLEC1B Homo sapiens C-type lectin domain family 1, 
member B (CLEC1B), mRNA. 
1.01E-04 4.534882 up 
50856 CLEC4A Homo sapiens C-type lectin domain family 4, 
member A (CLEC4A), transcript variant 4, mRNA. 
5.35E-06 3.9043794 up 
338339 CLEC4D Homo sapiens C-type lectin domain family 4, 
member D (CLEC4D), mRNA. 
0.013338441 6.2865214 up 
1192 CLIC1 Homo sapiens chloride intracellular channel 1 
(CLIC1), mRNA. 
5.27E-06 3.0021625 up 
9022 CLIC3 Homo sapiens chloride intracellular channel 3 
(CLIC3), mRNA. 
1.17E-05 4.232528 down 
6249 CLIP1 Homo sapiens CAP-GLY domain containing linker 
protein 1 (CLIP1), transcript variant 1, mRNA. 
1.28E-05 2.2602222 up 
22883 CLSTN1 Homo sapiens calsyntenin 1 (CLSTN1), transcript 
variant 1, mRNA. 
5.13E-06 2.889167 down 
1213 CLTC Homo sapiens clathrin, heavy polypeptide (Hc) 
(CLTC), mRNA. 
1.09E-05 2.247254 up 
171425 CLYBL Homo sapiens citrate lyase beta like (CLYBL), 
mRNA. 
3.80E-04 2.326929 down 
29097 CNIH4 Homo sapiens cornichon homolog 4 (Drosophila) 
(CNIH4), mRNA. 
5.13E-06 5.2493296 up 
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22796 COG2 Homo sapiens component of oligomeric golgi 
complex 2 (COG2), mRNA. 
5.13E-06 2.0754697 down 
10087 COL4A3BP Homo sapiens collagen, type IV, alpha 3 
(Goodpasture antigen) binding protein 
(COL4A3BP), transcript variant 1, mRNA. 
0.004497504 2.289607 up 
51122 COMMD2 Homo sapiens COMM domain containing 2 
(COMMD2), mRNA. 
2.57E-05 2.039293 up 
54951 COMMD8 Homo sapiens COMM domain containing 8 
(COMMD8), mRNA. 
4.12E-04 2.0294437 up 
114769 COP1 Homo sapiens caspase-1 dominant-negative 
inhibitor pseudo-ICE (COP1), transcript variant 2, 
mRNA. 
0.002195084 2.6545103 up 
114769 COP1 Homo sapiens caspase-1 dominant-negative 
inhibitor pseudo-ICE (COP1), transcript variant 2, 
mRNA. 
1.54E-04 2.2014716 up 
10987 COPS5 Homo sapiens COP9 constitutive 
photomorphogenic homolog subunit 5 
(Arabidopsis) (COPS5), mRNA. 
5.35E-06 2.1435437 up 
27235 COQ2 Homo sapiens coenzyme Q2 homolog, 
prenyltransferase (yeast) (COQ2), mRNA. 
5.13E-06 2.334017 up 
23603 CORO1C Homo sapiens coronin, actin binding protein, 1C 
(CORO1C), mRNA. 
5.91E-06 2.095292 up 
7464 CORO2A Homo sapiens coronin, actin binding protein, 2A 
(CORO2A), transcript variant 2, mRNA. 
5.13E-06 3.0214834 up 
1352 COX10 Homo sapiens COX10 homolog, cytochrome c 
oxidase assembly protein, heme A: 
farnesyltransferase (yeast) (COX10), nuclear gene 
encoding mitochondrial protein, mRNA. 
5.13E-06 2.0721776 down 
10063 COX17 Homo sapiens COX17 cytochrome c oxidase 
assembly homolog (S. cerevisiae) (COX17), nuclear 
gene encoding mitochondrial protein, mRNA. 
7.25E-06 2.1722808 up 
1347 COX7A2 Homo sapiens cytochrome c oxidase subunit VIIa 
polypeptide 2 (liver) (COX7A2), mRNA. 
3.87E-05 2.5286677 up 
1349 COX7B Homo sapiens cytochrome c oxidase subunit VIIb 
(COX7B), nuclear gene encoding mitochondrial 
protein, mRNA. 
3.65E-04 2.8020906 up 
1362 CPD Homo sapiens carboxypeptidase D (CPD), mRNA. 5.13E-06 5.0072336 up 
80315 CPEB4 Homo sapiens cytoplasmic polyadenylation 
element binding protein 4 (CPEB4), mRNA. 
1.87E-04 3.4604418 up 
8895 CPNE3 Homo sapiens copine III (CPNE3), mRNA. 1.17E-05 2.3390002 up 
54504 CPVL Homo sapiens carboxypeptidase, vitellogenic-like 
(CPVL), transcript variant 1, mRNA. 
0.003804619 2.2566674 down 
54504 CPVL Homo sapiens carboxypeptidase, vitellogenic-like 
(CPVL), transcript variant 1, mRNA. 
0.002355844 2.2606637 down 
1378 CR1 PREDICTED: Homo sapiens complement 
component (3b/4b) receptor 1 (Knops blood 
group) (CR1), mRNA. 
0.014260175 2.5448275 up 
1378 CR1 Homo sapiens complement component (3b/4b) 
receptor 1 (Knops blood group) (CR1), transcript 
variant F, mRNA. 
1.47E-04 3.6902504 up 
9586 CREB5 Homo sapiens cAMP responsive element binding 
protein 5 (CREB5), transcript variant 1, mRNA. 
0.001689941 2.7032115 up 
8804 CREG1 Homo sapiens cellular repressor of E1A-stimulated 
genes 1 (CREG1), mRNA. 
5.13E-06 2.3837616 up 
1396 CRIP1 Homo sapiens cysteine-rich protein 1 (intestinal) 
(CRIP1), mRNA. 
1.82E-05 2.199152 down 
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1438 CSF2RA Homo sapiens colony stimulating factor 2 receptor, 
alpha, low-affinity (granulocyte-macrophage) 
(CSF2RA), transcript variant 6, mRNA. 
5.27E-06 3.4945817 up 
1438 CSF2RA PREDICTED: Homo sapiens colony stimulating 
factor 2 receptor, alpha, low-affinity (granulocyte-
macrophage) (CSF2RA), mRNA. 
5.13E-06 3.6573358 up 
1441 CSF3R Homo sapiens colony stimulating factor 3 receptor 
(granulocyte) (CSF3R), transcript variant 4, mRNA. 
1.82E-05 2.3448637 up 
1441 CSF3R Homo sapiens colony stimulating factor 3 receptor 
(granulocyte) (CSF3R), transcript variant 1, mRNA. 
1.28E-05 3.6351035 up 
8530 CST7 Homo sapiens cystatin F (leukocystatin) (CST7), 
mRNA. 
1.66E-05 4.5753226 up 
1475 CSTA Homo sapiens cystatin A (stefin A) (CSTA), mRNA. 1.17E-04 2.297074 up 
1476 CSTB Homo sapiens cystatin B (stefin B) (CSTB), mRNA. 5.13E-06 2.0360916 up 
414189 CTGLF3 Homo sapiens centaurin, gamma-like family, 
member 3 (CTGLF3), mRNA. 
1.52E-05 2.2590318 down 
1495 CTNNA1 Homo sapiens catenin (cadherin-associated 
protein), alpha 1, 102kDa (CTNNA1), mRNA. 
7.68E-06 2.4322417 up 
1075 CTSC Homo sapiens cathepsin C (CTSC), transcript 
variant 1, mRNA. 
5.13E-06 3.614826 up 
1075 CTSC Homo sapiens cathepsin C (CTSC), transcript 
variant 1, mRNA. 
2.90E-05 2.2673752 up 
1509 CTSD Homo sapiens cathepsin D (CTSD), mRNA. 6.74E-06 3.128691 up 
1512 CTSH Homo sapiens cathepsin H (CTSH), transcript 
variant 1, mRNA. 
1.78E-04 2.1109343 up 
1512 CTSH Homo sapiens cathepsin H (CTSH), transcript 
variant 1, mRNA. 
0.009319386 2.005697 up 
1514 CTSL1 Homo sapiens cathepsin L1 (CTSL1), transcript 
variant 2, mRNA. 
1.65E-04 4.7943954 up 
1514 CTSL1 Homo sapiens cathepsin L1 (CTSL1), transcript 
variant 2, mRNA. 
1.98E-05 5.7686768 up 
1519 CTSO Homo sapiens cathepsin O (CTSO), mRNA. 6.31E-06 2.3710158 down 
1521 CTSW Homo sapiens cathepsin W (lymphopain) (CTSW), 
mRNA. 
5.48E-06 4.979813 down 
1522 CTSZ Homo sapiens cathepsin Z (CTSZ), mRNA. 2.17E-04 2.0581768 up 
51596 CUTA Homo sapiens cutA divalent cation tolerance 
homolog (E. coli) (CUTA), transcript variant 5, 
mRNA. 
5.27E-06 2.4104688 down 
51596 CUTA Homo sapiens cutA divalent cation tolerance 
homolog (E. coli) (CUTA), transcript variant 1, 
mRNA. 
5.27E-06 2.0102203 down 
51076 CUTC Homo sapiens cutC copper transporter homolog (E. 
coli) (CUTC), mRNA. 
9.10E-06 2.1719136 up 
1524 CX3CR1 Homo sapiens chemokine (C-X3-C motif) receptor 1 
(CX3CR1), mRNA. 
3.18E-05 2.7759042 down 
58191 CXCL16 Homo sapiens chemokine (C-X-C motif) ligand 16 
(CXCL16), mRNA. 
5.13E-06 4.317199 up 
139231 CXorf39 Homo sapiens chromosome X open reading frame 
39 (CXorf39), mRNA. 
1.31E-05 2.0749292 up 
51523 CXXC5 Homo sapiens CXXC finger 5 (CXXC5), mRNA. 9.10E-06 2.487575 down 
51706 CYB5R1 Homo sapiens cytochrome b5 reductase 1 
(CYB5R1), mRNA. 
8.44E-06 2.9186919 up 
51167 CYB5R4 Homo sapiens cytochrome b5 reductase 4 
(CYB5R4), mRNA. 
1.08E-05 3.213936 up 
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1535 CYBA Homo sapiens cytochrome b-245, alpha 
polypeptide (CYBA), mRNA. 
5.13E-06 2.2248816 up 
220002 CYBASC3 Homo sapiens cytochrome b, ascorbate dependent 
3 (CYBASC3), mRNA. 
1.28E-05 2.310716 down 
1536 CYBB Homo sapiens cytochrome b-245, beta polypeptide 
(chronic granulomatous disease) (CYBB), mRNA. 
5.27E-06 2.9885292 up 
246126 CYorf15A Homo sapiens chromosome Y open reading frame 
15A (CYorf15A), mRNA. 
0.0019786 2.0988035 down 
1545 CYP1B1 Homo sapiens cytochrome P450, family 1, 
subfamily B, polypeptide 1 (CYP1B1), mRNA. 
6.17E-06 11.84795 up 
1595 CYP51A1 Homo sapiens cytochrome P450, family 51, 
subfamily A, polypeptide 1 (CYP51A1), mRNA. 
4.99E-04 2.0392642 up 
27065 D4S234E Homo sapiens DNA segment on chromosome 4 
(unique) 234 expressed sequence (D4S234E), 
mRNA. 
0.006639309 3.2519257 down 
1602 DACH1 Homo sapiens dachshund homolog 1 (Drosophila) 
(DACH1), transcript variant 1, mRNA. 
6.17E-06 10.448672 up 
1622 DBI Homo sapiens diazepam binding inhibitor (GABA 
receptor modulator, acyl-Coenzyme A binding 
protein) (DBI), transcript variant 2, mRNA. 
2.17E-04 2.1242292 up 
167227 DCP2 Homo sapiens DCP2 decapping enzyme homolog 
(S. cerevisiae) (DCP2), mRNA. 
5.47E-06 2.4441154 up 
51164 DCTN4 Homo sapiens dynactin 4 (p62) (DCTN4), mRNA. 8.44E-06 2.1044273 up 
123879 DCUN1D3 Homo sapiens DCN1, defective in cullin 
neddylation 1, domain containing 3 (S. cerevisiae) 
(DCUN1D3), mRNA. 
1.66E-05 2.5469155 up 
23564 DDAH2 Homo sapiens dimethylarginine 
dimethylaminohydrolase 2 (DDAH2), mRNA. 
1.08E-02 3.4107604 up 
50807 DDEF1 Homo sapiens development and differentiation 
enhancing factor 1 (DDEF1), mRNA. 
3.18E-05 2.189919 up 
1649 DDIT3 Homo sapiens DNA-damage-inducible transcript 3 
(DDIT3), mRNA. 
8.28E-05 2.3088243 up 
57062 DDX24 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 24 (DDX24), mRNA. 
5.13E-06 3.6519904 down 
51202 DDX47 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 47 (DDX47), transcript variant 2, 
mRNA. 
1.08E-05 2.0098073 down 
83479 DDX59 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 59 (DDX59), transcript variant 1, 
mRNA. 
1.00E-05 2.3997624 up 
83479 DDX59 Homo sapiens DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 59 (DDX59), transcript variant 1, 
mRNA. 
1.22E-04 2.0845 up 
1667 DEFA1 Homo sapiens defensin, alpha 1 (DEFA1), mRNA. 2.45E-02 2.4638147 up 
79961 DENND2D Homo sapiens DENN/MADD domain containing 2D 
(DENND2D), mRNA. 
5.13E-06 2.1206117 down 
22898 DENND3 Homo sapiens DENN/MADD domain containing 3 
(DENND3), mRNA. 
3.87E-05 2.1982214 up 
28955 DEXI Homo sapiens dexamethasone-induced transcript 
(DEXI), mRNA. 
8.44E-06 2.0605617 down 
84649 DGAT2 Homo sapiens diacylglycerol O-acyltransferase 
homolog 2 (mouse) (DGAT2), mRNA. 
4.54E-04 3.2562783 up 
1609 DGKQ Homo sapiens diacylglycerol kinase, theta 110kDa 
(DGKQ), mRNA. 
2.61E-04 2.0521948 down 
9249 DHRS3 Homo sapiens dehydrogenase/reductase (SDR 
family) member 3 (DHRS3), mRNA. 
5.95E-04 2.559416 down 
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51635 DHRS7 Homo sapiens dehydrogenase/reductase (SDR 
family) member 7 (DHRS7), mRNA. 
8.44E-06 2.4672217 up 
10170 DHRS9 Homo sapiens dehydrogenase/reductase (SDR 
family) member 9 (DHRS9), transcript variant 1, 
mRNA. 
5.35E-06 9.970834 up 
10170 DHRS9 Homo sapiens dehydrogenase/reductase (SDR 
family) member 9 (DHRS9), transcript variant 1, 
mRNA. 
6.31E-06 8.799593 up 
23405 DICER1 Homo sapiens Dicer1, Dcr-1 homolog (Drosophila) 
(DICER1), transcript variant 2, mRNA. 
1.08E-05 3.2951527 up 
84925 DIRC2 Homo sapiens disrupted in renal carcinoma 2 
(DIRC2), mRNA. 
5.13E-06 4.497308 up 
25923 DKFZP564J0863 Homo sapiens DKFZP564J0863 protein 
(DKFZP564J0863), mRNA. 
5.13E-06 3.3129492 up 
91056 DKFZp761E198 Homo sapiens DKFZp761E198 protein 
(DKFZp761E198), mRNA. 
3.71E-03 2.0044436 up 
1738 DLD Homo sapiens dihydrolipoamide dehydrogenase 
(E3 component of pyruvate dehydrogenase 
complex, 2-oxo-glutarate complex, branched chain 
keto acid dehydrogenase complex) (DLD), mRNA. 
1.57E-05 2.079882 up 
9093 DNAJA3 Homo sapiens DnaJ (Hsp40) homolog, subfamily A, 
member 3 (DNAJA3), mRNA. 
1.66E-05 2.1748948 down 
10049 DNAJB6 Homo sapiens DnaJ (Hsp40) homolog, subfamily B, 
member 6 (DNAJB6), transcript variant 1, mRNA. 
9.10E-06 2.0758972 up 
80331 DNAJC5 Homo sapiens DnaJ (Hsp40) homolog, subfamily C, 
member 5 (DNAJC5), mRNA. 
5.27E-06 2.5996194 up 
1774 DNASE1L1 Homo sapiens deoxyribonuclease I-like 1 
(DNASE1L1), transcript variant 4, mRNA. 
5.27E-06 3.1884494 up 
83658 DNCL2A Homo sapiens dynein, cytoplasmic, light 
polypeptide 2A (DNCL2A), transcript variant 2, 
mRNA. 
2.98E-05 2.0942302 up 
1786 DNMT1 Homo sapiens DNA (cytosine-5-)-methyltransferase 
1 (DNMT1), mRNA. 
5.13E-06 2.9878216 down 
116092 DNTTIP1 Homo sapiens deoxynucleotidyltransferase, 
terminal, interacting protein 1 (DNTTIP1), mRNA. 
5.27E-06 2.5209358 up 
55619 DOCK10 Homo sapiens dedicator of cytokinesis 10 
(DOCK10), mRNA. 
3.18E-05 2.9987986 down 
80005 DOCK5 Homo sapiens dedicator of cytokinesis 5 (DOCK5), 
mRNA. 
1.47E-04 2.2335734 up 
1802 DPH2 Homo sapiens DPH2 homolog (S. cerevisiae) 
(DPH2), transcript variant 1, mRNA. 
5.35E-06 2.048709 down 
285381 DPH3 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) 
(DPH3), transcript variant 2, mRNA. 
5.13E-06 3.376012 up 
29952 DPP7 Homo sapiens dipeptidyl-peptidase 7 (DPP7), 
mRNA. 
5.19E-05 2.3446808 down 
1806 DPYD Homo sapiens dihydropyrimidine dehydrogenase 
(DPYD), mRNA. 
9.55E-04 2.2364478 up 
51108 DREV1 Homo sapiens DORA reverse strand protein 1 
(DREV1), mRNA. 
5.91E-06 4.0783753 up 
1824 DSC2 Homo sapiens desmocollin 2 (DSC2), transcript 
variant Dsc2b, mRNA. 
3.18E-05 4.42125 up 
1843 DUSP1 Homo sapiens dual specificity phosphatase 1 
(DUSP1), mRNA. 
5.35E-06 4.0786195 up 
1845 DUSP3 Homo sapiens dual specificity phosphatase 3 
(vaccinia virus phosphatase VH1-related) (DUSP3), 
mRNA. 
1.28E-05 2.2295356 up 
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1847 DUSP5 Homo sapiens dual specificity phosphatase 5 
(DUSP5), mRNA. 
5.20E-04 2.0630016 down 
6993 DYNLT1 Homo sapiens dynein, light chain, Tctex-type 1 
(DYNLT1), mRNA. 
1.39E-05 3.1938145 up 
8445 DYRK2 Homo sapiens dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 2 (DYRK2), 
transcript variant 1, mRNA. 
2.42E-05 2.9621196 down 
8291 DYSF Homo sapiens dysferlin, limb girdle muscular 
dystrophy 2B (autosomal recessive) (DYSF), mRNA. 
1.28E-05 4.5595326 up 
1870 E2F2 Homo sapiens E2F transcription factor 2 (E2F2), 
mRNA. 
2.37E-04 2.3872674 up 
1871 E2F3 Homo sapiens E2F transcription factor 3 (E2F3), 
mRNA. 
1.52E-05 3.0421667 up 
1880 EBI2 Homo sapiens Epstein-Barr virus induced gene 2 
(lymphocyte-specific G protein-coupled receptor) 
(EBI2), mRNA. 
3.07E-05 2.7170253 down 
1889 ECE1 Homo sapiens endothelin converting enzyme 1 
(ECE1), mRNA. 
5.73E-03 2.105879 up 
55268 ECHDC2 Homo sapiens enoyl Coenzyme A hydratase 
domain containing 2 (ECHDC2), mRNA. 
5.13E-06 3.6648486 down 
79746 ECHDC3 Homo sapiens enoyl Coenzyme A hydratase 
domain containing 3 (ECHDC3), mRNA. 
3.26E-05 8.847016 up 
80267 EDEM3 Homo sapiens ER degradation enhancer, 
mannosidase alpha-like 3 (EDEM3), mRNA. 
5.35E-06 2.2210698 up 
53637 EDG8 Homo sapiens endothelial differentiation, 
sphingolipid G-protein-coupled receptor, 8 (EDG8), 
mRNA. 
3.80E-04 5.379586 down 
10289 EIF1B Homo sapiens eukaryotic translation initiation 
factor 1B (EIF1B), mRNA. 
6.74E-06 2.4711375 up 
192670 EIF2C4 Homo sapiens eukaryotic translation initiation 
factor 2C, 4 (EIF2C4), mRNA. 
2.84E-04 2.6301434 up 
317649 EIF4E3 Homo sapiens eukaryotic translation initiation 
factor 4E family member 3 (EIF4E3), mRNA. 
1.17E-05 2.9506123 up 
1998 ELF2 Homo sapiens E74-like factor 2 (ets domain 
transcription factor) (ELF2), transcript variant 2, 
mRNA. 
1.95E-04 2.1745768 down 
255520 ELMOD2 Homo sapiens ELMO/CED-12 domain containing 2 
(ELMOD2), mRNA. 
1.00E-04 3.9240546 up 
55140 ELP3 Homo sapiens elongation protein 3 homolog (S. 
cerevisiae) (ELP3), mRNA. 
5.13E-06 2.1816473 down 
84034 EMILIN2 Homo sapiens elastin microfibril interfacer 2 
(EMILIN2), mRNA. 
5.35E-06 4.6457095 up 
2015 EMR1 Homo sapiens egf-like module containing, mucin-
like, hormone receptor-like 1 (EMR1), mRNA. 
5.47E-06 4.5677238 up 
30817 EMR2 Homo sapiens egf-like module containing, mucin-
like, hormone receptor-like 2 (EMR2), transcript 
variant 2, mRNA. 
2.42E-05 3.4380198 up 
84658 EMR3 Homo sapiens egf-like module containing, mucin-
like, hormone receptor-like 3 (EMR3), transcript 
variant 1, mRNA. 
2.37E-04 3.4959276 down 
55556 ENOSF1 Homo sapiens enolase superfamily member 1 
(ENOSF1), mRNA. 
2.51E-05 2.3088577 down 
22875 ENPP4 Homo sapiens ectonucleotide 
pyrophosphatase/phosphodiesterase 4 (putative 
function) (ENPP4), mRNA. 
4.41E-04 2.450817 up 
953 ENTPD1 Homo sapiens ectonucleoside triphosphate 
diphosphohydrolase 1 (ENTPD1), mRNA. 
2.30E-04 2.4557087 up 
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56943 ENY2 Homo sapiens enhancer of yellow 2 homolog 
(Drosophila) (ENY2), mRNA. 
5.47E-06 3.3467193 up 
8320 EOMES Homo sapiens eomesodermin homolog (Xenopus 
laevis) (EOMES), mRNA. 
1.31E-03 3.7983854 down 
57634 EP400 Homo sapiens E1A binding protein p400 (EP400), 
mRNA. 
6.14E-06 2.0384111 down 
54749 EPDR1 Homo sapiens ependymin related protein 1 
(zebrafish) (EPDR1), mRNA. 
1.96E-02 2.021042 up 
2041 EPHA1 Homo sapiens EPH receptor A1 (EPHA1), mRNA. 2.09E02 2.0412483 down 
94240 EPSTI1 Homo sapiens epithelial stromal interaction 1 
(breast) (EPSTI1), transcript variant 2, mRNA. 
9.78E-05 4.230828 down 
51327 ERAF Homo sapiens erythroid associated factor (ERAF), 
mRNA. 
3.51E-03 2.3858838 up 
30001 ERO1L Homo sapiens ERO1-like (S. cerevisiae) (ERO1L), 
mRNA. 
5.13E-06 3.475923 up 
2107 ETF1 Homo sapiens eukaryotic translation termination 
factor 1 (ETF1), mRNA. 
5.91E-06 2.065806 up 
2110 ETFDH Homo sapiens electron-transferring-flavoprotein 
dehydrogenase (ETFDH), nuclear gene encoding 
mitochondrial protein, mRNA. 
5.27E-06 2.23076 up 
55500 ETNK1 Homo sapiens ethanolamine kinase 1 (ETNK1), 
mRNA. 
1.74E-04 2.2017987 up 
2113 ETS1 Homo sapiens v-ets erythroblastosis virus E26 
oncogene homolog 1 (avian) (ETS1), mRNA. 
9.97E-06 2.558997 down 
2114 ETS2 Homo sapiens v-ets erythroblastosis virus E26 
oncogene homolog 2 (avian) (ETS2), mRNA. 
5.13E-06 8.58237 up 
51466 EVL Homo sapiens Enah/Vasp-like (EVL), mRNA. 5.13E-06 4.689364 down 
54536 EXOC6 Homo sapiens exocyst complex component 6 
(EXOC6), transcript variant 2, mRNA. 
1.08E-05 4.4522514 up 
54512 EXOSC4 Homo sapiens exosome component 4 (EXOSC4), 
mRNA. 
5.27E-06 7.319126 up 
56915 EXOSC5 Homo sapiens exosome component 5 (EXOSC5), 
mRNA. 
2.07E-05 2.0822344 down 
2161 F12 Homo sapiens coagulation factor XII (Hageman 
factor) (F12), mRNA. 
6.99E-04 2.637752 up 
9214 FAIM3 Homo sapiens Fas apoptotic inhibitory molecule 3 
(FAIM3), mRNA. 
5.13E-06 3.2987125 down 
359845 FAM101B Homo sapiens family with sequence similarity 101, 
member B (FAM101B), mRNA. 
4.69E-05 2.82394 up 
399665 FAM102A Homo sapiens family with sequence similarity 102, 
member A (FAM102A), transcript variant 1, mRNA. 
5.13E-06 4.415383 down 
54491 FAM105A Homo sapiens family with sequence similarity 105, 
member A (FAM105A), mRNA. 
1.47E-03 2.868355 up 
91523 FAM113B Homo sapiens family with sequence similarity 113, 
member B (FAM113B), mRNA. 
5.13E-06 3.6542397 down 
83982 FAM14A Homo sapiens family with sequence similarity 14, 
member A (FAM14A), mRNA. 
2.17E-04 2.1707006 up 
56975 FAM20C Homo sapiens family with sequence similarity 20, 
member C (FAM20C), mRNA. 
2.70E-04 2.9187624 up 
9780 FAM38A Homo sapiens family with sequence similarity 38, 
member A (FAM38A), mRNA. 
5.13E-06 2.3264341 down 
404636 FAM45A Homo sapiens family with sequence similarity 45, 
member A (FAM45A), mRNA. 
7.25E-06 2.554875 up 
81553 FAM49A Homo sapiens family with sequence similarity 49, 
member A (FAM49A), mRNA. 
2.63E-05 2.0053241 up 
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51571 FAM49B Homo sapiens family with sequence similarity 49, 
member B (FAM49B), mRNA. 
5.27E-06 2.8720198 up 
26240 FAM50B Homo sapiens family with sequence similarity 50, 
member B (FAM50B), mRNA. 
5.90E-05 2.0443442 down 
51307 FAM53C Homo sapiens family with sequence similarity 53, 
member C (FAM53C), mRNA. 
1.11E-04 2.2430544 up 
23344 FAM62A Homo sapiens family with sequence similarity 62 
(C2 domain containing), member A (FAM62A), 
mRNA. 
5.13E-06 3.2714174 down 
57488 FAM62B Homo sapiens family with sequence similarity 62 
(C2 domain containing) member B (FAM62B), 
mRNA. 
1.08E-05 2.0318565 down 
54629 FAM63B Homo sapiens family with sequence similarity 63, 
member B (FAM63B), mRNA. 
1.08E-05 2.1487174 up 
375061 FAM89A Homo sapiens family with sequence similarity 89, 
member A (FAM89A), mRNA. 
4.38E-02 3.9909568 up 
375061 FAM89A Homo sapiens family with sequence similarity 89, 
member A (FAM89A), mRNA. 
5.13E-06 3.994492 up 
157769 FAM91A1 Homo sapiens family with sequence similarity 91, 
member A1 (FAM91A1), mRNA. 
9.36E-04 2.0552425 up 
10667 FARS2 Homo sapiens phenylalanine-tRNA synthetase 2 
(mitochondrial) (FARS2), nuclear gene encoding 
mitochondrial protein, mRNA. 
5.62E-06 2.2093713 down 
2194 FASN Homo sapiens fatty acid synthase (FASN), mRNA. 2.08E-04 2.1970415 down 
2091 FBL Homo sapiens fibrillarin (FBL), mRNA. 5.27E-06 2.6103055 down 
2201 FBN2 Homo sapiens fibrillin 2 (congenital contractural 
arachnodactyly) (FBN2), mRNA. 
4.12E-04 2.5507998 up 
2203 FBP1 Homo sapiens fructose-1,6-bisphosphatase 1 
(FBP1), mRNA. 
7.57E-05 2.1626742 up 
84678 FBXL10 Homo sapiens F-box and leucine-rich repeat 
protein 10 (FBXL10), transcript variant 1, mRNA. 
5.13E-06 2.3947892 down 
26234 FBXL5 Homo sapiens F-box and leucine-rich repeat 
protein 5 (FBXL5), transcript variant 1, mRNA. 
6.74E-05 2.429683 up 
26234 FBXL5 Homo sapiens F-box and leucine-rich repeat 
protein 5 (FBXL5), transcript variant 1, mRNA. 
1.39E-05 2.7659962 up 
23014 FBXO21 Homo sapiens F-box protein 21 (FBXO21), 
transcript variant 2, mRNA. 
5.35E-06 2.3136113 down 
84085 FBXO30 Homo sapiens F-box protein 30 (FBXO30), mRNA. 5.13E-06 4.14862 up 
79791 FBXO31 Homo sapiens F-box protein 31 (FBXO31), mRNA. 5.13E-06 2.6231027 down 
81545 FBXO38 Homo sapiens F-box protein 38 (FBXO38), 
transcript variant 1, mRNA. 
9.10E-06 2.018637 up 
26190 FBXW2 Homo sapiens F-box and WD-40 domain protein 2 
(FBXW2), mRNA. 
5.27E-06 2.899193 up 
2204 FCAR Homo sapiens Fc fragment of IgA, receptor for 
(FCAR), transcript variant 10, mRNA. 
8.09E-05 5.352728 up 
2207 FCER1G Homo sapiens Fc fragment of IgE, high affinity I, 
receptor for; gamma polypeptide (FCER1G), mRNA. 
5.13E-06 6.26573 up 
2208 FCER2 Homo sapiens Fc fragment of IgE, low affinity II, 
receptor for (CD23) (FCER2), mRNA. 
3.07E-05 2.8810222 down 
8857 FCGBP Homo sapiens Fc fragment of IgG binding protein 
(FCGBP), mRNA. 
8.18E-03 2.414376 down 
2209 FCGR1A Homo sapiens Fc fragment of IgG, high affinity Ia, 
receptor (CD64) (FCGR1A), mRNA. 
8.55E-04 3.9725544 up 
2210 FCGR1B Homo sapiens Fc fragment of IgG, high affinity Ib, 
receptor (CD64) (FCGR1B), transcript variant 2, 
mRNA. 
1.00E-03 4.0869117 up 
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2210 FCGR1B Homo sapiens Fc fragment of IgG, high affinity Ib, 
receptor (CD64) (FCGR1B), transcript variant 1, 
mRNA. 
4.99E-04 4.0404263 up 
2212 FCGR2A Homo sapiens Fc fragment of IgG, low affinity IIa, 
receptor (CD32) (FCGR2A), mRNA. 
1.89E-03 2.2866335 up 
2212 FCGR2A Homo sapiens Fc fragment of IgG, low affinity IIa, 
receptor (CD32) (FCGR2A), mRNA. 
1.55E-03 2.3266907 up 
115548 FCHO2 Homo sapiens FCH domain only 2 (FCHO2), mRNA. 1.47E-03 2.0208118 up 
84824 FCRLM1 Homo sapiens Fc receptor-like A (FCRLA), mRNA. 1.94E-04 2.5381489 down 
56929 FEM1C Homo sapiens fem-1 homolog c (C.elegans) 
(FEM1C), mRNA. 
5.27E-06 2.2946901 up 
26509 FER1L3 Homo sapiens fer-1-like 3, myoferlin (C. elegans) 
(FER1L3), transcript variant 1, mRNA. 
1.11E-03 2.2462935 up 
2242 FES Homo sapiens feline sarcoma oncogene (FES), 
mRNA. 
4.26E-05 2.876374 up 
2867 FFAR2 Homo sapiens free fatty acid receptor 2 (FFAR2), 
mRNA. 
7.79E-04 2.1559656 up 
26127 FGFR1OP2 Homo sapiens FGFR1 oncogene partner 2 
(FGFR1OP2), mRNA. 
1.79E-03 2.002944 up 
2268 FGR Homo sapiens Gardner-Rasheed feline sarcoma 
viral (v-fgr) oncogene homolog (FGR), transcript 
variant 3, mRNA. 
5.13E-06 3.743808 up 
2268 FGR Homo sapiens Gardner-Rasheed feline sarcoma 
viral (v-fgr) oncogene homolog (FGR), mRNA. 
5.13E-06 4.515146 up 
2274 FHL2 Homo sapiens four and a half LIM domains 2 
(FHL2), transcript variant 1, mRNA. 
2.23E-03 2.1835103 up 
29109 FHOD1 Homo sapiens formin homology 2 domain 
containing 1 (FHOD1), mRNA. 
5.13E-06 2.517802 up 
2280 FKBP1A Homo sapiens FK506 binding protein 1A, 12kDa 
(FKBP1A), transcript variant 12B, mRNA. 
5.13E-06 2.599086 up 
2280 FKBP1A Homo sapiens FK506 binding protein 1A, 12kDa 
(FKBP1A), transcript variant 12A, mRNA. 
5.47E-06 4.229929 up 
2280 FKBP1A Homo sapiens FK506 binding protein 1A, 12kDa 
(FKBP1A), transcript variant 12A, mRNA. 
1.17E-05 3.3661363 up 
2289 FKBP5 Homo sapiens FK506 binding protein 5 (FKBP5), 
mRNA. 
5.27E-06 7.846178 up 
55277 FLJ10986 Homo sapiens hypothetical protein FLJ10986 
(FLJ10986), mRNA. 
5.13E-06 2.177325 up 
55314 FLJ11155 Homo sapiens transmembrane protein 144 
(TMEM144), mRNA. 
8.89E-03 2.1348088 up 
55332 FLJ11259 Homo sapiens hypothetical protein FLJ11259 
(FLJ11259), mRNA. 
6.17E-06 5.74057 up 
79621 FLJ11712 Homo sapiens ribonuclease H2, subunit B 
(RNASEH2B), mRNA. 
2.04E-05 2.285728 down 
65095 FLJ12949 Homo sapiens hypothetical protein FLJ12949 
(FLJ12949), transcript variant 1, mRNA. 
7.68E-06 2.2615159 down 
55601 FLJ20035 Homo sapiens hypothetical protein FLJ20035 
(FLJ20035), mRNA. 
1.39E-02 2.1092248 down 
54863 FLJ20245 Homo sapiens hypothetical protein FLJ20245 
(FLJ20245), mRNA. 
5.13E-06 2.6427622 up 
55622 FLJ20272 Homo sapiens tetratricopeptide repeat domain 27 
(TTC27), mRNA. 
5.69E-05 2.1794796 down 
54502 FLJ20273 Homo sapiens RNA-binding protein (FLJ20273), 
mRNA. 
5.47E-06 3.967706 up 
80194 FLJ21749 Homo sapiens hypothetical protein FLJ21749 
(FLJ21749), mRNA. 
6.74E-06 2.1933904 down 
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79641 FLJ22386 Homo sapiens rogdi homolog (Drosophila) (ROGDI), 
mRNA. 
6.74E-06 2.9610865 up 
80212 FLJ22471 Homo sapiens coiled-coil domain containing 92 
(CCDC92), mRNA. 
5.13E-06 2.2204547 down 
79887 FLJ22662 Homo sapiens hypothetical protein FLJ22662 
(FLJ22662), mRNA. 
1.17E-05 3.7287767 up 
220042 FLJ25416 Homo sapiens chromosome 11 open reading frame 
82 (C11orf82), mRNA. 
4.90E-05 3.7852185 up 
122060 FLJ30046 Homo sapiens hypothetical protein FLJ30046 
(FLJ30046), mRNA. 
2.97E-05 2.1388574 down 
220388 FLJ38159 Homo sapiens coiled-coil domain containing 89 
(CCDC89), mRNA. 
1.67E-04 2.0847433 up 
353116 FLJ39378 Homo sapiens hypothetical protein FLJ39378 
(FLJ39378), mRNA. 
3.82E-04 2.1353474 up 
286006 FLJ39575 Homo sapiens hypothetical protein FLJ39575 
(FLJ39575), mRNA. 
9.06E-03 2.4017336 up 
10211 FLOT1 Homo sapiens flotillin 1 (FLOT1), mRNA. 5.13E-06 5.5313544 up 
2319 FLOT2 Homo sapiens flotillin 2 (FLOT2), mRNA. 1.08E-05 2.4410415 up 
2323 FLT3LG Homo sapiens fms-related tyrosine kinase 3 ligand 
(FLT3LG), mRNA. 
5.35E-06 4.096451 down 
79672 FN3KRP Homo sapiens fructosamine-3-kinase-related 
protein (FN3KRP), mRNA. 
5.27E-06 2.313113 down 
22862 FNDC3A Homo sapiens fibronectin type III domain 
containing 3A (FNDC3A), mRNA. 
3.87E-05 2.7806582 up 
22862 FNDC3A Homo sapiens fibronectin type III domain 
containing 3A (FNDC3A), transcript variant 1, 
mRNA. 
4.22E-05 2.6544664 up 
2352 FOLR3 Homo sapiens folate receptor 3 (gamma) (FOLR3), 
mRNA. 
6.74E-06 8.076672 up 
2353 FOS Homo sapiens v-fos FBJ murine osteosarcoma viral 
oncogene homolog (FOS), mRNA. 
6.25E-05 2.8882043 up 
2355 FOSL2 Homo sapiens FOS-like antigen 2 (FOSL2), mRNA. 1.47E-02 2.664296 up 
2308 FOXO1A Homo sapiens forkhead box O1A 
(rhabdomyosarcoma) (FOXO1A), mRNA. 
5.13E-06 2.1501672 down 
2357 FPR1 Homo sapiens formyl peptide receptor 1 (FPR1), 
mRNA. 
5.47E-06 3.370015 up 
2358 FPRL1 Homo sapiens formyl peptide receptor-like 1 
(FPRL1), transcript variant 1, mRNA. 
1.08E-05 4.9162574 up 
2358 FPRL1 Homo sapiens formyl peptide receptor-like 1 
(FPRL1), transcript variant 1, mRNA. 
7.68E-06 4.874851 up 
10023 FRAT1 Homo sapiens frequently rearranged in advanced 
T-cell lymphomas (FRAT1), transcript variant 2, 
mRNA. 
5.10E-03 2.0954587 up 
2503 FTHL11 Homo sapiens ferritin, heavy polypeptide-like 11 
(FTHL11) on chromosome 8. 
1.01E-04 2.1077788 up 
2497 FTHL2 Homo sapiens ferritin, heavy polypeptide-like 2 
(FTHL2) on chromosome 1. 
8.33E-05 2.1774118 up 
2498 FTHL3 Homo sapiens ferritin, heavy polypeptide-like 3 
(FTHL3) on chromosome 2. 
8.33E-05 2.0295854 up 
5045 FURIN Homo sapiens furin (paired basic amino acid 
cleaving enzyme) (FURIN), mRNA. 
5.47E-06 2.4903831 up 
2529 FUT7 Homo sapiens fucosyltransferase 7 (alpha (1,3) 
fucosyltransferase) (FUT7), mRNA. 
2.48E-03 3.273772 up 
2534 FYN Homo sapiens FYN oncogene related to SRC, FGR, 
YES (FYN), transcript variant 1, mRNA. 
5.13E-06 3.246567 down 
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2534 FYN Homo sapiens FYN oncogene related to SRC, FGR, 
YES (FYN), transcript variant 1, mRNA. 
5.48E-06 4.2108383 down 
2534 FYN Homo sapiens FYN oncogene related to SRC, FGR, 
YES (FYN), transcript variant 3, mRNA. 
8.34E-06 2.8713717 down 
2537 G1P3 Homo sapiens interferon, alpha-inducible protein 
(clone IFI-6-16) (G1P3), transcript variant 1, mRNA. 
3.46E-04 2.0230227 down 
2539 G6PD Homo sapiens glucose-6-phosphate 
dehydrogenase (G6PD), nuclear gene encoding 
mitochondrial protein, mRNA. 
5.13E-06 3.3805568 up 
2539 G6PD Homo sapiens glucose-6-phosphate 
dehydrogenase (G6PD), nuclear gene encoding 
mitochondrial protein, transcript variant 1, mRNA. 
5.47E-06 2.9979424 up 
11345 GABARAPL2 Homo sapiens GABA(A) receptor-associated 
protein-like 2 (GABARAPL2), mRNA. 
5.13E-06 2.5661192 up 
1647 GADD45A Homo sapiens growth arrest and DNA-damage-
inducible, alpha (GADD45A), mRNA. 
5.27E-06 15.739641 up 
2581 GALC Homo sapiens galactosylceramidase (Krabbe 
disease) (GALC), mRNA. 
5.27E-06 2.274529 up 
55454 GALNACT-2 Homo sapiens chondroitin sulfate GalNAcT-2 
(GALNACT-2), mRNA. 
4.51E-02 2.7099066 up 
8693 GALNT4 Homo sapiens UDP-N-acetyl-alpha-D-
galactosamine:polypeptide N-
acetylgalactosaminyltransferase 4 (GalNAc-T4) 
(GALNT4), mRNA. 
1.52E-05 3.0352993 up 
2597 GAPDH Homo sapiens glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), mRNA. 
5.13E-06 2.756057 up 
2597 GAPDH Homo sapiens glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), mRNA. 
5.13E-06 3.2379358 up 
8522 GAS7 Homo sapiens growth arrest-specific 7 (GAS7), 
transcript variant b, mRNA. 
1.17E-05 3.5803542 up 
2629 GBA Homo sapiens glucosidase, beta; acid (includes 
glucosylceramidase) (GBA), transcript variant 3, 
mRNA. 
5.13E-06 4.539533 up 
2632 GBE1 Homo sapiens glucan (1,4-alpha-), branching 
enzyme 1 (glycogen branching enzyme, Andersen 
disease, glycogen storage disease type IV) (GBE1), 
mRNA. 
5.27E-06 3.4127076 up 
2633 GBP1 Homo sapiens guanylate binding protein 1, 
interferon-inducible, 67kDa (GBP1), mRNA. 
2.37E-04 3.2470932 down 
115361 GBP4 Homo sapiens guanylate binding protein 4 (GBP4), 
mRNA. 
2.75E-05 4.328669 down 
115362 GBP5 Homo sapiens guanylate binding protein 5 (GBP5), 
mRNA. 
3.87E-05 3.633565 down 
25801 GCA Homo sapiens grancalcin, EF-hand calcium binding 
protein (GCA), mRNA. 
5.13E-06 4.173537 up 
10985 GCN1L1 Homo sapiens GCN1 general control of amino-acid 
synthesis 1-like 1 (yeast) (GCN1L1), mRNA. 
1.52E-05 2.0828094 down 
2648 GCN5L2 Homo sapiens GCN5 general control of amino-acid 
synthesis 5-like 2 (yeast) (GCN5L2), mRNA. 
9.78E-05 2.1211884 down 
50628 GEMIN4 Homo sapiens gem (nuclear organelle) associated 
protein 4 (GEMIN4), mRNA. 
5.88E-06 2.248674 down 
23062 GGA2 Homo sapiens golgi associated, gamma adaptin ear 
containing, ARF binding protein 2 (GGA2), mRNA. 
1.67E-05 2.2716928 down 
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8836 GGH Homo sapiens gamma-glutamyl hydrolase 
(conjugase, folylpolygammaglutamyl hydrolase) 
(GGH), mRNA. 
2.25E-04 2.856294 up 
55340 GIMAP5 Homo sapiens GTPase, IMAP family member 5 
(GIMAP5), mRNA. 
5.13E-06 5.042632 down 
474344 GIMAP6 Homo sapiens GTPase, IMAP family member 6 
(GIMAP6), transcript variant 3, mRNA. 
5.27E-06 2.0248408 down 
168537 GIMAP7 Homo sapiens GTPase, IMAP family member 7 
(GIMAP7), mRNA. 
4.02E-05 2.5305545 down 
10755 GIPC1 Homo sapiens GIPC PDZ domain containing family, 
member 1 (GIPC1), transcript variant 3, mRNA. 
6.74E-06 2.4096584 down 
2710 GK Homo sapiens glycerol kinase (GK), transcript 
variant 1, mRNA. 
2.42E-05 4.174195 up 
2717 GLA Homo sapiens galactosidase, alpha (GLA), mRNA. 5.13E-06 3.0528233 up 
2745 GLRX Homo sapiens glutaredoxin (thioltransferase) 
(GLRX), mRNA. 
9.10E-06 3.4667118 up 
51022 GLRX2 Homo sapiens glutaredoxin 2 (GLRX2), transcript 
variant 1, mRNA. 
5.35E-06 2.002984 up 
79709 GLT25D1 Homo sapiens glycosyltransferase 25 domain 
containing 1 (GLT25D1), mRNA. 
5.13E-06 3.0869725 up 
51228 GLTP Homo sapiens glycolipid transfer protein (GLTP), 
mRNA. 
5.13E-06 2.156737 up 
29997 GLTSCR2 Homo sapiens glioma tumor suppressor candidate 
region gene 2 (GLTSCR2), mRNA. 
5.13E-06 2.1925943 down 
2760 GM2A Homo sapiens GM2 ganglioside activator (GM2A), 
mRNA. 
1.08E-02 2.3641477 up 
2764 GMFB Homo sapiens glia maturation factor, beta (GMFB), 
mRNA. 
5.13E-06 2.363177 up 
9535 GMFG Homo sapiens glia maturation factor, gamma 
(GMFG), mRNA. 
5.91E-06 2.7988567 up 
2769 GNA15 Homo sapiens guanine nucleotide binding protein 
(G protein), alpha 15 (Gq class) (GNA15), mRNA. 
5.13E-06 4.735776 up 
2773 GNAI3 Homo sapiens guanine nucleotide binding protein 
(G protein), alpha inhibiting activity polypeptide 3 
(GNAI3), mRNA. 
6.31E-06 3.7357645 up 
2776 GNAQ Homo sapiens guanine nucleotide binding protein 
(G protein), q polypeptide (GNAQ), mRNA. 
6.13E-05 4.012052 up 
2783 GNB2 Homo sapiens guanine nucleotide binding protein 
(G protein), beta polypeptide 2 (GNB2), mRNA. 
7.68E-06 2.3462515 up 
2790 GNG10 Homo sapiens guanine nucleotide binding protein 
(G protein), gamma 10 (GNG10), mRNA. 
1.22E-04 4.1735535 up 
2787 GNG5 Homo sapiens guanine nucleotide binding protein 
(G protein), gamma 5 (GNG5), mRNA. 
5.13E-06 3.2356536 up 
10578 GNLY Homo sapiens granulysin (GNLY), transcript variant 
NKG5, mRNA. 
6.49E-05 4.525536 down 
10578 GNLY Homo sapiens granulysin (GNLY), transcript variant 
519, mRNA. 
3.50E-05 4.8709884 down 
2799 GNS Homo sapiens glucosamine (N-acetyl)-6-sulfatase 
(Sanfilippo disease IIID) (GNS), mRNA. 
1.28E-05 3.1057098 up 
440270 GOLGA8B Homo sapiens golgi autoantigen, golgin subfamily 
a, 8B (GOLGA8B), mRNA. 
5.13E-06 3.4558465 down 
9570 GOSR2 Homo sapiens golgi SNAP receptor complex 
member 2 (GOSR2), transcript variant B, mRNA. 
1.17E-05 2.0457952 up 
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151306 GPBAR1 Homo sapiens G protein-coupled bile acid receptor 
1 (GPBAR1), mRNA. 
2.32E-03 2.3214679 down 
151306 GPBAR1 Homo sapiens G protein-coupled bile acid receptor 
1 (GPBAR1), transcript variant 1, mRNA. 
9.03E-05 3.1991289 down 
2821 GPI Homo sapiens glucose phosphate isomerase (GPI), 
mRNA. 
1.34E-04 2.0323052 up 
221188 GPR114 Homo sapiens G protein-coupled receptor 114 
(GPR114), mRNA. 
1.66E-05 3.541269 down 
7107 GPR137B Homo sapiens G protein-coupled receptor 137B 
(GPR137B), mRNA. 
7.19E-05 2.6216893 up 
353345 GPR141 Homo sapiens G protein-coupled receptor 141 
(GPR141), mRNA. 
1.14E-02 3.8366795 up 
387129 GPR154 Homo sapiens neuropeptide S receptor 1 (NPSR1), 
transcript variant 1, mRNA. 
1.39E-03 2.4623287 down 
26996 GPR160 Homo sapiens G protein-coupled receptor 160 
(GPR160), mRNA. 
7.68E-06 4.6498666 up 
2841 GPR18 Homo sapiens G protein-coupled receptor 18 
(GPR18), mRNA. 
7.04E-05 3.0063965 down 
9289 GPR56 Homo sapiens G protein-coupled receptor 56 
(GPR56), transcript variant 2, mRNA. 
2.90E-05 7.2792954 down 
9289 GPR56 Homo sapiens G protein-coupled receptor 56 
(GPR56), transcript variant 3, mRNA. 
5.81E-05 6.536251 down 
8477 GPR65 Homo sapiens G protein-coupled receptor 65 
(GPR65), mRNA. 
3.87E-05 2.542324 up 
53831 GPR84 Homo sapiens G protein-coupled receptor 84 
(GPR84), mRNA. 
1.08E-02 21.183023 up 
57121 GPR92 Homo sapiens G protein-coupled receptor 92 
(GPR92), mRNA. 
5.27E-06 2.9020178 down 
222487 GPR97 Homo sapiens G protein-coupled receptor 97 
(GPR97), mRNA. 
5.91E-06 4.3022423 up 
222487 GPR97 Homo sapiens G protein-coupled receptor 97 
(GPR97), mRNA. 
3.60E-05 4.3218193 up 
57655 GRAMD1A Homo sapiens GRAM domain containing 1A 
(GRAMD1A), mRNA. 
1.82E-05 2.3442535 up 
10750 GRAP Homo sapiens GRB2-related adaptor protein 
(GRAP), mRNA. 
5.13E-06 3.9750528 down 
2887 GRB10 Homo sapiens growth factor receptor-bound 
protein 10 (GRB10), transcript variant 1, mRNA. 
3.59E-02 5.036894 up 
2907 GRINA Homo sapiens glutamate receptor, ionotropic, N-
methyl D-asparate-associated protein 1 (glutamate 
binding) (GRINA), transcript variant 1, mRNA. 
5.13E-06 5.1376505 up 
2907 GRINA Homo sapiens glutamate receptor, ionotropic, N-
methyl D-asparate-associated protein 1 (glutamate 
binding) (GRINA), transcript variant 2, mRNA. 
5.13E-06 4.68124 up 
2870 GRK6 Homo sapiens G protein-coupled receptor kinase 6 
(GRK6), transcript variant 2, mRNA. 
9.97E-06 2.1693056 up 
2870 GRK6 Homo sapiens G protein-coupled receptor kinase 6 
(GRK6), transcript variant 2, mRNA. 
2.63E-05 2.0858104 up 
2896 GRN Homo sapiens granulin (GRN), transcript variant 2, 
mRNA. 
6.88E-05 2.3178787 up 
2896 GRN Homo sapiens granulin (GRN), mRNA. 1.17E-05 2.5333452 up 
55876 GSDML Homo sapiens gasdermin-like (GSDML), mRNA. 5.78E-05 2.4000099 down 
2934 GSN Homo sapiens gelsolin (amyloidosis, Finnish type) 
(GSN), transcript variant 2, mRNA. 
2.78E-04 2.350788 up 
227 
 
23708 GSPT2 Homo sapiens G1 to S phase transition 2 (GSPT2), 
mRNA. 
1.11E-04 2.0439358 down 
2944 GSTM1 Homo sapiens glutathione S-transferase M1 
(GSTM1), transcript variant 1, mRNA. 
1.25E-02 2.3481777 down 
2946 GSTM2 Homo sapiens glutathione S-transferase M2 
(muscle) (GSTM2), mRNA. 
2.56-02 2.2712932 down 
9446 GSTO1 Homo sapiens glutathione S-transferase omega 1 
(GSTO1), mRNA. 
5.13E-06 3.0588915 up 
79712 GTDC1 Homo sapiens glycosyltransferase-like domain 
containing 1 (GTDC1), transcript variant 1, mRNA. 
3.71E-03 3.36884 up 
84705 GTPBP3 Homo sapiens GTP binding protein 3 
(mitochondrial) (GTPBP3), transcript variant V, 
mRNA. 
5.27E-06 2.6767316 down 
29083 GTPBP8 Homo sapiens GTP-binding protein 8 (putative) 
(GTPBP8), transcript variant 1, mRNA. 
5.35E-06 2.015749 down 
375513 GUSBL2 Homo sapiens glucuronidase, beta-like 2 (GUSBL2), 
transcript variant 3, mRNA. 
2.65E-05 2.0234268 down 
2992 GYG1 Homo sapiens glycogenin 1 (GYG1), mRNA. 5.13E-06 9.672594 up 
2994 GYPB Homo sapiens glycophorin B (MNS blood group) 
(GYPB), mRNA. 
2.68E-02 2.1582923 up 
3001 GZMA Homo sapiens granzyme A (granzyme 1, cytotoxic 
T-lymphocyte-associated serine esterase 3) 
(GZMA), mRNA. 
2.09E-05 3.887896 down 
3002 GZMB Homo sapiens granzyme B (granzyme 2, cytotoxic 
T-lymphocyte-associated serine esterase 1) 
(GZMB), mRNA. 
9.29E-04 3.0920699 down 
2999 GZMH Homo sapiens granzyme H (cathepsin G-like 2, 
protein h-CCPX) (GZMH), mRNA. 
1.32E-05 6.2872043 down 
3003 GZMK Homo sapiens granzyme K (granzyme 3; tryptase II) 
(GZMK), mRNA. 
1.67E-05 4.805156 down 
3004 GZMM Homo sapiens granzyme M (lymphocyte met-ase 1) 
(GZMM), mRNA. 
2.51E-05 4.4124956 down 
55766 H2AFJ Homo sapiens H2A histone family, member J 
(H2AFJ), transcript variant 2, mRNA. 
5.35E-06 3.563822 up 
55506 H2AFY2 Homo sapiens H2A histone family, member Y2 
(H2AFY2), mRNA. 
2.90E-05 2.1035583 down 
3015 H2AFZ Homo sapiens H2A histone family, member Z 
(H2AFZ), mRNA. 
5.13E-06 2.0381615 up 
54145 H2BFS Homo sapiens H2B histone family, member S 
(H2BFS), mRNA. 
6.53E-04 2.321558 up 
3033 HADHSC Homo sapiens L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain (HADHSC), mRNA. 
5.35E-06 2.2370574 down 
8520 HAT1 Homo sapiens histone acetyltransferase 1 (HAT1), 
transcript variant 1, mRNA. 
1.43E-05 3.015796 up 
10542 HBXIP Homo sapiens hepatitis B virus x interacting 
protein (HBXIP), mRNA. 
5.13E-06 3.0590484 up 
3055 HCK Homo sapiens hemopoietic cell kinase (HCK), 
mRNA. 
5.13E-06 3.530682 up 
10866 HCP5 Homo sapiens HLA complex P5 (HCP5), mRNA. 5.27E-06 2.039402 down 
10870 HCST Homo sapiens hematopoietic cell signal transducer 
(HCST), transcript variant 1, mRNA. 
1.66E-05 2.0092502 down 
9759 HDAC4 Homo sapiens histone deacetylase 4 (HDAC4), 
mRNA. 
7.25E-06 2.7702913 up 
23593 HEBP2 Homo sapiens heme binding protein 2 (HEBP2), 
mRNA. 
5.13E-06 2.7443266 up 
51191 HERC5 Homo sapiens hect domain and RLD 5 (HERC5), 
mRNA. 
1.28E-05 3.366833 down 
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55008 HERC6 Homo sapiens hect domain and RLD 6 (HERC6), 
transcript variant 4, mRNA. 
6.88E-05 2.8096554 down 
57801 HES4 Homo sapiens hairy and enhancer of split 4 
(Drosophila) (HES4), mRNA. 
1.58E-03 2.5995913 down 
3087 HHEX Homo sapiens hematopoietically expressed 
homeobox (HHEX), mRNA. 
2.20E-05 2.217241 up 
84641 HIATL1 Homo sapiens hippocampus abundant transcript-
like 1 (HIATL1), mRNA. 
7.59E-06 2.417627 up 
3091 HIF1A Homo sapiens hypoxia-inducible factor 1, alpha 
subunit (basic helix-loop-helix transcription factor) 
(HIF1A), transcript variant 1, mRNA. 
4.24E-05 2.4934282 up 
3091 HIF1A Homo sapiens hypoxia-inducible factor 1, alpha 
subunit (basic helix-loop-helix transcription factor) 
(HIF1A), transcript variant 2, mRNA. 
7.68E-06 2.9970105 up 
25994 HIGD1A Homo sapiens HIG1 domain family, member 1A 
(HIGD1A), mRNA. 
7.25E-06 2.981488 up 
3092 HIP1 Homo sapiens huntingtin interacting protein 1 
(HIP1), mRNA. 
8.41E-04 2.9434607 up 
3006 HIST1H1C Homo sapiens histone cluster 1, H1c (HIST1H1C), 
mRNA. 
4.54E-04 2.0319352 up 
8334 HIST1H2AC Homo sapiens histone cluster 1, H2ac (HIST1H2AC), 
mRNA. 
3.14E-04 2.0233493 up 
3017 HIST1H2BD Homo sapiens histone cluster 1, H2bd 
(HIST1H2BD), transcript variant 2, mRNA. 
1.08E-05 3.1049051 up 
3017 HIST1H2BD Homo sapiens histone cluster 1, H2bd 
(HIST1H2BD), transcript variant 2, mRNA. 
8.44E-06 3.0353427 up 
8344 HIST1H2BE Homo sapiens histone cluster 1, H2be (HIST1H2BE), 
mRNA. 
1.47E-03 2.3153474 up 
85236 HIST1H2BK Homo sapiens histone cluster 1, H2bk (HIST1H2BK), 
mRNA. 
2.42E-05 2.2010486 up 
8351 HIST1H3D Homo sapiens histone cluster 1, H3d (HIST1H3D), 
mRNA. 
1.62E-05 2.476441 up 
8365 HIST1H4H Homo sapiens histone cluster 1, H4h (HIST1H4H), 
mRNA. 
1.11E-02 2.050118 up 
8337 HIST2H2AA3 Homo sapiens histone cluster 2, H2aa3 
(HIST2H2AA3), mRNA. 
1.17E-05 3.6270607 up 
8338 HIST2H2AC Homo sapiens histone cluster 2, H2ac (HIST2H2AC), 
mRNA. 
5.35E-06 3.8891788 up 
8349 HIST2H2BE Homo sapiens histone cluster 2, H2be (HIST2H2BE), 
mRNA. 
1.82E-05 2.9119258 up 
3099 HK2 Homo sapiens hexokinase 2 (HK2), mRNA. 9.10E-06 2.731334 up 
3101 HK3 Homo sapiens hexokinase 3 (white cell) (HK3), 
nuclear gene encoding mitochondrial protein, 
mRNA. 
5.13E-06 9.296805 up 
3108 HLA-DMA Homo sapiens major histocompatibility complex, 
class II, DM alpha (HLA-DMA), mRNA. 
7.68E-06 3.18049 down 
3109 HLA-DMB Homo sapiens major histocompatibility complex, 
class II, DM beta (HLA-DMB), mRNA. 
5.47E-06 3.6686242 down 
3111 HLA-DOA Homo sapiens major histocompatibility complex, 
class II, DO alpha (HLA-DOA), mRNA. 
1.39E-05 3.3640552 down 
3112 HLA-DOB Homo sapiens major histocompatibility complex, 
class II, DO beta (HLA-DOB), mRNA. 
1.00E-04 2.6358018 down 
3113 HLA-DPA1 Homo sapiens major histocompatibility complex, 
class II, DP alpha 1 (HLA-DPA1), mRNA. 
5.47E-06 3.927301 down 
3115 HLA-DPB1 Homo sapiens major histocompatibility complex, 
class II, DP beta 1 (HLA-DPB1), mRNA. 
4.19E-03 2.0948849 down 
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3117 HLA-DQA1 PREDICTED: Homo sapiens major 
histocompatibility complex, class II, DQ alpha 1, 
transcript variant 2 (HLA-DQA1), mRNA. 
2.68E-05 3.730297 down 
3119 HLA-DQB1 Homo sapiens major histocompatibility complex, 
class II, DQ beta 1 (HLA-DQB1), mRNA. 
1.02E-04 3.3586028 down 
3122 HLA-DRA Homo sapiens major histocompatibility complex, 
class II, DR alpha (HLA-DRA), mRNA. 
1.66E-05 2.1284666 down 
3125 HLA-DRB3 Homo sapiens major histocompatibility complex, 
class II, DR beta 3 (HLA-DRB3), mRNA. 
1.08E-05 3.6839347 down 
3128 HLA-DRB6 Homo sapiens major histocompatibility complex, 
class II, DR beta 6 (pseudogene) (HLA-DRB6) on 
chromosome 6. 
1.17E-05 3.099395 down 
3142 HLX1 Homo sapiens H2.0-like homeobox (HLX), mRNA. 1.76E-04 2.6222506 up 
84803 HMFN0839 Homo sapiens lung cancer metastasis-associated 
protein (MAG1), mRNA. 
1.28E-05 3.180867 up 
10042 HMG2L1 Homo sapiens high-mobility group protein 2-like 1 
(HMG2L1), transcript variant 1, mRNA. 
1.05E-03 2.5495625 up 
3148 HMGB2 Homo sapiens high-mobility group box 2 (HMGB2), 
mRNA. 
5.13E-06 4.538895 up 
3156 HMGCR Homo sapiens 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase (HMGCR), mRNA. 
5.27E-06 2.139759 up 
3162 HMOX1 Homo sapiens heme oxygenase (decycling) 1 
(HMOX1), mRNA. 
5.13E-06 3.8246636 up 
664709 HNRPA1L-2 Homo sapiens heterogeneous nuclear 
ribonucleoprotein A1 pseudogene (HNRPA1L-2) on 
chromosome 19. 
2.62E-05 2.2492115 down 
9987 HNRPDL Homo sapiens heterogeneous nuclear 
ribonucleoprotein D-like (HNRPDL), transcript 
variant 2, mRNA. 
9.10E-06 2.0014539 down 
92906 HNRPLL Homo sapiens heterogeneous nuclear 
ribonucleoprotein L-like (HNRPLL), mRNA. 
9.18E-05 2.000882 up 
84376 HOOK3 Homo sapiens hook homolog 3 (Drosophila) 
(HOOK3), mRNA. 
7.42E-03 2.0374558 up 
3211 HOXB1 Homo sapiens homeo box B1 (HOXB1), mRNA. 5.13E-06 2.4493742 up 
3240 HP Homo sapiens haptoglobin (HP), mRNA. 1.00E-04 56.395782 up 
3248 HPGD Homo sapiens hydroxyprostaglandin 
dehydrogenase 15-(NAD) (HPGD), mRNA. 
1.43E-03 9.55992 up 
3251 HPRT1 Homo sapiens hypoxanthine 
phosphoribosyltransferase 1 (Lesch-Nyhan 
syndrome) (HPRT1), mRNA. 
7.57E-05 2.0362668 up 
10855 HPSE Homo sapiens heparanase (HPSE), mRNA. 3.09E-04 2.5663595 up 
84263 HSDL2 Homo sapiens hydroxysteroid dehydrogenase like 
2 (HSDL2), mRNA. 
1.28E-05 2.8731604 up 
84941 HSH2D Homo sapiens hematopoietic SH2 domain 
containing (HSH2D), mRNA. 
2.86E-04 2.708776 down 
3303 HSPA1A Homo sapiens heat shock 70kDa protein 1A 
(HSPA1A), mRNA. 
4.26E-05 2.4528234 up 
3304 HSPA1B Homo sapiens heat shock 70kDa protein 1B 
(HSPA1B), mRNA. 
4.26E-05 2.8954086 up 
29094 HSPC159 Homo sapiens galectin-related protein (HSPC159), 
mRNA. 
3.59E-02 4.072594 up 
10553 HTATIP2 Homo sapiens HIV-1 Tat interactive protein 2, 
30kDa (HTATIP2), mRNA. 
5.91E-06 3.2115207 up 
3344 HTLF Homo sapiens human T-cell leukemia virus 
enhancer factor (HTLF), mRNA. 
5.35E-06 2.65232 up 
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255488 IBRDC2 Homo sapiens IBR domain containing 2 (IBRDC2), 
mRNA. 
5.13E-06 3.5402398 up 
3384 ICAM2 Homo sapiens intercellular adhesion molecule 2 
(ICAM2), mRNA. 
5.13E-06 2.3652453 down 
29851 ICOS Homo sapiens inducible T-cell co-stimulator (ICOS), 
mRNA. 
1.20E-04 2.6306055 down 
3399 ID3 Homo sapiens inhibitor of DNA binding 3, 
dominant negative helix-loop-helix protein (ID3), 
mRNA. 
5.13E-06 3.3014498 down 
3417 IDH1 Homo sapiens isocitrate dehydrogenase 1 (NADP+), 
soluble (IDH1), mRNA. 
5.13E-06 3.8925538 up 
3422 IDI1 Homo sapiens isopentenyl-diphosphate delta 
isomerase 1 (IDI1), mRNA. 
6.74E-06 7.6172905 up 
8870 IER3 Homo sapiens immediate early response 3 (IER3), 
transcript variant long, mRNA. 
4.90E-05 5.1915226 up 
10437 IFI30 Homo sapiens interferon, gamma-inducible protein 
30 (IFI30), mRNA. 
5.91E-06 2.7071104 up 
10561 IFI44 Homo sapiens interferon-induced protein 44 
(IFI44), mRNA. 
4.37E-03 2.9018476 down 
10964 IFI44L Homo sapiens interferon-induced protein 44-like 
(IFI44L), mRNA. 
2.88E-02 2.9018915 down 
2537 IFI6 Homo sapiens interferon, alpha-inducible protein 6 
(IFI6), transcript variant 2, mRNA. 
2.42E-03 2.4678319 down 
64135 IFIH1 Homo sapiens interferon induced with helicase C 
domain 1 (IFIH1), mRNA. 
1.86E-04 2.667858 down 
3433 IFIT2 Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 2 (IFIT2), mRNA. 
6.25E-05 5.4927115 down 
3437 IFIT3 Homo sapiens interferon-induced protein with 
tetratricopeptide repeats 3 (IFIT3), mRNA. 
1.13E-04 6.5571265 down 
10581 IFITM2 Homo sapiens interferon induced transmembrane 
protein 2 (1-8D) (IFITM2), mRNA. 
3.50E-05 2.0075166 up 
10410 IFITM3 Homo sapiens interferon induced transmembrane 
protein 3 (1-8U) (IFITM3), mRNA. 
1.10E-03 3.0724144 up 
3454 IFNAR1 Homo sapiens interferon (alpha, beta and omega) 
receptor 1 (IFNAR1), mRNA. 
5.13E-06 2.283704 up 
3459 IFNGR1 Homo sapiens interferon gamma receptor 1 
(IFNGR1), mRNA. 
5.13E-06 4.2705493 up 
3460 IFNGR2 Homo sapiens interferon gamma receptor 2 
(interferon gamma transducer 1) (IFNGR2), mRNA. 
5.13E-06 2.3572378 up 
3475 IFRD1 Homo sapiens interferon-related developmental 
regulator 1 (IFRD1), transcript variant 1, mRNA. 
3.14E-04 2.2098625 up 
10643 IGF2BP3 Homo sapiens insulin-like growth factor 2 mRNA 
binding protein 3 (IGF2BP3), mRNA. 
1.29E-04 2.824558 up 
3490 IGFBP7 Homo sapiens insulin-like growth factor binding 
protein 7 (IGFBP7), mRNA. 
2.85E-04 2.6079216 up 
10261 IGSF6 Homo sapiens immunoglobulin superfamily, 
member 6 (IGSF6), mRNA. 
2.63E-05 3.0399635 up 
3588 IL10RB Homo sapiens interleukin 10 receptor, beta 
(IL10RB), mRNA. 
5.13E-06 2.7541602 up 
3590 IL11RA Homo sapiens interleukin 11 receptor, alpha 
(IL11RA), transcript variant 1, mRNA. 
5.27E-06 2.9951108 down 
3594 IL12RB1 Homo sapiens interleukin 12 receptor, beta 1 
(IL12RB1), transcript variant 2, mRNA. 
1.68E-05 2.462098 down 
23765 IL17R Homo sapiens interleukin 17 receptor (IL17R), 
mRNA. 
9.15E-05 2.2415168 up 
10068 IL18BP Homo sapiens interleukin 18 binding protein 
(IL18BP), transcript variant A, mRNA. 
2.09E-05 2.3088887 down 
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8809 IL18R1 Homo sapiens interleukin 18 receptor 1 (IL18R1), 
mRNA. 
6.74E-06 15.37721 up 
8807 IL18RAP Homo sapiens interleukin 18 receptor accessory 
protein (IL18RAP), mRNA. 
5.35E-06 6.7150755 up 
3553 IL1B Homo sapiens interleukin 1, beta (IL1B), mRNA. 1.34E-04 2.4005222 up 
7850 IL1R2 Homo sapiens interleukin 1 receptor, type II 
(IL1R2), transcript variant 1, mRNA. 
3.71E-02 6.081163 up 
7850 IL1R2 Homo sapiens interleukin 1 receptor, type II 
(IL1R2), transcript variant 2, mRNA. 
5.13E-06 43.003864 up 
3556 IL1RAP Homo sapiens interleukin 1 receptor accessory 
protein (IL1RAP), transcript variant 1, mRNA. 
5.35E-06 9.201493 up 
3556 IL1RAP Homo sapiens interleukin 1 receptor accessory 
protein (IL1RAP), transcript variant 2, mRNA. 
3.86E-02 6.361552 up 
3557 IL1RN Homo sapiens interleukin 1 receptor antagonist 
(IL1RN), transcript variant 1, mRNA. 
6.25E-05 3.7269661 up 
3557 IL1RN Homo sapiens interleukin 1 receptor antagonist 
(IL1RN), transcript variant 1, mRNA. 
4.15E-04 3.0954857 up 
50615 IL21R Homo sapiens interleukin 21 receptor (IL21R), 
transcript variant 2, mRNA. 
1.25E-05 2.160711 down 
9466 IL27RA Homo sapiens interleukin 27 receptor, alpha 
(IL27RA), mRNA. 
5.13E-06 2.29831 down 
3560 IL2RB Homo sapiens interleukin 2 receptor, beta (IL2RB), 
mRNA. 
3.40E-05 5.49469 down 
9235 IL32 Homo sapiens interleukin 32 (IL32), transcript 
variant 3, mRNA. 
7.25E-06 3.5453367 down 
9235 IL32 Homo sapiens interleukin 32 (IL32), transcript 
variant 4, mRNA. 
5.13E-06 4.5582767 down 
3566 IL4R Homo sapiens interleukin 4 receptor (IL4R), 
transcript variant 1, mRNA. 
6.25E-05 2.0086331 up 
3575 IL7R Homo sapiens interleukin 7 receptor (IL7R), mRNA. 3.87E-05 3.04446 down 
3576 IL8 Homo sapiens interleukin 8 (IL8), mRNA. 1.37E-03 5.659095 up 
3577 IL8RA Homo sapiens interleukin 8 receptor, alpha 
(IL8RA), mRNA. 
2.11E-03 2.431496 up 
3609 ILF3 Homo sapiens interleukin enhancer binding factor 
3, 90kDa (ILF3), transcript variant 1, mRNA. 
6.14E-06 2.3132324 down 
3613 IMPA2 Homo sapiens inositol(myo)-1(or 4)-
monophosphatase 2 (IMPA2), mRNA. 
5.47E-06 4.700455 up 
3614 IMPDH1 Homo sapiens IMP (inosine monophosphate) 
dehydrogenase 1 (IMPDH1), transcript variant 1, 
mRNA. 
9.10E-06 2.7492611 up 
3615 IMPDH2 Homo sapiens IMP (inosine monophosphate) 
dehydrogenase 2 (IMPDH2), mRNA. 
9.10E-06 2.2711034 down 
3632 INPP5A PREDICTED: Homo sapiens inositol polyphosphate-
5-phosphatase, 40kDa (INPP5A), mRNA. 
1.34E-04 2.2702928 up 
51141 INSIG2 Homo sapiens insulin induced gene 2 (INSIG2), 
mRNA. 
2.11E-05 2.3774726 up 
51194 IPO11 Homo sapiens importin 11 (IPO11), mRNA. 5.13E-06 4.0466456 up 
8826 IQGAP1 Homo sapiens IQ motif containing GTPase 
activating protein 1 (IQGAP1), mRNA. 
2.42E-05 2.3597813 up 
3656 IRAK2 Homo sapiens interleukin-1 receptor-associated 
kinase 2 (IRAK2), mRNA. 
3.75E-04 2.0473778 up 
11213 IRAK3 Homo sapiens interleukin-1 receptor-associated 
kinase 3 (IRAK3), mRNA. 
5.13E-06 14.552744 up 
8660 IRS2 Homo sapiens insulin receptor substrate 2 (IRS2), 
mRNA. 
1.52E-05 3.6279347 up 
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9636 ISG15 Homo sapiens ISG15 ubiquitin-like modifier 
(ISG15), mRNA. 
6.53E-04 2.964672 down 
64782 ISG20L1 Homo sapiens interferon stimulated exonuclease 
gene 20kDa-like 1 (ISG20L1), mRNA. 
3.68E-05 2.0694807 down 
51015 ISOC1 Homo sapiens isochorismatase domain containing 
1 (ISOC1), mRNA. 
4.37E-04 2.0040698 down 
3684 ITGAM Homo sapiens integrin, alpha M (complement 
component receptor 3, alpha; also known as 
CD11b (p170), macrophage antigen alpha 
polypeptide) (ITGAM), mRNA. 
5.13E-06 5.406939 up 
3687 ITGAX Homo sapiens integrin, alpha X (complement 
component 3 receptor 4 subunit) (ITGAX), mRNA. 
6.53E-04 2.201949 up 
3695 ITGB7 Homo sapiens integrin, beta 7 (ITGB7), mRNA. 5.13E-06 4.3152237 down 
3702 ITK Homo sapiens IL2-inducible T-cell kinase (ITK), 
mRNA. 
2.63E-05 2.8544672 down 
9452 ITM2A Homo sapiens integral membrane protein 2A 
(ITM2A), mRNA. 
1.11E-04 2.8810825 down 
81618 ITM2C Homo sapiens integral membrane protein 2C 
(ITM2C), transcript variant 1, mRNA. 
1.39E-05 3.3436434 down 
81618 ITM2C Homo sapiens integral membrane protein 2C 
(ITM2C), transcript variant 2, mRNA. 
1.17E-05 3.1908162 down 
3710 ITPR3 Homo sapiens inositol 1,4,5-triphosphate receptor, 
type 3 (ITPR3), mRNA. 
5.13E-06 3.7986212 down 
10625 IVNS1ABP Homo sapiens influenza virus NS1A binding protein 
(IVNS1ABP), mRNA. 
5.91E-06 2.5936842 up 
10625 IVNS1ABP Homo sapiens influenza virus NS1A binding protein 
(IVNS1ABP), mRNA. 
1.39E-05 2.729983 up 
3717 JAK2 Homo sapiens Janus kinase 2 (a protein tyrosine 
kinase) (JAK2), mRNA. 
2.33E-05 2.7726579 up 
126119 JOSD2 Homo sapiens Josephin domain containing 2 
(JOSD2), mRNA. 
5.10E-04 2.247258 up 
3726 JUNB Homo sapiens jun B proto-oncogene (JUNB), 
mRNA. 
1.17E-05 2.3996542 up 
9119 K6HF Homo sapiens keratin 75 (KRT75), mRNA. 7.57E-05 2.390776 up 
84078 KBTBD7 Homo sapiens kelch repeat and BTB (POZ) domain 
containing 7 (KBTBD7), mRNA. 
8.33E-05 3.0779214 up 
56888 KCMF1 Homo sapiens potassium channel modulatory 
factor 1 (KCMF1), mRNA. 
3.93E-02 3.3099513 up 
3772 KCNJ15 Homo sapiens potassium inwardly-rectifying 
channel, subfamily J, member 15 (KCNJ15), 
transcript variant 2, mRNA. 
7.79E-04 2.254441 up 
3772 KCNJ15 Homo sapiens potassium inwardly-rectifying 
channel, subfamily J, member 15 (KCNJ15), 
transcript variant 3, mRNA. 
6.50E-04 2.4360135 up 
3759 KCNJ2 Homo sapiens potassium inwardly-rectifying 
channel, subfamily J, member 2 (KCNJ2), mRNA. 
2.20E-05 3.027121 up 
23199 KIAA0182 Homo sapiens KIAA0182 (KIAA0182), mRNA. 1.37E-03 2.0617087 down 
23080 KIAA0241 Homo sapiens KIAA0241 (KIAA0241), mRNA. 1.83E-04 2.3476229 up 
9710 KIAA0355 Homo sapiens KIAA0355 (KIAA0355), mRNA. 5.47E-06 2.5729055 down 
23223 KIAA0690 Homo sapiens ribosomal RNA processing 12 
homolog (S. cerevisiae) (RRP12), mRNA. 
1.01E-03 2.109059 up 
22904 KIAA0963 Homo sapiens strawberry notch homolog 2 
(Drosophila) (SBNO2), mRNA. 
6.74E-06 2.5096743 up 
56261 KIAA1434 Homo sapiens hypothetical protein KIAA1434 
(KIAA1434), mRNA. 
5.13E-06 3.3259358 up 
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80256 KIAA1539 Homo sapiens KIAA1539 (KIAA1539), mRNA. 5.91E-06 2.7394087 up 
57700 KIAA1600 Homo sapiens KIAA1600 (KIAA1600), mRNA. 2.63E-05 2.3203564 up 
80856 KIAA1715 Homo sapiens KIAA1715 (KIAA1715), mRNA. 3.36E-05 2.4645565 up 
57498 KIDINS220 Homo sapiens kinase D-interacting substrate of 
220 kDa (KIDINS220), mRNA. 
5.69E-05 2.167831 up 
23095 KIF1B Homo sapiens kinesin family member 1B (KIF1B), 
transcript variant 2, mRNA. 
2.87E-05 3.790065 up 
23095 KIF1B Homo sapiens kinesin family member 1B (KIF1B), 
transcript variant 1, mRNA. 
7.25E-06 4.390986 up 
3799 KIF5B Homo sapiens kinesin family member 5B (KIF5B), 
mRNA. 
1.00E-05 2.1791384 up 
22920 KIFAP3 Homo sapiens kinesin-associated protein 3 
(KIFAP3), mRNA. 
4.51E-02 2.1541207 down 
54758 KLHDC4 Homo sapiens kelch domain containing 4 
(KLHDC4), mRNA. 
1.32E-05 2.488812 down 
11275 KLHL2 Homo sapiens kelch-like 2, Mayven (Drosophila) 
(KLHL2), mRNA. 
5.27E-06 7.49346 up 
84861 KLHL22 Homo sapiens kelch-like 22 (Drosophila) (KLHL22), 
mRNA. 
5.13E-06 2.5531943 down 
26249 KLHL3 Homo sapiens kelch-like 3 (Drosophila) (KLHL3), 
mRNA. 
6.15E-03 3.6103013 down 
57563 KLHL8 Homo sapiens kelch-like 8 (Drosophila) (KLHL8), 
mRNA. 
5.35E-06 3.3154922 up 
3820 KLRB1 Homo sapiens killer cell lectin-like receptor 
subfamily B, member 1 (KLRB1), mRNA. 
9.97E-06 4.9018617 down 
3824 KLRD1 Homo sapiens killer cell lectin-like receptor 
subfamily D, member 1 (KLRD1), transcript variant 
1, mRNA. 
4.04E-05 2.783256 down 
51348 KLRF1 Homo sapiens killer cell lectin-like receptor 
subfamily F, member 1 (KLRF1), mRNA. 
1.92E-05 4.0498667 down 
3840 KPNA4 Homo sapiens karyopherin alpha 4 (importin alpha 
3) (KPNA4), mRNA. 
9.97E-06 2.3995998 up 
3845 KRAS Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS), transcript variant b, 
mRNA. 
8.44E-06 2.2416167 up 
83999 KREMEN1 Homo sapiens kringle containing transmembrane 
protein 1 (KREMEN1), transcript variant 1, mRNA. 
3.70E-02 2.5115707 up 
337973 KRTAP19-6 Homo sapiens keratin associated protein 19-6 
(KRTAP19-6), mRNA. 
1.01E-04 2.9269497 up 
83888 KSP37 Homo sapiens fibroblast growth factor binding 
protein 2 (FGFBP2), mRNA. 
1.66E-05 6.4447947 down 
83746 L3MBTL2 Homo sapiens l(3)mbt-like 2 (Drosophila) 
(L3MBTL2), mRNA. 
5.13E-06 2.0660145 down 
114294 LACTB Homo sapiens lactamase, beta (LACTB), nuclear 
gene encoding mitochondrial protein, transcript 
variant 2, mRNA. 
4.04E-04 2.121644 up 
3903 LAIR1 Homo sapiens leukocyte-associated Ig-like receptor 
1 (LAIR1), transcript variant c, mRNA. 
1.52E-05 3.1167188 up 
3920 LAMP2 Homo sapiens lysosomal-associated membrane 
protein 2 (LAMP2), transcript variant LAMP2B, 
mRNA. 
1.17E-05 2.3016438 up 
3920 LAMP2 Homo sapiens lysosomal-associated membrane 
protein 2 (LAMP2), transcript variant LAMP2A, 
mRNA. 
9.29E-04 2.1473026 up 
10314 LANCL1 Homo sapiens LanC lantibiotic synthetase 
component C-like 1 (bacterial) (LANCL1), mRNA. 
9.10E-06 2.3512146 down 
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9741 LAPTM4A Homo sapiens lysosomal-associated protein 
transmembrane 4 alpha (LAPTM4A), mRNA. 
6.88E-05 2.215206 up 
27040 LAT Homo sapiens linker for activation of T cells (LAT), 
transcript variant 2, mRNA. 
3.50E-05 2.6552627 down 
7462 LAT2 Homo sapiens linker for activation of T cells family, 
member 2 (LAT2), transcript variant 1, mRNA. 
5.47E-06 2.9489973 up 
7462 LAT2 Homo sapiens linker for activation of T cells family, 
member 2 (LAT2), transcript variant 1, mRNA. 
5.13E-06 2.945858 up 
54900 LAX1 Homo sapiens lymphocyte transmembrane 
adaptor 1 (LAX1), mRNA. 
6.31E-06 3.5568678 down 
81606 LBH Homo sapiens limb bud and heart development 
homolog (mouse) (LBH), mRNA. 
5.27E-06 3.9515767 down 
3930 LBR Homo sapiens lamin B receptor (LBR), transcript 
variant 1, mRNA. 
2.37E-04 2.1497772 up 
3932 LCK Homo sapiens lymphocyte-specific protein tyrosine 
kinase (LCK), transcript variant 1, mRNA. 
2.18E-05 3.151416 down 
3934 LCN2 Homo sapiens lipocalin 2 (oncogene 24p3) (LCN2), 
mRNA. 
1.17E-05 33.34258 up 
3939 LDHA Homo sapiens lactate dehydrogenase A (LDHA), 
mRNA. 
5.13E-06 4.387206 up 
3945 LDHB Homo sapiens lactate dehydrogenase B (LDHB), 
mRNA. 
6.74E-06 2.9264965 down 
3949 LDLR Homo sapiens low density lipoprotein receptor 
(familial hypercholesterolemia) (LDLR), mRNA. 
2.02E-05 2.6210842 up 
26119 LDLRAP1 Homo sapiens low density lipoprotein receptor 
adaptor protein 1 (LDLRAP1), mRNA. 
3.82E-04 2.3112795 down 
51176 LEF1 Homo sapiens lymphoid enhancer-binding factor 1 
(LEF1), mRNA. 
1.17E-05 4.554513 down 
79143 LENG4 Homo sapiens leukocyte receptor cluster (LRC) 
member 4 (LENG4), mRNA. 
3.87E-05 2.7409623 up 
54741 LEPROT Homo sapiens leptin receptor overlapping 
transcript (LEPROT), mRNA. 
4.26E-05 2.0608938 up 
3956 LGALS1 Homo sapiens lectin, galactoside-binding, soluble, 
1 (galectin 1) (LGALS1), mRNA. 
5.13E-06 4.3865237 up 
3964 LGALS8 Homo sapiens lectin, galactoside-binding, soluble, 
8 (galectin 8) (LGALS8), transcript variant 1, mRNA. 
6.74E-06 2.463588 up 
3964 LGALS8 Homo sapiens lectin, galactoside-binding, soluble, 
8 (galectin 8) (LGALS8), transcript variant 4, mRNA. 
5.35E-06 2.5453434 up 
64077 LHPP Homo sapiens phospholysine phosphohistidine 
inorganic pyrophosphate phosphatase (LHPP), 
mRNA. 
7.57E-05 2.0409107 down 
11026 LILRA3 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily A (without TM domain), 
member 3 (LILRA3), mRNA. 
1.17E-05 8.7037945 up 
11026 LILRA3 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily A (without TM domain), 
member 3 (LILRA3), mRNA. 
9.37E-05 4.8643785 up 
353514 LILRA5 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily A (with TM domain), member 5 
(LILRA5), transcript variant 4, mRNA. 
6.17E-06 11.198167 up 
353514 LILRA5 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily A (with TM domain), member 5 
(LILRA5), transcript variant 1, mRNA. 
5.13E-06 11.616155 up 
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353514 LILRA5 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily A (with TM domain), member 5 
(LILRA5), transcript variant 1, mRNA. 
5.13E-06 5.443482 up 
10859 LILRB1 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM domains), 
member 1 (LILRB1), mRNA. 
3.27E-03 2.1504884 up 
10288 LILRB2 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM domains), 
member 2 (LILRB2), transcript variant 2, mRNA. 
1.08E-05 2.9256861 up 
11025 LILRB3 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM domains), 
member 3 (LILRB3), mRNA. 
7.25E-06 3.2037485 up 
11006 LILRB4 Homo sapiens leukocyte immunoglobulin-like 
receptor, subfamily B (with TM and ITIM domains), 
member 4 (LILRB4), transcript variant 2, mRNA. 
3.62E-05 2.7389982 up 
54923 LIME1 Homo sapiens Lck interacting transmembrane 
adaptor 1 (LIME1), mRNA. 
5.13E-06 4.7727413 down 
3985 LIMK2 Homo sapiens LIM domain kinase 2 (LIMK2), 
transcript variant 1, mRNA. 
9.35E-05 3.3913217 up 
8825 LIN7A Homo sapiens lin-7 homolog A (C. elegans) (LIN7A), 
mRNA. 
1.08E-02 5.788392 up 
4001 LMNB1 Homo sapiens lamin B1 (LMNB1), mRNA. 5.69E-05 2.468467 up 
116236 LOC116236 Homo sapiens hypothetical protein LOC116236 
(LOC116236), mRNA. 
1.64E-04 2.068167 down 
130355 LOC130355 Homo sapiens hypothetical protein LOC130355 
(LOC130355), mRNA. 
2.39E-04 2.1371233 up 
152195 LOC152195 Homo sapiens hypothetical protein LOC152195 
(LOC152195), mRNA. 
7.4E-03 2.180511 up 
152485 LOC152485 Homo sapiens hypothetical protein LOC152485 
(LOC152485), mRNA. 
2.18E-05 2.6333103 down 
283345 LOC283345 Homo sapiens RPL13-2 pseudogene (LOC283345) 
on chromosome 12. 
1.52E-05 2.3650246 down 
349114 LOC349114 Homo sapiens hypothetical protein LOC349114 
(LOC349114), mRNA. 
2.37E-04 2.696288 up 
400924 LOC400924 Homo sapiens hypothetical gene supported by 
AK056895 (LOC400924), mRNA. 
7.82E-03 2.0152562 up 
400986 LOC400986 Homo sapiens protein immuno-reactive with anti-
PTH polyclonal antibodies (LOC400986), mRNA. 
5.73E-04 2.4265492 down 
401152 LOC401152 Homo sapiens HCV F-transactivated protein 1 
(LOC401152), mRNA. 
5.91E-06 2.2763355 up 
401233 LOC401233 Homo sapiens similar to HIV TAT specific factor 1; 
cofactor required for Tat activation of HIV-1 
transcription (LOC401233), mRNA. 
1.81E-03 2.783016 up 
401357 LOC401357 Homo sapiens hypothetical LOC401357 
(LOC401357), mRNA. 
2.86E-04 2.3805585 up 
440348 LOC440348 Homo sapiens similar to nuclear pore complex 
interacting protein (LOC440348), mRNA. 
1.28E-05 2.0378263 down 
440686 LOC440686 Homo sapiens similar to histone H2B histone family 
(LOC440686), mRNA. 
4.69E-05 2.5389736 up 
440926 LOC440926 Homo sapiens H3 histone, family 3A pseudogene 
(LOC440926) on chromosome 2. 
1.62E-04 2.1827402 up 
441743 LOC441743 Homo sapiens similar to C367G8.3 (novel protein 
similar to RPL23A (60S ribosomal protein L23A)) 
(LOC441743), mRNA. 
3.14E-04 2.4742877 down 
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497661 LOC497661 Homo sapiens chromosome 18 open reading frame 
32 (C18orf32), mRNA. 
5.27E-06 3.9173088 up 
57149 LOC57149 Homo sapiens hypothetical protein A-211C6.1 
(LOC57149), mRNA. 
5.13E-06 3.2778876 up 
643940 LOC643940 PREDICTED: Homo sapiens similar to HIG1 domain 
family member 1A (Hypoxia-inducible gene 1 
protein) (LOC643940), mRNA. 
5.13E-06 2.5235357 up 
648293 LOC648293 PREDICTED: Homo sapiens similar to RNA-binding 
motif, single-stranded interacting protein 1 (Single-
stranded DNA-binding protein MSSP-1) 
(Suppressor of CDC2 with RNA binding motif 2), 
transcript variant 2 (LOC648293), mRNA. 
5.13E-06 2.9746206 up 
649946 LOC649946 Homo sapiens ribosomal protein L23a pseudogene 
(LOC649946) on chromosome 11. 
4.69E-05 2.1075044 down 
653745 LOC653745 PREDICTED: Homo sapiens similar to 
phosphoprotein associated with glycosphingolipid 
microdomains 1 (LOC653745), mRNA. 
5.27E-06 2.370234 up 
92017 LOC92017 Homo sapiens similar to RIKEN cDNA 4933437K13 
(LOC92017), mRNA. 
4.47E-05 2.4074538 down 
93622 LOC93622 Homo sapiens hypothetical protein BC006130 
(LOC93622), mRNA. 
1.12E-05 2.2445498 down 
23175 LPIN1 Homo sapiens lipin 1 (LPIN1), mRNA. 8.44E-06 2.6209936 down 
64748 LPPR2 Homo sapiens lipid phosphate phosphatase-related 
protein type 2 (LPPR2), mRNA. 
9.15E-05 2.3464527 up 
987 LRBA Homo sapiens LPS-responsive vesicle trafficking, 
beach and anchor containing (LRBA), mRNA. 
9.15E-05 2.2243772 down 
79414 LRFN3 Homo sapiens leucine rich repeat and fibronectin 
type III domain containing 3 (LRFN3), mRNA. 
1.54E-02 2.4170325 down 
116844 LRG1 Homo sapiens leucine-rich alpha-2-glycoprotein 1 
(LRG1), mRNA. 
5.13E-06 7.3497386 up 
26018 LRIG1 Homo sapiens leucine-rich repeats and 
immunoglobulin-like domains 1 (LRIG1), mRNA. 
1.08E-05 2.5177758 down 
4043 LRPAP1 Homo sapiens low density lipoprotein receptor-
related protein associated protein 1 (LRPAP1), 
mRNA. 
1.64E-05 3.3948061 up 
126364 LRRC25 Homo sapiens leucine rich repeat containing 25 
(LRRC25), mRNA. 
8.44E-06 3.1618698 up 
9209 LRRFIP2 Homo sapiens leucine rich repeat (in FLII) 
interacting protein 2 (LRRFIP2), transcript variant 2, 
mRNA. 
5.13E-06 3.2521398 up 
9209 LRRFIP2 Homo sapiens leucine rich repeat (in FLII) 
interacting protein 2 (LRRFIP2), transcript variant 1, 
mRNA. 
5.27E-06 2.8964818 up 
54674 LRRN3 Homo sapiens leucine rich repeat neuronal 3 
(LRRN3), mRNA. 
4.60E-03 4.3025613 down 
7940 LST1 Homo sapiens leukocyte specific transcript 1 
(LST1), transcript variant 5, mRNA. 
7.68E-06 2.461821 up 
7940 LST1 Homo sapiens leukocyte specific transcript 1 
(LST1), transcript variant 1, mRNA. 
2.86E-04 2.084269 up 
7940 LST1 Homo sapiens leukocyte specific transcript 1 
(LST1), transcript variant 2, mRNA. 
6.74E-06 2.489791 up 
4049 LTA Homo sapiens lymphotoxin alpha (TNF superfamily, 
member 1) (LTA), mRNA. 
7.25E-06 3.170064 down 
4048 LTA4H Homo sapiens leukotriene A4 hydrolase (LTA4H), 
mRNA. 
5.98E-04 2.0738096 up 
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4050 LTB Homo sapiens lymphotoxin beta (TNF superfamily, 
member 3) (LTB), transcript variant 1, mRNA. 
6.31E-06 2.1910212 down 
1241 LTB4R Homo sapiens leukotriene B4 receptor (LTB4R), 
mRNA. 
1.46E-05 7.688201 up 
4054 LTBP3 Homo sapiens latent transforming growth factor 
beta binding protein 3 (LTBP3), mRNA. 
1.68E-04 2.2814333 down 
4055 LTBR Homo sapiens lymphotoxin beta receptor (TNFR 
superfamily, member 3) (LTBR), mRNA. 
1.52E-05 2.398385 up 
4061 LY6E Homo sapiens lymphocyte antigen 6 complex, 
locus E (LY6E), mRNA. 
1.28E-05 4.5243306 down 
4062 LY6H Homo sapiens lymphocyte antigen 6 complex, 
locus H (LY6H), mRNA. 
6.88E-05 2.0198467 up 
4063 LY9 Homo sapiens lymphocyte antigen 9 (LY9), 
transcript variant 1, mRNA. 
3.38E-04 2.243713 down 
4063 LY9 Homo sapiens lymphocyte antigen 9 (LY9), 
transcript variant 2, mRNA. 
4.04E-05 5.2320733 down 
23643 LY96 Homo sapiens lymphocyte antigen 96 (LY96), 
mRNA. 
1.66E-05 4.751109 up 
55646 LYAR Homo sapiens Ly1 antibody reactive homolog 
(mouse) (LYAR), mRNA. 
5.47E-06 2.1611404 down 
145748 LYSMD4 Homo sapiens LysM, putative peptidoglycan-
binding, domain containing 4 (LYSMD4), mRNA. 
1.06E-05 2.0743074 down 
10226 M6PRBP1 Homo sapiens mannose-6-phosphate receptor 
binding protein 1 (M6PRBP1), mRNA. 
5.13E-06 3.590438 up 
10459 MAD2L2 Homo sapiens MAD2 mitotic arrest deficient-like 2 
(yeast) (MAD2L2), mRNA. 
5.47E-06 2.1591587 up 
9935 MAFB Homo sapiens v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog B (avian) (MAFB), 
mRNA. 
2.08E-04 2.363313 up 
4097 MAFG Homo sapiens v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog G (avian) (MAFG), 
transcript variant 1, mRNA. 
3.71E-03 3.8623326 up 
9500 MAGED1 Homo sapiens melanoma antigen family D, 1 
(MAGED1), transcript variant 1, mRNA. 
5.13E-06 3.0279837 down 
4117 MAK Homo sapiens male germ cell-associated kinase 
(MAK), mRNA. 
9.1E-03 2.1963909 up 
4118 MAL Homo sapiens mal, T-cell differentiation protein 
(MAL), transcript variant a, mRNA. 
1.12E-05 3.9078624 down 
4118 MAL Homo sapiens mal, T-cell differentiation protein 
(MAL), transcript variant d, mRNA. 
5.13E-06 4.6572356 down 
4121 MAN1A1 Homo sapiens mannosidase, alpha, class 1A, 
member 1 (MAN1A1), mRNA. 
5.13E-06 2.6231341 up 
4122 MAN2A2 Homo sapiens mannosidase, alpha, class 2A, 
member 2 (MAN2A2), mRNA. 
7.57E-05 2.2634175 up 
54682 MANSC1 Homo sapiens MANSC domain containing 1 
(MANSC1), mRNA. 
1.19E-05 4.713355 up 
84557 MAP1LC3A Homo sapiens microtubule-associated protein 1 
light chain 3 alpha (MAP1LC3A), transcript variant 
2, mRNA. 
2.63E-05 2.5346806 up 
81631 MAP1LC3B Homo sapiens microtubule-associated protein 1 
light chain 3 beta (MAP1LC3B), mRNA. 
5.47E-06 2.3305001 up 
5604 MAP2K1 Homo sapiens mitogen-activated protein kinase 
kinase 1 (MAP2K1), mRNA. 
7.68E-06 2.0153897 up 
8649 MAP2K1IP1 Homo sapiens mitogen-activated protein kinase 
kinase 1 interacting protein 1 (MAP2K1IP1), mRNA. 
5.13E-06 3.926849 up 
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1326 MAP3K8 Homo sapiens mitogen-activated protein kinase 
kinase kinase 8 (MAP3K8), mRNA. 
5.27E-06 2.972384 up 
11184 MAP4K1 Homo sapiens mitogen-activated protein kinase 
kinase kinase kinase 1 (MAP4K1), mRNA. 
5.13E-06 4.119623 down 
5594 MAPK1 Homo sapiens mitogen-activated protein kinase 1 
(MAPK1), transcript variant 2, mRNA. 
1.08E-05 2.282172 up 
5594 MAPK1 Homo sapiens mitogen-activated protein kinase 1 
(MAPK1), transcript variant 2, mRNA. 
2.20E-05 2.4498398 up 
1432 MAPK14 Homo sapiens mitogen-activated protein kinase 14 
(MAPK14), transcript variant 3, mRNA. 
3.55E-04 3.5409217 up 
1432 MAPK14 Homo sapiens mitogen-activated protein kinase 14 
(MAPK14), transcript variant 1, mRNA. 
1.18E-03 3.5875697 up 
5595 MAPK3 Homo sapiens mitogen-activated protein kinase 3 
(MAPK3), transcript variant 2, mRNA. 
2.37E-04 2.1232176 up 
9261 MAPKAPK2 Homo sapiens mitogen-activated protein kinase-
activated protein kinase 2 (MAPKAPK2), transcript 
variant 2, mRNA. 
7.25E-06 2.4520648 up 
7867 MAPKAPK3 Homo sapiens mitogen-activated protein kinase-
activated protein kinase 3 (MAPKAPK3), mRNA. 
5.13E-06 2.0537193 up 
22919 MAPRE1 Homo sapiens microtubule-associated protein, 
RP/EB family, member 1 (MAPRE1), mRNA. 
5.13E-06 2.0557313 up 
22924 MAPRE3 Homo sapiens microtubule-associated protein, 
RP/EB family, member 3 (MAPRE3), mRNA. 
6.27E-04 2.0587041 up 
4082 MARCKS Homo sapiens myristoylated alanine-rich protein 
kinase C substrate (MARCKS), mRNA. 
4.26E-05 2.4990919 up 
65108 MARCKSL1 Homo sapiens MARCKS-like 1 (MARCKSL1), mRNA. 2.37E-04 2.2064352 down 
8685 MARCO Homo sapiens macrophage receptor with 
collagenous structure (MARCO), mRNA. 
3.6E-03 7.2993226 up 
4145 MATK Homo sapiens megakaryocyte-associated tyrosine 
kinase (MATK), transcript variant 3, mRNA. 
5.13E-06 6.6152873 down 
199675 MCEMP1 Homo sapiens mast cell-expressed membrane 
protein 1 (MCEMP1), mRNA. 
5.13E-06 34.225372 up 
4172 MCM3 Homo sapiens MCM3 minichromosome 
maintenance deficient 3 (S. cerevisiae) (MCM3), 
mRNA. 
6.74E-06 2.4873135 down 
4176 MCM7 Homo sapiens minichromosome maintenance 
complex component 7 (MCM7), transcript variant 
2, mRNA. 
1.66E-05 2.0628264 down 
57192 MCOLN1 Homo sapiens mucolipin 1 (MCOLN1), mRNA. 8.52E-04 2.3145444 up 
79772 MCTP1 Homo sapiens multiple C2 domains, 
transmembrane 1 (MCTP1), transcript variant S, 
mRNA. 
2.42E-05 3.7156835 up 
55784 MCTP2 Homo sapiens multiple C2 domains, 
transmembrane 2 (MCTP2), mRNA. 
4.49E-02 2.0433655 up 
55846 MDS028 Homo sapiens integrin alpha FG-GAP repeat 
containing 2 (ITFG2), mRNA. 
5.13E-06 2.5022576 down 
4200 ME2 Homo sapiens malic enzyme 2, NAD(+)-dependent, 
mitochondrial (ME2), nuclear gene encoding 
mitochondrial protein, mRNA. 
7.68E-06 2.3333006 up 
4205 MEF2A Homo sapiens myocyte enhancer factor 2A 
(MEF2A), mRNA. 
02.08E-03 2.0866954 up 
4208 MEF2C Homo sapiens myocyte enhancer factor 2C 
(MEF2C), mRNA. 
4.26E-05 2.4912832 down 
4209 MEF2D Homo sapiens myocyte enhancer factor 2D 
(MEF2D), mRNA. 
3.90E-05 2.2114096 down 
1955 MEGF9 Homo sapiens multiple EGF-like-domains 9 
(MEGF9), mRNA. 
1.39E-05 3.4256182 up 
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284207 METRNL PREDICTED: Homo sapiens meteorin, glial cell 
differentiation regulator-like (METRNL), mRNA. 
1.08E-04 2.3629737 up 
51108 METTL9 Homo sapiens methyltransferase like 9 (METTL9), 
transcript variant 2, mRNA. 
1.82E-05 3.223023 up 
4242 MFNG Homo sapiens MFNG O-fucosylpeptide 3-beta-N-
acetylglucosaminyltransferase (MFNG), mRNA. 
5.27E-06 2.3311167 down 
64747 MFSD1 Homo sapiens major facilitator superfamily domain 
containing 1 (MFSD1), mRNA. 
5.13E-06 2.8031132 up 
8972 MGAM Homo sapiens maltase-glucoamylase (alpha-
glucosidase) (MGAM), mRNA. 
2.09E-02 3.1408262 up 
11320 MGAT4A Homo sapiens mannosyl (alpha-1,3-)-glycoprotein 
beta-1,4-N-acetylglucosaminyltransferase, 
isoenzyme A (MGAT4A), mRNA. 
6.88E-05 2.1486535 up 
84798 MGC13170 Homo sapiens chromosome 19 open reading frame 
48 (C19orf48), mRNA. 
5.31E-05 2.071528 down 
84981 MGC14376 Homo sapiens hypothetical protein MGC14376 
(MGC14376), transcript variant 2, mRNA. 
4.78E-04 2.395438 up 
124565 MGC15523 Homo sapiens hypothetical protein MGC15523 
(MGC15523), mRNA. 
5.27E-06 2.5845926 up 
84329 MGC15619 Homo sapiens hypothetical protein MGC15619 
(MGC15619), mRNA. 
7.25E-06 2.557482 down 
113791 MGC17330 Homo sapiens phosphoinositide-3-kinase 
interacting protein 1 (PIK3IP1), mRNA. 
1.66E-05 2.6615613 down 
147015 MGC23280 Homo sapiens dehydrogenase/reductase (SDR 
family) member 13 (DHRS13), mRNA. 
2.78E-02 2.5649884 up 
153339 MGC23909 Homo sapiens hypothetical protein MGC23909 
(MGC23909), mRNA. 
5.27E-06 4.853771 up 
79037 MGC2463 Homo sapiens poliovirus receptor related 
immunoglobulin domain containing (PVRIG), 
mRNA. 
5.13E-06 5.0382767 down 
80776 MGC4093 Homo sapiens hypothetical protein MGC4093 
(MGC4093), mRNA. 
5.17E-05 2.2752244 up 
115752 MGC4562 Homo sapiens DIS3 mitotic control homolog (S. 
cerevisiae)-like (DIS3L), mRNA. 
5.27E-06 2.0363624 down 
112597 MGC4677 Homo sapiens hypothetical protein MGC4677 
(MGC4677), mRNA. 
7.25E-06 3.2602782 up 
196383 MGC7036 Homo sapiens hypothetical protein MGC7036 
(MGC7036), mRNA. 
7.25E-06 2.4407103 up 
4255 MGMT Homo sapiens O-6-methylguanine-DNA 
methyltransferase (MGMT), mRNA. 
2.02E-05 2.0105166 down 
4257 MGST1 Homo sapiens microsomal glutathione S-
transferase 1 (MGST1), transcript variant 1a, 
mRNA. 
9.10E-06 3.8062382 up 
64780 MICAL1 Homo sapiens microtubule associated 
monoxygenase, calponin and LIM domain 
containing 1 (MICAL1), mRNA. 
1.66E-05 2.2026234 up 
57708 MIER1 Homo sapiens mesoderm induction early response 
1 homolog (Xenopus laevis) (MIER1), mRNA. 
1.39E-05 2.1699524 up 
8569 MKNK1 Homo sapiens MAP kinase interacting 
serine/threonine kinase 1 (MKNK1), transcript 
variant 1, mRNA. 
5.13E-06 6.2824764 up 
8079 MLF2 Homo sapiens myeloid leukemia factor 2 (MLF2), 
mRNA. 
5.69E-05 2.0656548 up 
197259 MLKL Homo sapiens mixed lineage kinase domain-like 
(MLKL), mRNA. 
1.17E-05 2.4420292 up 
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4302 MLLT6 Homo sapiens myeloid/lymphoid or mixed-lineage 
leukemia (trithorax homolog, Drosophila); 
translocated to, 6 (MLLT6), mRNA. 
1.28E-05 2.1529853 down 
55711 MLSTD1 Homo sapiens male sterility domain containing 1 
(MLSTD1), mRNA. 
5.91E-06 5.840736 up 
84188 MLSTD2 Homo sapiens male sterility domain containing 2 
(MLSTD2), mRNA. 
2.20E-05 2.1893146 up 
6945 MLX Homo sapiens MAX-like protein X (MLX), transcript 
variant 2, mRNA. 
6.05E-05 2.215094 up 
6945 MLX Homo sapiens MAX-like protein X (MLX), transcript 
variant 1, mRNA. 
2.09E-05 2.09683 up 
4311 MME Homo sapiens membrane metallo-endopeptidase 
(neutral endopeptidase, enkephalinase, CALLA, 
CD10) (MME), transcript variant 2a, mRNA. 
1.21E-02 2.605895 down 
10893 MMP24 Homo sapiens matrix metallopeptidase 24 
(membrane-inserted) (MMP24), mRNA. 
3.71E-02 2.0768743 up 
64386 MMP25 Homo sapiens matrix metallopeptidase 25 
(MMP25), transcript variant 2, mRNA. 
2.76E-03 2.3393626 up 
4318 MMP9 Homo sapiens matrix metallopeptidase 9 
(gelatinase B, 92kDa gelatinase, 92kDa type IV 
collagenase) (MMP9), mRNA. 
1.22E-04 7.122397 up 
64757 MOSC1 Homo sapiens MOCO sulphurase C-terminal 
domain containing 1 (MOSC1), mRNA. 
1.47E-04 3.456341 up 
158747 MOSPD2 Homo sapiens motile sperm domain containing 2 
(MOSPD2), mRNA. 
1.33E-05 3.45536 up 
4343 MOV10 Homo sapiens Mov10, Moloney leukemia virus 10, 
homolog (mouse) (MOV10), mRNA. 
7.73E-04 2.2217736 down 
4354 MPP1 Homo sapiens membrane protein, palmitoylated 1, 
55kDa (MPP1), mRNA. 
2.42E-05 2.498742 up 
9019 MPZL1 Homo sapiens myelin protein zero-like 1 (MPZL1), 
transcript variant 2, mRNA. 
2.15E-02 2.0017543 up 
3140 MR1 Homo sapiens major histocompatibility complex, 
class I-related (MR1), mRNA. 
5.91E-06 2.514702 up 
10627 MRCL3 Homo sapiens myosin regulatory light chain MRCL3 
(MRCL3), mRNA. 
9.10E-06 2.3504286 up 
23164 M-RIP Homo sapiens myosin phosphatase-Rho interacting 
protein (M-RIP), transcript variant 2, mRNA. 
6.74E-06 2.3044934 down 
103910 MRLC2 Homo sapiens myosin regulatory light chain MRLC2 
(MRLC2), mRNA. 
5.13E-06 2.2829878 up 
9553 MRPL33 Homo sapiens mitochondrial ribosomal protein L33 
(MRPL33), nuclear gene encoding mitochondrial 
protein, transcript variant 1, mRNA. 
5.13E-06 2.1818852 up 
84311 MRPL45 Homo sapiens mitochondrial ribosomal protein L45 
(MRPL45), nuclear gene encoding mitochondrial 
protein, mRNA. 
7.25E-06 2.4148643 down 
28973 MRPS18B Homo sapiens mitochondrial ribosomal protein 
S18B (MRPS18B), nuclear gene encoding 
mitochondrial protein, mRNA. 
5.13E-06 2.0923276 down 
10335 MRVI1 Homo sapiens murine retrovirus integration site 1 
homolog (MRVI1), transcript variant 2, mRNA. 
1.2E-03 2.9061346 up 
51338 MS4A4A Homo sapiens membrane-spanning 4-domains, 
subfamily A, member 4 (MS4A4A), transcript 
variant 2, mRNA. 
1.00E-04 14.504632 up 
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64231 MS4A6A Homo sapiens membrane-spanning 4-domains, 
subfamily A, member 6A (MS4A6A), transcript 
variant 3, mRNA. 
2.02E-05 2.68408 up 
64231 MS4A6A Homo sapiens membrane-spanning 4-domains, 
subfamily A, member 6A (MS4A6A), transcript 
variant 3, mRNA. 
3.80E-04 2.3065014 up 
64231 MS4A6A Homo sapiens membrane-spanning 4-domains, 
subfamily A, member 6A (MS4A6A), transcript 
variant 2, mRNA. 
8.52E-04 2.201362 up 
10943 MSL3L1 Homo sapiens male-specific lethal 3-like 1 
(Drosophila) (MSL3L1), transcript variant 2, mRNA. 
6.40E-05 2.547183 up 
10943 MSL3L1 Homo sapiens male-specific lethal 3-like 1 
(Drosophila) (MSL3L1), transcript variant 2, mRNA. 
1.84E-03 2.0834074 up 
10943 MSL3L1 Homo sapiens male-specific lethal 3-like 1 
(Drosophila) (MSL3L1), transcript variant 4, mRNA. 
2.37E-04 2.017259 up 
4482 MSRA Homo sapiens methionine sulfoxide reductase A 
(MSRA), mRNA. 
7.68E-06 2.7363937 up 
22921 MSRB2 Homo sapiens methionine sulfoxide reductase B2 
(MSRB2), mRNA. 
7.68E-06 3.0750158 up 
9112 MTA1 Homo sapiens metastasis associated 1 (MTA1), 
mRNA. 
5.13E-06 2.1497588 down 
4520 MTF1 Homo sapiens metal-regulatory transcription factor 
1 (MTF1), mRNA. 
5.35E-06 2.7945697 up 
10797 MTHFD2 Homo sapiens methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
(MTHFD2), nuclear gene encoding mitochondrial 
protein, transcript variant 2, mRNA. 
1.43E-05 2.7215648 up 
10797 MTHFD2 Homo sapiens methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
(MTHFD2), nuclear gene encoding mitochondrial 
protein, mRNA. 
1.08E-05 3.0921478 up 
10588 MTHFS Homo sapiens 5,10-methenyltetrahydrofolate 
synthetase (5-formyltetrahydrofolate cyclo-ligase) 
(MTHFS), mRNA. 
5.13E-06 3.9467278 up 
8897 MTMR3 Homo sapiens myotubularin related protein 3 
(MTMR3), transcript variant 1, mRNA. 
9.10E-06 2.5437033 up 
9107 MTMR6 Homo sapiens myotubularin related protein 6 
(MTMR6), mRNA. 
7.68E-06 2.627167 up 
4580 MTX1 Homo sapiens metaxin 1 (MTX1), transcript variant 
1, mRNA. 
5.27E-06 2.3217897 up 
4580 MTX1 Homo sapiens metaxin 1 (MTX1), transcript variant 
1, mRNA. 
8.44E-06 2.179208 up 
4599 MX1 Homo sapiens myxovirus (influenza virus) 
resistance 1, interferon-inducible protein p78 
(mouse) (MX1), mRNA. 
2.02E-05 4.646171 down 
4084 MXD1 Homo sapiens MAX dimerization protein 1 (MXD1), 
mRNA. 
1.66E-05 2.5458531 up 
83463 MXD3 Homo sapiens MAX dimerization protein 3 (MXD3), 
mRNA. 
4.54E-04 2.3566873 up 
10608 MXD4 Homo sapiens MAX dimerization protein 4 (MXD4), 
mRNA. 
5.13E-06 2.4440863 down 
4607 MYBPC3 Homo sapiens myosin binding protein C, cardiac 
(MYBPC3), mRNA. 
2.71E-04 2.8825052 up 
4609 MYC Homo sapiens v-myc myelocytomatosis viral 
oncogene homolog (avian) (MYC), mRNA. 
2.61E-04 2.1767058 down 
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4615 MYD88 Homo sapiens myeloid differentiation primary 
response gene (88) (MYD88), mRNA. 
5.27E-06 2.5324733 up 
4637 MYL6 Homo sapiens myosin, light chain 6, alkali, smooth 
muscle and non-muscle (MYL6), transcript variant 
1, mRNA. 
5.27E-06 3.1343985 up 
4637 MYL6 Homo sapiens myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle (MYL6), transcript 
variant 1, mRNA. 
5.27E-06 3.2141292 up 
27099 NAG8 Homo sapiens nasopharyngeal carcinoma 
associated gene protein-8 (NAG8), mRNA. 
2.18E-05 2.209735 down 
4671 NAIP Homo sapiens NLR family, apoptosis inhibitory 
protein (NAIP), transcript variant 1, mRNA. 
1.31E-02 3.9546847 up 
91662 NALP12 Homo sapiens NLR family, pyrin domain containing 
12 (NLRP12), transcript variant 2, mRNA. 
1.11E-04 2.534172 up 
91662 NALP12 Homo sapiens NLR family, pyrin domain containing 
12 (NLRP12), transcript variant 1, mRNA. 
1.01E-04 2.507363 up 
54187 NANS Homo sapiens N-acetylneuraminic acid synthase 
(sialic acid synthase) (NANS), mRNA. 
5.13E-06 2.6940114 up 
93100 NAPRT1 Homo sapiens nicotinate 
phosphoribosyltransferase domain containing 1 
(NAPRT1), mRNA. 
6.74E-06 2.6154768 up 
55226 NAT10 Homo sapiens N-acetyltransferase 10 (NAT10), 
mRNA. 
5.35E-06 2.4969296 down 
4683 NBN Homo sapiens nibrin (NBN), transcript variant 2, 
mRNA. 
3.18E-05 2.2353945 up 
83988 NCALD Homo sapiens neurocalcin delta (NCALD), 
transcript variant 3, mRNA. 
6.15E-03 3.7176452 down 
83988 NCALD Homo sapiens neurocalcin delta (NCALD), mRNA. 1.31E-03 3.8601446 down 
4688 NCF2 Homo sapiens neutrophil cytosolic factor 2 (65kDa, 
chronic granulomatous disease, autosomal 2) 
(NCF2), mRNA. 
9.15E-05 2.9413908 up 
4689 NCF4 Homo sapiens neutrophil cytosolic factor 4, 40kDa 
(NCF4), transcript variant 2, mRNA. 
5.17E-05 2.687491 up 
4689 NCF4 Homo sapiens neutrophil cytosolic factor 4, 40kDa 
(NCF4), transcript variant 1, mRNA. 
7.68E-06 3.285344 up 
259197 NCR3 Homo sapiens natural cytotoxicity triggering 
receptor 3 (NCR3), mRNA. 
2.16E-03 2.9139197 down 
10397 NDRG1 Homo sapiens N-myc downstream regulated gene 
1 (NDRG1), mRNA. 
5.35E-06 2.5748284 up 
4694 NDUFA1 Homo sapiens NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex, 1, 7.5kDa (NDUFA1), nuclear 
gene encoding mitochondrial protein, mRNA. 
5.47E-06 2.285143 up 
4697 NDUFA4 Homo sapiens NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex, 4, 9kDa (NDUFA4), nuclear 
gene encoding mitochondrial protein, mRNA. 
1.62E-04 2.5491014 up 
4709 NDUFB3 Homo sapiens NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 3, 12kDa (NDUFB3), mRNA. 
5.13E-06 6.483008 up 
4734 NEDD4 Homo sapiens neural precursor cell expressed, 
developmentally downregulated 4 (NEDD4), 
transcript variant 2, mRNA. 
1.09E-02 3.3570197 up 
26012 NELF Homo sapiens nasal embryonic LHRH factor (NELF), 
mRNA. 
5.43E-05 2.201417 down 
4753 NELL2 Homo sapiens NEL-like 2 (chicken) (NELL2), mRNA. 1.29E-04 4.6984506 down 
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4758 NEU1 Homo sapiens sialidase 1 (lysosomal sialidase) 
(NEU1), mRNA. 
5.27E-06 2.4314654 up 
4778 NFE2 Homo sapiens nuclear factor (erythroid-derived 2), 
45kDa (NFE2), mRNA. 
5.35E-06 3.1501188 up 
4783 NFIL3 Homo sapiens nuclear factor, interleukin 3 
regulated (NFIL3), mRNA. 
1.52E-05 3.5821507 up 
64332 NFKBIZ Homo sapiens nuclear factor of kappa light 
polypeptide gene enhancer in B-cells inhibitor, zeta 
(NFKBIZ), transcript variant 2, mRNA. 
2.63E-05 2.0495923 up 
9054 NFS1 Homo sapiens NFS1 nitrogen fixation 1 (S. 
cerevisiae) (NFS1), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
5.13E-06 5.309156 down 
4815 NINJ2 Homo sapiens ninjurin 2 (NINJ2), mRNA. 2.63E-05 3.1039634 up 
4824 NKX3-1 Homo sapiens NK3 homeobox 1 (NKX3-1), mRNA. 1.66E-02 2.712998 down 
64802 NMNAT1 Homo sapiens nicotinamide nucleotide 
adenylyltransferase 1 (NMNAT1), mRNA. 
4.0E-02 2.0726485 up 
10528 NOL5A Homo sapiens nucleolar protein 5A (56kDa with 
KKE/D repeat) (NOL5A), mRNA. 
1.52E-05 2.0307097 down 
54433 NOLA1 Homo sapiens nucleolar protein family A, member 
1 (H/ACA small nucleolar RNPs) (NOLA1), transcript 
variant 2, mRNA. 
2.98E-05 2.2350466 down 
55505 NOLA3 Homo sapiens nucleolar protein family A, member 
3 (H/ACA small nucleolar RNPs) (NOLA3), mRNA. 
5.13E-06 3.0532568 up 
57185 NPAL3 Homo sapiens NIPA-like domain containing 3 
(NPAL3), mRNA. 
5.13E-06 3.2218988 down 
4863 NPAT Homo sapiens nuclear protein, ataxia-
telangiectasia locus (NPAT), mRNA. 
1.51E-05 2.1471682 down 
9284 NPIP Homo sapiens nuclear pore complex interacting 
protein (NPIP), mRNA. 
7.25E-06 2.1705399 down 
80896 NPL Homo sapiens N-acetylneuraminate pyruvate lyase 
(dihydrodipicolinate synthase) (NPL), mRNA. 
7.68E-06 2.8866994 up 
27020 NPTN Homo sapiens neuroplastin (NPTN), transcript 
variant alpha, mRNA. 
6.31E-06 2.8675702 up 
4835 NQO2 Homo sapiens NAD(P)H dehydrogenase, quinone 2 
(NQO2), mRNA. 
3.27E-05 5.2974734 up 
4898 NRD1 Homo sapiens nardilysin (N-arginine dibasic 
convertase) (NRD1), mRNA. 
5.13E-06 2.2504551 up 
79685 NS4ATP2 Homo sapiens SAP30-like (SAP30L), mRNA. 5.35E-06 2.243592 up 
79730 NSUN7 Homo sapiens NOL1/NOP2/Sun domain family, 
member 7 (NSUN7), mRNA. 
2.20E-04 8.276363 up 
10908 NTE Homo sapiens neuropathy target esterase (NTE), 
mRNA. 
5.13E-06 3.7707965 up 
131870 NUDT16 Homo sapiens nudix (nucleoside diphosphate 
linked moiety X)-type motif 16 (NUDT16), mRNA. 
7.45E-03 2.312262 up 
11164 NUDT5 Homo sapiens nudix (nucleoside diphosphate 
linked moiety X)-type motif 5 (NUDT5), mRNA. 
9.97E-06 2.22799 up 
8650 NUMB Homo sapiens numb homolog (Drosophila) 
(NUMB), transcript variant 3, mRNA. 
1.28E-05 2.5121162 up 
8021 NUP214 Homo sapiens nucleoporin 214kDa (NUP214), 
mRNA. 
1.82E-05 2.5839055 up 
9688 NUP93 Homo sapiens nucleoporin 93kDa (NUP93), mRNA. 7.68E-06 2.0916955 down 
55916 NXT2 Homo sapiens nuclear transport factor 2-like 
export factor 2 (NXT2), mRNA. 
1.52E-05 2.4291992 up 
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10162 OACT5 Homo sapiens membrane bound O-acyltransferase 
domain containing 5 (MBOAT5), mRNA. 
2.61E-04 2.0393162 up 
4939 OAS2 Homo sapiens 2'-5'-oligoadenylate synthetase 2, 
69/71kDa (OAS2), transcript variant 1, mRNA. 
7.25E-06 4.486012 down 
4939 OAS2 Homo sapiens 2'-5'-oligoadenylate synthetase 2, 
69/71kDa (OAS2), transcript variant 3, mRNA. 
2.04E-03 2.6828973 down 
4942 OAT Homo sapiens ornithine aminotransferase (gyrate 
atrophy) (OAT), nuclear gene encoding 
mitochondrial protein, mRNA. 
1.00E-05 3.0850742 up 
64859 OBFC2A Homo sapiens oligonucleotide/oligosaccharide-
binding fold containing 2A (OBFC2A), transcript 
variant 2, mRNA. 
6.74E-06 3.4310498 up 
132299 OCIAD2 Homo sapiens OCIA domain containing 2 (OCIAD2), 
transcript variant 1, mRNA. 
1.52E-05 2.9381084 down 
132299 OCIAD2 Homo sapiens OCIA domain containing 2 (OCIAD2), 
transcript variant 2, mRNA. 
2.32E-05 2.5999365 down 
10562 OLFM4 Homo sapiens olfactomedin 4 (OLFM4), mRNA. 8.93E-05 46.051617 up 
26873 OPLAH Homo sapiens 5-oxoprolinase (ATP-hydrolysing) 
(OPLAH), mRNA. 
1.84E-03 8.579143 up 
4987 OPRL1 Homo sapiens opiate receptor-like 1 (OPRL1), 
transcript variant 2, mRNA. 
4.26E-05 2.3806522 up 
343169 OR6F1 Homo sapiens olfactory receptor, family 6, 
subfamily F, member 1 (OR6F1), mRNA. 
1.43E-02 2.2932305 up 
84418 ORF1-FL49 Homo sapiens putative nuclear protein ORF1-FL49 
(ORF1-FL49), mRNA. 
5.13E-06 22.005098 up 
5004 ORM1 Homo sapiens orosomucoid 1 (ORM1), mRNA. 1.62E-04 6.0118136 up 
114884 OSBPL10 Homo sapiens oxysterol binding protein-like 10 
(OSBPL10), mRNA. 
3.73E-04 2.2006912 down 
114885 OSBPL11 Homo sapiens oxysterol binding protein-like 11 
(OSBPL11), mRNA. 
7.68E-06 2.261094 up 
114879 OSBPL5 Homo sapiens oxysterol binding protein-like 5 
(OSBPL5), transcript variant 1, mRNA. 
5.15E-05 2.0881977 down 
114881 OSBPL7 Homo sapiens oxysterol binding protein-like 7 
(OSBPL7), transcript variant 1, mRNA. 
8.66E-06 2.5939014 down 
114882 OSBPL8 Homo sapiens oxysterol binding protein-like 8 
(OSBPL8), transcript variant 1, mRNA. 
2.17E-04 2.068802 up 
126014 OSCAR Homo sapiens osteoclast-associated receptor 
(OSCAR), transcript variant 3, mRNA. 
5.13E-06 5.1018496 up 
126014 OSCAR Homo sapiens osteoclast-associated receptor 
(OSCAR), transcript variant 4, mRNA. 
5.13E-06 4.6895657 up 
5008 OSM Homo sapiens oncostatin M (OSM), mRNA. 2.99E-04 4.1150975 up 
26578 OSTF1 Homo sapiens osteoclast stimulating factor 1 
(OSTF1), mRNA. 
5.47E-06 2.2837226 up 
5023 P2RX1 Homo sapiens purinergic receptor P2X, ligand-
gated ion channel, 1 (P2RX1), mRNA. 
1.82E-05 3.342325 up 
27334 P2RY10 Homo sapiens purinergic receptor P2Y, G-protein 
coupled, 10 (P2RY10), transcript variant 2, mRNA. 
3.90E-05 2.5403025 down 
53829 P2RY13 Homo sapiens purinergic receptor P2Y, G-protein 
coupled, 13 (P2RY13), transcript variant 2, mRNA. 
2.20E-05 3.1893687 up 
53829 P2RY13 Homo sapiens purinergic receptor P2Y, G-protein 
coupled, 13 (P2RY13), transcript variant 2, mRNA. 
6.31E-06 2.8593702 up 
286530 P2RY8 Homo sapiens purinergic receptor P2Y, G-protein 
coupled, 8 (P2RY8), mRNA. 
5.27E-06 2.86355 down 
245 
 
5033 P4HA1 Homo sapiens procollagen-proline, 2-oxoglutarate 
4-dioxygenase (proline 4-hydroxylase), alpha 
polypeptide I (P4HA1), transcript variant 1, mRNA. 
5.47E-06 2.4326131 up 
23569 PADI4 Homo sapiens peptidyl arginine deiminase, type IV 
(PADI4), mRNA. 
5.13E-06 5.0578814 up 
55824 PAG1 Homo sapiens phosphoprotein associated with 
glycosphingolipid microdomains 1 (PAG1), mRNA. 
6.74E-06 3.1861682 up 
23022 PALLD Homo sapiens palladin, cytoskeletal associated 
protein (PALLD), mRNA. 
5.77E-04 2.9062388 up 
5066 PAM Homo sapiens peptidylglycine alpha-amidating 
monooxygenase (PAM), transcript variant 3, 
mRNA. 
1.47E-04 2.491062 up 
196743 PAOX Homo sapiens polyamine oxidase (exo-N4-amino) 
(PAOX), transcript variant 5, mRNA. 
1.00E-05 2.515569 down 
167153 PAPD4 Homo sapiens PAP associated domain containing 4 
(PAPD4), mRNA. 
8.33E-05 2.0042925 up 
9061 PAPSS1 Homo sapiens 3'-phosphoadenosine 5'-
phosphosulfate synthase 1 (PAPSS1), mRNA. 
6.74E-06 3.177851 up 
85315 PAQR8 Homo sapiens progestin and adipoQ receptor 
family member VIII (PAQR8), mRNA. 
5.13E-06 3.165916 down 
142 PARP1 Homo sapiens poly (ADP-ribose) polymerase 
family, member 1 (PARP1), mRNA. 
7.25E-06 2.222497 down 
64761 PARP12 Homo sapiens poly (ADP-ribose) polymerase 
family, member 12 (PARP12), mRNA. 
2.20E-05 2.5176356 down 
54625 PARP14 Homo sapiens poly (ADP-ribose) polymerase 
family, member 14 (PARP14), mRNA. 
1.03E-04 2.6842163 down 
23178 PASK Homo sapiens PAS domain containing 
serine/threonine kinase (PASK), mRNA. 
2.22E-02 2.0209374 down 
10135 PBEF1 Homo sapiens pre-B-cell colony enhancing factor 1 
(PBEF1), transcript variant 2, mRNA. 
3.09E-04 3.2584221 up 
10135 PBEF1 Homo sapiens pre-B-cell colony enhancing factor 1 
(PBEF1), transcript variant 1, mRNA. 
1.82E-05 3.9533381 up 
5110 PCMT1 Homo sapiens protein-L-isoaspartate (D-aspartate) 
O-methyltransferase (PCMT1), mRNA. 
5.13E-06 3.1363792 up 
5116 PCNT2 Homo sapiens pericentrin 2 (kendrin) (PCNT2), 
mRNA. 
3.06E-05 2.0909164 down 
22990 PCNX Homo sapiens pecanex homolog (Drosophila) 
(PCNX), mRNA. 
8.44E-06 2.7226713 up 
58488 PCTP Homo sapiens phosphatidylcholine transfer protein 
(PCTP), mRNA. 
5.35E-06 3.1773274 up 
11235 PDCD10 Homo sapiens programmed cell death 10 
(PDCD10), transcript variant 3, mRNA. 
1.52E-05 3.3001914 up 
11235 PDCD10 Homo sapiens programmed cell death 10 
(PDCD10), transcript variant 3, mRNA. 
3.15E-04 2.277614 up 
5144 PDE4D Homo sapiens phosphodiesterase 4D, cAMP-
specific (phosphodiesterase E3 dunce homolog, 
Drosophila) (PDE4D), mRNA. 
1.21E-04 3.0916307 up 
5150 PDE7A Homo sapiens phosphodiesterase 7A (PDE7A), 
transcript variant 2, mRNA. 
7.25E-06 2.3359962 down 
56034 PDGFC Homo sapiens platelet derived growth factor C 
(PDGFC), mRNA. 
3.59E-02 4.8675795 up 
5166 PDK4 Homo sapiens pyruvate dehydrogenase kinase, 
isozyme 4 (PDK4), mRNA. 
3.48E-03 2.0584395 up 
9260 PDLIM7 Homo sapiens PDZ and LIM domain 7 (enigma) 
(PDLIM7), transcript variant 4, mRNA. 
3.93E-02 2.5412924 up 
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9260 PDLIM7 Homo sapiens PDZ and LIM domain 7 (enigma) 
(PDLIM7), transcript variant 4, mRNA. 
8.44E-06 4.006498 up 
23590 PDSS1 Homo sapiens prenyl (decaprenyl) diphosphate 
synthase, subunit 1 (PDSS1), mRNA. 
4.60E-05 7.2587 up 
57026 PDXP Homo sapiens pyridoxal (pyridoxine, vitamin B6) 
phosphatase (PDXP), mRNA. 
1.17E-05 2.230238 down 
118987 PDZD8 Homo sapiens PDZ domain containing 8 (PDZD8), 
mRNA. 
5.42E-05 2.796286 up 
5037 PEBP1 Homo sapiens phosphatidylethanolamine binding 
protein 1 (PEBP1), mRNA. 
5.47E-06 2.9926214 down 
10455 PECI Homo sapiens peroxisomal D3,D2-enoyl-CoA 
isomerase (PECI), transcript variant 1, mRNA. 
5.47E-06 2.3400588 down 
55825 PECR Homo sapiens peroxisomal trans-2-enoyl-CoA 
reductase (PECR), mRNA. 
5.13E-06 3.5108263 up 
57162 PELI1 Homo sapiens pellino homolog 1 (Drosophila) 
(PELI1), mRNA. 
3.80E-04 2.1798205 up 
53918 PELO Homo sapiens pelota homolog (Drosophila) (PELO), 
mRNA. 
1.17E-05 2.2285235 up 
27043 PELP1 Homo sapiens proline, glutamic acid and leucine 
rich protein 1 (PELP1), mRNA. 
7.25E-06 2.1486166 down 
93210 PERLD1 Homo sapiens per1-like domain containing 1 
(PERLD1), mRNA. 
1.34E-04 2.728937 down 
5209 PFKFB3 Homo sapiens 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 3 (PFKFB3), mRNA. 
5.13E-06 8.613797 up 
5210 PFKFB4 Homo sapiens 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 4 (PFKFB4), mRNA. 
6.31E-06 2.951753 up 
5218 PFTK1 Homo sapiens PFTAIRE protein kinase 1 (PFTK1), 
mRNA. 
1.35E-02 2.0808308 up 
5223 PGAM1 Homo sapiens phosphoglycerate mutase 1 (brain) 
(PGAM1), mRNA. 
2.20E-05 2.3780184 up 
441531 PGAM4 Homo sapiens phosphoglycerate mutase family 
member 4 (PGAM4), mRNA. 
7.32E-05 2.4739196 up 
5226 PGD Homo sapiens phosphogluconate dehydrogenase 
(PGD), mRNA. 
5.13E-06 7.489585 up 
5230 PGK1 Homo sapiens phosphoglycerate kinase 1 (PGK1), 
mRNA. 
5.13E-06 3.5695384 up 
8993 PGLYRP1 Homo sapiens peptidoglycan recognition protein 1 
(PGLYRP1), mRNA. 
5.13E-06 7.912276 up 
5236 PGM1 Homo sapiens phosphoglucomutase 1 (PGM1), 
mRNA. 
2.63E-05 2.081716 up 
55276 PGM2 Homo sapiens phosphoglucomutase 2 (PGM2), 
mRNA. 
5.27E-06 3.8444664 up 
9489 PGS1 Homo sapiens phosphatidylglycerophosphate 
synthase 1 (PGS1), mRNA. 
5.13E-06 5.2845798 up 
9749 PHACTR2 Homo sapiens phosphatase and actin regulator 2 
(PHACTR2), mRNA. 
1.67E-05 2.3536258 up 
1912 PHC2 Homo sapiens polyhomeotic-like 2 (Drosophila) 
(PHC2), transcript variant 1, mRNA. 
5.35E-06 3.3056862 up 
55331 PHCA Homo sapiens phytoceramidase, alkaline (PHCA), 
mRNA. 
5.13E-06 7.555555 up 
23338 PHF15 Homo sapiens PHD finger protein 15 (PHF15), 
mRNA. 
7.25E-06 2.9041357 down 
26147 PHF19 Homo sapiens PHD finger protein 19 (PHF19), 
transcript variant 2, mRNA. 
8.33E-05 2.2902544 up 
51105 PHF20L1 Homo sapiens PHD finger protein 20-like 1 
(PHF20L1), transcript variant 1, mRNA. 
2.20E-05 2.5001652 up 
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10745 PHTF1 Homo sapiens putative homeodomain 
transcription factor 1 (PHTF1), mRNA. 
7.25E-04 3.4732292 up 
5266 PI3 Homo sapiens peptidase inhibitor 3, skin-derived 
(SKALP) (PI3), mRNA. 
5.17E-05 9.3671 up 
8301 PICALM Homo sapiens phosphatidylinositol binding clathrin 
assembly protein (PICALM), transcript variant 1, 
mRNA. 
4.44E-03 2.0091095 up 
5281 PIGF Homo sapiens phosphatidylinositol glycan, class F 
(PIGF), transcript variant 2, mRNA. 
5.13E-06 2.3407953 up 
118788 PIK3AP1 Homo sapiens phosphoinositide-3-kinase adaptor 
protein 1 (PIK3AP1), mRNA. 
5.13E-06 3.4233067 up 
5292 PIM1 Homo sapiens pim-1 oncogene (PIM1), mRNA. 7.57E-05 2.1284213 up 
415116 PIM3 Homo sapiens pim-3 oncogene (PIM3), mRNA. 5.13E-06 3.4440582 up 
57605 PITPNM2 Homo sapiens phosphatidylinositol transfer 
protein, membrane-associated 2 (PITPNM2), 
mRNA. 
2.42E-05 2.345636 up 
9867 PJA2 Homo sapiens praja 2, RING-H2 motif containing 
(PJA2), mRNA. 
1.82E-05 2.2998512 up 
5569 PKIA Homo sapiens protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha (PKIA), transcript variant 
7, mRNA. 
2.42E-05 3.220068 down 
5569 PKIA Homo sapiens protein kinase (cAMP-dependent, 
catalytic) inhibitor alpha (PKIA), transcript variant 
6, mRNA. 
1.71E-03 2.0854526 down 
5315 PKM2 Homo sapiens pyruvate kinase, muscle (PKM2), 
transcript variant 3, mRNA. 
7.25E-06 2.279943 up 
5315 PKM2 Homo sapiens pyruvate kinase, muscle (PKM2), 
transcript variant 1, mRNA. 
1.38E-04 2.0353124 up 
8681 PLA2G4B Homo sapiens phospholipase A2, group IVB 
(cytosolic) (PLA2G4B), mRNA. 
4.47E-05 2.3315077 down 
51316 PLAC8 Homo sapiens placenta-specific 8 (PLAC8), mRNA. 5.13E-06 3.692069 up 
5329 PLAUR Homo sapiens plasminogen activator, urokinase 
receptor (PLAUR), transcript variant 2, mRNA. 
8.33E-05 2.0735471 up 
5329 PLAUR Homo sapiens plasminogen activator, urokinase 
receptor (PLAUR), transcript variant 2, mRNA. 
1.82E-05 2.2523324 up 
5329 PLAUR Homo sapiens plasminogen activator, urokinase 
receptor (PLAUR), transcript variant 1, mRNA. 
2.91e-03 2.1392767 up 
5335 PLCG1 Homo sapiens phospholipase C, gamma 1 (PLCG1), 
transcript variant 1, mRNA. 
1.12E-03 2.7355645 down 
59338 PLEKHA1 Homo sapiens pleckstrin homology domain 
containing, family A (phosphoinositide binding 
specific) member 1 (PLEKHA1), transcript variant 1, 
mRNA. 
5.13E-06 3.9215834 down 
59338 PLEKHA1 Homo sapiens pleckstrin homology domain 
containing, family A (phosphoinositide binding 
specific) member 1 (PLEKHA1), transcript variant 2, 
mRNA. 
1.67E-05 3.0099254 down 
55041 PLEKHB2 Homo sapiens pleckstrin homology domain 
containing, family B (evectins) member 2 
(PLEKHB2), transcript variant 1, mRNA. 
3.42E-05 2.2464712 up 
79156 PLEKHF1 Homo sapiens pleckstrin homology domain 
containing, family F (with FYVE domain) member 1 
(PLEKHF1), mRNA. 
1.34E-04 3.2834024 down 
51177 PLEKHO1 Homo sapiens pleckstrin homology domain 
containing, family O member 1 (PLEKHO1), mRNA. 
5.47E-06 2.2154317 down 
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80301 PLEKHQ1 Homo sapiens pleckstrin homology domain 
containing, family Q member 1 (PLEKHQ1), mRNA. 
6.74E-06 2.5815039 up 
5351 PLOD1 Homo sapiens procollagen-lysine 1, 2-oxoglutarate 
5-dioxygenase 1 (PLOD1), mRNA. 
2.63E-05 2.609169 up 
5355 PLP2 Homo sapiens proteolipid protein 2 (colonic 
epithelium-enriched) (PLP2), mRNA. 
5.13E-06 4.525847 up 
5359 PLSCR1 Homo sapiens phospholipid scramblase 1 (PLSCR1), 
mRNA. 
2.25e-02 2.221066 up 
57048 PLSCR3 Homo sapiens phospholipid scramblase 3 (PLSCR3), 
mRNA. 
5.13E-06 2.0319176 down 
10154 PLXNC1 Homo sapiens plexin C1 (PLXNC1), mRNA. 1.39E-03 2.3656461 up 
25953 PNKD Homo sapiens paroxysmal nonkinesiogenic 
dyskinesia (PNKD), transcript variant 2, mRNA. 
7.25E-06 2.7308388 up 
50640 PNPLA8 Homo sapiens patatin-like phospholipase domain 
containing 8 (PNPLA8), mRNA. 
4.53E-05 2.0974667 up 
9533 POLR1C Homo sapiens polymerase (RNA) I polypeptide C, 
30kDa (POLR1C), transcript variant 1, mRNA. 
1.52E-05 2.1059377 down 
64425 POLR1E Homo sapiens polymerase (RNA) I polypeptide E, 
53kDa (POLR1E), mRNA. 
5.47E-06 2.5342016 down 
171568 POLR3H Homo sapiens polymerase (RNA) III (DNA directed) 
polypeptide H (22.9kD) (POLR3H), transcript 
variant 1, mRNA. 
2.90E-05 2.0133684 down 
5442 POLRMT Homo sapiens polymerase (RNA) mitochondrial 
(DNA directed) (POLRMT), nuclear gene encoding 
mitochondrial protein, mRNA. 
1.09E-05 2.1016157 down 
55624 POMGNT1 Homo sapiens protein O-linked mannose beta1,2-
N-acetylglucosaminyltransferase (POMGNT1), 
mRNA. 
7.25E-06 2.089137 down 
5447 POR Homo sapiens P450 (cytochrome) oxidoreductase 
(POR), mRNA. 
5.13E-06 4.7600846 up 
27068 PPA2 Homo sapiens inorganic pyrophosphatase 2 
(PPA2), transcript variant 2, mRNA. 
8.44E-06 2.362274 up 
8495 PPFIBP2 Homo sapiens PTPRF interacting protein, binding 
protein 2 (liprin beta 2) (PPFIBP2), mRNA. 
5.88E-06 2.0940454 down 
5476 PPGB Homo sapiens protective protein for beta-
galactosidase (galactosialidosis) (PPGB), mRNA. 
3.46E-04 2.035785 up 
5495 PPM1B Homo sapiens protein phosphatase 1B (formerly 
2C), magnesium-dependent, beta isoform 
(PPM1B), transcript variant 2, mRNA. 
2.63E-05 2.0785377 up 
132160 PPM1M Homo sapiens protein phosphatase 1M (PP2C 
domain containing) (PPM1M), mRNA. 
5.13E-06 3.082389 up 
4659 PPP1R12A Homo sapiens protein phosphatase 1, regulatory 
(inhibitor) subunit 12A (PPP1R12A), mRNA. 
1.09E-05 2.7240088 up 
26051 PPP1R16B Homo sapiens protein phosphatase 1, regulatory 
(inhibitor) subunit 16B (PPP1R16B), mRNA. 
5.47E-06 2.5043619 down 
5509 PPP1R3D Homo sapiens protein phosphatase 1, regulatory 
(inhibitor) subunit 3D (PPP1R3D), mRNA. 
1.39E-05 2.3330824 up 
5515 PPP2CA Homo sapiens protein phosphatase 2 (formerly 
2A), catalytic subunit, alpha isoform (PPP2CA), 
mRNA. 
7.68E-06 2.0384812 up 
55012 PPP2R3C Homo sapiens protein phosphatase 2 (formerly 
2A), regulatory subunit B'', gamma (PPP2R3C), 
mRNA. 
5.13E-06 2.3775802 up 
5525 PPP2R5A Homo sapiens protein phosphatase 2, regulatory 
subunit B', alpha isoform (PPP2R5A), mRNA. 
5.27E-06 2.0492773 up 
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5533 PPP3CC Homo sapiens protein phosphatase 3 (formerly 
2B), catalytic subunit, gamma isoform (PPP3CC), 
mRNA. 
2.51E-05 2.3324587 down 
9989 PPP4R1 Homo sapiens protein phosphatase 4, regulatory 
subunit 1 (PPP4R1), mRNA. 
6.74E-06 2.503474 up 
9989 PPP4R1 Homo sapiens protein phosphatase 4, regulatory 
subunit 1 (PPP4R1), mRNA. 
1.17E-05 2.4836266 up 
23082 PPRC1 Homo sapiens peroxisome proliferator-activated 
receptor gamma, coactivator-related 1 (PPRC1), 
mRNA. 
7.75E-06 2.2690568 down 
84106 PRAM1 Homo sapiens PML-RARA regulated adaptor 
molecule 1 (PRAM1), mRNA. 
1.52E-05 2.7370472 up 
9055 PRC1 Homo sapiens protein regulator of cytokinesis 1 
(PRC1), transcript variant 1, mRNA. 
1.53E-04 2.332725 up 
5547 PRCP Homo sapiens prolylcarboxypeptidase 
(angiotensinase C) (PRCP), transcript variant 1, 
mRNA. 
5.35E-06 2.48072 up 
5547 PRCP Homo sapiens prolylcarboxypeptidase 
(angiotensinase C) (PRCP), transcript variant 2, 
mRNA. 
5.35E-06 2.284883 up 
10935 PRDX3 Homo sapiens peroxiredoxin 3 (PRDX3), nuclear 
gene encoding mitochondrial protein, transcript 
variant 1, mRNA. 
3.50E-05 2.2023947 up 
25824 PRDX5 Homo sapiens peroxiredoxin 5 (PRDX5), nuclear 
gene encoding mitochondrial protein, transcript 
variant 3, mRNA. 
5.35E-06 2.0069947 up 
5551 PRF1 Homo sapiens perforin 1 (pore forming protein) 
(PRF1), mRNA. 
7.25E-06 4.4908586 down 
5562 PRKAA1 Homo sapiens protein kinase, AMP-activated, 
alpha 1 catalytic subunit (PRKAA1), transcript 
variant 2, mRNA. 
9.97E-06 2.0555694 up 
5576 PRKAR2A Homo sapiens protein kinase, cAMP-dependent, 
regulatory, type II, alpha (PRKAR2A), mRNA. 
1.68E-04 2.2692022 up 
5578 PRKCA Homo sapiens protein kinase C, alpha (PRKCA), 
mRNA. 
8.33E-05 2.1191745 down 
5580 PRKCD Homo sapiens protein kinase C, delta (PRKCD), 
transcript variant 2, mRNA. 
6.74E-06 2.4898765 up 
5583 PRKCH Homo sapiens protein kinase C, eta (PRKCH), 
mRNA. 
6.74E-06 2.521592 down 
55170 PRMT6 Homo sapiens protein arginine methyltransferase 6 
(PRMT6), mRNA. 
1.06E-04 2.032957 down 
29035 PRO0149 Homo sapiens chromosome 16 open reading frame 
72 (C16orf72), mRNA. 
2.63E-05 2.2502391 up 
60675 PROK2 Homo sapiens prokineticin 2 (PROK2), mRNA. 1.66E-05 3.53497 up 
27339 PRPF19 Homo sapiens PRP19/PSO4 pre-mRNA processing 
factor 19 homolog (S. cerevisiae) (PRPF19), mRNA. 
5.13E-06 2.4614246 down 
5678 PSG9 Homo sapiens pregnancy specific beta-1-
glycoprotein 9 (PSG9), mRNA. 
3.81E-05 2.53786 up 
5682 PSMA1 Homo sapiens proteasome (prosome, macropain) 
subunit, alpha type, 1 (PSMA1), transcript variant 
2, mRNA. 
6.13E-05 2.3995247 up 
5687 PSMA6 Homo sapiens proteasome (prosome, macropain) 
subunit, alpha type, 6 (PSMA6), mRNA. 
9.97E-06 3.1489394 up 
5698 PSMB9 Homo sapiens proteasome (prosome, macropain) 
subunit, beta type, 9 (large multifunctional 
peptidase 2) (PSMB9), transcript variant 1, mRNA. 
2.86E-04 2.0245085 down 
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5718 PSMD12 Homo sapiens proteasome (prosome, macropain) 
26S subunit, non-ATPase, 12 (PSMD12), mRNA. 
XM_946055 XM_946058 
5.13E-06 2.4008436 up 
5710 PSMD4 Homo sapiens proteasome (prosome, macropain) 
26S subunit, non-ATPase, 4 (PSMD4), transcript 
variant 1, mRNA. 
5.13E-06 2.008342 up 
5710 PSMD4 Homo sapiens proteasome (prosome, macropain) 
26S subunit, non-ATPase, 4 (PSMD4), mRNA. 
5.13E-06 2.055561 up 
9861 PSMD6 Homo sapiens proteasome (prosome, macropain) 
26S subunit, non-ATPase, 6 (PSMD6), mRNA. 
5.13E-06 2.1160266 up 
9050 PSTPIP2 Homo sapiens proline-serine-threonine 
phosphatase interacting protein 2 (PSTPIP2), 
mRNA. 
5.47E-06 4.849586 up 
5724 PTAFR Homo sapiens platelet-activating factor receptor 
(PTAFR), mRNA. 
5.69E-05 2.4204898 up 
23210 PTDSR Homo sapiens phosphatidylserine receptor 
(PTDSR), mRNA. 
1.08E-02 2.7324207 up 
5728 PTEN Homo sapiens phosphatase and tensin homolog 
(mutated in multiple advanced cancers 1) (PTEN), 
mRNA. 
5.47E-06 2.9733253 up 
5732 PTGER2 Homo sapiens prostaglandin E receptor 2 (subtype 
EP2), 53kDa (PTGER2), mRNA. 
1.82E-05 2.6291232 up 
5747 PTK2 Homo sapiens PTK2 protein tyrosine kinase 2 
(PTK2), transcript variant 1, mRNA. 
7.68E-06 2.2727175 down 
5782 PTPN12 Homo sapiens protein tyrosine phosphatase, non-
receptor type 12 (PTPN12), mRNA. 
5.13E-06 3.5356245 up 
26191 PTPN22 Homo sapiens protein tyrosine phosphatase, non-
receptor type 22 (lymphoid) (PTPN22), transcript 
variant 1, mRNA. 
2.20E-05 2.430728 up 
26191 PTPN22 Homo sapiens protein tyrosine phosphatase, non-
receptor type 22 (lymphoid) (PTPN22), transcript 
variant 2, mRNA. 
5.81E-05 2.1528652 up 
5775 PTPN4 Homo sapiens protein tyrosine phosphatase, non-
receptor type 4 (megakaryocyte) (PTPN4), mRNA. 
5.35E-06 3.3845642 down 
140885 PTPNS1 Homo sapiens protein tyrosine phosphatase, non-
receptor type substrate 1 (PTPNS1), mRNA. 
6.74E-06 3.1488357 up 
140885 PTPNS1 Homo sapiens protein tyrosine phosphatase, non-
receptor type substrate 1 (PTPNS1), mRNA. 
5.27E-06 3.9575012 up 
5790 PTPRCAP Homo sapiens protein tyrosine phosphatase, 
receptor type, C-associated protein (PTPRCAP), 
mRNA. 
2.02E-05 2.6824536 down 
754 PTTG1IP Homo sapiens pituitary tumor-transforming 1 
interacting protein (PTTG1IP), mRNA. 
5.27E-06 2.1541073 up 
80324 PUS1 Homo sapiens pseudouridylate synthase 1 (PUS1), 
transcript variant 1, mRNA. 
9.10E-06 2.3368845 down 
54899 PXK Homo sapiens PX domain containing 
serine/threonine kinase (PXK), mRNA. 
9.03E-06 2.2016213 up 
5828 PXMP3 Homo sapiens peroxisomal membrane protein 3, 
35kDa (Zellweger syndrome) (PXMP3), mRNA. 
3.10E-05 2.2489338 up 
29108 PYCARD Homo sapiens PYD and CARD domain containing 
(PYCARD), transcript variant 2, mRNA. 
5.46E-04 2.1096709 up 
5836 PYGL Homo sapiens phosphorylase, glycogen; liver (Hers 
disease, glycogen storage disease type VI) (PYGL), 
mRNA. 
5.27E-06 4.1182103 up 
149628 PYHIN1 Homo sapiens pyrin and HIN domain family, 
member 1 (PYHIN1), transcript variant a1, mRNA. 
2.20E-04 3.2838683 down 
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149628 PYHIN1 Homo sapiens pyrin and HIN domain family, 
member 1 (PYHIN1), transcript variant b1, mRNA. 
1.06E-05 5.2302647 down 
27089 QP-C Homo sapiens low molecular mass ubiquinone-
binding protein (9.5kD) (QP-C), nuclear gene 
encoding mitochondrial protein, mRNA. 
9.29E-04 2.023069 up 
5768 QSCN6 Homo sapiens quiescin Q6 sulfhydryl oxidase 1 
(QSOX1), transcript variant 2, mRNA. 
5.13E-06 6.234041 up 
10890 RAB10 Homo sapiens RAB10, member RAS oncogene 
family (RAB10), mRNA. 
6.74E-06 2.2074714 up 
22841 RAB11FIP2 Homo sapiens RAB11 family interacting protein 2 
(class I) (RAB11FIP2), mRNA. 
7.63E-05 2.080287 up 
9727 RAB11FIP3 Homo sapiens RAB11 family interacting protein 3 
(class II) (RAB11FIP3), mRNA. 
5.35E-06 2.5425746 down 
5861 RAB1A Homo sapiens RAB1A, member RAS oncogene 
family (RAB1A), mRNA. 
2.95E-05 2.1740088 up 
5862 RAB2 Homo sapiens RAB2A, member RAS oncogene 
family (RAB2A), mRNA. 
3.47E-05 2.6897438 up 
55647 RAB20 Homo sapiens RAB20, member RAS oncogene 
family (RAB20), mRNA. 
4.44E-02 3.799992 up 
23011 RAB21 Homo sapiens RAB21, member RAS oncogene 
family (RAB21), mRNA. 
1.31E-05 2.2059155 up 
53917 RAB24 Homo sapiens RAB24, member RAS oncogene 
family (RAB24), transcript variant 2, mRNA. 
1.34E-04 2.096354 up 
53917 RAB24 Homo sapiens RAB24, member RAS oncogene 
family (RAB24), transcript variant 1, mRNA. 
1.66E-05 2.0745072 up 
5873 RAB27A Homo sapiens RAB27A, member RAS oncogene 
family (RAB27A), transcript variant 1, mRNA. 
9.10E-06 3.3393779 up 
11031 RAB31 Homo sapiens RAB31, member RAS oncogene 
family (RAB31), mRNA. 
5.13E-06 4.293371 up 
10981 RAB32 Homo sapiens RAB32, member RAS oncogene 
family (RAB32), mRNA. 
5.13E-06 4.4661 up 
83452 RAB33B Homo sapiens RAB33B, member RAS oncogene 
family (RAB33B), mRNA. 
3.87E-05 2.075901 up 
5866 RAB3IL1 Homo sapiens RAB3A interacting protein (rabin3)-
like 1 (RAB3IL1), mRNA. 
3.90E-03 2.310113 up 
117177 RAB3IP Homo sapiens RAB3A interacting protein (rabin3) 
(RAB3IP), transcript variant A, mRNA. 
3.06E-05 2.2733204 down 
5868 RAB5A Homo sapiens RAB5A, member RAS oncogene 
family (RAB5A), mRNA. 
4.22E-05 2.0943434 up 
5878 RAB5C Homo sapiens RAB5C, member RAS oncogene 
family (RAB5C), transcript variant 2, mRNA. 
5.27E-06 2.0098603 up 
5870 RAB6A Homo sapiens RAB6A, member RAS oncogene 
family (RAB6A), transcript variant 2, mRNA. 
7.68E-06 2.3078442 up 
51762 RAB8B Homo sapiens RAB8B, member RAS oncogene 
family (RAB8B), mRNA. 
7.68E-06 2.1526594 up 
10567 RABAC1 Homo sapiens Rab acceptor 1 (prenylated) 
(RABAC1), mRNA. 
5.17E-05 2.112801 up 
27342 RABGEF1 Homo sapiens RAB guanine nucleotide exchange 
factor (GEF) 1 (RABGEF1), mRNA. 
5.13E-06 3.7175806 up 
11159 RABL2A Homo sapiens RAB, member of RAS oncogene 
family-like 2A (RABL2A), transcript variant 1, 
mRNA. 
5.47E-06 2.2879565 down 
11158 RABL2B Homo sapiens RAB, member of RAS oncogene 
family-like 2B (RABL2B), transcript variant 2, 
mRNA. 
5.48E-06 2.1370454 down 
8480 RAE1 Homo sapiens RAE1 RNA export 1 homolog (S. 
pombe) (RAE1), transcript variant 1, mRNA. 
5.13E-06 2.2723718 up 
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23180 RAFTLIN Homo sapiens raftlin, lipid raft linker 1 (RFTN1), 
mRNA. 
5.13E-06 2.5688217 down 
5899 RALB Homo sapiens v-ral simian leukemia viral oncogene 
homolog B (ras related; GTP binding protein) 
(RALB), mRNA. 
2.20E-05 3.0170004 up 
5900 RALGDS Homo sapiens ral guanine nucleotide dissociation 
stimulator (RALGDS), transcript variant 1, mRNA. 
3.50E-05 2.470266 down 
57826 RAP2C Homo sapiens RAP2C, member of RAS oncogene 
family (RAP2C), mRNA. 
5.27E-06 2.45151 up 
5914 RARA Homo sapiens retinoic acid receptor, alpha (RARA), 
transcript variant 2, mRNA. 
8.33E-05 2.0344188 up 
5920 RARRES3 Homo sapiens retinoic acid receptor responder 
(tazarotene induced) 3 (RARRES3), mRNA. 
7.68E-06 3.5678754 down 
10125 RASGRP1 Homo sapiens RAS guanyl releasing protein 1 
(calcium and DAG-regulated) (RASGRP1), mRNA. 
5.13E-06 4.654138 down 
25780 RASGRP3 Homo sapiens RAS guanyl releasing protein 3 
(calcium and DAG-regulated) (RASGRP3), mRNA. 
2.50E-05 2.5557296 down 
115727 RASGRP4 Homo sapiens RAS guanyl releasing protein 4 
(RASGRP4), transcript variant 1, mRNA. 
1.53E-02 2.1501565 up 
9770 RASSF2 Homo sapiens Ras association (RalGDS/AF-6) 
domain family 2 (RASSF2), transcript variant 2, 
mRNA. 
9.97E-06 2.6524665 up 
9770 RASSF2 Homo sapiens Ras association (RalGDS/AF-6) 
domain family 2 (RASSF2), transcript variant 2, 
mRNA. 
9.97E-06 2.30542 up 
8045 RASSF7 Homo sapiens Ras association (RalGDS/AF-6) 
domain family 7 (RASSF7), mRNA. 
5.47E-06 2.208971 down 
23352 RBAF600 Homo sapiens retinoblastoma-associated factor 
600 (RBAF600), mRNA. 
6.31E-06 2.0767138 up 
84549 RBM13 Homo sapiens RNA binding motif protein 13 
(RBM13), mRNA. 
1.67E-05 2.0225883 down 
5937 RBMS1 Homo sapiens RNA binding motif, single stranded 
interacting protein 1 (RBMS1), transcript variant 3, 
mRNA. 
5.13E-06 4.021259 up 
3516 RBPSUH Homo sapiens recombining binding protein 
suppressor of hairless (Drosophila) (RBPSUH), 
transcript variant 4, mRNA. 
4.69E-05 2.2581666 up 
9978 RBX1 Homo sapiens ring-box 1 (RBX1), mRNA. 7.57E-05 2.1960974 up 
9185 REPS2 Homo sapiens RALBP1 associated Eps domain 
containing 2 (REPS2), mRNA. 
1.10E-02 2.1453114 up 
9185 REPS2 PREDICTED: Homo sapiens RALBP1 associated Eps 
domain containing 2 (REPS2), mRNA. 
1.55E-03 2.0997515 up 
56729 RETN Homo sapiens resistin (RETN), mRNA. 2.20E-04 112.82527 up 
5990 RFX2 Homo sapiens regulatory factor X, 2 (influences 
HLA class II expression) (RFX2), transcript variant 2, 
mRNA. 
7.70E-03 2.8042586 up 
5990 RFX2 Homo sapiens regulatory factor X, 2 (influences 
HLA class II expression) (RFX2), transcript variant 1, 
mRNA. 
7.57E-03 2.0874906 up 
5993 RFX5 Homo sapiens regulatory factor X, 5 (influences 
HLA class II expression) (RFX5), transcript variant 1, 
mRNA. 
5.13E-06 2.2252 down 
23179 RGL1 Homo sapiens ral guanine nucleotide dissociation 
stimulator-like 1 (RGL1), mRNA. 
2.9E-02 2.059209 up 
266747 Rgr Homo sapiens Ral-GDS related protein Rgr (Rgr), 
mRNA. 
5.13E-06 10.970202 up 
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64407 RGS18 Homo sapiens regulator of G-protein signalling 18 
(RGS18), mRNA. 
1.28E-05 3.1929123 up 
10287 RGS19 Homo sapiens regulator of G-protein signalling 19 
(RGS19), mRNA. 
5.13E-06 3.0821266 up 
57414 RHBDD2 Homo sapiens rhomboid domain containing 2 
(RHBDD2), transcript variant 1, mRNA. 
5.47E-06 2.434615 up 
57414 RHBDD2 Homo sapiens rhomboid domain containing 2 
(RHBDD2), mRNA. 
5.13E-06 2.4721975 up 
391 RHOG Homo sapiens ras homolog gene family, member G 
(rho G) (RHOG), mRNA. 
5.91E-06 2.721033 up 
55288 RHOT1 Homo sapiens ras homolog gene family, member 
T1 (RHOT1), transcript variant 3, mRNA. 
1.39E-05 2.4219975 up 
55288 RHOT1 Homo sapiens ras homolog gene family, member 
T1 (RHOT1), transcript variant 2, mRNA. 
9.31E-05 2.163114 up 
83547 RILP Homo sapiens Rab interacting lysosomal protein 
(RILP), mRNA. 
5.13E-06 2.2058845 up 
79890 RIN3 Homo sapiens Ras and Rab interactor 3 (RIN3), 
mRNA. 
2.86E-04 2.0112429 up 
8780 RIOK3 Homo sapiens RIO kinase 3 (yeast) (RIOK3), 
transcript variant 1, mRNA. 
4.69E-05 2.0572739 up 
6016 RIT1 Homo sapiens Ras-like without CAAX 1 (RIT1), 
mRNA. 
5.22E-04 3.5757074 up 
80010 RMI1 Homo sapiens RMI1, RecQ mediated genome 
instability 1, homolog (S. cerevisiae) (RMI1), mRNA. 
5.47E-06 2.5162008 up 
6036 RNASE2 Homo sapiens ribonuclease, RNase A family, 2 
(liver, eosinophil-derived neurotoxin) (RNASE2), 
mRNA. 
5.13E-06 5.5336666 up 
6037 RNASE3 Homo sapiens ribonuclease, RNase A family, 3 
(eosinophil cationic protein) (RNASE3), mRNA. 
3.20E-04 3.9439726 up 
246243 RNASEH1 Homo sapiens ribonuclease H1 (RNASEH1), mRNA. 5.27E-06 2.2097256 down 
6041 RNASEL Homo sapiens ribonuclease L (2',5'-
oligoisoadenylate synthetase-dependent) 
(RNASEL), mRNA. 
1.39E-05 2.4552608 up 
55658 RNF126 Homo sapiens ring finger protein 126 (RNF126), 
mRNA. 
5.47E-06 2.113235 down 
11342 RNF13 Homo sapiens ring finger protein 13 (RNF13), 
transcript variant 4, mRNA. 
1.39E-05 2.6303022 up 
84282 RNF135 Homo sapiens ring finger protein 135 (RNF135), 
transcript variant 1, mRNA. 
6.65E-03 2.019627 up 
50862 RNF141 Homo sapiens ring finger protein 141 (RNF141), 
mRNA. 
6.17E-04 3.1523561 up 
9781 RNF144 Homo sapiens ring finger protein 144 (RNF144), 
mRNA. 
3.53E-04 2.483058 down 
81847 RNF146 Homo sapiens ring finger protein 146 (RNF146), 
mRNA. 
2.88E-05 3.2138133 up 
284996 RNF149 Homo sapiens ring finger protein 149 (RNF149), 
mRNA. 
6.88E-05 2.4710698 up 
494470 RNF165 Homo sapiens ring finger protein 165 (RNF165), 
mRNA. 
4.38E-02 2.776474 down 
6093 ROCK1 Homo sapiens Rho-associated, coiled-coil 
containing protein kinase 1 (ROCK1), mRNA. 
9.48E-04 2.0793455 up 
83853 ROPN1L Homo sapiens ropporin 1-like (ROPN1L), mRNA. 5.13E-06 6.6726146 up 
6095 RORA Homo sapiens RAR-related orphan receptor A 
(RORA), transcript variant 3, mRNA. 
3.01E-03 2.7249856 down 
6102 RP2 Homo sapiens retinitis pigmentosa 2 (X-linked 
recessive) (RP2), mRNA. 
1.27E-04 2.4424632 up 
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6137 RPL13 Homo sapiens ribosomal protein L13 (RPL13), 
transcript variant 2, mRNA. 
2.42E-05 2.0406044 down 
23521 RPL13A Homo sapiens ribosomal protein L13a (RPL13A), 
mRNA. 
1.47E-04 2.0675883 down 
9045 RPL14 Homo sapiens ribosomal protein L14 (RPL14), 
mRNA. 
1.47E-04 2.2580352 down 
6146 RPL22 Homo sapiens ribosomal protein L22 (RPL22), 
mRNA. 
5.91E-06 2.7956874 down 
56969 RPL23AP13 Homo sapiens ribosomal protein L23a pseudogene 
13 (RPL23AP13) on chromosome 2. 
8.06E-05 2.4020362 down 
6159 RPL29 Homo sapiens ribosomal protein L29 (RPL29), 
mRNA. 
8.68E-04 2.031099 up 
6228 RPS23 Homo sapiens ribosomal protein S23 (RPS23), 
mRNA. 
1.01E-04 2.7326667 down 
6191 RPS4X Homo sapiens ribosomal protein S4, X-linked 
(RPS4X), mRNA. 
2.90E-05 2.3750894 down 
6195 RPS6KA1 Homo sapiens ribosomal protein S6 kinase, 90kDa, 
polypeptide 1 (RPS6KA1), transcript variant 2, 
mRNA. 
2.63E-05 2.0691285 up 
9252 RPS6KA5 Homo sapiens ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 (RPS6KA5), transcript variant 1, 
mRNA. 
4.18E-05 3.2871196 down 
27079 RPUSD2 Homo sapiens RNA pseudouridylate synthase 
domain containing 2 (RPUSD2), mRNA. 
5.13E-06 2.3987536 down 
58528 RRAGD Homo sapiens Ras-related GTP binding D (RRAGD), 
mRNA. 
5.13E-06 3.5632248 up 
91543 RSAD2 Homo sapiens radical S-adenosyl methionine 
domain containing 2 (RSAD2), mRNA. 
1.37E-02 3.4684372 down 
8634 RTCD1 Homo sapiens RNA terminal phosphate cyclase 
domain 1 (RTCD1), mRNA. 
6.74E-06 2.1010933 up 
10313 RTN3 Homo sapiens reticulon 3 (RTN3), transcript variant 
1, mRNA. 
7.68E-06 2.698501 up 
10313 RTN3 Homo sapiens reticulon 3 (RTN3), transcript variant 
4, mRNA. 
1.82E-05 2.6037283 up 
57142 RTN4 Homo sapiens reticulon 4 (RTN4), transcript variant 
1, mRNA. 
5.13E-06 3.10555 up 
57142 RTN4 Homo sapiens reticulon 4 (RTN4), transcript variant 
3, mRNA. 
5.13E-06 2.8561363 up 
864 RUNX3 Homo sapiens runt-related transcription factor 3 
(RUNX3), transcript variant 2, mRNA. 
5.13E-06 2.8488808 down 
6256 RXRA Homo sapiens retinoid X receptor, alpha (RXRA), 
mRNA. 
1.52E-05 2.1180124 up 
6282 S100A11 Homo sapiens S100 calcium binding protein A11 
(S100A11), mRNA. 
5.27E-06 3.2982779 up 
6283 S100A12 Homo sapiens S100 calcium binding protein A12 
(S100A12), mRNA. 
5.13E-06 12.397408 up 
6277 S100A6 Homo sapiens S100 calcium binding protein A6 
(S100A6), mRNA. 
5.13E-06 2.9247186 up 
6279 S100A8 Homo sapiens S100 calcium binding protein A8 
(S100A8), mRNA. 
5.13E-06 3.185351 up 
6286 S100P Homo sapiens S100 calcium binding protein P 
(S100P), mRNA. 
5.91E-06 12.538133 up 
154075 SAMD3 Homo sapiens sterile alpha motif domain 
containing 3 (SAMD3), transcript variant 1, mRNA. 
1.66E-05 5.683149 down 
64092 SAMSN1 Homo sapiens SAM domain, SH3 domain and 
nuclear localization signals 1 (SAMSN1), mRNA. 
9.10E-06 13.222396 up 
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8819 SAP30 Homo sapiens sin3-associated polypeptide, 30kDa 
(SAP30), mRNA. 
2.81E-05 3.1501167 up 
51128 SAR1B Homo sapiens SAR1 gene homolog B (S. cerevisiae) 
(SAR1B), transcript variant 2, mRNA. 
5.13E-06 3.7790694 up 
51128 SAR1B Homo sapiens SAR1 gene homolog B (S. cerevisiae) 
(SAR1B), transcript variant 1, mRNA. 
2.88E-05 2.3820426 up 
29940 SART2 Homo sapiens squamous cell carcinoma antigen 
recognized by T cells 2 (SART2), mRNA. 
5.47E-06 3.3033214 up 
6303 SAT Homo sapiens spermidine/spermine N1-
acetyltransferase 1 (SAT1), mRNA. 
7.25E-06 2.8385026 up 
81846 SBF2 Homo sapiens SET binding factor 2 (SBF2), mRNA. 1.82E-04 2.2637892 up 
388228 SBK1 Homo sapiens SH3-binding domain kinase 1 (SBK1), 
mRNA. 
5.13E-06 5.0247912 down 
8631 SCAP1 Homo sapiens src family associated 
phosphoprotein 1 (SCAP1), mRNA. 
5.13E-06 5.5414057 down 
59342 SCPEP1 Homo sapiens serine carboxypeptidase 1 (SCPEP1), 
mRNA. 
5.13E-06 4.6054783 up 
55681 SCYL2 Homo sapiens SCY1-like 2 (S. cerevisiae) (SCYL2), 
mRNA. 
7.25E-06 2.2322147 up 
6386 SDCBP Homo sapiens syndecan binding protein (syntenin) 
(SDCBP), transcript variant 2, mRNA. 
1.52E-05 3.1811771 up 
10807 SDCCAG3 Homo sapiens serologically defined colon cancer 
antigen 3 (SDCCAG3), mRNA. 
3.14E-05 2.0585663 down 
10194 SDCCAG33 Homo sapiens serologically defined colon cancer 
antigen 33 (SDCCAG33), mRNA. 
7.66E-05 2.2308984 down 
6388 SDF2 Homo sapiens stromal cell-derived factor 2 (SDF2), 
mRNA. 
5.13E-06 2.6602075 up 
27020 SDFR1 Homo sapiens stromal cell derived factor receptor 
1 (SDFR1), transcript variant beta, mRNA. 
6.74E-06 2.806331 up 
9117 SEC22C Homo sapiens SEC22 vesicle trafficking protein 
homolog C (S. cerevisiae) (SEC22C), transcript 
variant 2, mRNA. 
2.25E-05 2.3320997 up 
10802 SEC24A Homo sapiens SEC24 related gene family, member 
A (S. cerevisiae) (SEC24A), mRNA. 
1.09E-05 2.5405312 up 
6402 SELL Homo sapiens selectin L (lymphocyte adhesion 
molecule 1) (SELL), mRNA. 
1.78E-04 2.008816 up 
51714 SELT Homo sapiens selenoprotein T (SELT), mRNA. 6.15E-05 2.498092 up 
64218 SEMA4A Homo sapiens sema domain, immunoglobulin 
domain (Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 4A 
(SEMA4A), mRNA. 
1.52E-05 3.6353498 up 
51734 SEPX1 Homo sapiens selenoprotein X, 1 (SEPX1), mRNA. 6.74E-06 2.9104857 up 
57515 SERINC1 Homo sapiens serine incorporator 1 (SERINC1), 
mRNA. 
1.28E-05 2.5843377 up 
5265 SERPINA1 Homo sapiens serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 
(SERPINA1), transcript variant 1, mRNA. 
1.26E-02 2.581325 up 
5265 SERPINA1 Homo sapiens serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 
(SERPINA1), transcript variant 3, mRNA. 
5.27E-06 3.6783197 up 
5265 SERPINA1 Homo sapiens serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 
(SERPINA1), transcript variant 2, mRNA. 
5.27E-06 3.6435215 up 
5265 SERPINA1 Homo sapiens serpin peptidase inhibitor, clade A 
(alpha-1 antiproteinase, antitrypsin), member 1 
(SERPINA1), transcript variant 2, mRNA. 
1.0E-02 2.7376792 up 
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1992 SERPINB1 Homo sapiens serpin peptidase inhibitor, clade B 
(ovalbumin), member 1 (SERPINB1), mRNA. 
5.13E-06 7.584304 up 
5271 SERPINB8 Homo sapiens serpin peptidase inhibitor, clade B 
(ovalbumin), member 8 (SERPINB8), transcript 
variant 1, mRNA. 
4.90E-05 3.092629 up 
5271 SERPINB8 Homo sapiens serpin peptidase inhibitor, clade B 
(ovalbumin), member 8 (SERPINB8), transcript 
variant 3, mRNA. 
9.10E-06 3.0228734 up 
5270 SERPINE2 Homo sapiens serpin peptidase inhibitor, clade E 
(nexin, plasminogen activator inhibitor type 1), 
member 2 (SERPINE2), mRNA. 
6.66E-04 2.0740278 down 
29946 SERTAD3 Homo sapiens SERTA domain containing 3 
(SERTAD3), transcript variant 2, mRNA. 
4.69E-05 2.0235457 up 
387893 SETD8 Homo sapiens SET domain containing (lysine 
methyltransferase) 8 (SETD8), mRNA. 
5.35E-06 2.3038507 up 
10946 SF3A3 Homo sapiens splicing factor 3a, subunit 3, 60kDa 
(SF3A3), mRNA. 
6.74E-06 2.0442965 down 
51639 SF3B14 Homo sapiens splicing factor 3B, 14 kDa subunit 
(SF3B14), mRNA. 
7.25E-06 2.85155 up 
23450 SF3B3 Homo sapiens splicing factor 3b, subunit 3, 130kDa 
(SF3B3), mRNA. 
9.21E-06 2.2218034 down 
113402 SFT2D1 Homo sapiens SFT2 domain containing 1 (SFT2D1), 
mRNA. 
5.13E-06 2.701378 up 
94081 SFXN1 Homo sapiens sideroflexin 1 (SFXN1), mRNA. 1.08E-05 3.7567773 up 
119559 SFXN4 Homo sapiens sideroflexin 4 (SFXN4), transcript 
variant 2, mRNA. 
1.39E-05 2.0434752 up 
94097 SFXN5 Homo sapiens sideroflexin 5 (SFXN5), mRNA. 8.95E-05 2.9185047 up 
4068 SH2D1A Homo sapiens SH2 domain protein 1A, Duncan's 
disease (lymphoproliferative syndrome) (SH2D1A), 
mRNA. 
1.28E-05 3.318976 down 
51100 SH3GLB1 Homo sapiens SH3-domain GRB2-like endophilin 
B1 (SH3GLB1), mRNA. 
5.13E-06 4.4182706 up 
30011 SH3KBP1 Homo sapiens SH3-domain kinase binding protein 
1 (SH3KBP1), transcript variant 2, mRNA. 
2.70E-04 3.7459664 down 
26751 SH3YL1 Homo sapiens SH3 domain containing, Ysc84-like 1 
(S. cerevisiae) (SH3YL1), mRNA. 
6.31E-06 2.408518 down 
92799 SHKBP1 Homo sapiens SH3KBP1 binding protein 1 
(SHKBP1), mRNA. 
3.18E-05 2.62271 up 
8036 SHOC2 Homo sapiens soc-2 suppressor of clear homolog 
(C. elegans) (SHOC2), mRNA. 
1.39E-05 2.5338082 up 
54847 SIDT1 Homo sapiens SID1 transmembrane family, 
member 1 (SIDT1), mRNA. 
3.55E-02 2.239598 down 
89790 SIGLEC10 Homo sapiens sialic acid binding Ig-like lectin 10 
(SIGLEC10), mRNA. 
5.13E-06 5.184889 up 
8778 SIGLEC5 Homo sapiens sialic acid binding Ig-like lectin 5 
(SIGLEC5), mRNA. 
5.13E-06 5.2311654 up 
27036 SIGLEC7 Homo sapiens sialic acid binding Ig-like lectin 7 
(SIGLEC7), transcript variant 1, mRNA. 
3.76E-02 3.021048 up 
64374 SIL1 Homo sapiens SIL1 homolog, endoplasmic 
reticulum chaperone (S. cerevisiae) (SIL1), 
transcript variant 1, mRNA. 
1.26E-05 2.7031844 up 
64374 SIL1 Homo sapiens SIL1 homolog, endoplasmic 
reticulum chaperone (S. cerevisiae) (SIL1), mRNA. 
1.28E-05 2.7401364 up 
57568 SIPA1L2 Homo sapiens signal-induced proliferation-
associated 1 like 2 (SIPA1L2), mRNA. 
5.91E-06 5.884139 up 
10326 SIRPB1 Homo sapiens signal-regulatory protein beta 1 
(SIRPB1), mRNA. 
1.54E-04 2.47641 up 
257 
 
128646 SIRPD Homo sapiens signal-regulatory protein delta 
(SIRPD), mRNA. 
5.12E-03 2.7034366 up 
55423 SIRPG Homo sapiens signal-regulatory protein gamma 
(SIRPG), transcript variant 2, mRNA. 
6.15E-03 3.2933543 down 
23408 SIRT5 Homo sapiens sirtuin (silent mating type 
information regulation 2 homolog) 5 (S. cerevisiae) 
(SIRT5), transcript variant 1, mRNA. 
1.47E-04 2.4177494 up 
8631 SKAP1 Homo sapiens src kinase associated 
phosphoprotein 1 (SKAP1), transcript variant 2, 
mRNA. 
1.34E-04 3.3015227 down 
8935 SKAP2 Homo sapiens src kinase associated 
phosphoprotein 2 (SKAP2), mRNA. 
5.13E-06 3.7175558 up 
6503 SLA Homo sapiens Src-like-adaptor (SLA), transcript 
variant 1, mRNA. 
1.79E-05 3.3963377 up 
6503 SLA Homo sapiens Src-like-adaptor (SLA), transcript 
variant 2, mRNA. 
5.13E-06 4.604537 up 
114836 SLAMF6 Homo sapiens SLAM family member 6 (SLAMF6), 
mRNA. 
5.13E-06 2.5163615 down 
6556 SLC11A1 Homo sapiens solute carrier family 11 (proton-
coupled divalent metal ion transporters), member 
1 (SLC11A1), transcript variant 2, mRNA. 
3.87E-05 2.799787 up 
9990 SLC12A6 Homo sapiens solute carrier family 12 
(potassium/chloride transporters), member 6 
(SLC12A6), mRNA. 
1.28E-05 2.38768 up 
9123 SLC16A3 Homo sapiens solute carrier family 16, member 3 
(monocarboxylic acid transporter 4) (SLC16A3), 
transcript variant 2, mRNA. 
5.91E-06 3.2691417 up 
9120 SLC16A6 Homo sapiens solute carrier family 16 
(monocarboxylic acid transporters), member 6 
(SLC16A6), mRNA. 
6.38E-05 3.6259203 up 
6573 SLC19A1 Homo sapiens solute carrier family 19 (folate 
transporter), member 1 (SLC19A1), transcript 
variant 1, mRNA. 
8.78E-04 2.0835345 up 
55356 SLC22A15 Homo sapiens solute carrier family 22 (organic 
cation transporter), member 15 (SLC22A15), 
mRNA. 
4.19E-03 2.4700074 up 
6583 SLC22A4 Homo sapiens solute carrier family 22 (organic 
cation transporter), member 4 (SLC22A4), mRNA. 
1.28E-05 3.9389577 up 
55972 SLC25A40 Homo sapiens solute carrier family 25, member 40 
(SLC25A40), mRNA. 
1.36E-03 5.8174376 up 
65010 SLC26A6 Homo sapiens solute carrier family 26, member 6 
(SLC26A6), transcript variant 3, mRNA. 
8.98E-03 2.2475884 up 
66035 SLC2A11 Homo sapiens solute carrier family 2 (facilitated 
glucose transporter), member 11 (SLC2A11), 
transcript variant 3, mRNA. 
1.09E-03 12.1210575 up 
144195 SLC2A14 Homo sapiens solute carrier family 2 (facilitated 
glucose transporter), member 14 (SLC2A14), 
mRNA. 
1.33E-05 5.573804 up 
6515 SLC2A3 Homo sapiens solute carrier family 2 (facilitated 
glucose transporter), member 3 (SLC2A3), mRNA. 
5.13E-06 3.8878593 up 
1318 SLC31A2 Homo sapiens solute carrier family 31 (copper 
transporters), member 2 (SLC31A2), mRNA. 
1.39E-05 2.8930454 up 
10559 SLC35A1 Homo sapiens solute carrier family 35 (CMP-sialic 
acid transporter), member A1 (SLC35A1), mRNA. 
1.52E-05 2.2966766 up 
80255 SLC35F5 Homo sapiens solute carrier family 35, member F5 
(SLC35F5), mRNA. 
1.71E-03 2.2013497 up 
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206358 SLC36A1 Homo sapiens solute carrier family 36 
(proton/amino acid symporter), member 1 
(SLC36A1), mRNA. 
5.27E-06 4.276486 up 
120103 SLC36A4 Homo sapiens solute carrier family 36 
(proton/amino acid symporter), member 4 
(SLC36A4), mRNA. 
7.25E-06 2.5944667 up 
81539 SLC38A1 Homo sapiens solute carrier family 38, member 1 
(SLC38A1), mRNA. 
5.47E-06 3.1893635 down 
54407 SLC38A2 Homo sapiens solute carrier family 38, member 2 
(SLC38A2), mRNA. 
5.91E-06 2.5765672 up 
27173 SLC39A1 Homo sapiens solute carrier family 39 (zinc 
transporter), member 1 (SLC39A1), mRNA. 
5.13E-06 2.3091557 up 
64116 SLC39A8 Homo sapiens solute carrier family 39 (zinc 
transporter), member 8 (SLC39A8), mRNA. 
1.81E-04 4.246782 up 
30061 SLC40A1 Homo sapiens solute carrier family 40 (iron-
regulated transporter), member 1 (SLC40A1), 
mRNA. 
4.15E-04 2.5611005 up 
54946 SLC41A3 Homo sapiens solute carrier family 41, member 3 
(SLC41A3), transcript variant 2, mRNA. 
5.62E-06 2.17463 down 
54946 SLC41A3 Homo sapiens solute carrier family 41, member 3 
(SLC41A3), transcript variant 1, mRNA. 
9.10E-06 2.2424684 down 
23446 SLC44A1 Homo sapiens solute carrier family 44, member 1 
(SLC44A1), transcript variant 2, mRNA. 
1.11E-04 2.156885 up 
23446 SLC44A1 Homo sapiens solute carrier family 44, member 1 
(SLC44A1), transcript variant 1, mRNA. 
5.13E-06 2.4726274 up 
9057 SLC7A6 Homo sapiens solute carrier family 7 (cationic 
amino acid transporter, y+ system), member 6 
(SLC7A6), mRNA. 
6.09E-06 2.7540555 down 
10479 SLC9A6 Homo sapiens solute carrier family 9 
(sodium/hydrogen exchanger), member 6 
(SLC9A6), mRNA. 
5.35E-06 2.1164196 up 
353189 SLCO4C1 Homo sapiens solute carrier organic anion 
transporter family, member 4C1 (SLCO4C1), mRNA. 
3.81E-02 2.4337308 up 
9748 SLK Homo sapiens STE20-like kinase (yeast) (SLK), 
mRNA. 
8.44E-06 3.3453143 up 
6590 SLPI Homo sapiens secretory leukocyte peptidase 
inhibitor (SLPI), mRNA. 
2.20E-04 8.641318 up 
11039 SMA4 Homo sapiens SMA4 (SMA4), mRNA. 1.03E-05 2.3718147 down 
4088 SMAD3 Homo sapiens SMAD family member 3 (SMAD3), 
mRNA. 
5.13E-06 2.3363004 down 
10924 SMPDL3A Homo sapiens sphingomyelin phosphodiesterase, 
acid-like 3A (SMPDL3A), mRNA. 
7.17E-04 11.779018 up 
6525 SMTN Homo sapiens smoothelin (SMTN), transcript 
variant 3, mRNA. 
2.84E-04 2.0053816 up 
8773 SNAP23 Homo sapiens synaptosomal-associated protein, 
23kDa (SNAP23), transcript variant 2, mRNA. 
6.88E-05 2.0804262 up 
55509 SNFT Homo sapiens Jun dimerization protein p21SNFT 
(SNFT), mRNA. 
1.86E-02 2.6653688 up 
6637 SNRPG Homo sapiens small nuclear ribonucleoprotein 
polypeptide G (SNRPG), mRNA. 
6.55E-03 2.0086162 up 
6638 SNRPN Homo sapiens small nuclear ribonucleoprotein 
polypeptide N (SNRPN), transcript variant 2, mRNA. 
5.27E-06 2.903949 down 
8926 SNURF Homo sapiens SNRPN upstream reading frame 
(SNURF), transcript variant 1, mRNA. 
8.93E-06 2.9593873 down 
29887 SNX10 Homo sapiens sorting nexin 10 (SNX10), mRNA. 1.82E-05 2.7822063 up 
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29916 SNX11 Homo sapiens sorting nexin 11 (SNX11), transcript 
variant 1, mRNA. 
6.31E-06 2.0708773 up 
23161 SNX13 Homo sapiens sorting nexin 13 (SNX13), mRNA. 3.87E-05 2.4602334 up 
57231 SNX14 Homo sapiens sorting nexin 14 (SNX14), transcript 
variant 2, mRNA. 
5.47E-06 2.4378521 up 
81609 SNX27 Homo sapiens sorting nexin family member 27 
(SNX27), mRNA. 
2.02E-05 2.0202353 up 
8724 SNX3 Homo sapiens sorting nexin 3 (SNX3), transcript 
variant 3, mRNA. 
5.13E-06 3.4656262 up 
8835 SOCS2 Homo sapiens suppressor of cytokine signaling 2 
(SOCS2), mRNA. 
5.70E-04 2.4129548 down 
6648 SOD2 Homo sapiens superoxide dismutase 2, 
mitochondrial (SOD2), nuclear gene encoding 
mitochondrial protein, transcript variant 3, mRNA. 
6.88E-05 2.7007437 up 
6648 SOD2 Homo sapiens superoxide dismutase 2, 
mitochondrial (SOD2), nuclear gene encoding 
mitochondrial protein, transcript variant 2, mRNA. 
2.63E-05 2.4178562 up 
6272 SORT1 Homo sapiens sortilin 1 (SORT1), mRNA. 5.13E-06 7.3709874 up 
6672 SP100 Homo sapiens SP100 nuclear antigen (SP100), 
transcript variant 1, mRNA. 
1.34E-04 2.216641 up 
11262 SP140 Homo sapiens SP140 nuclear body protein (SP140), 
transcript variant 1, mRNA. 
7.68E-06 2.5960333 down 
60559 SPCS3 Homo sapiens signal peptidase complex subunit 3 
homolog (S. cerevisiae) (SPCS3), mRNA. 
4.60E-05 2.8208823 up 
11160 SPFH2 Homo sapiens SPFH domain family, member 2 
(SPFH2), transcript variant 1, mRNA. 
2.29E-05 2.4365819 up 
6688 SPI1 Homo sapiens spleen focus forming virus (SFFV) 
proviral integration oncogene spi1 (SPI1), mRNA. 
1.66E-05 2.9030843 up 
6688 SPI1 Homo sapiens spleen focus forming virus (SFFV) 
proviral integration oncogene spi1 (SPI1), 
transcript variant 2, mRNA. 
5.35E-06 3.2189314 up 
6689 SPIB Homo sapiens Spi-B transcription factor (Spi-
1/PU.1 related) (SPIB), mRNA. 
5.78E-05 2.4692757 down 
9806 SPOCK2 Homo sapiens sparc/osteonectin, cwcv and kazal-
like domains proteoglycan (testican) 2 (SPOCK2), 
mRNA. 
5.13E-06 4.714466 down 
84888 SPPL2A Homo sapiens signal peptide peptidase-like 2A 
(SPPL2A), mRNA. 
5.13E-06 4.0812507 up 
9517 SPTLC2 Homo sapiens serine palmitoyltransferase, long 
chain base subunit 2 (SPTLC2), mRNA. 
1.43E-03 2.195914 up 
58472 SQRDL Homo sapiens sulfide quinone reductase-like 
(yeast) (SQRDL), mRNA. 
7.68E-06 3.2714407 up 
5552 SRGN Homo sapiens serglycin (SRGN), mRNA. 6.74E-06 2.9109418 up 
390284 SRP14P1 Homo sapiens signal recognition particle 14kDa 
(homologous Alu RNA binding protein) pseudogene 
1 (SRP14P1) on chromosome 12. 
2.02E-05 2.058656 up 
6732 SRPK1 Homo sapiens SFRS protein kinase 1 (SRPK1), 
mRNA. 
1.96E-04 2.5812087 up 
140809 SRXN1 Homo sapiens sulfiredoxin 1 homolog (S. 
cerevisiae) (SRXN1), mRNA. 
4.68E-05 2.3871 up 
23648 SSBP3 Homo sapiens single stranded DNA binding protein 
3 (SSBP3), transcript variant 1, mRNA. 
1.83E-04 2.1193433 down 
170463 SSBP4 Homo sapiens single stranded DNA binding protein 
4 (SSBP4), transcript variant 1, mRNA. 
5.27E-06 2.2562535 down 
54434 SSH1 Homo sapiens slingshot homolog 1 (Drosophila) 
(SSH1), mRNA. 
7.19E-04 2.279053 up 
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85464 SSH2 Homo sapiens slingshot homolog 2 (Drosophila) 
(SSH2), mRNA. 
6.74E-06 2.4406815 up 
6484 ST3GAL4 Homo sapiens ST3 beta-galactoside alpha-2,3-
sialyltransferase 4 (ST3GAL4), mRNA. 
2.86E-03 2.4027174 up 
8869 ST3GAL5 Homo sapiens ST3 beta-galactoside alpha-2,3-
sialyltransferase 5 (ST3GAL5), mRNA. 
5.35E-06 2.7190828 down 
6480 ST6GAL1 Homo sapiens ST6 beta-galactosamide alpha-2,6-
sialyltranferase 1 (ST6GAL1), transcript variant 3, 
mRNA. 
6.31E-06 2.2134047 down 
256435 ST6GALNAC3 Homo sapiens ST6 (alpha-N-acetyl-neuraminyl-2,3-
beta-galactosyl-1, 3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 3 (ST6GALNAC3), 
mRNA. 
3.60E-03 8.124919 up 
30815 ST6GALNAC6 Homo sapiens ST6 (alpha-N-acetyl-neuraminyl-2,3-
beta-galactosyl-1, 3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 6 (ST6GALNAC6), 
mRNA. 
9.95E-05 2.0022986 down 
23166 STAB1 Homo sapiens stabilin 1 (STAB1), mRNA. 6.88E-05 2.6656153 up 
83930 STARD3NL Homo sapiens STARD3 N-terminal like (STARD3NL), 
mRNA. 
2.51E-05 2.5439224 up 
6772 STAT1 Homo sapiens signal transducer and activator of 
transcription 1, 91kDa (STAT1), transcript variant 
alpha, mRNA. 
1.47E-04 2.320497 down 
6772 STAT1 Homo sapiens signal transducer and activator of 
transcription 1, 91kDa (STAT1), transcript variant 
beta, mRNA. 
1.34E-04 2.5204864 down 
6772 STAT1 Homo sapiens signal transducer and activator of 
transcription 1, 91kDa (STAT1), transcript variant 
beta, mRNA. 
9.15E-05 3.1338727 down 
6775 STAT4 Homo sapiens signal transducer and activator of 
transcription 4 (STAT4), mRNA. 
1.17E-05 3.587767 down 
79689 STEAP4 Homo sapiens STEAP family member 4 (STEAP4), 
mRNA. 
1.89E-03 2.6824038 up 
8576 STK16 Homo sapiens serine/threonine kinase 16 (STK16), 
transcript variant 1, mRNA. 
3.41E-03 2.0608761 up 
9262 STK17B Homo sapiens serine/threonine kinase 17b 
(STK17B), mRNA. 
2.3E-03 2.107266 up 
6788 STK3 Homo sapiens serine/threonine kinase 3 (STE20 
homolog, yeast) (STK3), mRNA. 
1.09E-05 4.4723954 up 
23012 STK38L Homo sapiens serine/threonine kinase 38 like 
(STK38L), mRNA. 
1.17E-03 2.07433 up 
27347 STK39 Homo sapiens serine threonine kinase 39 
(STE20/SPS1 homolog, yeast) (STK39), mRNA. 
1.67E-05 2.5048876 down 
2040 STOM Homo sapiens stomatin (STOM), transcript variant 
1, mRNA. 
4.90E-05 6.5691223 up 
2040 STOM Homo sapiens stomatin (STOM), transcript variant 
1, mRNA. 
5.13E-06 7.167354 up 
6809 STX3A Homo sapiens syntaxin 3 (STX3), mRNA. 1.39E-05 3.2399926 up 
8417 STX7 Homo sapiens syntaxin 7 (STX7), mRNA. 1.32E-02 2.061515 up 
6813 STXBP2 Homo sapiens syntaxin binding protein 2 (STXBP2), 
mRNA. 
5.13E-06 6.9053655 up 
6814 STXBP3 Homo sapiens syntaxin binding protein 3 (STXBP3), 
mRNA. 
5.17E-05 2.184866 up 
134957 STXBP5 Homo sapiens syntaxin binding protein 5 
(tomosyn) (STXBP5), mRNA. 
8.44E-06 2.893183 up 
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10923 SUB1 Homo sapiens SUB1 homolog (S. cerevisiae) 
(SUB1), mRNA. 
1.1E-03 2.1046803 up 
55959 SULF2 Homo sapiens sulfatase 2 (SULF2), transcript 
variant 1, mRNA. 
1.12E-02 2.018624 down 
55959 SULF2 Homo sapiens sulfatase 2 (SULF2), transcript 
variant 1, mRNA. 
1.66E-04 2.5312667 down 
285362 SUMF1 Homo sapiens sulfatase modifying factor 1 
(SUMF1), mRNA. 
3.87E-05 2.0271306 up 
6821 SUOX Homo sapiens sulfite oxidase (SUOX), nuclear gene 
encoding mitochondrial protein, transcript variant 
2, mRNA. 
2.58E-03 2.2054517 up 
6821 SUOX Homo sapiens sulfite oxidase (SUOX), nuclear gene 
encoding mitochondrial protein, transcript variant 
2, mRNA. 
5.47E-06 2.2596295 up 
64420 SUSD1 Homo sapiens sushi domain containing 1 (SUSD1), 
mRNA. 
5.13E-06 2.4038653 up 
6840 SVIL Homo sapiens supervillin (SVIL), transcript variant 
1, mRNA. 
5.91E-06 2.8247247 up 
6845 SYBL1 Homo sapiens synaptobrevin-like 1 (SYBL1), mRNA. 5.35E-06 2.481822 up 
6850 SYK Homo sapiens spleen tyrosine kinase (SYK), mRNA. 7.68E-06 2.0453272 up 
23224 SYNE2 Homo sapiens spectrin repeat containing, nuclear 
envelope 2 (SYNE2), transcript variant 1, mRNA. 
2.29E-04 2.319495 down 
8867 SYNJ1 Homo sapiens synaptojanin 1 (SYNJ1), transcript 
variant 2, mRNA. 
2.90E-05 2.0787117 up 
54843 SYTL2 Homo sapiens synaptotagmin-like 2 (SYTL2), 
transcript variant e, mRNA. 
1.69E-05 3.6670816 down 
6879 TAF7 Homo sapiens TAF7 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 55kDa 
(TAF7), mRNA. 
2.20E-05 2.3324485 up 
117289 TAGAP Homo sapiens T-cell activation GTPase activating 
protein (TAGAP), transcript variant 3, mRNA. 
9.10E-06 2.5182037 down 
117289 TAGAP Homo sapiens T-cell activation GTPase activating 
protein (TAGAP), transcript variant 2, mRNA. 
7.68E-06 2.3894684 down 
10010 TANK Homo sapiens TRAF family member-associated 
NFKB activator (TANK), transcript variant 1, mRNA. 
5.69E-05 2.4050903 up 
6891 TAP2 Homo sapiens transporter 2, ATP-binding cassette, 
sub-family B (MDR/TAP) (TAP2), transcript variant 
1, mRNA. 
1.11E-04 2.161089 down 
8887 TAX1BP1 Homo sapiens Tax1 (human T-cell leukemia virus 
type I) binding protein 1 (TAX1BP1), mRNA. 
9.10E-06 2.3963335 up 
8887 TAX1BP1 Homo sapiens Tax1 (human T-cell leukemia virus 
type I) binding protein 1 (TAX1BP1), transcript 
variant 2, mRNA. 
5.27E-06 2.4154434 up 
57533 TBC1D14 Homo sapiens TBC1 domain family, member 14 
(TBC1D14), mRNA. 
5.13E-06 2.5938985 up 
55357 TBC1D2 Homo sapiens TBC1 domain family, member 2 
(TBC1D2), mRNA. 
5.13E-06 3.0845976 up 
9882 TBC1D4 Homo sapiens TBC1 domain family, member 4 
(TBC1D4), mRNA. 
3.81E-03 2.0122747 down 
51256 TBC1D7 Homo sapiens TBC1 domain family, member 7 
(TBC1D7), mRNA. 
7.25E-06 2.1340473 up 
6902 TBCA Homo sapiens tubulin-specific chaperone a (TBCA), 
mRNA. 
5.35E-06 2.2097712 up 
29110 TBK1 Homo sapiens TANK-binding kinase 1 (TBK1), 
mRNA. 
4.26E-05 2.145113 up 
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6916 TBXAS1 Homo sapiens thromboxane A synthase 1 (platelet, 
cytochrome P450, family 5, subfamily A) (TBXAS1), 
transcript variant TXS-I, mRNA. 
5.13E-06 4.053732 up 
6919 TCEA2 Homo sapiens transcription elongation factor A 
(SII), 2 (TCEA2), transcript variant 1, mRNA. 
5.13E-06 2.2153099 down 
6920 TCEA3 Homo sapiens transcription elongation factor A 
(SII), 3 (TCEA3), mRNA. 
1.31E-03 2.8047628 down 
6921 TCEB1 Homo sapiens transcription elongation factor B 
(SIII), polypeptide 1 (15kDa, elongin C) (TCEB1), 
mRNA. 
5.35E-06 2.0938437 up 
6932 TCF7 Homo sapiens transcription factor 7 (T-cell specific, 
HMG-box) (TCF7), transcript variant 2, mRNA. 
1.34E-02 2.2970107 down 
6932 TCF7 Homo sapiens transcription factor 7 (T-cell specific, 
HMG-box) (TCF7), transcript variant 3, mRNA. 
1.65E-02 2.2085178 down 
10312 TCIRG1 Homo sapiens T-cell, immune regulator 1, ATPase, 
H+ transporting, lysosomal V0 subunit A3 (TCIRG1), 
transcript variant 2, mRNA. 
2.42E-05 2.1058588 up 
6947 TCN1 Homo sapiens transcobalamin I (vitamin B12 
binding protein, R binder family) (TCN1), mRNA. 
8.44E-06 13.522709 up 
6948 TCN2 Homo sapiens transcobalamin II; macrocytic 
anemia (TCN2), mRNA. 
9.97E-03 2.5073173 up 
122402 TDRD9 Homo sapiens tudor domain containing 9 (TDRD9), 
mRNA. 
1.45E-04 9.490689 up 
7008 TEF Homo sapiens thyrotrophic embryonic factor (TEF), 
mRNA. 
9.10E-06 2.4008708 up 
54997 TESC Homo sapiens tescalcin (TESC), mRNA. 5.61E-03 2.0003784 up 
7037 TFRC Homo sapiens transferrin receptor (p90, CD71) 
(TFRC), mRNA. 
7.15E-04 2.4574177 up 
7039 TGFA Homo sapiens transforming growth factor, alpha 
(TGFA), mRNA. 
1.00E-05 4.844284 up 
7045 TGFBI Homo sapiens transforming growth factor, beta-
induced, 68kDa (TGFBI), mRNA. 
3.72E-03 2.1941187 down 
7049 TGFBR3 Homo sapiens transforming growth factor, beta 
receptor III (TGFBR3), mRNA. 
1.34E-04 4.7717967 down 
60436 TGIF2 Homo sapiens TGFB-induced factor 2 (TALE family 
homeobox) (TGIF2), mRNA. 
6.85E-04 2.0344095 down 
7057 THBS1 Homo sapiens thrombospondin 1 (THBS1), mRNA. 5.48E-04 14.143862 up 
90459 THEX1 Homo sapiens three prime histone mRNA 
exonuclease 1 (THEX1), mRNA. 
4.1E-02 2.9041352 up 
7076 TIMP1 Homo sapiens TIMP metallopeptidase inhibitor 1 
(TIMP1), mRNA. 
5.27E-06 3.5237439 up 
7077 TIMP2 Homo sapiens TIMP metallopeptidase inhibitor 2 
(TIMP2), mRNA. 
3.60E-05 3.552546 up 
7077 TIMP2 Homo sapiens TIMP metallopeptidase inhibitor 2 
(TIMP2), mRNA. 
5.47E-06 3.2073245 up 
25976 TIPARP Homo sapiens TCDD-inducible poly(ADP-ribose) 
polymerase (TIPARP), mRNA. 
1.39E-05 2.9189072 up 
7084 TK2 Homo sapiens thymidine kinase 2, mitochondrial 
(TK2), mRNA. 
6.88E-04 2.0480692 up 
7086 TKT Homo sapiens transketolase (Wernicke-Korsakoff 
syndrome) (TKT), mRNA. 
1.22E-04 2.030949 up 
7096 TLR1 Homo sapiens toll-like receptor 1 (TLR1), mRNA. 1.11E-04 2.3303494 up 
7097 TLR2 Homo sapiens toll-like receptor 2 (TLR2), mRNA. 2.20E-04 5.9200134 up 
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7099 TLR4 Homo sapiens toll-like receptor 4 (TLR4), transcript 
variant 4, mRNA. 
6.74E-06 3.5023856 up 
7100 TLR5 Homo sapiens toll-like receptor 5 (TLR5), mRNA. 5.27E-06 5.570661 up 
51284 TLR7 Homo sapiens toll-like receptor 7 (TLR7), mRNA. 3.18E-05 2.8307898 down 
51311 TLR8 Homo sapiens toll-like receptor 8 (TLR8), transcript 
variant 1, mRNA. 
9.10E-06 4.0001364 up 
51311 TLR8 Homo sapiens toll-like receptor 8 (TLR8), transcript 
variant 2, mRNA. 
8.44E-06 3.8374279 up 
53346 TM6SF1 Homo sapiens transmembrane 6 superfamily 
member 1 (TM6SF1), mRNA. 
7.68E-06 3.1814644 up 
9375 TM9SF2 Homo sapiens transmembrane 9 superfamily 
member 2 (TM9SF2), mRNA. 
6.74E-06 2.3152728 up 
64114 TMBIM1 Homo sapiens transmembrane BAX inhibitor motif 
containing 1 (TMBIM1), mRNA. 
1.39E-05 2.0240154 up 
51643 TMBIM4 Homo sapiens transmembrane BAX inhibitor motif 
containing 4 (TMBIM4), mRNA. 
5.13E-06 2.1981583 up 
54499 TMCO1 Homo sapiens transmembrane and coiled-coil 
domains 1 (TMCO1), mRNA. 
6.88E-05 2.277675 up 
55002 TMCO3 Homo sapiens transmembrane and coiled-coil 
domains 3 (TMCO3), mRNA. 
1.09E-05 4.236887 up 
50999 TMED5 Homo sapiens transmembrane emp24 protein 
transport domain containing 5 (TMED5), mRNA. 
5.47E-06 3.1973817 up 
79073 TMEM109 Homo sapiens transmembrane protein 109 
(TMEM109), mRNA. 
5.27E-06 2.2828548 down 
79134 TMEM185B Homo sapiens transmembrane protein 185B 
(TMEM185B) on chromosome 2. 
1.08E-05 2.634556 up 
23670 TMEM2 Homo sapiens transmembrane protein 2 (TMEM2), 
mRNA. 
9.10E-06 2.0314133 up 
120224 TMEM45B Homo sapiens transmembrane protein 45B 
(TMEM45B), mRNA. 
4.51E-02 2.1744459 up 
55529 TMEM55A Homo sapiens transmembrane protein 55A 
(TMEM55A), mRNA. 
3.09E-04 2.226089 up 
54968 TMEM70 Homo sapiens transmembrane protein 70 
(TMEM70), mRNA. 
2.62E-03 2.0122697 up 
58986 TMEM8 Homo sapiens transmembrane protein 8 (five 
membrane-spanning domains) (TMEM8), mRNA. 
5.46E-04 2.111879 up 
641649 TMEM91 Homo sapiens transmembrane protein 91 
(TMEM91), mRNA. 
1.16E-02 2.068093 up 
147184 TMEM99 Homo sapiens transmembrane protein 99 
(TMEM99), mRNA. 
8.18E-05 2.0539787 down 
83862 TMPIT Homo sapiens transmembrane protein 120A 
(TMEM120A), mRNA. 
5.13E-06 5.330161 up 
79089 TMUB2 Homo sapiens transmembrane and ubiquitin-like 
domain containing 2 (TMUB2), transcript variant 1, 
mRNA. 
5.27E-06 2.0301595 up 
7128 TNFAIP3 Homo sapiens tumor necrosis factor, alpha-
induced protein 3 (TNFAIP3), mRNA. 
5.13E-06 2.535046 up 
126282 TNFAIP8L1 Homo sapiens tumor necrosis factor, alpha-
induced protein 8-like 1 (TNFAIP8L1), mRNA. 
4.02E-05 2.3987746 down 
7132 TNFRSF1A Homo sapiens tumor necrosis factor receptor 
superfamily, member 1A (TNFRSF1A), mRNA. 
6.88E-05 2.2245054 up 
8718 TNFRSF25 Homo sapiens tumor necrosis factor receptor 
superfamily, member 25 (TNFRSF25), transcript 
variant 10, mRNA. 
7.25E-06 5.231462 down 
939 TNFRSF7 Homo sapiens tumor necrosis factor receptor 
superfamily, member 7 (TNFRSF7), mRNA. 
5.27E-06 6.002582 down 
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54472 TOLLIP Homo sapiens toll interacting protein (TOLLIP), 
mRNA. 
5.13E-06 2.223728 up 
10043 TOM1 Homo sapiens target of myb1 (chicken) (TOM1), 
mRNA. 
1.39E-05 2.5397213 up 
1861 TOR1A Homo sapiens torsin family 1, member A (torsin A) 
(TOR1A), mRNA. 
9.97E-06 2.355419 up 
26092 TOR1AIP1 Homo sapiens torsin A interacting protein 1 
(TOR1AIP1), mRNA. 
2.42E-05 2.074896 up 
9540 TP53I3 Homo sapiens tumor protein p53 inducible protein 
3 (TP53I3), transcript variant 2, mRNA. 
1.08E-02 5.992417 up 
55858 TPARL Homo sapiens transmembrane protein 165 
(TMEM165), mRNA. 
3.13E-04 2.313302 up 
7167 TPI1 Homo sapiens triosephosphate isomerase 1 (TPI1), 
mRNA. 
6.31E-06 2.151335 up 
27010 TPK1 Homo sapiens thiamin pyrophosphokinase 1 
(TPK1), transcript variant 2, mRNA. 
3.08E-03 3.0417762 up 
27010 TPK1 Homo sapiens thiamin pyrophosphokinase 1 
(TPK1), mRNA. 
5.13E-06 3.9716504 up 
8460 TPST1 Homo sapiens tyrosylprotein sulfotransferase 1 
(TPST1), mRNA. 
8.12E-04 5.207051 up 
8459 TPST2 Homo sapiens tyrosylprotein sulfotransferase 2 
(TPST2), transcript variant 1, mRNA. 
5.13E-06 2.8909817 up 
7188 TRAF5 Homo sapiens TNF receptor-associated factor 5 
(TRAF5), transcript variant 1, mRNA. 
5.62E-06 3.0638025 down 
79865 TREML2 Homo sapiens triggering receptor expressed on 
myeloid cells-like 2 (TREML2), mRNA. 
1.82E-05 2.6735244 up 
10221 TRIB1 Homo sapiens tribbles homolog 1 (Drosophila) 
(TRIB1), mRNA. 
5.27E-06 4.1030045 up 
28951 TRIB2 Homo sapiens tribbles homolog 2 (Drosophila) 
(TRIB2), mRNA. 
8.62E-05 2.7836354 down 
7706 TRIM25 Homo sapiens tripartite motif-containing 25 
(TRIM25), mRNA. 
2.90E-05 2.73022 up 
23650 TRIM29 Homo sapiens tripartite motif-containing 29 
(TRIM29), transcript variant 1, mRNA. 
3.64E-05 2.2921526 up 
54765 TRIM44 Homo sapiens tripartite motif-containing 44 
(TRIM44), mRNA. 
5.13E-06 2.1404412 down 
6738 TROVE2 Homo sapiens TROVE domain family, member 2 
(TROVE2), mRNA. 
7.50E-04 2.1647313 up 
140803 TRPM6 Homo sapiens transient receptor potential cation 
channel, subfamily M, member 6 (TRPM6), mRNA. 
1.60E-04 2.230239 up 
79042 TSEN34 Homo sapiens tRNA splicing endonuclease 34 
homolog (S. cerevisiae) (TSEN34), mRNA. 
1.17E-05 2.6112914 up 
79042 TSEN34 Homo sapiens tRNA splicing endonuclease 34 
homolog (S. cerevisiae) (TSEN34), transcript variant 
2, mRNA. 
2.90E-05 2.4600291 up 
283989 TSEN54 Homo sapiens tRNA splicing endonuclease 54 
homolog (S. cerevisiae) (TSEN54), mRNA. 
4.33E-02 2.2225332 down 
81619 TSPAN14 Homo sapiens tetraspanin 14 (TSPAN14), mRNA. 1.52E-05 2.302972 up 
10100 TSPAN2 Homo sapiens tetraspanin 2 (TSPAN2), mRNA. 9.65E-04 2.7537334 up 
10077 TSPAN32 Homo sapiens tetraspanin 32 (TSPAN32), transcript 
variant 1, mRNA. 
5.35E-06 2.1602862 down 
706 TSPO Homo sapiens translocator protein (18kDa) (TSPO), 
transcript variant PBR-S, mRNA. 
5.13E-06 6.5941825 up 
706 TSPO Homo sapiens translocator protein (18kDa) (TSPO), 
transcript variant PBR, mRNA. 
5.13E-06 3.5931153 up 
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706 TSPO Homo sapiens translocator protein (18kDa) (TSPO), 
transcript variant PBR, mRNA. 
5.13E-06 6.5472555 up 
7267 TTC3 Homo sapiens tetratricopeptide repeat domain 3 
(TTC3), transcript variant 1, mRNA. 
9.10E-06 2.5195348 down 
7294 TXK Homo sapiens TXK tyrosine kinase (TXK), mRNA. 1.31E-04 2.4760602 down 
7295 TXN Homo sapiens thioredoxin (TXN), mRNA. 5.13E-06 5.347241 up 
81542 TXNDC Homo sapiens thioredoxin domain containing 
(TXNDC), mRNA. 
2.90E-05 2.2423642 up 
51314 TXNDC3 Homo sapiens thioredoxin domain containing 3 
(spermatozoa) (TXNDC3), mRNA. 
5.65E-03 2.644698 up 
84817 TXNL5 Homo sapiens thioredoxin-like 5 (TXNL5), mRNA. 5.13E-06 3.4908164 up 
7296 TXNRD1 Homo sapiens thioredoxin reductase 1 (TXNRD1), 
transcript variant 1, mRNA. 
5.13E-06 2.4054728 up 
7305 TYROBP Homo sapiens TYRO protein tyrosine kinase 
binding protein (TYROBP), transcript variant 1, 
mRNA. 
9.97E-06 2.0423567 up 
219743 TYSND1 Homo sapiens trypsin domain containing 1 
(TYSND1), mRNA. 
5.13E-06 2.4522114 down 
51271 UBAP1 Homo sapiens ubiquitin associated protein 1 
(UBAP1), mRNA. 
5.35E-06 2.5244715 up 
53347 UBASH3A Homo sapiens ubiquitin associated and SH3 
domain containing, A (UBASH3A), transcript variant 
2, mRNA. 
2.34E-02 2.0363843 down 
55236 UBE1L2 Homo sapiens ubiquitin-activating enzyme E1-like 
2 (UBE1L2), mRNA. 
1.39E-05 2.293835 up 
7319 UBE2A Homo sapiens ubiquitin-conjugating enzyme E2A 
(RAD6 homolog) (UBE2A), transcript variant 2, 
mRNA. 
7.68E-06 2.0290892 up 
11065 UBE2C Homo sapiens ubiquitin-conjugating enzyme E2C 
(UBE2C), transcript variant 6, mRNA. 
1.99E-03 2.1636586 up 
140739 UBE2F Homo sapiens ubiquitin-conjugating enzyme E2F 
(putative) (UBE2F), mRNA. 
5.27E-06 2.6726508 up 
7328 UBE2H Homo sapiens ubiquitin-conjugating enzyme E2H 
(UBC8 homolog, yeast) (UBE2H), transcript variant 
1, mRNA. 
1.00E-05 4.5497627 up 
7328 UBE2H Homo sapiens ubiquitin-conjugating enzyme E2H 
(UBC8 homolog, yeast) (UBE2H), transcript variant 
2, mRNA. 
1.08E-05 2.8271759 up 
51465 UBE2J1 Homo sapiens ubiquitin-conjugating enzyme E2, J1 
(UBC6 homolog, yeast) (UBE2J1), mRNA. 
6.74E-06 2.4162953 up 
9246 UBE2L6 Homo sapiens ubiquitin-conjugating enzyme E2L 6 
(UBE2L6), transcript variant 1, mRNA. 
8.33E-05 2.174446 down 
59286 UBL5 Homo sapiens ubiquitin-like 5 (UBL5), transcript 
variant 2, mRNA. 
5.47E-06 2.7284927 up 
29979 UBQLN1 Homo sapiens ubiquilin 1 (UBQLN1), transcript 
variant 2, mRNA. 
2.20E-05 2.063639 up 
80019 UBTD1 Homo sapiens ubiquitin domain containing 1 
(UBTD1), mRNA. 
9.10E-06 4.6596165 up 
7357 UGCG Homo sapiens UDP-glucose ceramide 
glucosyltransferase (UGCG), mRNA. 
5.13E-06 5.3274803 up 
7360 UGP2 Homo sapiens UDP-glucose pyrophosphorylase 2 
(UGP2), transcript variant 1, mRNA. 
1.08E-05 2.282324 up 
7360 UGP2 Homo sapiens UDP-glucose pyrophosphorylase 2 
(UGP2), transcript variant 1, mRNA. 
8.44E-06 2.6670218 up 
7360 UGP2 Homo sapiens UDP-glucose pyrophosphorylase 2 
(UGP2), transcript variant 1, mRNA. 
5.91E-06 2.4629483 up 
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23353 UNC84A Homo sapiens unc-84 homolog A (C. elegans) 
(UNC84A), mRNA. 
3.90E-05 2.0030198 down 
7374 UNG Homo sapiens uracil-DNA glycosylase (UNG), 
transcript variant 2, mRNA. 
2.20E-05 2.3123088 down 
284415 UNQ3033 Homo sapiens LAIR hlog (UNQ3033), mRNA. 1.62E-05 5.5203085 up 
65110 UPF3A Homo sapiens UPF3 regulator of nonsense 
transcripts homolog A (yeast) (UPF3A), transcript 
variant 1, mRNA. 
4.99E-05 2.1988344 down 
7378 UPP1 Homo sapiens uridine phosphorylase 1 (UPP1), 
transcript variant 2, mRNA. 
5.13E-06 7.378657 up 
7390 UROS Homo sapiens uroporphyrinogen III synthase 
(congenital erythropoietic porphyria) (UROS), 
mRNA. 
7.25E-06 2.0056314 down 
83706 URP2 Homo sapiens UNC-112 related protein 2 (URP2), 
transcript variant URP2SF, mRNA. 
1.66E-05 2.1923494 up 
83706 URP2 Homo sapiens UNC-112 related protein 2 (URP2), 
transcript variant URP2SF, mRNA. 
1.39E-05 2.1220028 up 
9958 USP15 Homo sapiens ubiquitin specific peptidase 15 
(USP15), mRNA. 
3.40E-04 2.256709 up 
9098 USP6 Homo sapiens ubiquitin specific peptidase 6 (Tre-2 
oncogene) (USP6), mRNA. 
2.51E-04 2.4982307 up 
9341 VAMP3 Homo sapiens vesicle-associated membrane 
protein 3 (cellubrevin) (VAMP3), mRNA. 
6.31E-06 2.7583616 up 
8674 VAMP4 Homo sapiens vesicle-associated membrane 
protein 4 (VAMP4), transcript variant 2, mRNA. 
8.93E-05 2.3848705 up 
7407 VARS Homo sapiens valyl-tRNA synthetase (VARS), 
mRNA. 
1.92E-05 2.0157428 down 
7408 VASP Homo sapiens vasodilator-stimulated 
phosphoprotein (VASP), transcript variant 2, 
mRNA. 
8.44E-06 3.081069 up 
10493 VAT1 Homo sapiens vesicle amine transport protein 1 
homolog (T californica) (VAT1), mRNA. 
5.28E-05 2.1259196 up 
7423 VEGFB PREDICTED: Homo sapiens vascular endothelial 
growth factor B (VEGFB), mRNA. 
8.44E-06 2.5253143 down 
7431 VIM Homo sapiens vimentin (VIM), mRNA. 1.52E-05 2.125174 up 
8876 VNN1 Homo sapiens vanin 1 (VNN1), mRNA. 5.13E-06 6.509467 up 
8875 VNN2 Homo sapiens vanin 2 (VNN2), transcript variant 1, 
mRNA. 
1.30E-03 3.028327 up 
8875 VNN2 Homo sapiens vanin 2 (VNN2), transcript variant 1, 
mRNA. 
2.42E-05 2.9667041 up 
29802 VPREB3 Homo sapiens pre-B lymphocyte gene 3 (VPREB3), 
mRNA. 
7.27E-05 2.9298446 down 
54832 VPS13C Homo sapiens vacuolar protein sorting 13 homolog 
C (S. cerevisiae) (VPS13C), transcript variant 1B, 
mRNA. 
9.55E-04 2.0049055 down 
84313 VPS25 Homo sapiens vacuolar protein sorting 25 homolog 
(S. cerevisiae) (VPS25), mRNA. 
7.25E-06 2.0142643 up 
51699 VPS29 Homo sapiens vacuolar protein sorting 29 (yeast) 
(VPS29), transcript variant 1, mRNA. 
6.74E-06 2.2137716 up 
55737 VPS35 Homo sapiens vacuolar protein sorting 35 homolog 
(S. cerevisiae) (VPS35), mRNA. 
6.31E-06 2.0989456 up 
84277 WBSCR18 Homo sapiens Williams Beuren syndrome 
chromosome region 18 (WBSCR18), mRNA. 
5.13E-06 2.7013147 down 
114049 WBSCR22 Homo sapiens Williams Beuren syndrome 
chromosome region 22 (WBSCR22), mRNA. 
5.13E-06 2.18183 down 
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23001 WDFY3 Homo sapiens WD repeat and FYVE domain 
containing 3 (WDFY3), transcript variant 2, mRNA. 
8.29E-03 2.4394045 up 
55339 WDR33 Homo sapiens WD repeat domain 33 (WDR33), 
transcript variant 3, mRNA. 
3.00E-04 2.155574 down 
282809 WDR51B Homo sapiens WD repeat domain 51B (WDR51B), 
mRNA. 
2.81E-05 2.2347162 up 
84058 WDR54 Homo sapiens WD repeat domain 54 (WDR54), 
mRNA. 
5.13E-06 2.8456492 down 
54663 WDR74 PREDICTED: Homo sapiens WD repeat domain 74 
(WDR74), mRNA. 
4.58E-05 2.2829664 down 
55062 WIPI1 Homo sapiens WD repeat domain, 
phosphoinositide interacting 1 (WIPI1), mRNA. 
5.27E-06 4.774687 up 
7485 WRB Homo sapiens tryptophan rich basic protein (WRB), 
mRNA. 
9.10E-06 2.1208797 up 
26118 WSB1 Homo sapiens WD repeat and SOCS box-containing 
1 (WSB1), transcript variant 3, mRNA. 
5.35E-06 3.253631 up 
26118 WSB1 Homo sapiens WD repeat and SOCS box-containing 
1 (WSB1), transcript variant 2, mRNA. 
5.27E-06 3.7353961 up 
55884 WSB2 Homo sapiens WD repeat and SOCS box-containing 
2 (WSB2), mRNA. 
5.35E-06 2.6757147 up 
11060 WWP2 Homo sapiens WW domain containing E3 ubiquitin 
protein ligase 2 (WWP2), transcript variant 2, 
mRNA. 
1.55E-3 2.622582 up 
54739 XAF1 Homo sapiens XIAP associated factor-1 (XAF1), 
transcript variant 2, mRNA. 
6.37E-05 4.115252 down 
54739 XAF1 Homo sapiens XIAP associated factor-1 (XAF1), 
transcript variant 2, mRNA. 
8.17E-03 2.0057201 down 
7504 XK Homo sapiens X-linked Kx blood group (McLeod 
syndrome) (XK), mRNA. 
4.04E-04 2.7637672 up 
64328 XPO4 Homo sapiens exportin 4 (XPO4), mRNA. 1.85E-05 2.0293672 down 
54432 YIPF1 Homo sapiens Yip1 domain family, member 1 
(YIPF1), mRNA. 
6.74E-06 2.4743662 up 
7532 YWHAG Homo sapiens tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase 
activation protein, gamma polypeptide (YWHAG), 
mRNA. 
5.13E-06 2.2790608 up 
7533 YWHAH Homo sapiens tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase 
activation protein, eta polypeptide (YWHAH), 
mRNA. 
7.68E-06 2.1762502 up 
51776 ZAK Homo sapiens sterile alpha motif and leucine 
zipper containing kinase AZK (ZAK), transcript 
variant 2, mRNA. 
1.67E-04 2.360896 up 
7535 ZAP70 Homo sapiens zeta-chain (TCR) associated protein 
kinase 70kDa (ZAP70), transcript variant 2, mRNA. 
8.66E-06 4.574251 down 
81030 ZBP1 Homo sapiens Z-DNA binding protein 1 (ZBP1), 
mRNA. 
2.86E-04 2.3077092 down 
7704 ZBTB16 Homo sapiens zinc finger and BTB domain 
containing 16 (ZBTB16), transcript variant 1, mRNA. 
5.78E-05 4.2436647 up 
9841 ZBTB24 Homo sapiens zinc finger and BTB domain 
containing 24 (ZBTB24), mRNA. 
8.44E-06 2.0458806 down 
57659 ZBTB4 Homo sapiens zinc finger and BTB domain 
containing 4 (ZBTB4), mRNA. 
8.44E-06 2.0443172 down 
285381 ZCSL2 Homo sapiens DPH3, KTI11 homolog (S. cerevisiae) 
(DPH3), transcript variant 1, mRNA. 
9.10E-06 3.1996632 up 
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84885 ZDHHC12 Homo sapiens zinc finger, DHHC-type containing 12 
(ZDHHC12), mRNA. 
7.57E-05 2.0542245 up 
131540 ZDHHC19 Homo sapiens zinc finger, DHHC-type containing 19 
(ZDHHC19), mRNA. 
5.22E-04 33.226856 up 
51304 ZDHHC3 Homo sapiens zinc finger, DHHC-type containing 3 
(ZDHHC3), mRNA. 
6.17E-06 3.297276 up 
29801 ZDHHC8 Homo sapiens zinc finger, DHHC-type containing 8 
(ZDHHC8), mRNA. 
5.47E-06 2.30029 down 
9839 ZFHX1B Homo sapiens zinc finger homeobox 1b (ZFHX1B), 
mRNA. 
1.17E-05 2.8815064 up 
64397 ZFP106 Homo sapiens zinc finger protein 106 homolog 
(mouse) (ZFP106), mRNA. 
5.47E-06 2.404434 up 
7538 ZFP36 Homo sapiens zinc finger protein 36, C3H type, 
homolog (mouse) (ZFP36), mRNA. 
1.28E-05 2.074414 up 
678 ZFP36L2 Homo sapiens zinc finger protein 36, C3H type-like 
2 (ZFP36L2), mRNA. 
5.42E-05 2.1886992 down 
9765 ZFYVE16 Homo sapiens zinc finger, FYVE domain containing 
16 (ZFYVE16), mRNA. 
1.08E-05 2.2273862 up 
10269 ZMPSTE24 Homo sapiens zinc metallopeptidase (STE24 
homolog, yeast) (ZMPSTE24), mRNA. 
5.13E-06 2.5700939 up 
10838 ZNF275 Homo sapiens zinc finger protein 275 (ZNF275), 
mRNA. 
5.13E-06 3.1497006 down 
7580 ZNF32 Homo sapiens zinc finger protein 32 (ZNF32), 
transcript variant 1, mRNA. 
5.50E-03 2.4229715 up 
26152 ZNF337 Homo sapiens zinc finger protein 337 (ZNF337), 
mRNA. 
9.21E-06 2.4192097 down 
162979 ZNF342 Homo sapiens zinc finger protein 342 (ZNF342), 
mRNA. 
7.25E-06 2.2081544 down 
55893 ZNF395 Homo sapiens zinc finger protein 395 (ZNF395), 
mRNA. 
5.35E-06 2.7907915 down 
220929 ZNF438 Homo sapiens zinc finger protein 438 (ZNF438), 
mRNA. 
9.97E-06 5.368193 up 
168544 ZNF467 Homo sapiens zinc finger protein 467 (ZNF467), 
mRNA. 
5.98E-04 2.5720587 up 
57711 ZNF529 Homo sapiens zinc finger protein 529 (ZNF529), 
mRNA. 
1.17E-05 2.1962404 down 
57616 ZNF537 Homo sapiens zinc finger protein 537 (ZNF537), 
mRNA. 
2.12E-03 3.029457 up 
91120 ZNF682 Homo sapiens zinc finger protein 682 (ZNF682), 
mRNA. 
9.69E-03 2.1394207 up 
257101 ZNF683 Homo sapiens zinc finger protein 683 (ZNF683), 
mRNA. 
2.09E-02 3.0123246 down 
7644 ZNF91 Homo sapiens zinc finger protein 91 (HPF7, HTF10) 
(ZNF91), mRNA. 
3.87E-05 2.5146646 down 
7791 ZYX Homo sapiens zyxin (ZYX), transcript variant 1, 
mRNA. 
3.14E-04 2.1189222 up 
7791 ZYX Homo sapiens zyxin (ZYX), transcript variant 1, 
mRNA. 
8.33E-05 2.4799135 up 
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Appendix 8.2: Signalling pathways from 1780 SDE gene transcripts 
Ingenuity Canonical 
Pathways 
B H  
p value 
Ratio % Molecules No. of 
molecule 
CD28 Signaling in T 
Helper Cells 
2.63E+09 2.40E-01 24 CD247,FYN,HLA-
DOA,CD3E,CDC42,CD4,ARPC5,HLA-
DQA1,HLA-DMB,LCK,ACTR3,HLA-
DRA,ARPC3,ARPC1A,CHUK,MAP2K1,ITK,AT
M,HLA-
DMA,ACTR2,CHP,PPP3CC,CD3D,CD3G,SYK,Z
AP70,LAT,ITPR3,FCER1G,CD86,CARD11 
31 
Role of NFAT in 
Regulation of the 
Immune Response 
8.71E+06 1.74E-01 17.4 CD247,FYN,HLA-
DOA,CD3E,MAPK1,CD4,HLA-DQA1,HLA-
DMB,KRAS,CD79A,LCK,GNA15,HLA-
DRA,CHUK,MAP2K1,ITK,ATM,HLA-
DMA,CD79B,CHP,PPP3CC,CD3D,GNG5,GNAI
3,CD3G,SYK,MEF2D,ZAP70,LAT,ITPR3,GNB2,
FCER1G,CD86,MEF2C 
34 
Calcium-induced T 
Lymphocyte Apoptosis 
8.71E+06 2.88E-01 28.8 CD247,HLA-DMA,HLA-
DOA,CD3E,CD4,CHP,HLA-DQA1,HLA-
DMB,PPP3CC,CD3D,CD3G,LCK,PRKCD,MEF2
D,ZAP70,HLA-DRA,ITPR3,FCER1G,PRKCH 
19 
Phospholipase C 
Signaling 
5.89E+06 1.56E-01 15.6 PEBP1,CD247,FYN,MPRIP,CD3E,MAPK1,MYL
6,KRAS,CD79A,HMOX1,LCK,RHOG,AHNAK,R
HOT1,MARCKS,MAP2K1,RALGDS,ITK,HDAC4,
CD79B,CHP,RALB,PPP3CC,CD3D,GNG5,CD3G
,MYL12A,MYL12B,SYK,PRKCD,MEF2D,LAT,J
MJD7-
PLA2G4B,ZAP70,ITPR3,GNB2,FCER1G,PPP1R
12A,MEF2C,PRKCH 
40 
CTLA4 Signaling in 
Cytotoxic T Lymphocytes 
3.63E+06 2.40E-01 24 CD247,HLA-DMA,FYN,HLA-
DOA,CD3E,PPP2CA,CD4,CLTC,HLA-
DQA1,HLA-
DMB,JAK2,CD3D,PPP2R5A,CD3G,LCK,SYK,LA
T,HLA-
DRA,ZAP70,FCER1G,CD86,PTPN22,ATM 
23 
Cdc42 Signaling 3.63E+06 1.92E-01 19.2 CD247,HLA-
DOA,MPRIP,MYL6,MAPK1,CD3E,CDC42,ARP
C5,HLA-DQA1,HLA-
DMB,EXOC6,IQGAP1,HLA-
DPA1,CLIP1,ACTR3,HLA-
DRA,ARPC3,ARPC1A,ITK,HLA-
DMA,ACTR2,HLA-DRB3 (includes 
others),CD3D,CD3G,MYL12A,MYL12B,FCER1
G,PPP1R12A 
28 
Nur77 Signaling in T 
Lymphocytes 
3.63E+06 2.88E-01 28.8 CD247,HLA-DMA,HLA-DOA,CD3E,CHP,HLA-
DQA1,APAF1,HLA-
DMB,PPP3CC,CD3D,BCL2,CD3G,MEF2D,HLA-
DRA,FCER1G,CD86,RXRA 
17 
Glycolysis/Gluconeogene
sis 
3.98E+05 1.61E-01 16.1 PGK1,PKM2,ACSL3,PGM2,ACSS1,GAPDH,PG
M1,TPI1,LDHB,HK2,DHRS9,PGAM1,ACSS2,DL
D,ALDOA,ALDH3B1,PECR,HK3,LDHA,ACSL1 
20 
iCOS-iCOSL Signaling in T 
Helper Cells 
3.98E+05 1.93E-01 19.3 CD247,HLA-DMA,HLA-
DOA,CD3E,CD4,CHP,HLA-DQA1,HLA-
DMB,PPP3CC,CD3D,IL2RB,PTEN,CD3G,LCK,L
AT,HLA-
DRA,ZAP70,ITPR3,FCER1G,CHUK,PLEKHA1,A
TM,ITK 
23 
PKCθ Signaling in T 
Lymphocytes 
3.09E+05 1.76E-01 17.6 CD247,HLA-DMA,FYN,HLA-
DOA,MAPK1,CD3E,CD4,CHP,HLA-DQA1,HLA-
DMB,KRAS,PPP3CC,CD3D,CD3G,LCK,LAT,HLA
-
DRA,ZAP70,FCER1G,CD86,MAP3K8,CHUK,CA
RD11,ATM 
24 
Cytotoxic T Lymphocyte-
mediated Apoptosis of 
Target Cells 
1.95E+05 2.83E-01 28.3 CD247,HLA-DMA,HLA-DOA,CD3E,HLA-
DQA1,APAF1,HLA-DRB3 (includes 
others),HLA-DMB,CD3D,HLA-
DPA1,BCL2,CD3G,PRF1,HLA-DRA,FCER1G 
15 
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Type I Diabetes Mellitus 
Signaling 
5.89E+04 1.86E-01 18.6 CD247,HLA-DMA,HLA-
DOA,MAPK1,CD3E,MYD88,IFNGR2,HLA-
DQA1,APAF1,HLA-
DMB,IFNGR1,JAK2,CD3D,BCL2,CD3G,PRF1,L
TA,HLA-DRA,FCER1G,CD86,CHUK,IL1RAP 
22 
OX40 Signaling Pathway 5.62E+04 2.38E-01 23.8 CD247,HLA-DMA,HLA-DOA,CD3E,CD4,HLA-
DQA1,HLA-DRB3 (includes others),HLA-
DMB,CD3D,HLA-DPA1,BCL2,CD3G,HLA-
DRA,FCER1G,TRAF5 
15 
T Cell Receptor Signaling 2.63E+04 1.85E-01 18.5 CD247,FYN,MAPK1,CD3E,CD4,KRAS,PPP3CC,
CD8A,CD3D,CD3G,LCK,RASGRP1,PAG1,LAT,Z
AP70,CHUK,MAP2K1,CARD11,ATM,ITK 
20 
fMLP Signaling in 
Neutrophils 
1.86E+04 1.65E-01 16.5 ACTR2,MAPK1,CDC42,CHP,ARPC5,FPR2,KRA
S,PPP3CC,GNG5,FPR1,GNAI3,ACTR3,PRKCD,I
TPR3,CYBB,GNB2,ARPC3,ARPC1A,PRKCH,MA
P2K1,ATM 
21 
T Helper Cell 
Differentiation 
1.78E+04 2.29E-01 22.9 HLA-DMA,HLA-DOA,IL12RB1,IL21R,HLA-
DQA1,IFNGR2,IFNGR1,HLA-
DMB,BCL6,IL18R1,STAT4,HLA-
DRA,IL10RB,FCER1G,CD86,CXCR5 
16 
Natural Killer Cell 
Signaling 
2.75E+03 1.73E-01 17.3 CD247,FYN,MAPK1,LAIR1,TYROBP,KLRD1,KR
AS,LCK,SH2D1A,KLRB1,PRKCD,SYK,ZAP70,LA
T,FCER1G,PRKCH,HCST,MAP2K1,ATM 
19 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
1.55E+03 1.84E-01 18.4 HLA-DMA,HLA-DOA,CD79B,TLR8,HLA-
DQA1,LTB,HLA-
DMB,CD79A,TLR4,TLR5,LTA,HLA-
DRA,TLR7,FCER1G,CD86,CHUK 
16 
B Cell Development 1.20E+03 3.00E-01 30 IL7R,HLA-DMA,HLA-DOA,CD79B,HLA-
DRA,HLA-DQA1,CD86,HLA-DMB,CD79A 
9 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
1.20E+03 1.68E-01 16.8 ACTR2,FYN,MAPK1,CDC42,ARPC5,PTEN,HM
OX1,ACTR3,PRKCD,SYK,HCK,VAMP3,ARPC3,
ARPC1A,PRKCH,VASP,FGR 
17 
Regulation of IL-2 
Expression in Activated 
and Anergic T 
Lymphocytes 
7.41E+02 1.70E-01 17 CD247,FYN,CD3E,MAPK1,SMAD3,CHP,KRAS,
PPP3CC,CD3D,CD3G,LAT,ZAP70,CHUK,CARD
11,MAP2K1 
15 
Primary 
Immunodeficiency 
Signaling 
6.76E+02 2.00E-01 20 IL7R,LCK,CD3E,CD4,ZAP70,ADA,RFX5,CD8A,C
D3D,UNG,CD79A 
11 
Toll-like Receptor 
Signaling 
3.80E+02 2.00E-01 20 TLR4,LY96 (includes 
EG:17087),TOLLIP,TLR5,MAPK1,MYD88,TLR8
,TLR7,CD14,CHUK,IRAK3 
11 
Integrin Signaling 3.80E+02 1.27E-01 12.7 FYN,MPRIP,MAPK1,CDC42,ARPC5,KRAS,ITGB
7,PTEN,PTK2 (includes 
EG:14083),RHOG,ACTR3,RHOT1,ARF4,ARPC
3,ARPC1A,MAP2K1,VASP,ATM,ACTR2,ASAP1
,RALB,MYL12A,ITGAM (includes 
EG:16409),MYL12B,PPP1R12A,CAPN3 
26 
Dendritic Cell Maturation 3.80E+02 1.23E-01 12.3 HLA-DMA,HLA-
DOA,MAPK1,TYROBP,MYD88,HLA-
DQA1,CD58,LTB,HLA-DMB,HLA-DRB3 
(includes others),JAK2,STAT4,TLR4,LTA,HLA-
DRA,FCER1G,CD86,LTBR,CHUK,CCR7,IFNAR1
,ATM 
22 
CCR5 Signaling in 
Macrophages 
3.39E+02 1.48E-01 14.8 CD247,CD3E,MAPK1,CD4,CCL5,CD3D,GNG5,
GNAI3,CD3G,PRKCD,GNB2,FCER1G,PRKCH 
13 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
2.75E+02 1.06E-01 10.6 IL18RAP,MAPK1,IL32,TLR8,LTB,KRAS,JAK2,C
CL5,IL18R1,IL1R2,C5AR1,GNA15,CEBPA,TLR7
,LTBR,CHUK,TRAF5,MAPKAPK2,MAP2K1,IL1
RAP,ATM,VEGFB,MYD88,CHP,CEBPB 
(includes 
EG:1051),PPP3CC,IRAK3,TLR4,TLR5,CEBPD,P
RKCD,LTA,LEF1,PRKCH 
34 
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Production of Nitric 
Oxide and Reactive 
Oxygen Species in 
Macrophages 
2.75E+02 1.14E-01 11.4 MAPK1,PPP2CA,IFNGR2,IFNGR1,JAK2,NCF4,
SPI1 (includes 
EG:20375),PPP2R5A,TLR4,PPP1R3D,RHOG,R
HOT1,PRKCD,CYBA,CYBB,PPP1R12A,SERPIN
A1,S100A8,MAP3K8,PRKCH,CHUK,MAP2K1,S
IRPA,ATM 
24 
IL-8 Signaling 2.09E+02 1.20E-01 12 VEGFB,MAPK1,KRAS,IRAK3,CSTB,GNG5,BCL2
,PTK2 (includes 
EG:14083),HMOX1,GNAI3,ITGAM (includes 
EG:16409),CCND2,RHOG,CCND3,RHOT1,MY
L12B,PRKCD,GNB2,CYBB,PRKCH,CHUK,MAP
2K1,ATM 
23 
NF-κB Signaling 1.74E+02 1.29E-01 12.9 AZI2,MYD88,TLR8,TNFAIP3,TBK1,KRAS,IRAK
3,IL1R2,TLR4,LCK,TLR5,LTA,ZAP70,TGFA,TLR
7,FCER1G,MAP3K8,LTBR,CHUK,TRAF5,CARD
11,ATM 
22 
Molecular Mechanisms 
of Cancer 
1.74E+02 9.95E-02 9.95 FYN,APH1B,CDC42,MAPK1,SMAD3,CTNNA1,
KRAS,HIF1A,JAK2,E2F3,BCL2,CDC25B,PTK2 
(includes 
EG:14083),LAMTOR3,RHOG,GNA15,RHOT1,
MAP2K1,RALGDS,ATM,HAT1,CDKN2D,RALB,
CDK6,APAF1,NBN,GNAI3,CCND2,CCND3,FOX
O1,PRKCD,CDK4,RASGRP1,RBPJ,LEF1,PRKCH,
BIRC2 
37 
Role of Pattern 
Recognition Receptors in 
Recognition of Bacteria 
and Viruses 
1.74E+02 1.59E-01 15.9 OAS2,MAPK1,MYD88,TLR8,CCL5,RNASEL,TL
R4,C5AR1,TLR5,SYK,TLR7,NLRC4,ATM 
13 
Actin Nucleation by ARP-
WASP Complex 
1.58E+02 1.67E-01 16.7 ACTR2,ACTR3,RHOG,CDC42,RHOT1,ARPC5,P
PP1R12A,ARPC3,ARPC1A,KRAS,VASP 
11 
Allograft Rejection 
Signaling 
1.51E+02 1.67E-01 16.7 HLA-DMA,PRF1,HLA-DOA,HLA-DRA,HLA-
DQA1,FCER1G,CD86,HLA-DRB3 (includes 
others),HLA-DMB,HLA-DPA1 
10 
Antigen Presentation 
Pathway 
1.51E+02 2.09E-01 20.9 HLA-DMA,HLA-DOA,HLA-DRA,HLA-
DQA1,HLA-DRB3 (includes others),HLA-
DMB,CD74,HLA-DPA1,MR1 
9 
Pyruvate Metabolism 9.55E+01 8.53E-02 8.53 PKM2,ACSL3,ACSS2,DLD,ACSS1,ME2,ACOT9,
AKR1B1,ACSL1,LDHA,LDHB 
11 
PI3K Signaling in B 
Lymphocytes 
8.91E+01 1.27E-01 12.7 FYN,MAPK1,CD79B,CHP,KRAS,ATF6,PPP3CC,
CD79A,PTEN,TLR4,GNA15,SYK,ITPR3,IRS2,PI
K3AP1,CHUK,PLEKHA1,MAP2K1 
18 
Fructose and Mannose 
Metabolism 
7.94E+01 6.98E-02 6.98 NUDT5,PFKFB3,PGM2,HK2,PFKFB4,ALDOA,H
K3,TPI1,AKR1B1 
9 
Regulation of Actin-
based Motility by Rho 
6.92E+01 1.46E-01 14.6 ACTR2,MPRIP,CDC42,MYL6,ARPC5,MYL12A,
ACTR3,RHOG,RHOT1,MYL12B,PPP1R12A,AR
PC3,ARPC1A 
13 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
5.37E+01 1.25E-01 12.5 IL18RAP,VEGFB,MYL6,SMAD3,IFNGR2,IFNGR
1,CCL5,BCL2,IL1R2,TLR4,LY96 (includes 
EG:17087),TIMP1,TGFA,CD14,IL1RAP,CCR7,I
FNAR1,TIMP2 (includes EG:21858) 
18 
Role of Tissue Factor in 
Cancer 
5.01E+01 1.35E-01 13.5 FYN,CDC42,MAPK1,PLAUR,KRAS,JAK2,PDXP,
PTEN,LCK,ARRB2,HCK,RPS6KA5,RPS6KA1 
(includes EG:20111),FGR,ATM 
15 
Signaling by Rho Family 
GTPases 
5.01E+01 1.03E-01 10.3 MYL6,MAPK1,CDC42,ARPC5,IQGAP1,SEPT9,
CLIP1,PTK2 (includes 
EG:14083),RHOG,ACTR3,GNA15,RHOT1,CYB
B,ARPC3,ARPC1A,MAP2K1,ATM,ACTR2,VIM,
GNG5,GNAI3,MYL12A,MYL12B,GNB2,PPP1R
12A,SEPT6 
26 
Glioma Invasiveness 
Signaling 
4.79E+01 1.67E-01 16.7 PTK2 (includes 
EG:14083),RHOG,MAPK1,RHOT1,TIMP1,CD4
4 (includes 
EG:100330801),PLAUR,KRAS,TIMP2 
(includes EG:21858),ATM 
10 
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IL-12 Signaling and 
Production in 
Macrophages 
4.27E+01 1.12E-01 11.2 MAPK1,IL12RB1,MYD88,IFNGR1,CEBPB 
(includes EG:1051),SPI1 (includes 
EG:20375),STAT4,TLR4,PRKCD,PRKCH,MAP3
K8,SERPINA1,S100A8,CHUK,RXRA,MAP2K1,A
TM 
17 
Nicotinate and 
Nicotinamide 
Metabolism 
4.27E+01 1.04E-01 10.4 MAPK1,CDK6,NAPRT1,VNN1,VNN2,PRKCD,C
DK4,PRKAA1,GRK6,PRKCH,NAMPT,MAP3K8,
MAP2K1,BST1 (includes EG:12182) 
14 
Crosstalk between 
Dendritic Cells and 
Natural Killer Cells 
3.89E+01 1.37E-01 13.7 KLRD1,TYROBP,LTB,HLA-DRB3 (includes 
others),IL2RB,TLR4,PRF1,LTA,HLA-
DRA,TLR7,CD86,LTBR,CCR7 
13 
p70S6K Signaling 3.89E+01 1.22E-01 12.2 YWHAG,CD79B,MAPK1,YWHAH,PPP2CA,KR
AS,PPP2R5A,CD79A,GNAI3,GNA15,PRKCD,SY
K,PRKCH,BCAP31,MAP2K1,ATM 
16 
Oxidative 
Phosphorylation 
3.63E+01 1.14E-01 11.4 ATP6V0E2,COX17 (includes 
EG:10063),NDUFB3,COX7A2,ATP6V1D 
(includes 
EG:299159),ATP6V0B,ATP6V1C1,TCIRG1,CO
X10 (includes 
EG:1352),ATP6V1A,ATP6AP1,NDUFA1,ATP6
V1E1,PPA2 (includes 
EG:27068),ATP6V0D1,ATP6V0E1,ATP6V1B2 
17 
TREM1 Signaling 3.55E+01 1.45E-01 14.5 TLR4,TLR5,MAPK1,TYROBP,TLR8,TLR7,LAT2,
CD86,JAK2 
9 
Autoimmune Thyroid 
Disease Signaling 
3.55E+01 1.45E-01 14.5 HLA-DMA,PRF1,HLA-DOA,HLA-DRA,HLA-
DQA1,FCER1G,CD86,HLA-DMB 
8 
IL-15 Signaling 3.47E+01 1.49E-01 14.9 PTK2 (includes 
EG:14083),LCK,MAPK1,SYK,KRAS,JAK2,MAP2
K1,IL2RB,ATM,BCL2 
10 
Role of JAK1 and JAK3 in 
γc Cytokine Signaling 
3.47E+01 1.52E-01 15.2 IL7R,FES,MAPK1,SYK,IL21R,IRS2,KRAS,JAK2,I
L2RB,ATM 
10 
Small Cell Lung Cancer 
Signaling 
3.47E+01 1.25E-01 12.5 PTK2 (includes 
EG:14083),CDK4,APAF1,CDK6,TRAF5,CHUK,
RXRA,PTEN,ATM,BCL2,BIRC2 
11 
Clathrin-mediated 
Endocytosis Signaling 
3.47E+01 1.09E-01 10.9 ACTR2,VEGFB,RAB5A,CDC42,CHP,CLTC,ARPC
5,NUMB,SH3GLB1,PPP3CC,ITGB7,ARRB2,AC
TR3,LDLR,SYNJ1,RAB5C,ARPC3,ARPC1A,SERP
INA1,S100A8,ATM 
21 
Rac Signaling 3.39E+01 1.15E-01 11.5 ACTR2,CDC42,MAPK1,ARPC5,KRAS,IQGAP1,
PTK2 (includes EG:14083),ACTR3,CD44 
(includes 
EG:100330801),CYBB,ARPC3,ARPC1A,MAP2
K1,ATM 
14 
Communication between 
Innate and Adaptive 
Immune Cells 
3.39E+01 1.21E-01 12.1 TLR4,TLR5,CD4,HLA-
DRA,TLR8,TLR7,FCER1G,CD86,HLA-DRB3 
(includes others),CCL5,CD8A,CCR7 
12 
Graft-versus-Host 
Disease Signaling 
3.09E+01 1.67E-01 16.7 HLA-DMA,PRF1,HLA-DOA,HLA-DRA,HLA-
DQA1,FCER1G,CD86,HLA-DMB 
8 
ERK/MAPK Signaling 3.09E+01 1.03E-01 10.3 ETS1,FYN,YWHAG,YWHAH,MAPK1,PPP2CA,E
TS2,KRAS,PPP2R5A,PTK2 (includes 
EG:14083),LAMTOR3,PPP1R3D,DUSP1,PRKC
D,MKNK1,JMJD7-
PLA2G4B,PPP1R12A,RPS6KA5,RPS6KA1 
(includes EG:20111),MAP2K1,ATM 
21 
Pancreatic 
Adenocarcinoma 
Signaling 
3.02E+01 1.19E-01 11.9 VEGFB,MAPK1,CDC42,SMAD3,KRAS,JAK2,E2
F3,BCL2,HMOX1,CDK4,TGFA,MAP2K1,RALG
DS,ATM 
14 
Lymphotoxin β Receptor 
Signaling 
2.95E+01 1.50E-01 15 MAPK1,LTA,APAF1,LTB,TRAF5,CHUK,LTBR,A
TM,BIRC2 
9 
CXCR4 Signaling 2.63E+01 1.07E-01 10.7 MYL6,MAPK1,CD4,KRAS,GNG5,PTK2 
(includes 
EG:14083),GNAI3,MYL12A,RHOG,GNA15,MY
L12B,RHOT1,PRKCD,ITPR3,GNB2,PRKCH,MA
P2K1,ATM 
18 
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RhoA Signaling 2.24E+01 1.25E-01 12.5 ACTR2,MPRIP,MYL6,ARPC5,SEPT9,PTK2 
(includes 
EG:14083),MYL12A,ACTR3,MYL12B,LPAR5,P
PP1R12A,ARPC3,ARPC1A,SEPT6 
14 
Galactose Metabolism 2.14E+01 7.14E-02 7.14 PGM2,GLA,HK2,UGP2,PGM1,HK3,AKR1B1 7 
VDR/RXR Activation 2.04E+01 1.36E-01 13.6 SERPINB1,FOXO1,GADD45A,PRKCD,MXD1,C
EBPA,CD14,PRKCH,CEBPB (includes 
EG:1051),CCL5,RXRA 
11 
Ephrin Receptor Signaling 1.78E+01 9.60E-02 9.6 ACTR2,FYN,VEGFB,MAPK1,CDC42,ARPC5,KR
AS,JAK2,GNG5,GRINA,PTK2 (includes 
EG:14083),GNAI3,ACTR3,SDCBP,GNA15,GNB
2,ARPC3,ARPC1A,MAP2K1 
19 
Inositol Phosphate 
Metabolism 
1.74E+01 8.90E-02 8.9 MAPK1,CDK6,PTEN,GNAI3,GNA15,SYNJ1,CD
K4,PRKCD,PRKAA1,GRK6,IMPA2,MAP3K8,PR
KCH,IRS2,MAP2K1,ATM,MTMR3 
17 
Glucocorticoid Receptor 
Signaling 
1.70E+01 8.90E-02 8.9 CD247,YWHAH,MAPK1,CD3E,HSPA1A/HSPA
1B,SMAD3,KRAS,CCL5,JAK2,TAF7,CD163,BCL
2,IL1R2,ANXA1,CEBPA,PRKAA1,CHUK,FKBP5,
MAP2K1,ATM,CHP,CEBPB (includes 
EG:1051),PPP3CC,CD3D,CD3G,DUSP1 
26 
IL-3 Signaling 1.55E+01 1.35E-01 13.5 FOXO1,MAPK1,PRKCD,CHP,KRAS,PRKCH,PPP
3CC,JAK2,MAP2K1,ATM 
10 
CD40 Signaling 1.38E+01 1.30E-01 13 MAPK1,LTA,TNFAIP3,TRAF5,CHUK,MAPKAPK
2,MAP2K1,ATM,FCER2 
9 
GM-CSF Signaling 1.38E+01 1.34E-01 13.4 ETS1,MAPK1,CSF2RA,HCK,KRAS,PPP3CC,JAK
2,MAP2K1,ATM 
9 
p38 MAPK Signaling 1.38E+01 1.23E-01 12.3 IL18RAP,MAPKAPK3,IRAK3,IL1R2,DUSP1,ME
F2D,MKNK1,JMJD7-
PLA2G4B,MAP4K1,MEF2C,RPS6KA5,MAPKA
PK2,IL1RAP 
13 
LPS-stimulated MAPK 
Signaling 
1.38E+01 1.22E-01 12.2 TLR4,CDC42,MAPK1,PRKCD,CD14,KRAS,PRK
CH,CHUK,MAP2K1,ATM 
10 
MIF-mediated 
Glucocorticoid 
Regulation 
1.35E+01 1.43E-01 14.3 TLR4,LY96 (includes 
EG:17087),MAPK1,JMJD7-
PLA2G4B,CD14,CD74 
6 
B Cell Receptor Signaling 1.35E+01 1.04E-01 10.4 ETS1,MAPK1,CD79B,CDC42,KRAS,PPP3CC,BC
L6,CD79A,PTEN,PAG1,SYK,MAP3K8,PIK3AP1,
CHUK,MAP2K1,ATM 
16 
Starch and Sucrose 
Metabolism 
1.23E+01 5.52E-02 5.52 NUDT5,PGM2,HK2,UGP2,GBA,PGM1,GBE1,P
YGL,HK3 
9 
Interferon Signaling 1.23E+01 1.67E-01 16.7 IFNGR2,MX1,IFNGR1,JAK2,IFNAR1,BCL2 6 
Cell Cycle: G1/S 
Checkpoint Regulation 
1.20E+01 1.36E-01 13.6 CCND3,CCND2,HDAC4,CDK4,SMAD3,CDK6,E
2F3,ATM 
8 
Aryl Hydrocarbon 
Receptor Signaling 
1.17E+01 9.68E-02 9.68 MGST1,MAPK1,NQO2,APAF1,CDK6,CYP1B1,
GSTO1,CTSD,CCND3,CCND2,CDK4,ALDH3B1,
RXRA,MCM7,ATM 
15 
Non-Small Cell Lung 
Cancer Signaling 
1.17E+01 1.14E-01 11.4 MAPK1,CDK4,ITPR3,TGFA,CDK6,KRAS,RXRA,
MAP2K1,ATM 
9 
Hypoxia Signaling in the 
Cardiovascular System 
1.17E+01 1.36E-01 13.6 UBE2H,UBE2A,COPS5,HIF1A,UBE2J1,LDHA,U
BE2F,PTEN,ATM 
9 
Cardiac Hypertrophy 
Signaling 
1.17E+01 9.13E-02 9.13 MYL6,MAPK1,MAPKAPK3,CHP,KRAS,ATF6,P
PP3CC,GNG5,GNAI3,MYL12A,RHOG,GNA15,
RHOT1,MYL12B,MEF2D,GNB2,MAP3K8,MEF
2C,RPS6KA1 (includes 
EG:20111),MAPKAPK2,MAP2K1,ATM 
22 
IL-17A Signaling in 
Fibroblasts 
1.17E+01 1.50E-01 15 MAPK1,CEBPD,LCN2,CHUK,CEBPB (includes 
EG:1051),NFKBIZ 
6 
Thrombopoietin 
Signaling 
1.17E+01 1.27E-01 12.7 MAPK1,PRKCD,IRS2,KRAS,PRKCH,JAK2,MAP
2K1,ATM 
8 
Acute Myeloid Leukemia 
Signaling 
1.15E+01 1.22E-01 12.2 CSF3R,MAPK1,CSF2RA,CEBPA,LEF1,KRAS,MA
P2K1,SPI1 (includes EG:20375),FLT3LG,ATM 
10 
Cyclins and Cell Cycle 
Regulation 
1.15E+01 1.15E-01 11.5 CCND3,CCND2,HDAC4,PPP2CA,CDK4,CDKN2
D,CDK6,E2F3,PPP2R5A,ATM 
10 
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PPARα/RXRα Activation 1.10E+01 9.60E-02 9.6 IL18RAP,MAPK1,ACAA1,SMAD3,ACOX1,KRA
S,JAK2,GK,ABCA1,ACVR1B,IL1R2,GNA15,PRK
AA1,CHUK,RXRA,IL1RAP,MAP2K1 
17 
IL-4 Signaling 1.07E+01 1.25E-01 12.5 HLA-DMA,HLA-DOA,HLA-DRA,HLA-
DQA1,KRAS,HLA-DMB,JAK2,ATM,FCER2 
9 
Glioblastoma Multiforme 
Signaling 
1.07E+01 9.58E-02 9.58 MAPK1,CDC42,CDK6,KRAS,E2F3,PTEN,RHOG
,GNA15,FOXO1,RHOT1,PRKCD,CDK4,ITPR3,L
EF1,MAP2K1,ATM 
16 
CCR3 Signaling in 
Eosinophils 
1.07E+01 1.04E-01 10.4 MPRIP,MAPK1,KRAS,GNG5,GNAI3,PRKCD,J
MJD7-
PLA2G4B,ITPR3,GNB2,PPP1R12A,PRKCH,MA
P2K1,ATM 
13 
IL-10 Signaling 1.02E+01 1.15E-01 11.5 IL1R2,CCR1,HMOX1,IL18RAP,MAPK1,IL10RB,
CD14,CHUK,IL1RAP 
9 
Thrombin Signaling 1.00E+01 9.31E-02 9.31 MPRIP,MYL6,MAPK1,KRAS,GNG5,PTK2 
(includes 
EG:14083),GNAI3,MYL12A,RHOG,GNA15,MY
L12B,RHOT1,PRKCD,ITPR3,GNB2,PPP1R12A,
PRKCH,MAP2K1,ATM 
19 
Synaptic Long Term 
Potentiation 
9.79E+00 1.06E-01 10.6 PPP1R3D,MAPK1,PRKCD,ITPR3,CHP,PPP1R1
2A,KRAS,PRKCH,PPP3CC,RPS6KA1 (includes 
EG:20111),MAP2K1,GRINA 
12 
PI3K/AKT Signaling 9.79E+00 9.56E-02 9.56 YWHAG,MAPK1,YWHAH,PPP2CA,KRAS,JAK2,
PPP2R5A,PTEN,BCL2,FOXO1,MAP3K8,CHUK,
MAP2K1 
13 
Renal Cell Carcinoma 
Signaling 
9.79E+00 1.23E-01 12.3 ETS1,CDC42,MAPK1,TGFA,KRAS,HIF1A,MAP
2K1,TCEB1,ATM 
9 
TNFR2 Signaling 9.59E+00 1.52E-01 15.2 LTA,TNFAIP3,TBK1,CHUK,BIRC2 5 
LXR/RXR Activation 9.48E+00 9.92E-02 9.92 IL18RAP,ABCA1,IL1R2,TLR4,LY96 (includes 
EG:17087),LDLR,CD14,SERPINA1,S100A8,H
MGCR,RXRA,IL1RAP,HADH 
13 
NRF2-mediated Oxidative 
Stress Response 
9.48E+00 9.47E-02 9.47 MGST1,MAPK1,NQO2,KRAS,JUNB,GSTO1,TX
NRD1,HMOX1,SOD2,DNAJC5,PRKCD,DNAJA3
,PRKCH,DNAJB6,TXN (includes 
EG:116484),FKBP5,MAP2K1,ATM 
18 
ILK Signaling 9.48E+00 9.68E-02 9.68 VEGFB,MYL6,MAPK1,CDC42,PPP2CA,VIM,HI
F1A,PPP2R5A,ITGB7,PTEN,PTK2 (includes 
EG:14083),RHOG,RHOT1,PPP1R12A,IRS2,LEF
1,RPS6KA5,ATM 
18 
HMGB1 Signaling 9.35E+00 1.11E-01 11.1 TLR4,RHOG,CDC42,MAPK1,RHOT1,HAT1,IFN
GR2,IFNGR1,KRAS,MAP2K1,ATM 
11 
Actin Cytoskeleton 
Signaling 
9.16E+00 8.70E-02 8.7 ACTR2,MPRIP,MYL6,MAPK1,CDC42,ARPC5,K
RAS,IQGAP1,PTK2 (includes 
EG:14083),MYL12A,ACTR3,MYL12B,CD14,PP
P1R12A,ARPC3,ARPC1A,SSH2,MAP2K1,ATM,
MATK 
20 
CNTF Signaling 9.16E+00 1.35E-01 13.5 MAPK1,KRAS,RPS6KA5,JAK2,RPS6KA1 
(includes EG:20111),MAP2K1,ATM 
7 
Glioma Signaling 9.16E+00 9.91E-02 9.91 MAPK1,PRKCD,CDK4,CDKN2D,CDK6,KRAS,P
RKCH,E2F3,MAP2K1,PTEN,ATM 
11 
IL-6 Signaling 9.16E+00 1.10E-01 11 IL1R2,IL18RAP,MAPK1,CD14,KRAS,CHUK,CE
BPB (includes 
EG:1051),JAK2,MAPKAPK2,MAP2K1,IL1RAP 
11 
Pentose Phosphate 
Pathway 
9.16E+00 6.33E-02 6.33 PGM2,PGD,G6PD,PGM1,ALDOA 5 
Gα12/13 Signaling 9.16E+00 1.02E-01 10.2 CDC42,MAPK1,MYL6,KRAS,PTK2 (includes 
EG:14083),MYL12A,MYL12B,MEF2D,LPAR5,
MEF2C,CHUK,MAP2K1,ATM 
13 
Inositol Metabolism 8.61E+00 1.18E-01 11.8 ALDOA,TPI1 2 
ERK5 Signaling 8.61E+00 1.27E-01 12.7 YWHAG,YWHAH,MEF2D,KRAS,MAP3K8,MEF
2C,RPS6KA5,RPS6KA1 (includes EG:20111) 
8 
NF-κB Activation by 
Viruses 
8.24E+00 1.10E-01 11 LCK,MAPK1,PRKCD,CD4,KRAS,PRKCH,CXCR5,
CHUK,ATM 
9 
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Prolactin Signaling 8.24E+00 1.12E-01 11.2 FYN,MAPK1,PRKCD,KRAS,PRKCH,CEBPB 
(includes EG:1051),JAK2,MAP2K1,ATM 
9 
MIF Regulation of Innate 
Immunity 
7.66E+00 1.20E-01 12 TLR4,LY96 (includes 
EG:17087),MAPK1,JMJD7-
PLA2G4B,CD14,CD74 
6 
Endometrial Cancer 
Signaling 
7.50E+00 1.23E-01 12.3 MAPK1,CTNNA1,LEF1,KRAS,MAP2K1,PTEN,A
TM 
7 
Leukocyte Extravasation 
Signaling 
7.46E+00 9.23E-02 9.23 MYL6,MAPK1,CDC42,CTNNA1,NCF4,PTK2 
(includes EG:14083),GNAI3,ITGAM (includes 
EG:16409),TIMP1,CYBA,PRKCD,CD44 
(includes 
EG:100330801),CYBB,PRKCH,VASP,ATM,TIM
P2 (includes EG:21858),ITK 
18 
RhoGDI Signaling 7.33E+00 8.54E-02 8.54 ACTR2,MYL6,CDC42,ARPC5,GNG5,GNAI3,M
YL12A,ACTR3,RHOG,GNA15,MYL12B,RHOT1,
GNB2,CD44 (includes 
EG:100330801),ARPC3,PPP1R12A,ARPC1A 
17 
α-Adrenergic Signaling 7.33E+00 9.52E-02 9.52 GNAI3,MAPK1,PRKCD,ITPR3,GNB2,PYGL,KR
AS,PRKCH,MAP2K1,GNG5 
10 
HGF Signaling 7.33E+00 1.05E-01 10.5 PTK2 (includes 
EG:14083),ETS1,CDC42,MAPK1,PRKCD,ETS2,
KRAS,MAP3K8,PRKCH,MAP2K1,ATM 
11 
Melanoma Signaling 7.29E+00 1.30E-01 13 MAPK1,CDK4,KRAS,MAP2K1,PTEN,ATM 6 
Polyamine Regulation in 
Colon Cancer 
7.29E+00 1.38E-01 13.8 AZIN1,MXD1,SAT1,KRAS 4 
IL-2 Signaling 7.29E+00 1.21E-01 12.1 LCK,MAPK1,SYK,KRAS,MAP2K1,IL2RB,ATM 7 
Apoptosis Signaling 7.13E+00 1.06E-01 10.6 MAPK1,APAF1,KRAS,CHUK,RPS6KA1 
(includes 
EG:20111),MAP2K1,PARP1,BCL2,CAPN3,BIR
C2 
10 
Type II Diabetes Mellitus 
Signaling 
6.95E+00 7.79E-02 7.79 PKM2,ACSL3,MAPK1,PRKCD,PRKAA1,ACSL4,I
RS2,PRKCH,CHUK,CEBPB (includes 
EG:1051),ACSL1,ATM 
12 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 
6.95E+00 1.25E-01 12.5 CDC25B,YWHAG,GADD45A,YWHAH,RPS6KA
1 (includes EG:20111),ATM 
6 
Cholecystokinin/Gastrin-
mediated Signaling 
6.95E+00 1.04E-01 10.4 PTK2 (includes 
EG:14083),RHOG,MAPK1,RHOT1,PRKCD,ME
F2D,ITPR3,KRAS,MEF2C,PRKCH,MAP2K1 
11 
Fatty Acid Metabolism 6.95E+00 6.75E-02 6.75 ACAD11,ACSL3,DHRS9,ACAA1,ECI2,ACOX1,A
CSL4,PECR,ACSL1,HADH,CYP1B1 
11 
mTOR Signaling 6.93E+00 8.72E-02 8.72 VEGFB,MAPK1,PPP2CA,FKBP1A,KRAS,HIF1A,
PPP2R5A,HMOX1,RPS4X,RHOG,RHOT1,PRKC
D,PRKAA1,RPS6KA5,PRKCH,RPS6KA1 
(includes EG:20111),ATM 
17 
DNA Double-Strand 
Break Repair by Non-
Homologous End Joining 
6.64E+00 1.58E-01 15.8 PARP1,ATM,NBN 3 
Fc Epsilon RI Signaling 6.34E+00 9.91E-02 9.91 FYN,MAPK1,PRKCD,SYK,LAT,JMJD7-
PLA2G4B,FCER1G,KRAS,PRKCH,MAP2K1,AT
M 
11 
Prostate Cancer Signaling 6.34E+00 9.47E-02 9.47 FOXO1,MAPK1,LEF1,KRAS,CHUK,MAP2K1,PT
EN,ATM,BCL2 
9 
Propanoate Metabolism 6.34E+00 5.79E-02 5.79 ACAD11,ACSL3,ACSS2,ACSS1,ACSL1,LDHA,L
DHB 
7 
Protein Kinase A 
Signaling 
6.34E+00 8.07E-02 8.07 YWHAH,MYL6,MAPK1,ANAPC1/LOC1002869
79,PDE7A,SMAD3,PTK2 (includes 
EG:14083),GNA15,CHUK,MAP2K1,VASP,YW
HAG,CHP,PYGL,PPP3CC,GNG5,GNAI3,MYL12
A,PPP1R3D,MYL12B,PRKCD,ITPR3,GNB2,PPP
1R12A,PRKCH,LEF1 
26 
NGF Signaling 6.34E+00 9.48E-02 9.48 RHOG,CDC42,MAPK1,PRKCD,KRAS,MAP3K8,
RPS6KA5,CHUK,RPS6KA1 (includes 
EG:20111),MAP2K1,ATM 
11 
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Role of JAK1, JAK2 and 
TYK2 in Interferon 
Signaling 
6.34E+00 1.48E-01 14.8 IFNGR2,IFNGR1,JAK2,IFNAR1 4 
Growth Hormone 
Signaling 
6.34E+00 1.07E-01 10.7 MAPK1,PRKCD,CEBPA,RPS6KA5,PRKCH,JAK2
,RPS6KA1 (includes EG:20111),ATM 
8 
Chemokine Signaling 6.34E+00 1.11E-01 11.1 PTK2 (includes 
EG:14083),GNAI3,MPRIP,MAPK1,PPP1R12A,
KRAS,CCL5,MAP2K1 
8 
Macropinocytosis 
Signaling 
6.34E+00 1.05E-01 10.5 RAB5A,CDC42,PRKCD,CD14,KRAS,PRKCH,ITG
B7,ATM 
8 
Chronic Myeloid 
Leukemia Signaling 
6.34E+00 9.71E-02 9.71 HDAC4,MAPK1,CDK4,SMAD3,CDK6,KRAS,CH
UK,E2F3,MAP2K1,ATM 
10 
IL-1 Signaling 6.34E+00 9.35E-02 9.35 GNAI3,TOLLIP,MAPK1,GNA15,MYD88,GNB2,
CHUK,IRAK3,IL1RAP,GNG5 
10 
14-3-3-mediated 
Signaling 
6.32E+00 9.92E-02 9.92 YWHAG,FOXO1,MAPK1,YWHAH,GNA15,PRK
CD,VIM,KRAS,PRKCH,RPS6KA1 (includes 
EG:20111),MAP2K1,ATM 
12 
Nitrogen Metabolism 6.12E+00 4.17E-02 4.17 VNN1,VNN2,CA4,CA5B,CCDC92 5 
FLT3 Signaling in 
Hematopoietic 
Progenitor Cells 
6.12E+00 1.13E-01 11.3 STAT4,MAPK1,KRAS,RPS6KA5,RPS6KA1 
(includes EG:20111),MAP2K1,FLT3LG,ATM 
8 
Aminosugars Metabolism 6.12E+00 6.72E-02 6.72 POR,CYB5R4,HK2,PDE7A,CYB5R1,HK3,NANS,
NPL 
8 
Sphingolipid Metabolism 6.12E+00 8.18E-02 8.18 NEU1,GLA,LPIN1,GALC,VNN1,GBA,PIGF,VNN
2,UGCG 
9 
Axonal Guidance 
Signaling 
6.08E+00 7.44E-02 7.44 FYN,CDC42,MAPK1,MYL6,ARPC5,KRAS,ABLI
M1,PTK2 (includes 
EG:14083),MICAL1,ACTR3,GNA15,MKNK1,A
RPC3,ARPC1A,SEMA4A,MAP2K1,VASP,ATM,
ACTR2,VEGFB,FES,CHP,PPP3CC,GNG5,GNAI3
,MYL12A,SDCBP,MYL12B,PRKCD,GNB2,RTN4 
(includes EG:57142),PRKCH 
32 
Eicosanoid Signaling 5.89E+00 9.09E-02 9.09 LTB4R,JMJD7-
PLA2G4B,FPR2,ALOX5AP,PTGER2,ALOX5,TB
XAS1 
7 
Granzyme B Signaling 5.45E+00 1.88E-01 18.8 PRF1,APAF1,PARP1 3 
Telomerase Signaling 5.37E+00 1.01E-01 10.1 ETS1,HDAC4,MAPK1,PPP2CA,ETS2,KRAS,MA
P2K1,IL2RB,PPP2R5A,ATM 
10 
Renin-Angiotensin 
Signaling 
5.31E+00 8.73E-02 8.73 PTK2 (includes 
EG:14083),MAPK1,PRKCD,ITPR3,KRAS,PRKC
H,PTGER2,JAK2,CCL5,MAP2K1,ATM 
11 
Notch Signaling 5.31E+00 1.22E-01 12.2 FURIN,APH1B,MFNG,NUMB,RBPJ 5 
Caveolar-mediated 
Endocytosis Signaling 
5.31E+00 9.64E-02 9.64 FYN,CD55,FLOT2,ITGAM (includes 
EG:16409),RAB5A,RAB5C,FLOT1,ITGB7 
8 
IL-17 Signaling 5.31E+00 1.08E-01 10.8 MAPK1,TIMP1,KRAS,CEBPB (includes 
EG:1051),JAK2,MAPKAPK2,MAP2K1,ATM 
8 
IGF-1 Signaling 5.26E+00 9.52E-02 9.52 PTK2 (includes 
EG:14083),YWHAG,FOXO1,MAPK1,YWHAH,I
RS2,KRAS,JAK2,MAP2K1,ATM 
10 
Hepatic Cholestasis 5.18E+00 7.56E-02 7.56 IL18RAP,MYD88,IRAK3,IL1R2,TLR4,LY96 
(includes 
EG:17087),PRKCD,PPRC1,CD14,PRKCH,CHUK
,RXRA,IL1RAP 
13 
VEGF Signaling 5.18E+00 9.28E-02 9.28 PTK2 (includes 
EG:14083),VEGFB,FOXO1,MAPK1,KRAS,HIF1
A,MAP2K1,ATM,BCL2 
9 
Role of PI3K/AKT 
Signaling in the 
Pathogenesis of Influenza 
5.11E+00 1.00E-01 10 GNAI3,MAPK1,CCL5,MAP2K1,PLAC8,IFNAR1,
ATM 
7 
Cell Cycle Control of 
Chromosomal 
Replication 
5.11E+00 1.29E-01 12.9 MCM3,CDK4,CDK6,MCM7 4 
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Granzyme A Signaling 5.06E+00 1.67E-01 16.7 GZMA,PRF1,HMGB2 3 
FAK Signaling 5.06E+00 8.91E-02 8.91 PTK2 (includes 
EG:14083),FYN,MAPK1,ASAP1,KRAS,MAP2K
1,PTEN,ATM,CAPN3 
9 
RANK Signaling in 
Osteoclasts 
5.06E+00 9.57E-02 9.57 MAPK1,CHP,MAP3K8,PPP3CC,TRAF5,CHUK,
MAP2K1,ATM,BIRC2 
9 
LPS/IL-1 Mediated 
Inhibition of RXR 
Function 
4.71E+00 7.98E-02 7.98 IL18RAP,MGST1,ACSL3,MYD88,MGMT,ACOX
1,GSTO1,ABCA1,IL1R2,TLR4,LY96 (includes 
EG:17087),ACSL4,CD14,ALDH3B1,RXRA,IL1R
AP,ACSL1 
17 
HER-2 Signaling in Breast 
Cancer 
4.71E+00 1.01E-01 10.1 CDC42,FOXO1,PRKCD,CDK6,KRAS,PRKCH,ITG
B7,ATM 
8 
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza 
4.71E+00 1.06E-01 10.6 MAPK1,JMJD7-
PLA2G4B,KRAS,CCL5,MAP2K1,RABGEF1,BCL
2 
7 
Role of NFAT in Cardiac 
Hypertrophy 
4.71E+00 7.88E-02 7.88 HDAC4,MAPK1,CHP,KRAS,PPP3CC,GNG5,GN
AI3,GNA15,MEF2D,PRKCD,ITPR3,GNB2,MEF
2C,PRKCH,MAP2K1,ATM 
16 
CD27 Signaling in 
Lymphocytes 
4.71E+00 1.07E-01 10.7 APAF1,MAP3K8,TRAF5,CHUK,CD27,MAP2K1 6 
PAK Signaling 4.70E+00 8.49E-02 8.49 PTK2 (includes 
EG:14083),MYL12A,CDC42,MAPK1,MYL6,MY
L12B,KRAS,MAP2K1,ATM 
9 
HIF1α Signaling 4.69E+00 9.43E-02 9.43 VEGFB,MAPK1,COPS5,KRAS,HIF1A,TCEB1,LD
HA,SLC2A3,LDHB,ATM 
10 
Fatty Acid Elongation in 
Mitochondria 
4.69E+00 6.52E-02 6.52 ACAA1,PECR,HADH 3 
Mechanisms of Viral Exit 
from Host Cells 
4.59E+00 1.11E-01 11.1 CHMP2A,PRKCD,SH3GLB1,PRKCH,VPS25 
(includes EG:28084) 
5 
Virus Entry via Endocytic 
Pathways 
4.59E+00 9.09E-02 9.09 FYN,CD55,CDC42,PRKCD,CLTC,KRAS,PRKCH,I
TGB7,ATM 
9 
G Beta Gamma Signaling 4.59E+00 7.96E-02 7.96 GNAI3,CDC42,MAPK1,GNA15,PRKCD,GNB2,
KRAS,PRKCH,GNG5 
9 
Semaphorin Signaling in 
Neurons 
4.57E+00 1.15E-01 11.5 PTK2 (includes 
EG:14083),FYN,RHOG,FES,MAPK1,RHOT1 
6 
Pathogenesis of Multiple 
Sclerosis 
4.53E+00 2.22E-01 22.2 CCR1,CCL5 2 
FcγRIIB Signaling in B 
Lymphocytes 
4.35E+00 9.09E-02 9.09 CD79B,SYK,KRAS,CD79A,ATM 5 
Glutathione Metabolism 4.35E+00 7.14E-02 7.14 MGST1,PGD,G6PD,GLRX,GSTO1,IDH1 6 
Role of IL-17A in Arthritis 4.08E+00 9.52E-02 9.52 MAPK1,CCL5,RPS6KA1 (includes 
EG:20111),MAPKAPK2,MAP2K1,ATM 
6 
Glycerolipid Metabolism 4.08E+00 6.25E-02 6.25 GLA,ABHD5,LPIN1,DHRS9,AGPAT2,PECR,AG
PAT9,GK,AKR1B1 
9 
Erythropoietin Signaling 3.98E+00 8.97E-02 8.97 MAPK1,PRKCD,KRAS,PRKCH,JAK2,MAP2K1,A
TM 
7 
G Protein Signaling 
Mediated by Tubby 
3.96E+00 1.03E-01 10.3 LCK,GNB2,JAK2,GNG5 4 
DNA Methylation and 
Transcriptional 
Repression Signaling 
3.96E+00 1.30E-01 13 MTA1,SAP30 (includes EG:60406),DNMT1 3 
One Carbon Pool by 
Folate 
3.96E+00 8.33E-02 8.33 MTHFS,MTHFD2,ATIC 3 
Systemic Lupus 
Erythematosus Signaling 
3.94E+00 7.48E-02 7.48 CD247,PRPF19,MAPK1,CD79B,CD3E,KRAS,C
D3D,CD79A,SNRPN,CD3G,LCK,LAT,TLR7,FCE
R1G,CD86,ATM 
16 
Thyroid Cancer Signaling 3.94E+00 1.11E-01 11.1 MAPK1,LEF1,KRAS,RXRA,MAP2K1 5 
PTEN Signaling 3.89E+00 8.13E-02 8.13 PTK2 (includes 
EG:14083),CDC42,FOXO1,MAPK1,YWHAH,K
RAS,CHUK,MAP2K1,PTEN,BCL2 
10 
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Biosynthesis of Steroids 3.63E+00 2.48E-02 2.48 IDI1,COX10 (includes EG:1352),HMGCR 3 
Colorectal Cancer 
Metastasis Signaling 
3.57E+00 7.51E-02 7.51 VEGFB,MAPK1,SMAD3,TLR8,KRAS,IFNGR1,J
AK2,GNG5,TLR4,RHOG,TLR5,RHOT1,GNB2,T
LR7,LEF1,PTGER2,MAP2K1,RALGDS,ATM 
19 
Insulin Receptor 
Signaling 
3.56E+00 8.27E-02 8.27 FYN,PPP1R3D,FOXO1,MAPK1,PPP1R12A,IRS
2,KRAS,JAK2,MAP2K1,PTEN,ATM 
11 
TGF-β Signaling 3.56E+00 8.99E-02 8.99 RUNX3,MAPK1,SMAD3,MAP4K1,KRAS,MAP2
K1,ACVR1B,BCL2 
8 
TWEAK Signaling 3.54E+00 1.05E-01 10.5 TNFRSF25,APAF1,CHUK,BIRC2 4 
Lysine Biosynthesis 3.54E+00 3.08E-02 3.08 VNN1,VNN2 2 
Breast Cancer Regulation 
by Stathmin1 
3.54E+00 7.66E-02 7.66 CDC42,MAPK1,PPP2CA,KRAS,E2F3,PPP2R5A,
GNG5,GNAI3,PPP1R3D,PRKCD,ITPR3,GNB2,P
PP1R12A,PRKCH,MAP2K1,ATM 
16 
Amyotrophic Lateral 
Sclerosis Signaling 
3.54E+00 7.76E-02 7.76 VEGFB,RAB5A,RAB5C,APAF1,GRINA,ATM,BC
L2,CAPN3,BIRC2 
9 
Synaptic Long Term 
Depression 
3.54E+00 7.86E-02 7.86 GNAI3,MAPK1,GNA15,PPP2CA,PRKCD,JMJD
7-
PLA2G4B,ITPR3,KRAS,PRKCH,MAP2K1,PPP2
R5A 
11 
Myc Mediated Apoptosis 
Signaling 
3.54E+00 1.00E-01 10 YWHAG,YWHAH,APAF1,KRAS,ATM,BCL2 6 
Death Receptor Signaling 3.54E+00 9.52E-02 9.52 TNFRSF25,APAF1,TBK1,CHUK,BCL2,BIRC2 6 
Oncostatin M Signaling 3.37E+00 1.14E-01 11.4 MAPK1,KRAS,JAK2,MAP2K1 4 
Retinoic acid Mediated 
Apoptosis Signaling 
3.37E+00 9.38E-02 9.38 APAF1,PARP12,RXRA,TIPARP,IFNAR1,PARP1 6 
Neuregulin Signaling 3.27E+00 8.00E-02 8 MAPK1,PRKCD,TGFA,KRAS,PRKCH,MAP2K1,
PTEN,MATK 
8 
TNFR1 Signaling 3.27E+00 9.62E-02 9.62 CDC42,APAF1,TNFAIP3,CHUK,BIRC2 5 
Cell Cycle Regulation by 
BTG Family Proteins 
3.20E+00 1.11E-01 11.1 PPP2CA,CDK4,E2F3,PPP2R5A 4 
Aldosterone Signaling in 
Epithelial Cells 
3.16E+00 7.51E-02 7.51 MAPK1,HSPA1A/HSPA1B,KRAS,DNAJC5,GNA
15,DUSP1,PRKCD,ITPR3,PRKCH,DNAJB6,DNA
JC30,MAP2K1,ATM 
13 
JAK/Stat Signaling 3.10E+00 9.38E-02 9.38 STAT4,MAPK1,KRAS,JAK2,MAP2K1,ATM 6 
Aminophosphonate 
Metabolism 
3.01E+00 5.26E-02 5.26 PIGF,MGMT,CHPT1 3 
Tumoricidal Function of 
Hepatic Natural Killer 
Cells 
3.01E+00 1.25E-01 12.5 PRF1,SRGN,APAF1 3 
Antiproliferative Role of 
Somatostatin Receptor 2 
2.99E+00 8.57E-02 8.57 MAPK1,GNB2,KRAS,MAP2K1,GNG5,ATM 6 
AMPK Signaling 2.92E+00 6.67E-02 6.67 CAB39,PFKFB3,MAPK1,PFKFB4,PPP2CA,PPM
1B,PRKAA1,IRS2,HMGCR,PPP2R5A,ATM 
11 
IL-17A Signaling in Airway 
Cells 
2.88E+00 8.33E-02 8.33 MAPK1,CHUK,JAK2,MAP2K1,PTEN,ATM 6 
Dopamine-DARPP32 
Feedback in cAMP 
Signaling 
2.80E+00 7.10E-02 7.1 KCNJ2,PPP2CA,CHP,PPP3CC,PPP2R5A,GRINA
,GNAI3,PPP1R3D,GNA15,PRKCD,ITPR3,PPP1
R12A,PRKCH 
13 
PPAR Signaling 2.79E+00 7.84E-02 7.84 IL1R2,IL18RAP,MAPK1,KRAS,CHUK,RXRA,MA
P2K1,IL1RAP 
8 
Docosahexaenoic Acid 
(DHA) Signaling 
2.74E+00 8.33E-02 8.33 FOXO1,APAF1,ATM,BCL2 4 
Ceramide Signaling 2.74E+00 8.05E-02 8.05 CTSD,PPP2CA,KRAS,MAP2K1,PPP2R5A,ATM,
BCL2 
7 
P2Y Purigenic Receptor 
Signaling Pathway 
2.72E+00 7.19E-02 7.19 GNAI3,MAPK1,GNA15,PRKCD,GNB2,KRAS,P
RKCH,MAP2K1,GNG5,ATM 
10 
DNA Double-Strand 
Break Repair by 
Homologous 
2.72E+00 1.18E-01 11.8 ATM,NBN 2 
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Recombination 
Folate Biosynthesis 2.72E+00 2.78E-02 2.78 ALPP/ALPPL2,ALPL 2 
Antiproliferative Role of 
TOB in T Cell Signaling 
2.70E+00 1.15E-01 11.5 MAPK1,SMAD3,RPS6KA1 (includes 
EG:20111) 
3 
p53 Signaling 2.68E+00 8.33E-02 8.33 CCND2,GADD45A,CDK4,APAF1,DRAM1,PTE
N,ATM,BCL2 
8 
SAPK/JNK Signaling 2.68E+00 7.92E-02 7.92 LCK,CDC42,GADD45A,FCER1G,MAP4K1,KRA
S,GNG5,ATM 
8 
Role of PKR in Interferon 
Induction and Antiviral 
Response 
2.54E+00 8.89E-02 8.89 APAF1,TRAF5,CHUK,RNASEL 4 
Role of IL-17F in Allergic 
Inflammatory Airway 
Diseases 
2.54E+00 9.30E-02 9.3 MAPK1,RPS6KA5,RPS6KA1 (includes 
EG:20111),MAP2K1 
4 
Corticotropin Releasing 
Hormone Signaling 
2.54E+00 6.92E-02 6.92 GNAI3,MAPK1,PRKCD,MEF2D,ARPC5,ITPR3,
MEF2C,PRKCH,MAP2K1 
9 
GNRH Signaling 2.48E+00 7.04E-02 7.04 PTK2 (includes 
EG:14083),GNAI3,CDC42,MAPK1,PRKCD,ITP
R3,KRAS,MAP3K8,PRKCH,MAP2K1 
10 
Neurotrophin/TRK 
Signaling 
2.45E+00 7.89E-02 7.89 CDC42,MAPK1,KRAS,RPS6KA1 (includes 
EG:20111),MAP2K1,ATM 
6 
Sulfur Metabolism 2.32E+00 3.64E-02 3.64 PAPSS1,SUOX 2 
Germ Cell-Sertoli Cell 
Junction Signaling 
2.31E+00 7.27E-02 7.27 PTK2 (includes 
EG:14083),RHOG,CDC42,MAPK1,RHOT1,CTN
NA1,KRAS,MAP3K8,IQGAP1,MAP2K1,RAB8B
,ATM 
12 
Role of BRCA1 in DNA 
Damage Response 
2.31E+00 8.20E-02 8.2 C17orf70,GADD45A,E2F3,ATM,NBN 5 
4-1BB Signaling in T 
Lymphocytes 
2.31E+00 8.82E-02 8.82 MAPK1,CHUK,MAP2K1 3 
Melatonin Signaling 2.31E+00 7.69E-02 7.69 GNAI3,MAPK1,GNA15,PRKCD,PRKCH,MAP2
K1 
6 
Hereditary Breast Cancer 
Signaling 
2.31E+00 7.26E-02 7.26 C17orf70,HDAC4,GADD45A,CDK4,CDK6,KRA
S,PTEN,ATM,NBN 
9 
Paxillin Signaling 2.29E+00 7.27E-02 7.27 PTK2 (includes EG:14083),ITGAM (includes 
EG:16409),CDC42,MAPK1,KRAS,PTPN12,ITG
B7,ATM 
8 
Melanocyte 
Development and 
Pigmentation Signaling 
2.27E+00 7.61E-02 7.61 MAPK1,KRAS,RPS6KA5,RPS6KA1 (includes 
EG:20111),MAP2K1,ATM,BCL2 
7 
MSP-RON Signaling 
Pathway 
2.17E+00 8.16E-02 8.16 TLR4,ITGAM (includes EG:16409),JAK2,ATM 4 
Mitotic Roles of Polo-Like 
Kinase 
2.17E+00 8.33E-02 8.33 CDC25B,SLK,ANAPC1/LOC100286979,PPP2C
A,PPP2R5A 
5 
CDK5 Signaling 2.15E+00 7.45E-02 7.45 PPP1R3D,MAPK1,PPP2CA,PPP1R12A,KRAS,
MAP2K1,PPP2R5A 
7 
Ovarian Cancer Signaling 2.15E+00 7.09E-02 7.09 VEGFB,MAPK1,CDK4,CD44 (includes 
EG:100330801),LEF1,KRAS,MAP2K1,PTEN,A
TM,BCL2 
10 
Mitochondrial 
Dysfunction 
2.10E+00 5.81E-02 5.81 COX7A2,NDUFB3,COX17 (includes 
EG:10063),PRDX3,FURIN,SOD2,APH1B,PRDX
5,COX10 (includes EG:1352),GLRX2 
10 
Stilbene, Coumarine and 
Lignin Biosynthesis 
2.08E+00 2.74E-02 2.74 GBA,PRDX5 2 
EGF Signaling 2.02E+00 7.69E-02 7.69 MAPK1,ITPR3,MAP2K1,ATM 4 
Xenobiotic Metabolism 
Signaling 
1.98E+00 6.69E-02 6.69 MGST1,MAPK1,PPP2CA,NQO2,MGMT,KRAS,
PPP2R5A,CYP1B1,GSTO1,HMOX1,PRKCD,MA
P3K8,PRKCH,ALDH3B1,RXRA,PNPLA6,MAP2
K1,ATM 
18 
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Lipid Antigen 
Presentation by CD1 
1.96E+00 9.09E-02 9.09 CD3E,FCER1G 2 
Role of CHK Proteins in 
Cell Cycle Checkpoint 
Control 
1.95E+00 8.57E-02 8.57 E2F3,ATM,NBN 3 
Role of JAK2 in Hormone-
like Cytokine Signaling 
1.95E+00 8.57E-02 8.57 IRS2,JAK2,SIRPA 3 
cAMP-mediated signaling 1.94E+00 6.88E-02 6.88 RGS18,PDE7A,MAPK1,FPR2,PPP3CC,OPRL1,F
PR1,P2RY13,LAMTOR3,LTB4R,DUSP1,RPS6K
A1 (includes 
EG:20111),PKIA,PTGER2,MAP2K1 
15 
RAR Activation 1.90E+00 6.52E-02 6.52 DHRS9,MAPK1,DUSP1,PRKCD,SMAD3,PRKC
H,JAK2,RXRA,MAPKAPK2,MAP2K1,PTEN,PAR
P1 
12 
Huntington's Disease 
Signaling 
1.90E+00 6.41E-02 6.41 HDAC4,MAPK1,HSPA1A/HSPA1B,CLTC,APAF
1,GNG5,CTSD,DNAJC5,PRKCD,GNB2,VAMP3,
PRKCH,GOSR2,CAPN3,ATM 
15 
IL-9 Signaling 1.90E+00 7.50E-02 7.5 IRS2,BCL3,ATM 3 
Pyrimidine Metabolism 1.90E+00 4.67E-02 4.67 NUDT5,POLR1C,POLR3H,POLR1E,UPP1,TXN 
(includes 
EG:116484),PUS1,POLRMT,UNG,TXNRD1 
10 
Glycerophospholipid 
Metabolism 
1.90E+00 4.86E-02 4.86 HMOX1,LPIN1,GNA15,PIGF,AGPAT2,JMJD7-
PLA2G4B,CHKA,CHPT1,AGPAT9 
9 
Leptin Signaling in 
Obesity 
1.90E+00 6.90E-02 6.9 FOXO1,MAPK1,GNA15,JAK2,MAP2K1,ATM 6 
CREB Signaling in 
Neurons 
1.86E+00 6.12E-02 6.12 GNAI3,MAPK1,GNA15,PRKCD,ITPR3,GNB2,K
RAS,PRKCH,RPS6KA1 (includes 
EG:20111),MAP2K1,GNG5,ATM 
12 
Reelin Signaling in 
Neurons 
1.86E+00 7.32E-02 7.32 FYN,LCK,HCK,MAP4K1,FGR,ATM 6 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 
1.84E+00 6.33E-02 6.33 IL18RAP,MAPK1,CHP,PPP3CC,BCL2,IL18R1,IL
1R2,FOXO1,LEF1,TRAF5,CHUK,IL1RAP,ALPL,
BIRC2,ATM 
15 
G-Protein Coupled 
Receptor Signaling 
1.84E+00 6.42E-02 6.42 FYN,RGS18,PDE7A,MAPK1,KRAS,CX3CR1,OP
RL1,LAMTOR3,P2RY10,LTB4R,C5AR1,GPR11
4,CHUK,MAP2K1,ATM,CCR1,GPR97,FPR2,PC
NX,FPR1,GPR183,GPR56,P2RY13,DUSP1,RAS
GRP1,GPR65,LPAR5,MAP3K8,GPR160,PTGER
2,EMR1,RPS6KA1 (includes 
EG:20111),EMR2,CCR7 
34 
Angiopoietin Signaling 1.82E+00 6.76E-02 6.76 PTK2 (includes 
EG:14083),FOXO1,KRAS,CHUK,ATM 
5 
Androgen Signaling 1.80E+00 5.76E-02 5.76 GNAI3,MAPK1,GNA15,PRKCD,SMAD3,GNB2,
PRKCH,GNG5 
8 
Nucleotide Sugars 
Metabolism 
1.74E+00 1.54E-02 1.54 UGP2 1 
Differential Regulation of 
Cytokine Production in 
Intestinal Epithelial Cells 
by IL-17A and IL-17F 
1.66E+00 8.70E-02 8.7 LCN2,CCL5 2 
April Mediated Signaling 1.66E+00 6.98E-02 6.98 MAPK1,TRAF5,CHUK 3 
TR/RXR Activation 1.62E+00 6.25E-02 6.25 SLC16A3,LDLR,BCL3,HIF1A,RXRA,ATM 6 
Assembly of RNA 
Polymerase I Complex 
1.61E+00 7.69E-02 7.69 POLR1C 1 
Arginine and Proline 
Metabolism 
1.61E+00 2.87E-02 2.87 P4HA1,VNN1,VNN2,OAT,SAT1 5 
IL-22 Signaling 1.61E+00 8.00E-02 8 MAPK1,IL10RB 2 
Endothelin-1 Signaling 1.59E+00 6.01E-02 6.01 HMOX1,GNAI3,MAPK1,GNA15,PRKCD,JMJD
7-PLA2G4B,ITPR3,KRAS,PRKCH,PTGER2,ATM 
11 
PDGF Signaling 1.59E+00 6.33E-02 6.33 MAPK1,KRAS,JAK2,MAP2K1,ATM 5 
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B Cell Activating Factor 
Signaling 
1.59E+00 6.67E-02 6.67 MAPK1,TRAF5,CHUK 3 
N-Glycan Biosynthesis 1.59E+00 3.85E-02 3.85 ST6GAL1,MAN1A1,B4GALT5 3 
Bladder Cancer Signaling 1.59E+00 6.67E-02 6.67 VEGFB,MAPK1,CDK4,KRAS,RPS6KA5,MAP2K
1 
6 
Neuropathic Pain 
Signaling In Dorsal Horn 
Neurons 
1.59E+00 6.31E-02 6.31 MAPK1,GNA15,PRKCD,ITPR3,PRKCH,GRINA,
ATM 
7 
N-Glycan Degradation 1.59E+00 8.00E-02 8 NEU1,MAN1A1 2 
IL-17A Signaling in 
Gastric Cells 
1.59E+00 8.00E-02 8 MAPK1,CCL5 2 
Role of JAK family kinases 
in IL-6-type Cytokine 
Signaling 
1.59E+00 7.41E-02 7.41 MAPK1,JAK2 2 
Acute Phase Response 
Signaling 
1.59E+00 6.18E-02 6.18 HMOX1,SOD2,MAPK1,MYD88,SERPINA1,KR
AS,CHUK,CEBPB (includes 
EG:1051),JAK2,MAP2K1,IL1RAP 
11 
Metabolism of 
Xenobiotics by 
Cytochrome P450 
1.59E+00 3.53E-02 3.53 MGST1,DHRS9,PECR,ALDH3B1,GSTO1,CYP1
B1 
6 
Role of RIG1-like 
Receptors in Antiviral 
Innate Immunity 
1.59E+00 6.52E-02 6.52 TBK1,CHUK,TRIM25 3 
Valine, Leucine and 
Isoleucine Biosynthesis 
1.59E+00 2.44E-02 2.44 VARS 1 
Fatty Acid Biosynthesis 1.59E+00 2.04E-02 2.04 ACSL3 1 
Induction of Apoptosis by 
HIV1 
1.50E+00 6.25E-02 6.25 APAF1,CHUK,BCL2,BIRC2 4 
IL-15 Production 1.50E+00 6.45E-02 6.45 PTK2 (includes EG:14083),JAK2 2 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
1.47E+00 5.80E-02 5.8 LTA,TBK1,CHUK,IFNAR1 4 
Citrate Cycle 1.45E+00 3.57E-02 3.57 DLD,IDH1 2 
Gap Junction Signaling 1.44E+00 5.56E-02 5.56 GNAI3,MAPK1,GNA15,PRKCD,ITPR3,KRAS,P
RKCH,PPP3CC,MAP2K1,ATM 
10 
Role of Oct4 in 
Mammalian Embryonic 
Stem Cell Pluripotency 
1.44E+00 6.67E-02 6.67 SH3GLB1,HOXB1,PARP1 3 
Sphingosine-1-phosphate 
Signaling 
1.40E+00 5.69E-02 5.69 PTK2 (includes 
EG:14083),GNAI3,RHOG,MAPK1,GNA15,RH
OT1,ATM 
7 
Role of IL-17A in Psoriasis 1.37E+00 7.69E-02 7.69 S100A8 1 
Complement System 1.30E+00 5.88E-02 5.88 CD55,C5AR1 2 
Telomere Extension by 
Telomerase 
1.27E+00 5.88E-02 5.88 NBN 1 
Methane Metabolism 1.27E+00 1.54E-02 1.54 PRDX5 1 
Phenylalanine, Tyrosine 
and Tryptophan 
Biosynthesis 
1.27E+00 1.54E-02 1.54 FARS2 1 
RAN Signaling 1.23E+00 4.35E-02 4.35 KPNA4 1 
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Appendix 8.3: Signalling pathways from 933 SDE upregulated gene transcripts 
Ingenuity Canonical 
Pathways 
B H  
p value 
Ratio % Molecules No. of 
molecule 
Glycolysis/ 
Gluconeogenesis 
2.82E+06 1.69E-01 16.9 PGK1,PKM2,ACSL3,PGM2,GAPDH,PGM1,
TPI1,PGAM4,GPI,HK2,DHRS9,PGAM1,ACS
S2,DLD,FBP1,ALDOA,ALDH3B1,PECR,HK3,
LDHA,ACSL1 
21 
Toll-like Receptor Signaling 2.24E+05 2.73E-01 27.3 TLR1,TOLLIP,MAPK1,MYD88,TLR8,IRAK3,
TLR2,TLR4,FOS,LY96 (includes 
EG:17087),MAPK14,TLR5,CD14,CHUK,IRA
K2 
15 
Production of Nitric Oxide 
and Reactive Oxygen 
Species in Macrophages 
8.51E+04 1.38E-01 13.8 MAPK1,PPP2CA,MAPK3,JAK2,SPI1 
(includes 
EG:20375),RHOG,RHOT1,CYBA,CYBB,S10
0A8,SERPINA1,CHUK,MAP2K1,ORM1/OR
M2,TNFRSF1A,IFNGR2,IFNGR1,NCF4,PPP
2R5A,TLR2,TLR4,FOS,PPP1R3D,MAPK14,P
RKCD,NCF2,PPP1R12A,MAP3K8,SIRPA 
29 
fMLP Signaling in 
Neutrophils 
1.07E+04 1.57E-01 15.7 ACTR2,MAPK1,CDC42,MAPK3,CHP,ARPC5
,FPR2,KRAS,GNG5,FPR1,GNG10,GNAI3,A
CTR3,PRKCD,NCF2,GNB2,CYBB,ARPC3,AR
PC1A,MAP2K1 
20 
Role of Macrophages, 
Fibroblasts and Endothelial 
Cells in Rheumatoid 
Arthritis 
1.82E+03 1.09E-01 10.9 IL18RAP,TLR1,MAPK1,MAPK3,TLR8,KRAS,
JAK2,IL17RA,IL18R1,IL1R2,C5AR1,GNA15,
CEBPA,OSM,LTBR,CHUK,MAPKAPK2,MAP
2K1,IL1RAP,TNFRSF1A,MYD88,CHP,GNAQ
,CEBPB (includes 
EG:1051),IRAK3,TLR2,TLR4,FOS,MAPK14,
TLR5,IL1RN,CEBPD,PRKCD,IL1B,IRAK2 
35 
IL-6 Signaling 1.78E+03 1.70E-01 17 IL18RAP,MAPK1,TNFRSF1A,MAPK3,KRAS,
CEBPB (includes 
EG:1051),JAK2,IL1R2,FOS,MAPK14,IL1RN,
IL1B,CD14,CHUK,MAPKAPK2,IL1RAP,MAP
2K1 
17 
IL-17A Signaling in 
Fibroblasts 
1.78E+03 2.50E-01 25 FOS,MAPK14,MAPK1,MAPK3,CEBPD,LCN
2,CHUK,CEBPB (includes 
EG:1051),NFKBIZ,IL17RA 
10 
IL-10 Signaling 1.66E+03 1.79E-01 17.9 CCR1,IL18RAP,IL4R,MAPK1,IL1R2,HMOX1
,FOS,MAPK14,IL1RN,IL10RB,IL1B,CD14,C
HUK,IL1RAP 
14 
Signaling by Rho Family 
GTPases 
1.26E+03 1.15E-01 11.5 MYL6,MAPK1,CDC42,MAPK3,ARPC5,LIMK
2,CDC42EP2,IQGAP1,CLIP1,RHOG,ACTR3,
GNA15,RHOT1,CYBB,ARPC3,ARPC1A,MA
P2K1,ACTR2,GNAQ,VIM,GNG5,GNG10,G
NAI3,FOS,MYL12A,MYL12B,NCF2,GNB2,P
PP1R12A 
29 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
1.07E+03 1.58E-01 15.8 ACTR2,MAPK1,CDC42,MAPK3,ARPC5,PTE
N,HMOX1,ACTR3,PRKCD,SYK,HCK,VAMP3
,ARPC3,ARPC1A,VASP,FGR 
16 
IL-1 Signaling 1.07E+03 1.50E-01 15 TOLLIP,MAPK1,MYD88,GNAQ,PRKAR2A,I
RAK3,GNG5,GNG10,GNAI3,FOS,MAPK14,
GNA15,GNB2,CHUK,IL1RAP,IRAK2 
16 
Role of Pattern Recognition 
Receptors in Recognition of 
Bacteria and Viruses 
1.07E+03 1.71E-01 17.1 TLR1,MAPK1,MYD88,MAPK3,TLR8,RNASE
L,TLR2,TLR4,C5AR1,TLR5,SYK,IL1B,C3AR1,
NLRC4 
14 
LXR/RXR Activation 7.94E+02 1.37E-01 13.7 IL18RAP,ORM1/ORM2,TNFRSF1A,CD36,A
BCA1,IL1R2,TLR4,LY96 (includes 
EG:17087),LDLR,IL1RN,IL1B,CD14,S100A8
,SERPINA1,RXRA,HMGCR,IL1RAP,MMP9 
18 
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IL-8 Signaling 7.94E+02 1.20E-01 12 MAPK1,MAPK3,LIMK2,KRAS,IRAK3,CSTB,
GNG5,GNG10,HMOX1,GNAI3,RHOG,CCN
D3,ITGAM (includes 
EG:16409),RHOT1,MYL12B,PRKCD,NCF2,
GNB2,CYBB,CHUK,MAP2K1,MMP9,IRAK2 
23 
PPARα/RXRα Activation 7.94E+02 1.24E-01 12.4 IL18RAP,MAPK1,ACAA1,MAPK3,ACOX1,G
NAQ,CD36,PRKAR2A,KRAS,JAK2,GK,ABCA
1,ACVR1B,IL1R2,MAPK14,GNA15,PRKAA1
,IL1B,CHUK,RXRA,IL1RAP,MAP2K1 
22 
Cdc42 Signaling 6.76E+02 1.30E-01 13 ACTR2,MYL6,MAPK1,CDC42,ARPC5,LIMK
2,EXOC6,CDC42EP2,IQGAP1,CLIP1,FOS,M
YL12A,MAPK14,ACTR3,MYL12B,FCER1G,
ARPC3,PPP1R12A,ARPC1A 
19 
TREM1 Signaling 6.61E+02 1.77E-01 17.7 TLR2,TLR4,TLR1,TLR5,MAPK1,TYROBP,M
APK3,TLR8,LAT2,IL1B,JAK2 
11 
Pentose Phosphate 
Pathway 
4.57E+02 1.01E-01 10.1 PGM2,GPI,PGD,TKT,G6PD,PGM1,FBP1,AL
DOA 
8 
Starch and Sucrose 
Metabolism 
3.72E+02 7.36E-02 7.36 NUDT5,PGM2,GPI,HK2,UGP2,GBA,PGM1,
GBE1,HPSE,PYGL,HK3,CSGALNACT1 
12 
Actin Nucleation by ARP-
WASP Complex 
3.24E+02 1.67E-01 16.7 ACTR2,ACTR3,RHOG,CDC42,RHOT1,ARPC
5,PPP1R12A,ARPC3,ARPC1A,KRAS,VASP 
11 
NF-κB Signaling 2.95E+02 1.23E-01 12.3 TLR1,AZI2,TNFRSF1A,MYD88,TLR8,TNFAI
P3,TBK1,KRAS,IRAK3,TANK,TLR2,IL1R2,TL
R4,TLR5,IL1RN,TGFA,FCER1G,IL1B,MAP3K
8,LTBR,CHUK 
21 
IL-12 Signaling and 
Production in Macrophages 
2.75E+02 1.18E-01 11.8 ORM1/ORM2,MAPK1,MYD88,MAPK3,IFN
GR1,CEBPB (includes EG:1051),SPI1 
(includes 
EG:20375),TLR2,FOS,TLR4,MAPK14,PRKC
D,S100A8,SERPINA1,MAP3K8,CHUK,RXRA
,MAP2K1 
18 
Nicotinate and 
Nicotinamide Metabolism 
2.63E+02 1.12E-01 11.2 MAPK1,MAPK3,LIMK2,NAPRT1,VNN1,CD
K5,PIM1,VNN2,PRKCD,PRKAA1,GRK6,NA
MPT,MAP3K8,MAP2K1,BST1 (includes 
EG:12182) 
15 
Oxidative Phosphorylation 2.24E+02 1.21E-01 12.1 NDUFA4,COX17 (includes 
EG:10063),NDUFB3,COX7B,COX7A2,ATP6
V1D 
(includesEG:299159),ATP6V0B,ATP6V1C1
,TCIRG1,ATP6V1A,ATP6AP1,NDUFA1,ATP
6V1E1,ATP5C1,PPA2 (includes EG:27068), 
ATP6V0D1, ATP6V0E1,ATP6V1B2 
18 
Integrin Signaling 2.00E+02 1.12E-01 11.2 ACTR2,MAPK1,CDC42,ASAP1,MAPK3,RAL
B,ARPC5,KRAS,PTEN,MYL12A,RHOG,ITGA
M 
(includesEG:16409),ACTR3,RHOT1,MYL12
B,ARF4,PPP1R12A,ARPC3,ZYX,ARPC1A,M
AP2K1,VASP,CAPN3 
23 
Inositol Phosphate 
Metabolism 
1.78E+02 9.95E-02 9.95 MAPK1,MAPK3,GNAQ,LIMK2,INPP5A,PTE
N,GNAI3,GNA15,CDK5,SYNJ1,PIM1,PRKC
D,GRK6,PRKAA1,IMPA2,IRS2,MAP3K8,M
AP2K1,MTMR3 
19 
Rac Signaling 1.78E+02 1.23E-01 12.3 ACTR2,MAPK1,CDC42,MAPK3,ARPC5,KRA
S,LIMK2,IQGAP1,ACTR3,NCF2,CD44 
(includes 
EG:100330801),CYBB,ARPC3,ARPC1A,MA
P2K1 
15 
Regulation of Actin-based 
Motility by Rho 
1.78E+02 1.46E-01 14.6 ACTR2,CDC42,MYL6,ARPC5,GSN,MYL12A,
ACTR3,RHOG,RHOT1,MYL12B,PPP1R12A,
ARPC3,ARPC1A 
13 
HMGB1 Signaling 1.78E+02 1.41E-01 14.1 MAPK1,CDC42,HAT1,TNFRSF1A,MAPK3,I
FNGR2,IFNGR1,KRAS,TLR4,FOS,RHOG,MA
14 
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PK14,RHOT1,MAP2K1 
Fructose and Mannose 
Metabolism 
1.70E+02 6.98E-02 6.98 NUDT5,PFKFB3,PGM2,HK2,PFKFB4,FBP1,
ALDOA,HK3,TPI1 
9 
Role of Tissue Factor in 
Cancer 
1.51E+02 1.35E-01 13.5 CDC42,MAPK1,MAPK3,GNAQ,PLAUR,KRA
S,LIMK2,JAK2,PTEN,ARRB2,MAPK14,HCK,
IL1B,RPS6KA1 (includes EG:20111),FGR 
15 
Acute Phase Response 
Signaling 
1.23E+02 1.12E-01 11.2 ORM1/ORM2,MAPK1,TNFRSF1A,MYD88,
MAPK3,KRAS,JAK2,CEBPB (includes 
EG:1051),FOS,HMOX1,HP,SOD2,MAPK14,
IL1RN,OSM,IL1B,SERPINA1,CHUK,IL1RAP,
MAP2K1 
20 
Glioma Invasiveness 
Signaling 
1.05E+02 1.67E-01 16.7 RHOG,MAPK1,RHOT1,TIMP1,MAPK3,CD4
4 (includes 
EG:100330801),PLAUR,KRAS,MMP9,TIMP
2 (includes EG:21858) 
10 
Ephrin Receptor Signaling 9.77E+01 1.01E-01 10.1 ACTR2,MAPK1,CDC42,MAPK3,ARPC5,GN
AQ,LIMK2,KRAS,JAK2,GNG5,GRINA,GNG1
0,GNAI3,ACTR3,SDCBP,GNA15,GNB2,ARP
C3,ARPC1A,MAP2K1 
20 
Hepatic Cholestasis 8.91E+01 9.88E-02 9.88 IL18RAP,TNFRSF1A,MYD88,PRKAR2A,IRA
K3,IL1R2,TLR4,LY96 (includes 
EG:17087),IL1RN,RARA,PRKCD,IL1B,CD14
,CHUK,RXRA,IL1RAP,IRAK2 
17 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
8.71E+01 1.18E-01 11.8 IL18RAP,IL4R,MYL6,TNFRSF1A,IFNGR2,IF
NGR1,IL1R2,TLR4,LY96 (includes 
EG:17087),TIMP1,TGFA,IL1B,CD14,IL1RA
P,MMP9,IFNAR1,TIMP2 (includes 
EG:21858) 
17 
PPAR Signaling 8.71E+01 1.27E-01 12.7 IL18RAP,MAPK1,TNFRSF1A,MAPK3,KRAS,
IL1R2,FOS,IL1RN,IL1B,CHUK,RXRA,MAP2K
1,IL1RAP 
13 
RhoGDI Signaling 8.71E+01 1.01E-01 10.1 ACTR2,MYL6,CDC42,ARPC5,GNAQ,LIMK2,
GNG5,GNG10,GNAI3,MYL12A,ACTR3,RH
OG,GNA15,RHOT1,MYL12B,GNB2,CD44 
(includes 
EG:100330801),PPP1R12A,ARPC3,ARPC1
A 
20 
p38 MAPK Signaling 6.31E+01 1.32E-01 13.2 IL18RAP,DDIT3,MAPKAPK3,TNFRSF1A,IRA
K3,IL1R2,MAPK14,DUSP1,IL1RN,MKNK1,I
L1B,MAPKAPK2,IL1RAP,IRAK2 
14 
PI3K Signaling in B 
Lymphocytes 
6.31E+01 1.13E-01 11.3 IL4R,MAPK1,MAPK3,CHP,GNAQ,KRAS,AT
F6,PTEN,TLR4,FOS,GNA15,SYK,IRS2,PIK3A
P1,CHUK,MAP2K1 
16 
LPS-stimulated MAPK 
Signaling 
6.31E+01 1.34E-01 13.4 TLR4,FOS,MAPK14,CDC42,MAPK1,PRKCD
,MAPK3,CD14,KRAS,CHUK,MAP2K1 
11 
Cardiac Hypertrophy 
Signaling 
6.03E+01 9.54E-02 9.54 MYL6,MAPK1,MAPKAPK3,MAPK3,CHP,G
NAQ,PRKAR2A,KRAS,ATF6,GNG5,GNG10,
GNAI3,MYL12A,MAPK14,RHOG,GNA15,R
HOT1,MYL12B,GNB2,MAP3K8,RPS6KA1 
(includes EG:20111),MAPKAPK2,MAP2K1 
23 
p70S6K Signaling 5.37E+01 1.15E-01 11.5 IL4R,YWHAG,MAPK1,YWHAH,PPP2CA,M
APK3,GNAQ,KRAS,PPP2R5A,GNAI3,GNA1
5,PRKCD,SYK,BCAP31,MAP2K1 
15 
α-Adrenergic Signaling 5.01E+01 1.14E-01 11.4 GNAI3,MAPK1,PRKCD,MAPK3,GNB2,PRK
AR2A,GNAQ,PYGL,KRAS,MAP2K1,GNG5,
GNG10 
12 
G Beta Gamma Signaling 4.17E+01 1.06E-01 10.6 GNAI3,CDC42,MAPK1,GNA15,PRKCD,MA
PK3,GNB2,PRKAR2A,GNAQ,KRAS,GNG5,G
NG10 
12 
TNFR2 Signaling 3.89E+01 1.82E-01 18.2 TANK,FOS,TNFAIP3,TBK1,CHUK,BIRC2 6 
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TNFR1 Signaling 3.89E+01 1.54E-01 15.4 TANK,FOS,CDC42,TNFRSF1A,APAF1,TNFA
IP3,CHUK,BIRC2 
8 
Chemokine Signaling 3.89E+01 1.39E-01 13.9 GNAI3,FOS,MAPK14,MAPK1,MAPK3,GNA
Q,PPP1R12A,KRAS,LIMK2,MAP2K1 
10 
CXCR4 Signaling 3.89E+01 1.01E-01 10.1 MYL6,MAPK1,MAPK3,GNAQ,KRAS,GNG5,
GNG10,GNAI3,FOS,MYL12A,RHOG,GNA1
5,RHOT1,MYL12B,PRKCD,GNB2,MAP2K1 
17 
Dendritic Cell Maturation 3.89E+01 9.50E-02 9.5 MAPK1,TYROBP,MYD88,TNFRSF1A,MAPK
3,CD58,JAK2,TLR2,TLR4,MAPK14,IL1RN,F
CER1G,IL1B,LTBR,CHUK,IFNAR1,FCGR1B 
17 
NRF2-mediated Oxidative 
Stress Response 
3.89E+01 1.00E-01 10 RBX1,MGST1,MAPK1,NQO2,MAPK3,KRAS
,JUNB,GSTO1,TXNRD1,FOS,HMOX1,DNAJ
C5,SOD2,MAPK14,PRKCD,DNAJB6,TXN 
(includes EG:116484),FKBP5,MAP2K1 
19 
Renal Cell Carcinoma 
Signaling 
3.80E+01 1.37E-01 13.7 FOS,RBX1,CDC42,MAPK1,MAPK3,TGFA,K
RAS,HIF1A,MAP2K1,TCEB1 
10 
IL-17 Signaling 2.82E+01 1.35E-01 13.5 MAPK14,MAPK1,TIMP1,MAPK3,KRAS,CE
BPB (includes 
EG:1051),JAK2,MAPKAPK2,IL17RA,MAP2
K1 
10 
CD40 Signaling 2.63E+01 1.30E-01 13 TANK,FOS,MAPK14,MAPK1,MAPK3,TNFA
IP3,CHUK,MAPKAPK2,MAP2K1 
9 
GM-CSF Signaling 2.63E+01 1.34E-01 13.4 MAPK1,CSF2RA,PIM1,MAPK3,HCK,KRAS,J
AK2,BCL2A1,MAP2K1 
9 
Phospholipase C Signaling 2.63E+01 8.59E-02 8.59 HDAC4,MYL6,MAPK1,MAPK3,CHP,RALB,
GNAQ,KRAS,GNG5,GNG10,HMOX1,MYL1
2A,RHOG,RHOT1,MYL12B,PRKCD,SYK,GN
B2,FCER1G,PPP1R12A,MARCKS,MAP2K1 
22 
Apoptosis Signaling 2.04E+01 1.17E-01 11.7 MAPK1,TNFRSF1A,MAPK3,APAF1,KRAS,C
HUK,RPS6KA1 (includes 
EG:20111),BCL2A1,MAP2K1,CAPN3,BIRC
2 
11 
Type II Diabetes Mellitus 
Signaling 
2.00E+01 8.44E-02 8.44 PKM2,ACSL3,MAPK1,TNFRSF1A,MAPK3,C
D36,CEBPB (includes 
EG:1051),PRKCD,PRKAA1,ACSL4,IRS2,CH
UK,ACSL1 
13 
Cholecystokinin/Gastrin-
mediated Signaling 
2.00E+01 1.13E-01 11.3 FOS,RHOG,MAPK14,MAPK1,RHOT1,IL1R
N,PRKCD,MAPK3,GNAQ,IL1B,KRAS,MAP2
K1 
12 
Acute Myeloid Leukemia 
Signaling 
2.00E+01 1.22E-01 12.2 CSF3R,MAPK1,CSF2RA,PIM1,MAPK3,RAR
A,CEBPA,KRAS,MAP2K1,SPI1 (includes 
EG:20375) 
10 
LPS/IL-1 Mediated 
Inhibition of RXR Function 
2.00E+01 8.92E-02 8.92 IL18RAP,MGST1,ACSL3,TNFRSF1A,MYD88
,ACOX1,GSTO1,ABCA1,IL1R2,TLR4,LY96 
(includes 
EG:17087),RARA,CD14,ACSL4,IL1B,ALDH3
B1,RXRA,IL1RAP,ACSL1 
19 
Breast Cancer Regulation 
by Stathmin1 
2.00E+01 9.09E-02 9.09 MAPK1,CDC42,PPP2CA,MAPK3,GNAQ,PR
KAR2A,LIMK2,KRAS,E2F3,PPP2R5A,GNG5
,GNG10,GNAI3,PPP1R3D,PRKCD,GNB2,PP
P1R12A,MAP2K1,E2F2 
19 
Molecular Mechanisms of 
Cancer 
2.00E+01 7.80E-02 7.8 MAPK1,APH1B,CDC42,MAPK3,CTNNA1,K
RAS,JAK2,HIF1A,E2F3,LAMTOR3,RHOG,G
NA15,RHOT1,MAP2K1,E2F2,HAT1,RALB,C
DKN2D,GNAQ,APAF1,PRKAR2A,NBN,GNA
I3,FOS,MAPK14,CCND3,PRKCD,RBPJ,BIRC
2 
29 
Oncostatin M Signaling 2.00E+01 1.71E-01 17.1 MAPK1,MAPK3,OSM,KRAS,JAK2,MAP2K1 6 
Thrombopoietin Signaling 2.00E+01 1.27E-01 12.7 FOS,MAPK1,PRKCD,MAPK3,IRS2,KRAS,JA
K2,MAP2K1 
8 
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Clathrin-mediated 
Endocytosis Signaling 
2.00E+01 9.38E-02 9.38 ACTR2,ORM1/ORM2,RAB5A,CDC42,CHP,
CLTC,ARPC5,NUMB,SH3GLB1,ARRB2,ACT
R3,LDLR,SYNJ1,RAB5C,ARPC3,S100A8,AR
PC1A,SERPINA1 
18 
Synaptic Long Term 
Potentiation 
2.00E+01 1.06E-01 10.6 PPP1R3D,MAPK1,PRKCD,MAPK3,CHP,PRK
AR2A,GNAQ,PPP1R12A,KRAS,RPS6KA1 
(includes EG:20111),MAP2K1,GRINA 
12 
CCR5 Signaling in 
Macrophages 
2.00E+01 1.02E-01 10.2 GNAI3,FOS,MAPK14,MAPK1,PRKCD,GNB
2,FCER1G,GNG5,GNG10 
9 
IL-17A Signaling in Gastric 
Cells 
2.00E+01 2.00E-01 20 FOS,MAPK14,MAPK1,MAPK3,IL17RA 5 
Role of JAK family kinases 
in IL-6-type Cytokine 
Signaling 
2.00E+01 1.85E-01 18.5 MAPK14,MAPK1,MAPK3,OSM,JAK2 5 
Germ Cell-Sertoli Cell 
Junction Signaling 
1.91E+01 9.70E-02 9.7 MAPK1,CDC42,TNFRSF1A,MAPK3,CTNNA
1,KRAS,LIMK2,IQGAP1,GSN,RHOG,MAPK
14,RHOT1,ZYX,MAP3K8,MAP2K1,RAB8B 
16 
14-3-3-mediated Signaling 1.91E+01 1.07E-01 10.7 YWHAG,MAPK1,YWHAH,TNFRSF1A,MAP
K3,GNAQ,VIM,KRAS,FOS,GNA15,PRKCD,R
PS6KA1 (includes EG:20111),MAP2K1 
13 
ERK/MAPK Signaling 1.82E+01 8.82E-02 8.82 YWHAG,YWHAH,MAPK1,PPP2CA,MAPK3,
PRKAR2A,ETS2,KRAS,PPP2R5A,FOS,PPP1
R3D,LAMTOR3,DUSP1,PRKCD,MKNK1,PP
P1R12A,RPS6KA1 (includes 
EG:20111),MAP2K1 
18 
Type I Diabetes Mellitus 
Signaling 
1.62E+01 1.02E-01 10.2 MAPK14,MAPK1,MYD88,TNFRSF1A,APAF
1,IFNGR2,FCER1G,IL1B,IFNGR1,CHUK,JAK
2,IL1RAP 
12 
Aryl Hydrocarbon Receptor 
Signaling 
1.62E+01 9.03E-02 9.03 MGST1,MAPK1,NQO2,MAPK3,APAF1,GST
O1,CYP1B1,CTSD,FOS,CCND3,RARA,IL1B,
ALDH3B1,RXRA 
14 
P2Y Purigenic Receptor 
Signaling Pathway 
1.62E+01 9.35E-02 9.35 MAPK1,MAPK3,PRKAR2A,GNAQ,KRAS,GN
G5,GNG10,GNAI3,FOS,GNA15,PRKCD,GN
B2,MAP2K1 
13 
Thrombin Signaling 1.58E+01 8.82E-02 8.82 MYL6,MAPK1,MAPK3,GNAQ,KRAS,GNG5,
GNG10,GNAI3,MYL12A,RHOG,MAPK14,G
NA15,RHOT1,MYL12B,PRKCD,GNB2,PPP1
R12A,MAP2K1 
18 
Glucocorticoid Receptor 
Signaling 
1.58E+01 7.88E-02 7.88 YWHAH,MAPK1,HSPA1A/HSPA1B,MAPK3
,CHP,SLPI,KRAS,JAK2,CEBPB (includes 
EG:1051),TAF7,CD163,IL1R2,FOS,MAPK1
4,IL1RN,DUSP1,ANXA1,CEBPA,PRKAA1,IL
1B,CHUK,FKBP5,MAP2K1 
23 
Pyruvate Metabolism 1.48E+01 6.20E-02 6.2 PKM2,ACSL3,ACSS2,DLD,ME2,ACOT9,ACS
L1,LDHA 
8 
Galactose Metabolism 1.45E+01 6.12E-02 6.12 PGM2,GLA,HK2,UGP2,PGM1,HK3 6 
IGF-1 Signaling 1.45E+01 1.05E-01 10.5 FOS,YWHAG,MAPK1,YWHAH,MAPK3,PRK
AR2A,IRS2,KRAS,IGFBP7,JAK2,MAP2K1 
11 
Actin Cytoskeleton 
Signaling 
1.45E+01 8.26E-02 8.26 ACTR2,MYL6,MAPK1,CDC42,MAPK3,ARP
C5,LIMK2,KRAS,IQGAP1,GSN,MYL12A,AC
TR3,MYL12B,ARPC3,CD14,PPP1R12A,ARP
C1A,SSH2,MAP2K1 
19 
Colorectal Cancer 
Metastasis Signaling 
1.45E+01 8.30E-02 8.3 TLR1,MAPK1,TNFRSF1A,MAPK3,PRKAR2A
,TLR8,KRAS,IFNGR1,JAK2,GNG5,GNG10,T
LR2,TLR4,FOS,RHOG,TLR5,RHOT1,GNB2,P
TGER2,MAP2K1,MMP9 
21 
Role of JAK1 and JAK3 in γc 
Cytokine Signaling 
1.41E+01 1.21E-01 12.1 IL4R,FES,MAPK1,MAPK3,SYK,IRS2,KRAS,J
AK2 
8 
Amyloid Processing 1.38E+01 1.30E-01 13 MAPK14,APH1B,CDK5,MAPK1,MAPK3,PR
KAR2A,CAPN3 
7 
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RANK Signaling in 
Osteoclasts 
1.38E+01 1.06E-01 10.6 FOS,MAPK14,MAPK1,MAPK3,CHP,MAP3
K8,CHUK,GSN,MAP2K1,BIRC2 
10 
CDK5 Signaling 1.29E+01 1.06E-01 10.6 PPP1R3D,CDK5,MAPK1,PPP2CA,MAPK3,P
RKAR2A,PPP1R12A,KRAS,MAP2K1,PPP2R
5A 
10 
CCR3 Signaling in 
Eosinophils 
1.29E+01 9.60E-02 9.6 GNAI3,MAPK14,MAPK1,PRKCD,MAPK3,G
NB2,PPP1R12A,KRAS,LIMK2,MAP2K1,GN
G5,GNG10 
12 
CD28 Signaling in T Helper 
Cells 
1.29E+01 9.30E-02 9.3 ACTR2,FOS,ACTR3,CDC42,SYK,ARPC5,CHP
,FCER1G,ARPC3,ARPC1A,CHUK,MAP2K1 
12 
Role of IL-17F in Allergic 
Inflammatory Airway 
Diseases 
1.29E+01 1.40E-01 14 MAPK1,MAPK3,IL1B,RPS6KA1 (includes 
EG:20111),IL17RA,MAP2K1 
6 
IL-17A Signaling in Airway 
Cells 
1.29E+01 1.11E-01 11.1 MAPK14,MAPK1,MAPK3,CHUK,JAK2,IL17
RA,MAP2K1,PTEN 
8 
Role of NFAT in Regulation 
of the Immune Response 
1.29E+01 8.21E-02 8.21 MAPK1,MAPK3,CHP,GNAQ,KRAS,GNG5,G
NG10,GNAI3,FOS,GNA15,SYK,GNB2,FCER
1G,CHUK,MAP2K1,FCGR1B 
16 
HIF1α Signaling 1.29E+01 1.04E-01 10.4 RBX1,MAPK14,MAPK1,MAPK3,COPS5,KR
AS,HIF1A,TCEB1,LDHA,MMP9,SLC2A3 
11 
Axonal Guidance Signaling 1.29E+01 7.21E-02 7.21 MAPK1,CDC42,MYL6,MAPK3,ARPC5,LIMK
2,KRAS,MICAL1,ACTR3,CDK5,GNA15,MK
NK1,ARPC3,ARPC1A,SEMA4A,MAP2K1,V
ASP,ACTR2,FES,CHP,GNAQ,PRKAR2A,GN
G5,GNG10,GNAI3,MYL12A,SDCBP,MYL12
B,PRKCD,GNB2,RTN4 (includes EG:57142) 
31 
Semaphorin Signaling in 
Neurons 
1.26E+01 1.35E-01 13.5 RHOG,FES,CDK5,MAPK1,RHOT1,MAPK3,L
IMK2 
7 
PI3K/AKT Signaling 1.26E+01 8.82E-02 8.82 YWHAG,MAPK1,YWHAH,PPP2CA,MAPK3,
KRAS,MAP3K8,CHUK,JAK2,MAP2K1,PPP2
R5A,PTEN 
12 
B Cell Receptor Signaling 1.26E+01 9.09E-02 9.09 CDC42,MAPK1,MAPK3,KRAS,BCL6,PTEN,
MAPK14,PAG1,SYK,PIK3AP1,MAP3K8,CH
UK,BCL2A1,MAP2K1 
14 
MIF Regulation of Innate 
Immunity 
1.26E+01 1.20E-01 12 TLR4,FOS,LY96 (includes 
EG:17087),MAPK1,MAPK3,CD14 
6 
Hypoxia Signaling in the 
Cardiovascular System 
1.17E+01 1.21E-01 12.1 UBE2H,UBE2A,COPS5,HIF1A,UBE2J1,LDH
A,UBE2F,PTEN 
8 
G Protein Signaling 
Mediated by Tubby 
1.17E+01 1.28E-01 12.8 GNB2,GNAQ,JAK2,GNG5,GNG10 5 
Leukocyte Extravasation 
Signaling 
1.17E+01 8.72E-02 8.72 MYL6,MAPK1,CDC42,CTNNA1,NCF4,GNAI
3,ITGAM (includes 
EG:16409),MAPK14,TIMP1,CYBA,PRKCD,
NCF2,CYBB,CD44 (includes 
EG:100330801),MMP9,VASP,TIMP2 
(includes EG:21858) 
17 
VDR/RXR Activation 1.15E+01 1.11E-01 11.1 SERPINB1,CAMP (includes 
EG:12796),GADD45A,PRKCD,MXD1,CEBP
A,CD14,CEBPB (includes EG:1051),RXRA 
9 
Role of IL-17A in Arthritis 1.12E+01 1.11E-01 11.1 MAPK14,MAPK1,MAPK3,RPS6KA1 
(includes 
EG:20111),MAPKAPK2,IL17RA,MAP2K1 
7 
Inositol Metabolism 1.12E+01 1.18E-01 11.8 ALDOA,TPI1 2 
Pancreatic 
Adenocarcinoma Signaling 
1.10E+01 9.32E-02 9.32 HMOX1,CDC42,MAPK1,MAPK3,TGFA,KRA
S,JAK2,E2F3,MAP2K1,MMP9,E2F2 
11 
T Helper Cell 
Differentiation 
1.07E+01 1.14E-01 11.4 IL4R,TNFRSF1A,IL10RB,IFNGR2,FCER1G,IF
NGR1,BCL6,IL18R1 
8 
288 
 
Relaxin Signaling 1.07E+01 8.28E-02 8.28 MAPK1,MAPK3,PRKAR2A,GNAQ,PDE4D,G
NG5,GNG10,GNAI3,FOS,GNA15,GNB2,M
AP2K1,MMP9 
13 
Polyamine Regulation in 
Colon Cancer 
1.07E+01 1.38E-01 13.8 AZIN1,MXD1,SAT1,KRAS 4 
Sphingolipid Metabolism 1.02E+01 8.18E-02 8.18 GLA,GALC,ARSD,VNN1,GBA,PIGF,VNN2,U
GCG,ASAH1 
9 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
1.02E+01 1.03E-01 10.3 TLR2,TLR4,TLR1,TLR5,IL1RN,TLR8,FCER1G
,IL1B,CHUK 
9 
MIF-mediated 
Glucocorticoid Regulation 
1.02E+01 1.19E-01 11.9 TLR4,LY96 (includes 
EG:17087),MAPK1,MAPK3,CD14 
5 
Aminosugars Metabolism 9.79E+00 6.72E-02 6.72 POR,CYB5R4,HK2,CYB5R1,HK3,NANS,PDE
4D,NPL 
8 
ILK Signaling 9.79E+00 8.60E-02 8.6 MYL6,MAPK1,CDC42,PPP2CA,TNFRSF1A,
MAPK3,VIM,HIF1A,PPP2R5A,PTEN,FOS,R
HOG,RHOT1,PPP1R12A,IRS2,MMP9 
16 
Renin-Angiotensin 
Signaling 
9.53E+00 8.73E-02 8.73 FOS,MAPK14,MAPK1,PRKCD,MAPK3,PRK
AR2A,GNAQ,KRAS,PTGER2,JAK2,MAP2K1 
11 
RhoA Signaling 9.53E+00 9.82E-02 9.82 ACTR2,MYL12A,ACTR3,MYL6,MYL12B,AR
PC5,PPP1R12A,ARPC3,ARPC1A,LIMK2,CD
C42EP2 
11 
Melatonin Signaling 9.38E+00 1.03E-01 10.3 GNAI3,MAPK1,GNA15,PRKCD,MAPK3,PR
KAR2A,GNAQ,MAP2K1 
8 
GNRH Signaling 9.08E+00 8.45E-02 8.45 GNAI3,FOS,MAPK14,CDC42,MAPK1,PRKC
D,MAPK3,PRKAR2A,GNAQ,KRAS,MAP3K8
,MAP2K1 
12 
Folate Biosynthesis 9.08E+00 4.17E-02 4.17 ALPP/ALPPL2,GGH,ALPL 3 
IL-3 Signaling 8.95E+00 1.08E-01 10.8 FOS,MAPK1,PRKCD,MAPK3,CHP,KRAS,JA
K2,MAP2K1 
8 
IL-22 Signaling 8.95E+00 1.60E-01 16 MAPK14,MAPK1,MAPK3,IL10RB 4 
Role of JAK1, JAK2 and 
TYK2 in Interferon Signaling 
8.95E+00 1.48E-01 14.8 IFNGR2,IFNGR1,JAK2,IFNAR1 4 
Protein Kinase A Signaling 8.75E+00 7.45E-02 7.45 HIST1H1C,YWHAG,YWHAH,MYL6,MAPK1,
MAPK3,CHP,GNAQ,PRKAR2A,PYGL,PDE4
D,GNG5,GNG10,GNAI3,MYL12A,PPP1R3D
,GNA15,MYL12B,PRKCD,GNB2,PPP1R12A
,CHUK,MAP2K1,VASP 
24 
Huntington's Disease 
Signaling 
8.09E+00 7.69E-02 7.69 HDAC4,MAPK1,HSPA1A/HSPA1B,MAPK3,
CLTC,GNAQ,APAF1,GNG5,GNG10,CTSD,D
NAJC5,CDK5,CACNA1B,PRKCD,VAMP3,G
NB2,GOSR2,CAPN3 
18 
Prolactin Signaling 8.09E+00 1.00E-01 10 FOS,MAPK1,PRKCD,MAPK3,KRAS,CEBPB 
(includes EG:1051),JAK2,MAP2K1 
8 
IL-15 Signaling 7.74E+00 1.04E-01 10.4 MAPK14,MAPK1,MAPK3,SYK,KRAS,JAK2,
MAP2K1 
7 
ERK5 Signaling 7.74E+00 1.11E-01 11.1 FOS,YWHAG,YWHAH,GNAQ,KRAS,MAP3K
8,RPS6KA1 (includes EG:20111) 
7 
CNTF Signaling 7.50E+00 1.15E-01 11.5 MAPK1,MAPK3,KRAS,JAK2,RPS6KA1 
(includes EG:20111),MAP2K1 
6 
PAK Signaling 7.45E+00 8.49E-02 8.49 MYL12A,CDC42,MAPK1,MYL6,MYL12B,M
APK3,KRAS,LIMK2,MAP2K1 
9 
Antiproliferative Role of 
Somatostatin Receptor 2 
7.36E+00 1.00E-01 10 MAPK1,MAPK3,GNB2,KRAS,MAP2K1,GN
G5,GNG10 
7 
AMPK Signaling 7.05E+00 7.27E-02 7.27 CAB39,PFKFB3,MAPK14,MAPK1,PFKFB4,P
PP2CA,PPM1B,PRKAA1,PRKAR2A,IRS2,H
MGCR,PPP2R5A 
12 
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Mitochondrial Dysfunction 6.78E+00 6.98E-02 6.98 NDUFA4,ATP5C1,COX7B,COX7A2,NDUFB
3,COX17 (includes 
EG:10063),PRDX3,FURIN,SOD2,APH1B,PR
DX5,GLRX2 
12 
NGF Signaling 6.75E+00 8.62E-02 8.62 RHOG,CDC42,MAPK1,PRKCD,MAPK3,KRA
S,MAP3K8,CHUK,RPS6KA1 (includes 
EG:20111),MAP2K1 
10 
Ceramide Signaling 6.28E+00 9.20E-02 9.2 CTSD,FOS,PPP2CA,TNFRSF1A,MAPK3,KRA
S,MAP2K1,PPP2R5A 
8 
Endometrial Cancer 
Signaling 
6.24E+00 1.05E-01 10.5 MAPK1,MAPK3,CTNNA1,KRAS,MAP2K1,P
TEN 
6 
Glioblastoma Multiforme 
Signaling 
6.24E+00 7.78E-02 7.78 CDC42,MAPK1,MAPK3,GNAQ,KRAS,E2F3,
PTEN,RHOG,GNA15,RHOT1,PRKCD,MAP2
K1,E2F2 
13 
Role of PKR in Interferon 
Induction and Antiviral 
Response 
6.17E+00 1.11E-01 11.1 MAPK14,TNFRSF1A,APAF1,CHUK,RNASEL 5 
Mechanisms of Viral Exit 
from Host Cells 
6.17E+00 1.11E-01 11.1 CHMP2A,PRKCD,SH3GLB1,VPS25 
(includes EG:28084),LMNB1 
5 
N-Glycan Biosynthesis 6.17E+00 6.41E-02 6.41 B4GALT4,MGAT4A,MAN1A1,MAN2A2,B4
GALT5 
5 
Role of NFAT in Cardiac 
Hypertrophy 
6.07E+00 7.39E-02 7.39 HDAC4,MAPK1,MAPK3,CHP,PRKAR2A,GN
AQ,KRAS,GNG5,GNG10,GNAI3,MAPK14,
GNA15,PRKCD,GNB2,MAP2K1 
15 
IL-2 Signaling 6.07E+00 1.03E-01 10.3 FOS,MAPK1,MAPK3,SYK,KRAS,MAP2K1 6 
Glutathione Metabolism 6.07E+00 7.14E-02 7.14 MGST1,PGD,G6PD,GLRX,GSTO1,IDH1 6 
Glioma Signaling 5.89E+00 8.11E-02 8.11 MAPK1,PRKCD,MAPK3,CDKN2D,KRAS,E2
F3,MAP2K1,E2F2,PTEN 
9 
4-1BB Signaling in T 
Lymphocytes 
5.85E+00 1.18E-01 11.8 MAPK1,MAPK3,CHUK,MAP2K1 4 
Erythropoietin Signaling 5.83E+00 8.97E-02 8.97 FOS,MAPK1,PRKCD,MAPK3,KRAS,JAK2,M
AP2K1 
7 
Lymphotoxin β Receptor 
Signaling 
5.81E+00 1.00E-01 10 MAPK1,MAPK3,APAF1,CHUK,LTBR,BIRC2 6 
Corticotropin Releasing 
Hormone Signaling 
5.78E+00 7.69E-02 7.69 GNAI3,FOS,MAPK14,MAPK1,PRKCD,MAP
K3,ARPC5,PRKAR2A,GNAQ,MAP2K1 
10 
RAR Activation 5.73E+00 7.61E-02 7.61 MAPK1,PRKAR2A,JAK2,PTEN,FOS,MAPK1
4,DHRS9,DUSP1,RARA,PRKCD,RXRA,MAP
KAPK2,ZBTB16,MAP2K1 
14 
Growth Hormone Signaling 5.66E+00 9.33E-02 9.33 FOS,MAPK1,PRKCD,MAPK3,CEBPA,JAK2,R
PS6KA1 (includes EG:20111) 
7 
Neurotrophin/TRK 
Signaling 
5.66E+00 9.21E-02 9.21 FOS,CDC42,MAPK1,MAPK3,KRAS,RPS6KA
1 (includes EG:20111),MAP2K1 
7 
Melanoma Signaling 5.66E+00 1.09E-01 10.9 MAPK1,MAPK3,KRAS,MAP2K1,PTEN 5 
Communication between 
Innate and Adaptive 
Immune Cells 
5.64E+00 8.08E-02 8.08 TLR2,TLR4,TLR1,TLR5,IL1RN,TLR8,FCER1G
,IL1B 
8 
Androgen Signaling 5.47E+00 7.19E-02 7.19 GNAI3,MAPK1,GNA15,PRKCD,MAPK3,GN
B2,PRKAR2A,GNAQ,GNG5,GNG10 
10 
Thyroid Cancer Signaling 5.32E+00 1.11E-01 11.1 MAPK1,MAPK3,KRAS,RXRA,MAP2K1 5 
HGF Signaling 4.94E+00 8.57E-02 8.57 FOS,CDC42,MAPK1,PRKCD,MAPK3,ETS2,
KRAS,MAP3K8,MAP2K1 
9 
Complement System 4.79E+00 1.18E-01 11.8 CR1,CD55,C5AR1,C3AR1 4 
Death Receptor Signaling 4.79E+00 9.52E-02 9.52 TANK,TNFRSF1A,APAF1,TBK1,CHUK,BIRC
2 
6 
Eicosanoid Signaling 4.79E+00 7.79E-02 7.79 LTB4R,FPR2,ALOX5AP,PTGER2,ALOX5,TB
XAS1 
6 
290 
 
Neuregulin Signaling 4.76E+00 8.00E-02 8 CDK5,MAPK1,PRKCD,MAPK3,TGFA,KRAS,
MAP2K1,PTEN 
8 
Fatty Acid Metabolism 4.65E+00 5.52E-02 5.52 ACSL3,DHRS9,ACAA1,ACOX1,ACSL4,PECR,
ACSL1,CYP51A1,CYP1B1 
9 
Dopamine-DARPP32 
Feedback in cAMP 
Signaling 
4.61E+00 7.10E-02 7.1 KCNJ2,PPP2CA,CHP,PRKAR2A,GNAQ,PPP
2R5A,GRINA,GNAI3,PPP1R3D,CDK5,GNA1
5,PRKCD,PPP1R12A 
13 
Inhibition of Angiogenesis 
by TSP1 
4.52E+00 1.05E-01 10.5 MAPK14,MAPK1,CD36,MMP9 4 
Xenobiotic Metabolism 
Signaling 
4.46E+00 7.06E-02 7.06 RBX1,MGST1,MAPK1,PPP2CA,NQO2,MAP
K3,KRAS,PPP2R5A,CYP1B1,GSTO1,HMOX
1,MAPK14,PRKCD,IL1B,ALDH3B1,MAP3K
8,RXRA,PNPLA6,MAP2K1 
19 
Metabolism of Xenobiotics 
by Cytochrome P450 
4.45E+00 4.71E-02 4.71 MGST1,DHRS9,PECR,ALDH3B1,CSGALNA
CT1,GSTO1,CYP51A1,CYP1B1 
8 
Natural Killer Cell Signaling 4.38E+00 8.18E-02 8.18 LAIR1,MAPK1,TYROBP,PRKCD,MAPK3,SY
K,FCER1G,KRAS,MAP2K1 
9 
Interferon Signaling 4.26E+00 1.11E-01 11.1 IFNGR2,IFNGR1,JAK2,IFNAR1 4 
Role of PI3K/AKT Signaling 
in the Pathogenesis of 
Influenza 
4.22E+00 8.57E-02 8.57 GNAI3,MAPK1,MAPK3,MAP2K1,PLAC8,IF
NAR1 
6 
cAMP-mediated signaling 4.16E+00 7.34E-02 7.34 RGS18,MAPK1,MAPK3,PRKAR2A,FPR2,PD
E4D,OPRL1,FPR1,P2RY13,LAMTOR3,LTB4
R,DUSP1,PTGER2,RPS6KA1 (includes 
EG:20111),ADORA2A,MAP2K1 
16 
Lysine Biosynthesis 4.09E+00 3.08E-02 3.08 VNN1,VNN2 2 
Cell Cycle Regulation by 
BTG Family Proteins 
4.03E+00 1.11E-01 11.1 PPP2CA,E2F3,E2F2,PPP2R5A 4 
Cyclins and Cell Cycle 
Regulation 
3.91E+00 8.05E-02 8.05 CCND3,HDAC4,PPP2CA,CDKN2D,E2F3,E2
F2,PPP2R5A 
7 
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza 
3.91E+00 9.09E-02 9.09 MAPK14,MAPK1,MAPK3,KRAS,MAP2K1,R
ABGEF1 
6 
Chronic Myeloid Leukemia 
Signaling 
3.91E+00 7.77E-02 7.77 HDAC4,MAPK1,MAPK3,KRAS,CHUK,E2F3,
MAP2K1,E2F2 
8 
Glycerolipid Metabolism 3.91E+00 5.56E-02 5.56 GLA,ABHD5,DHRS9,AGPAT2,DGAT2,PECR
,AGPAT9,GK 
8 
Leptin Signaling in Obesity 3.84E+00 8.05E-02 8.05 MAPK1,GNA15,MAPK3,PRKAR2A,GNAQ,J
AK2,MAP2K1 
7 
Regulation of IL-2 
Expression in Activated and 
Anergic T Lymphocytes 
3.84E+00 7.95E-02 7.95 FOS,MAPK1,MAPK3,CHP,KRAS,CHUK,MA
P2K1 
7 
Glycerophospholipid 
Metabolism 
3.84E+00 5.41E-02 5.41 HMOX1,LPCAT2,GNA15,PIGF,AGPAT2,CH
KA,GNAQ,CHPT1,ETNK1,AGPAT9 
10 
Insulin Receptor Signaling 3.84E+00 7.52E-02 7.52 PPP1R3D,MAPK1,MAPK3,PRKAR2A,PPP1
R12A,IRS2,KRAS,JAK2,MAP2K1,PTEN 
10 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 
3.84E+00 6.75E-02 6.75 IL18RAP,MAPK1,TNFRSF1A,MAPK3,CHP,
GSN,IL18R1,IL1R2,FOS,MAPK14,IL1RN,IL1
B,CHUK,ALPL,IL1RAP,BIRC2 
16 
CREB Signaling in Neurons 3.80E+00 6.63E-02 6.63 MAPK1,MAPK3,PRKAR2A,GNAQ,KRAS,GN
G5,GNG10,GNAI3,GNA15,PRKCD,GNB2,R
PS6KA1 (includes EG:20111),MAP2K1 
13 
Synaptic Long Term 
Depression 
3.76E+00 7.14E-02 7.14 GNAI3,MAPK1,GNA15,PPP2CA,PRKCD,M
APK3,GNAQ,KRAS,MAP2K1,PPP2R5A 
10 
Notch Signaling 3.71E+00 9.76E-02 9.76 FURIN,APH1B,NUMB,RBPJ 4 
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Non-Small Cell Lung Cancer 
Signaling 
3.70E+00 7.59E-02 7.59 MAPK1,MAPK3,TGFA,KRAS,RXRA,MAP2K
1 
6 
CD27 Signaling in 
Lymphocytes 
3.68E+00 8.93E-02 8.93 FOS,APAF1,MAP3K8,CHUK,MAP2K1 5 
April Mediated Signaling 3.52E+00 9.30E-02 9.3 FOS,MAPK14,MAPK1,CHUK 4 
Telomerase Signaling 3.52E+00 8.08E-02 8.08 HDAC4,MAPK1,PPP2CA,MAPK3,ETS2,KRA
S,MAP2K1,PPP2R5A 
8 
Role of IL-17A in Psoriasis 3.43E+00 1.54E-01 15.4 S100A8,IL17RA 2 
Sertoli Cell-Sertoli Cell 
Junction Signaling 
3.41E+00 6.70E-02 6.7 CDC42,MAPK1,TNFRSF1A,MAPK3,CTNNA
1,PRKAR2A,KRAS,PTEN,MAPK14,ZAK,MA
P3K8,MAP2K1,RAB8B 
13 
TGF-β Signaling 3.27E+00 7.87E-02 7.87 FOS,MAPK14,MAPK1,MAPK3,KRAS,MAP2
K1,ACVR1B 
7 
mTOR Signaling 3.25E+00 6.67E-02 6.67 MAPK1,PPP2CA,MAPK3,FKBP1A,KRAS,HI
F1A,PPP2R5A,HMOX1,RHOG,RHOT1,PRK
CD,PRKAA1,RPS6KA1 (includes EG:20111) 
13 
B Cell Activating Factor 
Signaling 
3.18E+00 8.89E-02 8.89 FOS,MAPK14,MAPK1,CHUK 4 
FLT3 Signaling in 
Hematopoietic Progenitor 
Cells 
3.18E+00 8.45E-02 8.45 MAPK14,MAPK1,MAPK3,KRAS,RPS6KA1 
(includes EG:20111),MAP2K1 
6 
Role of RIG1-like Receptors 
in Antiviral Innate 
Immunity 
3.02E+00 8.70E-02 8.7 TANK,TBK1,CHUK,TRIM25 4 
FAK Signaling 2.96E+00 6.93E-02 6.93 MAPK1,ASAP1,MAPK3,KRAS,MAP2K1,PT
EN,CAPN3 
7 
PDGF Signaling 2.95E+00 7.59E-02 7.59 FOS,MAPK1,MAPK3,KRAS,JAK2,MAP2K1 6 
Gα12/13 Signaling 2.90E+00 7.09E-02 7.09 MYL12A,CDC42,MAPK1,MYL6,MYL12B,M
APK3,KRAS,CHUK,MAP2K1 
9 
Caveolar-mediated 
Endocytosis Signaling 
2.89E+00 7.23E-02 7.23 CD55,FLOT2,ITGAM (includes 
EG:16409),RAB5A,RAB5C,FLOT1 
6 
BMP signaling pathway 2.89E+00 7.59E-02 7.59 MAPK14,MAPK1,MAPK3,PRKAR2A,KRAS,
MAP2K1 
6 
Fc Epsilon RI Signaling 2.89E+00 7.21E-02 7.21 MAPK14,MAPK1,PRKCD,MAPK3,SYK,FCER
1G,KRAS,MAP2K1 
8 
Neuropathic Pain Signaling 
In Dorsal Horn Neurons 
2.89E+00 7.21E-02 7.21 FOS,MAPK1,GNA15,PRKCD,MAPK3,PRKA
R2A,GNAQ,GRINA 
8 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 
2.81E+00 8.33E-02 8.33 YWHAG,GADD45A,YWHAH,RPS6KA1 
(includes EG:20111) 
4 
Tight Junction Signaling 2.81E+00 6.88E-02 6.88 FOS,CDC42,MYL6,PPP2CA,TNFRSF1A,CEB
PA,CTNNA1,PRKAR2A,VASP,PPP2R5A,PTE
N 
11 
Granzyme B Signaling 2.72E+00 1.25E-01 12.5 APAF1,LMNB1 2 
Sulfur Metabolism 2.72E+00 3.64E-02 3.64 PAPSS1,SUOX 2 
MSP-RON Signaling 
Pathway 
2.72E+00 8.16E-02 8.16 TLR2,TLR4,ITGAM (includes 
EG:16409),JAK2 
4 
Retinoic acid Mediated 
Apoptosis Signaling 
2.72E+00 7.81E-02 7.81 RARA,APAF1,RXRA,TIPARP,IFNAR1 5 
CTLA4 Signaling in 
Cytotoxic T Lymphocytes 
2.72E+00 7.29E-02 7.29 PPP2CA,SYK,CLTC,FCER1G,JAK2,PTPN22,P
PP2R5A 
7 
PTEN Signaling 2.62E+00 6.50E-02 6.5 CDC42,MAPK1,YWHAH,MAPK3,KRAS,CH
UK,MAP2K1,PTEN 
8 
Aldosterone Signaling in 
Epithelial Cells 
2.61E+00 6.36E-02 6.36 DNAJC5,MAPK1,GNA15,HSPA1A/HSPA1B
,DUSP1,PRKCD,MAPK3,GNAQ,KRAS,DNAJ
B6,MAP2K1 
11 
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Granzyme A Signaling 2.54E+00 1.11E-01 11.1 HIST1H1C,HMGB2 2 
JAK/Stat Signaling 2.54E+00 7.81E-02 7.81 MAPK1,MAPK3,KRAS,JAK2,MAP2K1 5 
EGF Signaling 2.52E+00 7.69E-02 7.69 FOS,MAPK1,MAPK3,MAP2K1 4 
Protein Ubiquitination 
Pathway 
2.44E+00 6.23E-02 6.23 RBX1,PSMA6,UBE2H,USP15,UBE2A,HSPA
1A/HSPA1B,PSMD6,PSMA1,USP6,TCEB1,
UBE2F,DNAJC5,PSMD12,DNAJB6,PSMD4,
UBE2J1,BIRC2 
17 
Fatty Acid Elongation in 
Mitochondria 
2.40E+00 4.35E-02 4.35 ACAA1,PECR 2 
Parkinson's Signaling 2.40E+00 1.11E-01 11.1 MAPK14,MAPK1 2 
Stilbene, Coumarine and 
Lignin Biosynthesis 
2.40E+00 2.74E-02 2.74 GBA,PRDX5 2 
Prostate Cancer Signaling 2.39E+00 6.32E-02 6.32 MAPK1,MAPK3,KRAS,CHUK,MAP2K1,PTE
N 
6 
Sphingosine-1-phosphate 
Signaling 
2.38E+00 6.50E-02 6.5 GNAI3,RHOG,MAPK1,GNA15,RHOT1,MA
PK3,GNAQ,ASAH1 
8 
Role of CHK Proteins in Cell 
Cycle Checkpoint Control 
2.38E+00 8.57E-02 8.57 E2F3,E2F2,NBN 3 
TWEAK Signaling 2.38E+00 7.89E-02 7.89 APAF1,CHUK,BIRC2 3 
Role of JAK2 in Hormone-
like Cytokine Signaling 
2.38E+00 8.57E-02 8.57 IRS2,JAK2,SIRPA 3 
Pentose and Glucuronate 
Interconversions 
2.38E+00 2.29E-02 2.29 UGP2,HPSE,CSGALNACT1 3 
T Cell Receptor Signaling 2.38E+00 6.48E-02 6.48 FOS,MAPK1,PAG1,MAPK3,KRAS,CHUK,M
AP2K1 
7 
PKCθ Signaling in T 
Lymphocytes 
2.35E+00 5.88E-02 5.88 FOS,MAPK1,MAPK3,CHP,FCER1G,KRAS,M
AP3K8,CHUK 
8 
Endothelin-1 Signaling 2.24E+00 6.01E-02 6.01 HMOX1,GNAI3,FOS,MAPK14,MAPK1,GN
A15,PRKCD,MAPK3,GNAQ,KRAS,PTGER2 
11 
Cardiac β-adrenergic 
Signaling 
2.22E+00 5.88E-02 5.88 PPP1R3D,PPP2CA,GNB2,PRKAR2A,PPP1R
12A,PDE4D,GNG5,PPP2R5A,GNG10 
9 
G-Protein Coupled 
Receptor Signaling 
2.21E+00 5.85E-02 5.85 RGS18,MAPK1,MAPK3,KRAS,PDE4D,OPRL
1,LTB4R,LAMTOR3,C5AR1,CHUK,MAP2K1
,CCR1,GPR97,GNAQ,FPR2,PRKAR2A,PCNX
,FPR1,P2RY13,GPR137B,DUSP1,GPR65,G
PR160,MAP3K8,EMR1,PTGER2,RPS6KA1 
(includes 
EG:20111),PTAFR,EMR2,C3AR1,ADORA2
A 
31 
Atherosclerosis Signaling 2.21E+00 6.20E-02 6.2 ORM1/ORM2,IL1RN,CD36,IL1B,SERPINA1
,S100A8,ALOX5,MMP9 
8 
Nitrogen Metabolism 2.21E+00 2.50E-02 2.5 VNN1,VNN2,CA4 3 
DNA Methylation and 
Transcriptional Repression 
Signaling 
2.21E+00 8.70E-02 8.7 MTA1,SAP30 (includes EG:60406) 2 
One Carbon Pool by Folate 2.21E+00 5.56E-02 5.56 MTHFS,MTHFD2 2 
Nur77 Signaling in T 
Lymphocytes 
2.20E+00 6.78E-02 6.78 CHP,APAF1,FCER1G,RXRA 4 
Macropinocytosis Signaling 2.14E+00 6.58E-02 6.58 RAB5A,CDC42,PRKCD,CD14,KRAS 5 
TR/RXR Activation 2.12E+00 6.25E-02 6.25 SLC16A3,HP,LDLR,BCL3,HIF1A,RXRA 6 
Melanocyte Development 
and Pigmentation Signaling 
2.12E+00 6.52E-02 6.52 MAPK1,MAPK3,PRKAR2A,KRAS,RPS6KA1 
(includes EG:20111),MAP2K1 
6 
Biosynthesis of Steroids 2.11E+00 1.65E-02 1.65 IDI1,HMGCR 2 
Arginine and Proline 
Metabolism 
2.03E+00 2.87E-02 2.87 P4HA1,VNN1,VNN2,OAT,SAT1 5 
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Cell Cycle: G1/S Checkpoint 
Regulation 
2.00E+00 6.78E-02 6.78 CCND3,HDAC4,E2F3,E2F2 4 
Docosahexaenoic Acid 
(DHA) Signaling 
2.00E+00 6.25E-02 6.25 APAF1,IL1B,BCL2A1 3 
Small Cell Lung Cancer 
Signaling 
2.00E+00 5.68E-02 5.68 APAF1,CHUK,RXRA,PTEN,BIRC2 5 
Differential Regulation of 
Cytokine Production in 
Intestinal Epithelial Cells by 
IL-17A and IL-17F 
1.92E+00 8.70E-02 8.7 LCN2,IL1B 2 
Nucleotide Sugars 
Metabolism 
1.92E+00 1.54E-02 1.54 UGP2 1 
Airway Pathology in 
Chronic Obstructive 
Pulmonary Disease 
1.92E+00 1.11E-01 11.1 MMP9 1 
Role of BRCA1 in DNA 
Damage Response 
1.92E+00 6.56E-02 6.56 GADD45A,E2F3,E2F2,NBN 4 
Propanoate Metabolism 1.92E+00 3.31E-02 3.31 ACSL3,ACSS2,ACSL1,LDHA 4 
NF-κB Activation by Viruses 1.92E+00 6.10E-02 6.1 MAPK1,PRKCD,MAPK3,KRAS,CHUK 5 
Regulation of eIF4 and 
p70S6K Signaling 
1.92E+00 5.36E-02 5.36 EIF2C4,MAPK14,MAPK1,PPP2CA,MAPK3,
MKNK1,KRAS,MAP2K1,PPP2R5A 
9 
Aminophosphonate 
Metabolism 
1.87E+00 3.51E-02 3.51 PIGF,CHPT1 2 
Tumoricidal Function of 
Hepatic Natural Killer Cells 
1.87E+00 8.33E-02 8.33 SRGN,APAF1 2 
Role of 
Hypercytokinemia/hyperch
emokinemia in the 
Pathogenesis of Influenza 
1.85E+00 7.32E-02 7.32 CCR1,IL1RN,IL1B 3 
Mitotic Roles of Polo-Like 
Kinase 
1.85E+00 6.67E-02 6.67 SLK,PPP2CA,PRC1 (includes 
EG:233406),PPP2R5A 
4 
Myc Mediated Apoptosis 
Signaling 
1.85E+00 6.67E-02 6.67 YWHAG,YWHAH,APAF1,KRAS 4 
SAPK/JNK Signaling 1.84E+00 5.94E-02 5.94 CDC42,GADD45A,ZAK,FCER1G,KRAS,GNG
5 
6 
Pathogenesis of Multiple 
Sclerosis 
1.84E+00 1.11E-01 11.1 CCR1 1 
Dopamine Receptor 
Signaling 
1.84E+00 5.26E-02 5.26 PPP1R3D,PPP2CA,PRKAR2A,PPP1R12A,PP
P2R5A 
5 
Glycosaminoglycan 
Degradation 
1.84E+00 3.64E-02 3.64 HPSE,GNS 2 
N-Glycan Degradation 1.84E+00 8.00E-02 8 MAN1A1,MAN2A2 2 
Induction of Apoptosis by 
HIV1 
1.83E+00 6.25E-02 6.25 TNFRSF1A,APAF1,CHUK,BIRC2 4 
Cellular Effects of Sildenafil 
(Viagra) 
1.80E+00 5.37E-02 5.37 MYL12A,MYL6,GNA15,MYL12B,PRKAR2A,
GNAQ,PPP1R12A,PDE4D 
8 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
1.80E+00 5.80E-02 5.8 TANK,TBK1,CHUK,IFNAR1 4 
Estrogen-Dependent 
Breast Cancer Signaling 
1.80E+00 5.71E-02 5.71 FOS,MAPK1,MAPK3,KRAS 4 
Antiproliferative Role of 
TOB in T Cell Signaling 
1.79E+00 7.69E-02 7.69 MAPK1,RPS6KA1 (includes EG:20111) 2 
Ovarian Cancer Signaling 1.79E+00 5.67E-02 5.67 MAPK1,MAPK3,CD44 (includes 
EG:100330801),PRKAR2A,KRAS,MAP2K1,
MMP9,PTEN 
8 
Fatty Acid Biosynthesis 1.75E+00 2.04E-02 2.04 ACSL3 1 
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Graft-versus-Host Disease 
Signaling 
1.75E+00 6.25E-02 6.25 IL1RN,FCER1G,IL1B 3 
Amyotrophic Lateral 
Sclerosis Signaling 
1.75E+00 5.17E-02 5.17 RAB5A,RAB5C,APAF1,GRINA,CAPN3,BIRC
2 
6 
Role of Oct4 in Mammalian 
Embryonic Stem Cell 
Pluripotency 
1.71E+00 6.67E-02 6.67 RARA,SH3GLB1,HOXB1 3 
Paxillin Signaling 1.69E+00 5.45E-02 5.45 ITGAM (includes 
EG:16409),MAPK14,CDC42,MAPK1,KRAS,
PTPN12 
6 
Citrate Cycle 1.68E+00 3.57E-02 3.57 DLD,IDH1 2 
Sonic Hedgehog Signaling 1.62E+00 6.06E-02 6.06 ARRB2,PRKAR2A 2 
FXR/RXR Activation 1.60E+00 5.05E-02 5.05 IL1RN,RARA,FBP1,IL1B,RXRA 5 
FGF Signaling 1.60E+00 5.56E-02 5.56 MAPK14,MAPK1,MAPK3,MAPKAPK2,MA
P2K1 
5 
VEGF Signaling 1.57E+00 5.15E-02 5.15 MAPK1,MAPK3,KRAS,HIF1A,MAP2K1 5 
Agrin Interactions at 
Neuromuscular Junction 
1.57E+00 5.88E-02 5.88 CDC42,MAPK1,MAPK3,KRAS 4 
Gap Junction Signaling 1.57E+00 5.00E-02 5 GNAI3,MAPK1,GNA15,PRKCD,MAPK3,PR
KAR2A,GNAQ,KRAS,MAP2K1 
9 
Bile Acid Biosynthesis 1.56E+00 2.97E-02 2.97 DHRS9,ACAA1,PECR 3 
Bladder Cancer Signaling 1.53E+00 5.56E-02 5.56 MAPK1,MAPK3,KRAS,MAP2K1,MMP9 5 
Chondroitin Sulfate 
Biosynthesis 
1.53E+00 4.62E-02 4.62 CHSY1,CSGALNACT1,DSE 3 
Virus Entry via Endocytic 
Pathways 
1.48E+00 5.05E-02 5.05 CD55,CDC42,PRKCD,CLTC,KRAS 5 
ATM Signaling 1.48E+00 5.56E-02 5.56 MAPK14,GADD45A,NBN 3 
DNA Double-Strand Break 
Repair by Homologous 
Recombination 
1.48E+00 5.88E-02 5.88 NBN 1 
DNA Double-Strand Break 
Repair by Non-Homologous 
End Joining 
1.48E+00 5.26E-02 5.26 NBN 1 
Glycine, Serine and 
Threonine Metabolism 
1.48E+00 2.74E-02 2.74 GNA15,CHKA,DLD,GNAQ 4 
IL-9 Signaling 1.45E+00 5.00E-02 5 IRS2,BCL3 2 
Telomere Extension by 
Telomerase 
1.43E+00 5.88E-02 5.88 NBN 1 
Methane Metabolism 1.43E+00 1.54E-02 1.54 PRDX5 1 
Coagulation System 1.42E+00 5.26E-02 5.26 PLAUR,SERPINA1 2 
Phenylalanine Metabolism 1.39E+00 1.83E-02 1.83 PRDX5,ALDH3B1 2 
RAN Signaling 1.39E+00 4.35E-02 4.35 KPNA4 1 
Glyoxylate and 
Dicarboxylate Metabolism 
1.35E+00 9.26E-03 0.926 MTHFD2 1 
Ascorbate and Aldarate 
Metabolism 
1.35E+00 1.30E-02 1.3 GSTO1 1 
Differential Regulation of 
Cytokine Production in 
Macrophages and T Helper 
Cells by IL-17A and IL-17F 
1.31E+00 5.56E-02 5.56 IL1B 1 
Endoplasmic Reticulum 
Stress Pathway 
1.31E+00 5.56E-02 5.56 ATF6 1 
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Appendix 8.4: Signalling pathways from 492 SDE downregulated gene transcripts 
Ingenuity Canonical 
Pathways 
B H p 
value 
Ratio % Molecules No. of 
molecules 
Calcium-induced T 
Lymphocyte Apoptosis 
2.00E+14 3.03E-01 30.3 CD247,HLA-DMA,HLA-
DOA,CD3E,CD4,HLA-
DQA1,PLCG1,HLA-DMB,PPP3CC,HLA-
DQB1,CD3D,CD3G,LCK,MEF2D,HLA-
DRA,ZAP70,ITPR3,HLA-
DOB,PRKCH,PRKCA 
20 
iCOS-iCOSL Signaling in T 
Helper Cells 
2.51E+12 1.93E-01 19.3 CD247,HLA-DMA,HLA-
DOA,CD3E,CD4,HLA-
DQA1,PLCG1,HLA-DMB,PPP3CC,HLA-
DQB1,CD3D,IL2RB,CD3G,ICOS,LCK,LA
T,HLA-DRA,ZAP70,ITPR3,HLA-
DOB,PLEKHA1,ATM,ITK 
23 
Cytotoxic T Lymphocyte-
mediated Apoptosis of 
Target Cells 
2.51E+12 3.21E-01 32.1 CD247,HLA-DMA,HLA-
DOA,CD3E,HLA-DQA1,HLA-DMB,HLA-
DRB3 (includes others),HLA-
DQB1,CD3D,HLA-
DPA1,BCL2,CD3G,PRF1,HLA-
DRA,HLA-DOB,HLA-DPB1,GZMB 
17 
CD28 Signaling in T 
Helper Cells 
6.31E+11 1.78E-01 17.8 CD247,HLA-DMA,FYN,HLA-
DOA,CD3E,CD4,HLA-
DQA1,PLCG1,HLA-DMB,PPP3CC,HLA-
DQB1,CD3D,CD3G,LCK,LAT,HLA-
DRA,ZAP70,ITPR3,CD86,HLA-
DOB,CARD11,ATM,ITK 
23 
OX40 Signaling Pathway 6.31E+11 2.70E-01 27 CD247,HLA-DMA,HLA-
DOA,CD3E,CD4,HLA-DQA1,HLA-
DMB,HLA-DRB3 (includes 
others),HLA-DQB1,CD3D,HLA-
DPA1,BCL2,CD3G,HLA-DRA,HLA-
DOB,TRAF5,HLA-DPB1 
17 
Role of NFAT in 
Regulation of the 
Immune Response 
5.01E+10 1.33E-01 13.3 CD247,FYN,HLA-DOA,CD3E,CD4,HLA-
DQA1,HLA-DMB,HLA-
DQB1,CD79A,LCK,HLA-
DRA,ITK,ATM,HLA-
DMA,CD79B,PLCG1,PPP3CC,CD3D,CD
3G,MEF2D,LAT,ZAP70,ITPR3,CD86,HL
A-DOB,MEF2C 
26 
PKCθ Signaling in T 
Lymphocytes 
1.26E+10 1.54E-01 15.4 CD247,HLA-DMA,FYN,HLA-
DOA,CD3E,CD4,HLA-
DQA1,PLCG1,HLA-DMB,PPP3CC,HLA-
DQB1,CD3D,CD3G,LCK,LAT,HLA-
DRA,ZAP70,CD86,HLA-
DOB,CARD11,ATM 
21 
CTLA4 Signaling in 
Cytotoxic T Lymphocytes 
1.26E+10 1.98E-01 19.8 CD247,HLA-DMA,FYN,HLA-
DOA,CD3E,CD4,HLA-
DQA1,PLCG1,HLA-DMB,HLA-
DQB1,CD3D,CD3G,LCK,LAT,HLA-
DRA,ZAP70,HLA-DOB,CD86,ATM 
19 
Nur77 Signaling in T 
Lymphocytes 
1.00E+10 2.54E-01 25.4 CD247,HLA-DMA,HLA-
DOA,CD3E,HLA-DQA1,HLA-
DMB,PPP3CC,HLA-
DQB1,CD3D,BCL2,CD3G,MEF2D,HLA-
DRA,HLA-DOB,CD86 
15 
B Cell Development 8.13E+09 4.00E-01 40 IL7R,HLA-DMA,CD19,HLA-
DOA,CD79B,HLA-DRA,HLA-
DQA1,CD86,HLA-DOB,HLA-DMB,HLA-
DQB1,CD79A 
12 
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Primary 
Immunodeficiency 
Signaling 
4.17E+09 2.55E-01 25.5 CD19,CD3E,CD4,RFX5,CD8A,CD3D,CD
79A,IL7R,ICOS,LCK,ZAP70,ADA,TAP2,
UNG 
14 
Allograft Rejection 
Signaling 
1.55E+08 2.17E-01 21.7 HLA-DMA,HLA-DOA,HLA-DQA1,HLA-
DRB3 (includes others),HLA-
DMB,HLA-DQB1,HLA-
DPA1,PRF1,HLA-DRA,CD86,HLA-
DOB,HLA-DPB1,GZMB 
13 
Antigen Presentation 
Pathway 
1.29E+08 2.79E-01 27.9 PSMB9,HLA-DMA,HLA-DOA,HLA-
DRA,HLA-DQA1,HLA-DOB,HLA-DRB3 
(includes others),HLA-
DMB,CD74,HLA-DPB1,TAP2,HLA-
DPA1 
12 
Type I Diabetes Mellitus 
Signaling 
1.02E+08 1.53E-01 15.3 CD247,HLA-DMA,HLA-
DOA,CD3E,SOCS2,HLA-DQA1,HLA-
DMB,HLA-
DQB1,CD3D,BCL2,CD3G,PRF1,LTA,HL
A-DRA,HLA-DOB,CD86,STAT1,GZMB 
18 
T Cell Receptor Signaling 8.13E+07 1.57E-01 15.7 CD247,FYN,CD3E,CD4,PLCG1,PPP3CC,
CD8A,CD3D,CD3G,LCK,TXK,RASGRP1,
ZAP70,LAT,CARD11,ATM,ITK 
17 
T Helper Cell 
Differentiation 
2.45E+07 2.00E-01 20 HLA-DMA,HLA-
DOA,IL12RB1,IL21R,HLA-DQA1,HLA-
DMB,HLA-DQB1,STAT4,ICOS,HLA-
DRA,CD86,HLA-DOB,CXCR5,STAT1 
14 
Phospholipase C 
Signaling 
1.20E+06 8.98E-02 8.98 CD247,PEBP1,FYN,MPRIP,CD3E,CD79
B,PLCG1,PPP3CC,CD3D,CD79A,CD3G,
LCK,AHNAK,MEF2D,LAT,JMJD7-
PLA2G4B,ZAP70,ITPR3,MEF2C,PRKCH
,RALGDS,PRKCA,ITK 
23 
Autoimmune Thyroid 
Disease Signaling 
4.90E+05 1.82E-01 18.2 HLA-DMA,PRF1,HLA-DOA,HLA-
DRA,HLA-DQA1,CD86,HLA-DOB,HLA-
DMB,HLA-DQB1,GZMB 
10 
Graft-versus-Host 
Disease Signaling 
3.24E+05 2.08E-01 20.8 HLA-DMA,PRF1,HLA-DOA,HLA-
DRA,HLA-DQA1,CD86,HLA-DOB,HLA-
DMB,HLA-DQB1,GZMB 
10 
Altered T Cell and B Cell 
Signaling in Rheumatoid 
Arthritis 
2.95E+05 1.49E-01 14.9 HLA-DMA,HLA-DOA,CD79B,HLA-
DQA1,LTB,HLA-DMB,HLA-
DQB1,CD79A,LTA,HLA-
DRA,TLR7,CD86,HLA-DOB 
13 
Cdc42 Signaling 1.95E+05 1.10E-01 11 CD247,HLA-DMA,HLA-
DOA,MPRIP,CD3E,HLA-DQA1,HLA-
DRB3 (includes others),HLA-
DMB,HLA-DQB1,CD3D,HLA-
DPA1,CD3G,HLA-DRA,HLA-DOB,HLA-
DPB1,ITK 
16 
Natural Killer Cell 
Signaling 
1.15E+05 1.27E-01 12.7 CD247,FYN,KLRD1,PLCG1,NCR3,LCK,S
H2D1A,KLRB1,LAT,ZAP70,PRKCH,HCS
T,ATM,PRKCA 
14 
Regulation of IL-2 
Expression in Activated 
and Anergic T 
Lymphocytes 
1.07E+04 1.25E-01 12.5 CD247,FYN,CD3G,CD3E,SMAD3,LAT,Z
AP70,PLCG1,PPP3CC,CD3D,CARD11 
11 
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Dendritic Cell Maturation 5.37E+03 8.38E-02 8.38 HLA-DMA,HLA-DOA,HLA-
DQA1,LTB,HLA-DRB3 (includes 
others),HLA-DMB,HLA-
DQB1,STAT4,LTA,HLA-
DRA,CD86,HLA-
DOB,STAT1,CCR7,ATM 
15 
Crosstalk between 
Dendritic Cells and 
Natural Killer Cells 
3.24E+03 1.16E-01 11.6 PRF1,KLRD1,LTA,HLA-
DRA,TLR7,LTB,CD86,NCR3,HLA-DRB3 
(includes others),IL2RB,CCR7 
11 
CCR5 Signaling in 
Macrophages 
1.23E+03 1.02E-01 10.2 CD247,CD3G,CD3E,CD4,PLCG1,PRKC
H,CCL5,CD3D,PRKCA 
9 
IL-4 Signaling 1.23E+03 1.25E-01 12.5 HLA-DMA,HLA-DOA,HLA-DRA,HLA-
DQA1,HLA-DOB,HLA-DMB,HLA-
DQB1,ATM,FCER2 
9 
Prolactin Signaling 6.46E+02 1.12E-01 11.2 MYC,FYN,SOCS2,PLCG1,PRKCH,STAT1
,TCF7,PRKCA,ATM 
9 
Systemic Lupus 
Erythematosus Signaling 
1.70E+02 6.54E-02 6.54 CD247,PRPF19,CD79B,CD3E,PLCG1,C
D3D,CD79A,SNRPN,CD3G,LCK,LAT,TL
R7,CD86,ATM 
14 
Cell Cycle: G1/S 
Checkpoint Regulation 
1.70E+02 1.19E-01 11.9 MYC,CCND2,CDK4,SMAD3,CDK6,ATR,
ATM 
7 
Communication between 
Innate and Adaptive 
Immune Cells 
6.31E+01 8.08E-02 8.08 CD4,HLA-DRA,TLR7,CD86,HLA-DRB3 
(includes others),CCL5,CD8A,CCR7 
8 
Growth Hormone 
Signaling 
4.57E+01 9.33E-02 9.33 SOCS2,PLCG1,RPS6KA5,PRKCH,STAT1
,PRKCA,ATM 
7 
Small Cell Lung Cancer 
Signaling 
3.63E+01 7.95E-02 7.95 PTK2 (includes 
EG:14083),MYC,CDK4,CDK6,TRAF5,AT
M,BCL2 
7 
Aryl Hydrocarbon 
Receptor Signaling 
3.47E+01 6.45E-02 6.45 MYC,GSTM1,GSTM2,ALDH1A1,CCND
2,CDK4,CDK6,ATR,ATM,MCM7 
10 
Thrombopoietin 
Signaling 
3.24E+01 9.52E-02 9.52 MYC,PLCG1,PRKCH,STAT1,PRKCA,AT
M 
6 
HER-2 Signaling in Breast 
Cancer 
2.88E+01 8.86E-02 8.86 FOXO1,CDK6,PLCG1,PRKCH,ITGB7,PR
KCA,ATM 
7 
Molecular Mechanisms 
of Cancer 
2.88E+01 4.84E-02 4.84 FYN,SMAD3,CDK6,BCL2,MYC,CDC25B
,PTK2 (includes 
EG:14083),CCND2,FOXO1,RASGRP1,C
DK4,PRKCH,LEF1,BIRC3,ATR,RALGDS,
ATM,PRKCA 
18 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
2.29E+01 8.70E-02 8.7 IFIH1,LTA,ZBP1,STAT1,IFIT2,ISG15 6 
Cell Cycle Control of 
Chromosomal 
Replication 
2.24E+01 1.29E-01 12.9 MCM3,CDK4,CDK6,MCM7 4 
IL-15 Signaling 2.19E+01 8.96E-02 8.96 PTK2 (includes 
EG:14083),LCK,PLCG1,IL2RB,ATM,BCL
2 
6 
EGF Signaling 1.74E+01 9.62E-02 9.62 ITPR3,PLCG1,STAT1,PRKCA,ATM 5 
VEGF Signaling 1.74E+01 7.22E-02 7.22 PTK2 (includes 
EG:14083),VEGFB,FOXO1,PLCG1,PRK
CA,ATM,BCL2 
7 
Non-Small Cell Lung 
Cancer Signaling 
1.74E+01 7.59E-02 7.59 CDK4,ITPR3,CDK6,PLCG1,PRKCA,ATM 6 
Granzyme B Signaling 1.66E+01 1.88E-01 18.8 PRF1,GZMB,PARP1 3 
Renin-Angiotensin 
Signaling 
1.58E+01 6.35E-02 6.35 PTK2 (includes 
EG:14083),ITPR3,PLCG1,PRKCH,CCL5,
STAT1,PRKCA,ATM 
8 
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Chemokine Signaling 1.51E+01 8.33E-02 8.33 PTK2 (includes 
EG:14083),CCR3,MPRIP,PLCG1,CCL5,
PRKCA 
6 
ERK/MAPK Signaling 1.38E+01 5.39E-02 5.39 PTK2 (includes 
EG:14083),ETS1,MYC,FYN,ELF2,JMJD
7-
PLA2G4B,PLCG1,RPS6KA5,STAT1,PRK
CA,ATM 
11 
Role of Macrophages, 
Fibroblasts and 
Endothelial Cells in 
Rheumatoid Arthritis 
1.32E+01 4.69E-02 4.69 VEGFB,IL32,PLCG1,LTB,PPP3CC,CCL5,
TCF7,MYC,LTA,TLR7,PRKCH,LEF1,TRA
F5,ATM,PRKCA 
15 
IL-3 Signaling 1.32E+01 8.11E-02 8.11 FOXO1,PRKCH,PPP3CC,STAT1,PRKCA,
ATM 
6 
Interferon Signaling 1.26E+01 1.11E-01 11.1 IFIT3,MX1,STAT1,BCL2 4 
NF-κB Activation by 
Viruses 
1.20E+01 7.32E-02 7.32 LCK,CD4,PRKCH,CXCR5,PRKCA,ATM 6 
HGF Signaling 9.62E+00 6.67E-02 6.67 PTK2 (includes 
EG:14083),ETS1,ELF2,PLCG1,PRKCH,P
RKCA,ATM 
7 
Fc Epsilon RI Signaling 8.05E+00 6.31E-02 6.31 FYN,LAT,JMJD7-
PLA2G4B,PLCG1,PRKCH,PRKCA,ATM 
7 
Pancreatic 
Adenocarcinoma 
Signaling 
7.53E+00 5.93E-02 5.93 VEGFB,CDK4,SMAD3,STAT1,RALGDS,
ATM,BCL2 
7 
Role of JAK1 and JAK3 in 
γc Cytokine Signaling 
7.53E+00 7.58E-02 7.58 IL7R,IL21R,STAT1,IL2RB,ATM 5 
PI3K Signaling in B 
Lymphocytes 
7.53E+00 5.63E-02 5.63 FYN,CD19,CD79B,ITPR3,PLCG1,PPP3C
C,PLEKHA1,CD79A 
8 
p38 MAPK Signaling 7.53E+00 6.60E-02 6.6 MYC,MEF2D,JMJD7-
PLA2G4B,MAP4K1,MEF2C,RPS6KA5,S
TAT1 
7 
Factors Promoting 
Cardiogenesis in 
Vertebrates 
6.22E+00 6.38E-02 6.38 TGFBR3,LEF1,MEF2C,PRKCH,TCF7,PR
KCA 
6 
CCR3 Signaling in 
Eosinophils 
5.85E+00 5.60E-02 5.6 CCR3,MPRIP,JMJD7-
PLA2G4B,ITPR3,PRKCH,PRKCA,ATM 
7 
Virus Entry via Endocytic 
Pathways 
5.85E+00 6.06E-02 6.06 FYN,PLCG1,PRKCH,ITGB7,PRKCA,ATM 6 
IL-15 Production 5.47E+00 9.68E-02 9.68 PTK2 (includes EG:14083),TXK,STAT1 3 
Macropinocytosis 
Signaling 
5.47E+00 6.58E-02 6.58 PLCG1,PRKCH,ITGB7,PRKCA,ATM 5 
FLT3 Signaling in 
Hematopoietic 
Progenitor Cells 
5.27E+00 7.04E-02 7.04 STAT4,RPS6KA5,STAT1,FLT3LG,ATM 5 
p53 Signaling 5.19E+00 6.25E-02 6.25 CCND2,CDK4,ATR,ATM,BCL2,SERPINE
2 
6 
Glioma Signaling 5.04E+00 5.41E-02 5.41 CDK4,CDK6,PLCG1,PRKCH,PRKCA,AT
M 
6 
PDGF Signaling 4.97E+00 6.33E-02 6.33 MYC,PLCG1,STAT1,PRKCA,ATM 5 
p70S6K Signaling 4.76E+00 5.34E-02 5.34 CD19,CD79B,PLCG1,PRKCH,CD79A,PR
KCA,ATM 
7 
Role of Pattern 
Recognition Receptors in 
Recognition of Bacteria 
and Viruses 
4.63E+00 6.10E-02 6.1 IFIH1,OAS2,TLR7,CCL5,ATM 5 
Glioblastoma Multiforme 
Signaling 
4.58E+00 4.79E-02 4.79 MYC,FOXO1,CDK4,ITPR3,CDK6,PLCG1
,LEF1,ATM 
8 
DNA Double-Strand 
Break Repair by Non-
Homologous End Joining 
4.12E+00 1.05E-01 10.5 PARP1,ATM 2 
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Cholecystokinin/Gastrin-
mediated Signaling 
4.11E+00 5.66E-02 5.66 PTK2 (includes 
EG:14083),MEF2D,ITPR3,MEF2C,PRK
CH,PRKCA 
6 
Acute Myeloid Leukemia 
Signaling 
4.11E+00 6.10E-02 6.1 MYC,LEF1,FLT3LG,TCF7,ATM 5 
Cyclins and Cell Cycle 
Regulation 
4.11E+00 5.75E-02 5.75 CCND2,CDK4,CDK6,ATR,ATM 5 
Lymphotoxin β Receptor 
Signaling 
4.10E+00 6.67E-02 6.67 LTA,LTB,TRAF5,ATM 4 
Prostate Cancer Signaling 3.88E+00 5.26E-02 5.26 FOXO1,NKX3-1,LEF1,ATM,BCL2 5 
IL-9 Signaling 3.88E+00 7.50E-02 7.5 SOCS2,STAT1,ATM 3 
Role of BRCA1 in DNA 
Damage Response 
3.88E+00 6.56E-02 6.56 C17orf70,STAT1,ATR,ATM 4 
Propanoate Metabolism 3.88E+00 3.31E-02 3.31 ACAD11,ALDH1A1,ACSS1,LDHB 4 
Role of Tissue Factor in 
Cancer 
3.79E+00 5.41E-02 5.41 FYN,LCK,RPS6KA5,PDXP,PRKCA,ATM 6 
NF-κB Signaling 3.53E+00 4.68E-02 4.68 LCK,LTA,TGFBR3,ZAP70,TLR7,TRAF5,C
ARD11,ATM 
8 
Corticotropin Releasing 
Hormone Signaling 
3.53E+00 4.62E-02 4.62 MEF2D,ITPR3,PLCG1,MEF2C,PRKCH,P
RKCA 
6 
RhoA Signaling 3.53E+00 5.36E-02 5.36 PTK2 (includes 
EG:14083),MPRIP,EPHA1,LPAR5,SEPT
9,SEPT6 
6 
Phospholipid 
Degradation 
3.49E+00 4.95E-02 4.95 LPIN1,DGKQ,CLC,JMJD7-
PLA2G4B,PLCG1 
5 
Granzyme A Signaling 3.49E+00 1.11E-01 11.1 GZMA,PRF1 2 
Pyruvate Metabolism 3.45E+00 3.10E-02 3.1 ALDH1A1,ACSS1,AKR1B1,LDHB 4 
ERK5 Signaling 3.42E+00 6.35E-02 6.35 MYC,MEF2D,MEF2C,RPS6KA5 4 
JAK/Stat Signaling 3.42E+00 6.25E-02 6.25 STAT4,SOCS2,STAT1,ATM 4 
Neuregulin Signaling 3.42E+00 5.00E-02 5 MYC,PLCG1,PRKCH,PRKCA,MATK 5 
Docosahexaenoic Acid 
(DHA) Signaling 
3.42E+00 6.25E-02 6.25 FOXO1,ATM,BCL2 3 
CD40 Signaling 3.37E+00 5.80E-02 5.8 LTA,TRAF5,ATM,FCER2 4 
GM-CSF Signaling 3.37E+00 5.97E-02 5.97 ETS1,PPP3CC,STAT1,ATM 4 
Apoptosis Signaling 3.32E+00 5.32E-02 5.32 PLCG1,BIRC3,PRKCA,PARP1,BCL2 5 
PXR/RXR Activation 3.32E+00 4.82E-02 4.82 GSTM1,GSTM2,ALDH1A1,FOXO1 4 
Role of MAPK Signaling in 
the Pathogenesis of 
Influenza 
3.32E+00 6.06E-02 6.06 JMJD7-PLA2G4B,CCL5,PRKCA,BCL2 4 
FcγRIIB Signaling in B 
Lymphocytes 
3.06E+00 5.45E-02 5.45 CD79B,CD79A,ATM 3 
Chronic Myeloid 
Leukemia Signaling 
2.97E+00 4.85E-02 4.85 MYC,CDK4,SMAD3,CDK6,ATM 5 
Erythropoietin Signaling 2.88E+00 5.13E-02 5.13 PLCG1,PRKCH,PRKCA,ATM 4 
Thyroid Cancer Signaling 2.86E+00 6.67E-02 6.67 MYC,LEF1,TCF7 3 
Cell Cycle: G2/M DNA 
Damage Checkpoint 
Regulation 
2.86E+00 6.25E-02 6.25 CDC25B,ATR,ATM 3 
Role of NFAT in Cardiac 
Hypertrophy 
2.82E+00 3.94E-02 3.94 MEF2D,ITPR3,PLCG1,MEF2C,PRKCH,P
PP3CC,PRKCA,ATM 
8 
Telomerase Signaling 2.74E+00 5.05E-02 5.05 ETS1,MYC,ELF2,IL2RB,ATM 5 
Melatonin Signaling 2.69E+00 5.13E-02 5.13 RORA,PLCG1,PRKCH,PRKCA 4 
Aminophosphonate 
Metabolism 
2.40E+00 3.51E-02 3.51 MGMT,PRMT6 2 
Tumoricidal Function of 
Hepatic Natural Killer 
Cells 
2.40E+00 8.33E-02 8.33 PRF1,GZMB 2 
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IL-12 Signaling and 
Production in 
Macrophages 
2.40E+00 3.95E-02 3.95 STAT4,IL12RB1,PRKCH,STAT1,PRKCA,
ATM 
6 
Ovarian Cancer Signaling 2.37E+00 4.26E-02 4.26 VEGFB,CDK4,LEF1,TCF7,ATM,BCL2 6 
Neuropathic Pain 
Signaling In Dorsal Horn 
Neurons 
2.37E+00 4.50E-02 4.5 ITPR3,PLCG1,PRKCH,PRKCA,ATM 5 
CNTF Signaling 2.37E+00 5.77E-02 5.77 RPS6KA5,STAT1,ATM 3 
Histidine Metabolism 2.37E+00 2.59E-02 2.59 ALDH1A1,MGMT,PRMT6 3 
Endothelin-1 Signaling 2.24E+00 3.83E-02 3.83 MYC,JMJD7-
PLA2G4B,ITPR3,PLCG1,PRKCH,PRKCA,
ATM 
7 
TREM1 Signaling 2.24E+00 4.84E-02 4.84 TLR7,PLCG1,CD86 3 
VDR/RXR Activation 2.24E+00 4.94E-02 4.94 FOXO1,PRKCH,CCL5,PRKCA 4 
Glucocorticoid Receptor 
Signaling 
2.24E+00 3.42E-02 3.42 CD247,CD3G,CD3E,SMAD3,PPP3CC,C
CL5,STAT1,CD3D,ATM,BCL2 
10 
fMLP Signaling in 
Neutrophils 
2.24E+00 3.94E-02 3.94 ITPR3,PRKCH,PPP3CC,PRKCA,ATM 5 
Hepatic Fibrosis / Hepatic 
Stellate Cell Activation 
2.24E+00 4.17E-02 4.17 VEGFB,SMAD3,CCL5,STAT1,CCR7,BCL
2 
6 
Reelin Signaling in 
Neurons 
2.24E+00 4.88E-02 4.88 FYN,LCK,MAP4K1,ATM 4 
Endometrial Cancer 
Signaling 
2.24E+00 5.26E-02 5.26 MYC,LEF1,ATM 3 
Pyrimidine Metabolism 2.22E+00 2.80E-02 2.8 POLR1C,POLR3H,POLR1E,PUS1,POLR
MT,UNG 
6 
IL-2 Signaling 2.19E+00 5.17E-02 5.17 LCK,IL2RB,ATM 3 
Purine Metabolism 2.18E+00 2.56E-02 2.56 CECR1,POLR1C,POLR3H,IMPDH2,PDE
7A,POLR1E,ADA,POLRMT,ATIC,APRT 
10 
TNFR2 Signaling 2.18E+00 6.06E-02 6.06 LTA,BIRC3 2 
IL-8 Signaling 2.17E+00 3.66E-02 3.66 PTK2 (includes 
EG:14083),VEGFB,CCND2,PRKCH,PRK
CA,ATM,BCL2 
7 
Colorectal Cancer 
Metastasis Signaling 
2.17E+00 3.56E-02 3.56 MYC,VEGFB,SMAD3,TLR7,LEF1,STAT1
,RALGDS,TCF7,ATM 
9 
B Cell Receptor Signaling 2.13E+00 3.90E-02 3.9 ETS1,CD19,CD79B,PPP3CC,CD79A,AT
M 
6 
TGF-β Signaling 2.13E+00 4.49E-02 4.49 RUNX3,SMAD3,MAP4K1,BCL2 4 
EIF2 Signaling 2.13E+00 3.68E-02 3.68 RPS4X,RPL22,RPL14,RPS23,RPL13A,R
PL13,ATM 
7 
Hereditary Breast Cancer 
Signaling 
2.13E+00 4.03E-02 4.03 C17orf70,CDK4,CDK6,ATR,ATM 5 
Protein Kinase A 
Signaling 
2.13E+00 3.42E-02 3.42 PTK2 (includes 
EG:14083),ANAPC1/LOC100286979,P
DE7A,SMAD3,ITPR3,PLCG1,LEF1,PRK
CH,PPP3CC,TCF7,PRKCA 
11 
FGF Signaling 2.13E+00 4.44E-02 4.44 PLCG1,RPS6KA5,PRKCA,ATM 4 
Melanocyte 
Development and 
Pigmentation Signaling 
2.13E+00 4.35E-02 4.35 PLCG1,RPS6KA5,ATM,BCL2 4 
mTOR Signaling 2.13E+00 3.59E-02 3.59 RPS4X,VEGFB,RPS6KA5,PRKCH,RPS23
,PRKCA,ATM 
7 
FAK Signaling 2.13E+00 3.96E-02 3.96 PTK2 (includes 
EG:14083),FYN,PLCG1,ATM 
4 
RANK Signaling in 
Osteoclasts 
2.13E+00 4.26E-02 4.26 PPP3CC,TRAF5,BIRC3,ATM 4 
ILK Signaling 2.13E+00 3.76E-02 3.76 PTK2 (includes 
EG:14083),MYC,VEGFB,LEF1,RPS6KA5
,ITGB7,ATM 
7 
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G Protein Signaling 
Mediated by Tubby 
2.13E+00 5.13E-02 5.13 LCK,PLCG1 2 
Myc Mediated Apoptosis 
Signaling 
2.13E+00 5.00E-02 5 MYC,ATM,BCL2 3 
Death Receptor Signaling 2.13E+00 4.76E-02 4.76 TNFRSF25,BIRC3,BCL2 3 
α-Adrenergic Signaling 2.13E+00 3.81E-02 3.81 ITPR3,PLCG1,PRKCH,PRKCA 4 
Bladder Cancer Signaling 2.13E+00 4.44E-02 4.44 MYC,VEGFB,CDK4,RPS6KA5 4 
14-3-3-mediated 
Signaling 
2.13E+00 4.13E-02 4.13 FOXO1,PLCG1,PRKCH,PRKCA,ATM 5 
Gα12/13 Signaling 2.12E+00 3.94E-02 3.94 PTK2 (includes 
EG:14083),MEF2D,LPAR5,MEF2C,AT
M 
5 
Retinoic acid Mediated 
Apoptosis Signaling 
2.12E+00 4.69E-02 4.69 PARP12,PARP14,PARP1 3 
Valine, Leucine and 
Isoleucine Degradation 
2.12E+00 2.94E-02 2.94 ACAD11,ALDH1A1,HADH 3 
Pathogenesis of Multiple 
Sclerosis 
2.12E+00 1.11E-01 11.1 CCL5 1 
Assembly of RNA 
Polymerase I Complex 
2.12E+00 7.69E-02 7.69 POLR1C 1 
P2Y Purigenic Receptor 
Signaling Pathway 
2.12E+00 3.60E-02 3.6 MYC,PLCG1,PRKCH,PRKCA,ATM 5 
Role of CHK Proteins in 
Cell Cycle Checkpoint 
Control 
2.12E+00 5.71E-02 5.71 ATR,ATM 2 
TWEAK Signaling 2.12E+00 5.26E-02 5.26 TNFRSF25,BIRC3 2 
MIF-mediated 
Glucocorticoid 
Regulation 
2.12E+00 4.76E-02 4.76 JMJD7-PLA2G4B,CD74 2 
Role of JAK2 in Hormone-
like Cytokine Signaling 
2.12E+00 5.71E-02 5.71 SOCS2,STAT1 2 
Aminoacyl-tRNA 
Biosynthesis 
2.12E+00 2.63E-02 2.63 FARS2,VARS 2 
CXCR4 Signaling 2.12E+00 3.57E-02 3.57 PTK2 (includes 
EG:14083),CD4,ITPR3,PRKCH,PRKCA,
ATM 
6 
Role of Osteoblasts, 
Osteoclasts and 
Chondrocytes in 
Rheumatoid Arthritis 
2.10E+00 3.38E-02 3.38 FOXO1,LEF1,PPP3CC,TRAF5,BIRC3,TC
F7,ATM,BCL2 
8 
Leukocyte Extravasation 
Signaling 
2.09E+00 3.59E-02 3.59 PTK2 (includes 
EG:14083),TXK,PLCG1,PRKCH,PRKCA,
ATM,ITK 
7 
Fcγ Receptor-mediated 
Phagocytosis in 
Macrophages and 
Monocytes 
2.09E+00 3.96E-02 3.96 FYN,PLCG1,PRKCH,PRKCA 4 
Glycerolipid Metabolism 2.09E+00 2.78E-02 2.78 LPIN1,ALDH1A1,DGKQ,AKR1B1 4 
Glycerophospholipid 
Metabolism 
2.09E+00 2.70E-02 2.7 LPIN1,DGKQ,CLC,JMJD7-
PLA2G4B,PLCG1 
5 
Thrombin Signaling 2.09E+00 3.43E-02 3.43 PTK2 (includes 
EG:14083),MPRIP,ITPR3,PLCG1,PRKC
H,PRKCA,ATM 
7 
Valine, Leucine and 
Isoleucine Biosynthesis 
2.09E+00 2.44E-02 2.44 VARS 1 
Fatty Acid Biosynthesis 2.09E+00 2.04E-02 2.04 FASN 1 
Aldosterone Signaling in 
Epithelial Cells 
2.09E+00 3.47E-02 3.47 ITPR3,PLCG1,PRKCH,DNAJC30,PRKCA,
ATM 
6 
Nitrogen Metabolism 2.09E+00 1.67E-02 1.67 CA5B,CCDC92 2 
Selenoamino Acid 2.09E+00 2.74E-02 2.74 MGMT,PRMT6 2 
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Metabolism 
Angiopoietin Signaling 2.02E+00 4.05E-02 4.05 PTK2 (includes 
EG:14083),FOXO1,ATM 
3 
Gap Junction Signaling 2.02E+00 3.33E-02 3.33 ITPR3,PLCG1,PRKCH,PPP3CC,PRKCA,A
TM 
6 
Amyotrophic Lateral 
Sclerosis Signaling 
1.98E+00 3.45E-02 3.45 VEGFB,BIRC3,ATM,BCL2 4 
IGF-1 Signaling 1.98E+00 3.81E-02 3.81 PTK2 (includes 
EG:14083),FOXO1,SOCS2,ATM 
4 
Human Embryonic Stem 
Cell Pluripotency 
1.94E+00 3.31E-02 3.31 S1PR5,SMAD3,LEF1,TCF7,ATM 5 
Cleavage and 
Polyadenylation of Pre-
mRNA 
1.87E+00 8.33E-02 8.33 WDR33 1 
Fatty Acid Metabolism 1.85E+00 2.45E-02 2.45 ACAD11,ALDH1A1,ECI2,HADH 4 
Wnt/β-catenin Signaling 1.84E+00 3.51E-02 3.51 MYC,AXIN2,TGFBR3,MAP4K1,LEF1,TC
F7 
6 
Role of PKR in Interferon 
Induction and Antiviral 
Response 
1.84E+00 4.44E-02 4.44 TRAF5,STAT1 2 
Mechanisms of Viral Exit 
from Host Cells 
1.84E+00 4.44E-02 4.44 PRKCH,PRKCA 2 
Synaptic Long Term 
Potentiation 
1.82E+00 3.54E-02 3.54 ITPR3,PRKCH,PPP3CC,PRKCA 4 
G-Protein Coupled 
Receptor Signaling 
1.82E+00 3.02E-02 3.02 CCR3,FYN,S1PR5,PDE7A,GPR18,CX3C
R1,EMR3,GPR183,GPR56,P2RY10,RAS
GRP1,GPR114,LPAR5,CCR7,ATM,PRK
CA 
16 
MIF Regulation of Innate 
Immunity 
1.82E+00 4.00E-02 4 JMJD7-PLA2G4B,CD74 2 
Caveolar-mediated 
Endocytosis Signaling 
1.82E+00 3.61E-02 3.61 FYN,ITGB7,PRKCA 3 
Androgen and Estrogen 
Metabolism 
1.82E+00 2.42E-02 2.42 MGMT,PRMT6,SULF2 3 
LPS-stimulated MAPK 
Signaling 
1.79E+00 3.66E-02 3.66 PRKCH,PRKCA,ATM 3 
Melanoma Signaling 1.79E+00 4.35E-02 4.35 CDK4,ATM 2 
DNA Double-Strand 
Break Repair by 
Homologous 
Recombination 
1.77E+00 5.88E-02 5.88 ATM 1 
Nitric Oxide Signaling in 
the Cardiovascular 
System 
1.77E+00 3.19E-02 3.19 VEGFB,ITPR3,ATM 3 
PTEN Signaling 1.76E+00 3.25E-02 3.25 PTK2 (includes 
EG:14083),FOXO1,TGFBR3,BCL2 
4 
Phenylalanine, Tyrosine 
and Tryptophan 
Biosynthesis 
1.70E+00 1.54E-02 1.54 FARS2 1 
Tryptophan Metabolism 1.70E+00 1.86E-02 1.86 ALDH1A1,MGMT,PRMT6,HADH 4 
β-alanine Metabolism 1.70E+00 2.20E-02 2.2 ACAD11,ALDH1A1 2 
NRF2-mediated Oxidative 
Stress Response 
1.70E+00 3.16E-02 3.16 GSTM1,GSTM2,DNAJA3,PRKCH,PRKC
A,ATM 
6 
Ceramide Signaling 1.69E+00 3.45E-02 3.45 S1PR5,ATM,BCL2 3 
Leptin Signaling in 
Obesity 
1.69E+00 3.45E-02 3.45 FOXO1,PLCG1,ATM 3 
Sphingosine-1-phosphate 
Signaling 
1.67E+00 3.25E-02 3.25 PTK2 (includes 
EG:14083),S1PR5,PLCG1,ATM 
4 
Clathrin-mediated 
Endocytosis Signaling 
1.67E+00 3.12E-02 3.12 VEGFB,LDLRAP1,PPP3CC,SH3KBP1,IT
GB7,ATM 
6 
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Type II Diabetes Mellitus 
Signaling 
1.66E+00 2.60E-02 2.6 SOCS2,PRKCH,PRKCA,ATM 4 
Glycolysis/Gluconeogene
sis 
1.66E+00 2.42E-02 2.42 ALDH1A1,ACSS1,LDHB 3 
Inositol Phosphate 
Metabolism 
1.66E+00 2.62E-02 2.62 CDK4,CDK6,PLCG1,PRKCH,ATM 5 
Sphingolipid Metabolism 1.64E+00 2.73E-02 2.73 NEU1,LPIN1,SULF2 3 
Ascorbate and Aldarate 
Metabolism 
1.64E+00 1.30E-02 1.3 ALDH1A1 1 
Fatty Acid Elongation in 
Mitochondria 
1.58E+00 2.17E-02 2.17 HADH 1 
Differential Regulation of 
Cytokine Production in 
Macrophages and T 
Helper Cells by IL-17A 
and IL-17F 
1.58E+00 5.56E-02 5.56 CCL5 1 
CD27 Signaling in 
Lymphocytes 
1.55E+00 3.57E-02 3.57 TRAF5,CD27 2 
Lipid Antigen 
Presentation by CD1 
1.53E+00 4.55E-02 4.55 CD3E 1 
Semaphorin Signaling in 
Neurons 
1.53E+00 3.85E-02 3.85 PTK2 (includes EG:14083),FYN 2 
Integrin Signaling 1.53E+00 2.93E-02 2.93 PTK2 (includes 
EG:14083),FYN,MPRIP,PLCG1,ITGB7,
ATM 
6 
Glutathione Metabolism 1.53E+00 2.38E-02 2.38 GSTM1,GSTM2 2 
DNA Methylation and 
Transcriptional 
Repression Signaling 
1.53E+00 4.35E-02 4.35 DNMT1 1 
Role of Lipids/Lipid Rafts 
in the Pathogenesis of 
Influenza 
1.53E+00 4.17E-02 4.17 RSAD2 1 
One Carbon Pool by 
Folate 
1.53E+00 2.78E-02 2.78 ATIC 1 
Synaptic Long Term 
Depression 
1.53E+00 2.86E-02 2.86 JMJD7-PLA2G4B,ITPR3,PRKCH,PRKCA 4 
GNRH Signaling 1.53E+00 2.82E-02 2.82 PTK2 (includes 
EG:14083),ITPR3,PRKCH,PRKCA 
4 
PPARα/RXRα Activation 1.53E+00 2.82E-02 2.82 FASN,SMAD3,TGFBR3,PLCG1,PRKCA 5 
Role of IL-17A in Arthritis 1.53E+00 3.17E-02 3.17 CCL5,ATM 2 
G Beta Gamma Signaling 1.53E+00 2.65E-02 2.65 PLCG1,PRKCH,PRKCA 3 
Dopamine-DARPP32 
Feedback in cAMP 
Signaling 
1.52E+00 2.73E-02 2.73 ITPR3,PLCG1,PRKCH,PPP3CC,PRKCA 5 
Biosynthesis of Steroids 1.51E+00 8.26E-03 0.82
6 
COX10 (includes EG:1352) 1 
Polyamine Regulation in 
Colon Cancer 
1.48E+00 3.45E-02 3.45 MYC 1 
Glioma Invasiveness 
Signaling 
1.48E+00 3.33E-02 3.33 PTK2 (includes EG:14083),ATM 2 
Butanoate Metabolism 1.48E+00 1.59E-02 1.59 ALDH1A1,HADH 2 
SAPK/JNK Signaling 1.48E+00 2.97E-02 2.97 LCK,MAP4K1,ATM 3 
Mitotic Roles of Polo-Like 
Kinase 
1.46E+00 3.33E-02 3.33 CDC25B,ANAPC1/LOC100286979 2 
Glycosphingolipid 
Biosynthesis - 
Neolactoseries 
1.46E+00 1.56E-02 1.56 ST3GAL5 1 
Differential Regulation of 
Cytokine Production in 
Intestinal Epithelial Cells 
1.46E+00 4.35E-02 4.35 CCL5 1 
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by IL-17A and IL-17F 
RAR Activation 1.46E+00 2.72E-02 2.72 ALDH1A1,SMAD3,PRKCH,PRKCA,PAR
P1 
5 
Induction of Apoptosis by 
HIV1 
1.46E+00 3.12E-02 3.12 BIRC3,BCL2 2 
Lysine Degradation 1.46E+00 1.47E-02 1.47 ALDH1A1,HADH 2 
CREB Signaling in 
Neurons 
1.46E+00 2.55E-02 2.55 ITPR3,PLCG1,PRKCH,PRKCA,ATM 5 
Glycosphingolipid 
Biosynthesis - 
Ganglioseries 
1.46E+00 1.82E-02 1.82 ST3GAL5 1 
IL-22 Signaling 1.46E+00 4.00E-02 4 STAT1 1 
Role of JAK1, JAK2 and 
TYK2 in Interferon 
Signaling 
1.46E+00 3.70E-02 3.7 STAT1 1 
Role of PI3K/AKT 
Signaling in the 
Pathogenesis of Influenza 
1.46E+00 2.86E-02 2.86 CCL5,ATM 2 
Nicotinate and 
Nicotinamide 
Metabolism 
1.46E+00 2.24E-02 2.24 CDK4,CDK6,PRKCH 3 
Glycosaminoglycan 
Degradation 
1.46E+00 1.82E-02 1.82 SULF2 1 
N-Glycan Degradation 1.46E+00 4.00E-02 4 NEU1 1 
IL-17A Signaling in 
Gastric Cells 
1.46E+00 4.00E-02 4 CCL5 1 
Role of JAK family kinases 
in IL-6-type Cytokine 
Signaling 
1.46E+00 3.70E-02 3.7 STAT1 1 
Paxillin Signaling 1.46E+00 2.73E-02 2.73 PTK2 (includes EG:14083),ITGB7,ATM 3 
Antiproliferative Role of 
TOB in T Cell Signaling 
1.44E+00 3.85E-02 3.85 SMAD3 1 
Methionine Metabolism 1.44E+00 1.33E-02 1.33 DNMT1 1 
HIF1α Signaling 1.44E+00 2.83E-02 2.83 VEGFB,LDHB,ATM 3 
Production of Nitric 
Oxide and Reactive 
Oxygen Species in 
Macrophages 
1.42E+00 2.38E-02 2.38 PLCG1,PRKCH,STAT1,PRKCA,ATM 5 
Hypoxia Signaling in the 
Cardiovascular System 
1.41E+00 3.03E-02 3.03 UBE2L6,ATM 2 
Xenobiotic Metabolism 
Signaling 
1.41E+00 2.60E-02 2.6 GSTM1,GSTM2,ALDH1A1,MGMT,PRK
CH,PRKCA,ATM 
7 
NGF Signaling 1.41E+00 2.59E-02 2.59 PLCG1,RPS6KA5,ATM 3 
Ubiquinone Biosynthesis 1.41E+00 1.82E-02 1.82 MGMT,PRMT6 2 
Citrate Cycle 1.41E+00 1.79E-02 1.79 CLYBL 1 
Tyrosine Metabolism 1.40E+00 1.04E-02 1.04 MGMT,PRMT6 2 
Neurotrophin/TRK 
Signaling 
1.38E+00 2.63E-02 2.63 PLCG1,ATM 2 
Renal Cell Carcinoma 
Signaling 
1.37E+00 2.74E-02 2.74 ETS1,ATM 2 
O-Glycan Biosynthesis 1.37E+00 2.27E-02 2.27 ST6GALNAC6 1 
Basal Cell Carcinoma 
Signaling 
1.36E+00 2.74E-02 2.74 LEF1,TCF7 2 
Androgen Signaling 1.34E+00 2.16E-02 2.16 SMAD3,PRKCH,PRKCA 3 
Complement System 1.33E+00 2.94E-02 2.94 CFD 1 
Inhibition of 
Angiogenesis by TSP1 
1.32E+00 2.63E-02 2.63 FYN 1 
Pentose and Glucuronate 1.32E+00 7.63E-03 0.76 AKR1B1 1 
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Interconversions 3 
Role of Wnt/GSK-3β 
Signaling in the 
Pathogenesis of Influenza 
1.32E+00 2.60E-02 2.6 LEF1,TCF7 2 
Oncostatin M Signaling 1.30E+00 2.86E-02 2.86 STAT1 1 
Cell Cycle Regulation by 
BTG Family Proteins 
1.28E+00 2.78E-02 2.78 CDK4 1 
Notch Signaling 1.25E+00 2.44E-02 2.44 MFNG 1 
Glutamate Metabolism 1.25E+00 1.33E-02 1.33 CCDC92 1 
Cellular Effects of 
Sildenafil (Viagra) 
1.80E+00 5.37E-02 5.37 MYL12A,MYL6,GNA15,MYL12B,PRKA
R2A,GNAQ,PPP1R12A,PDE4D 
8 
Activation of IRF by 
Cytosolic Pattern 
Recognition Receptors 
1.80E+00 5.80E-02 5.8 TANK,TBK1,CHUK,IFNAR1 4 
Estrogen-Dependent 
Breast Cancer Signaling 
1.80E+00 5.71E-02 5.71 FOS,MAPK1,MAPK3,KRAS 4 
Antiproliferative Role of 
TOB in T Cell Signaling 
1.79E+00 7.69E-02 7.69 MAPK1,RPS6KA1 (includes EG:20111) 2 
Ovarian Cancer Signaling 1.79E+00 5.67E-02 5.67 MAPK1,MAPK3,CD44 (includes 
EG:100330801),PRKAR2A,KRAS,MAP
2K1,MMP9,PTEN 
8 
Fatty Acid Biosynthesis 1.75E+00 2.04E-02 2.04 ACSL3 1 
Graft-versus-Host 
Disease Signaling 
1.75E+00 6.25E-02 6.25 IL1RN,FCER1G,IL1B 3 
Amyotrophic Lateral 
Sclerosis Signaling 
1.75E+00 5.17E-02 5.17 RAB5A,RAB5C,APAF1,GRINA,CAPN3,B
IRC2 
6 
Role of Oct4 in 
Mammalian Embryonic 
Stem Cell Pluripotency 
1.71E+00 6.67E-02 6.67 RARA,SH3GLB1,HOXB1 3 
Paxillin Signaling 1.69E+00 5.45E-02 5.45 ITGAM (includes 
EG:16409),MAPK14,CDC42,MAPK1,K
RAS,PTPN12 
6 
Citrate Cycle 1.68E+00 3.57E-02 3.57 DLD,IDH1 2 
Sonic Hedgehog Signaling 1.62E+00 6.06E-02 6.06 ARRB2,PRKAR2A 2 
FXR/RXR Activation 1.60E+00 5.05E-02 5.05 IL1RN,RARA,FBP1,IL1B,RXRA 5 
FGF Signaling 1.60E+00 5.56E-02 5.56 MAPK14,MAPK1,MAPK3,MAPKAPK2,
MAP2K1 
5 
VEGF Signaling 1.57E+00 5.15E-02 5.15 MAPK1,MAPK3,KRAS,HIF1A,MAP2K1 5 
Agrin Interactions at 
Neuromuscular Junction 
1.57E+00 5.88E-02 5.88 CDC42,MAPK1,MAPK3,KRAS 4 
Gap Junction Signaling 1.57E+00 5.00E-02 5 GNAI3,MAPK1,GNA15,PRKCD,MAPK3
,PRKAR2A,GNAQ,KRAS,MAP2K1 
9 
Bile Acid Biosynthesis 1.56E+00 2.97E-02 2.97 DHRS9,ACAA1,PECR 3 
Bladder Cancer Signaling 1.53E+00 5.56E-02 5.56 MAPK1,MAPK3,KRAS,MAP2K1,MMP9 5 
Chondroitin Sulfate 
Biosynthesis 
1.53E+00 4.62E-02 4.62 CHSY1,CSGALNACT1,DSE 3 
Virus Entry via Endocytic 
Pathways 
1.48E+00 5.05E-02 5.05 CD55,CDC42,PRKCD,CLTC,KRAS 5 
ATM Signaling 1.48E+00 5.56E-02 5.56 MAPK14,GADD45A,NBN 3 
DNA Double-Strand 
Break Repair by 
Homologous 
Recombination 
1.48E+00 5.88E-02 5.88 NBN 1 
DNA Double-Strand 
Break Repair by Non-
Homologous End Joining 
1.48E+00 5.26E-02 5.26 NBN 1 
Glycine, Serine and 
Threonine Metabolism 
1.48E+00 2.74E-02 2.74 GNA15,CHKA,DLD,GNAQ 4 
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IL-9 Signaling 1.45E+00 5.00E-02 5 IRS2,BCL3 2 
Telomere Extension by 
Telomerase 
1.43E+00 5.88E-02 5.88 NBN 1 
Methane Metabolism 1.43E+00 1.54E-02 1.54 PRDX5 1 
Coagulation System 1.42E+00 5.26E-02 5.26 PLAUR,SERPINA1 2 
Phenylalanine 
Metabolism 
1.39E+00 1.83E-02 1.83 PRDX5,ALDH3B1 2 
RAN Signaling 1.39E+00 4.35E-02 4.35 KPNA4 1 
Glyoxylate and 
Dicarboxylate 
Metabolism 
1.35E+00 9.26E-03 0.92
6 
MTHFD2 1 
Ascorbate and Aldarate 
Metabolism 
1.35E+00 1.30E-02 1.3 GSTO1 1 
Differential Regulation of 
Cytokine Production in 
Macrophages and T 
Helper Cells by IL-17A 
and IL-17F 
1.31E+00 5.56E-02 5.56 IL1B 1 
Endoplasmic Reticulum 
Stress Pathway 
1.31E+00 5.56E-02 5.56 ATF6 1 
 
 
  
 
